U.S. patent application number 16/823485 was filed with the patent office on 2020-09-03 for monobactam organic compounds for the treatment of bacterial infections.
The applicant listed for this patent is Novartis AG. Invention is credited to Virender Singh AULAKH, Anthony CASAREZ, Xiaodong LIN, Mika LINDVALL, Glenn MCENROE, Heinz Ernst MOSER, Folkert RECK, Robert Lowell SIMMONS, Meiliana TJANDRA, Aregahegn YIFRU, Qingming ZHU.
Application Number | 20200276169 16/823485 |
Document ID | / |
Family ID | 1000004810649 |
Filed Date | 2020-09-03 |
View All Diagrams
United States Patent
Application |
20200276169 |
Kind Code |
A1 |
AULAKH; Virender Singh ; et
al. |
September 3, 2020 |
MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL
INFECTIONS
Abstract
This invention pertains generally to antibacterial compounds of
Formula I, ##STR00001## as further described herein, and
pharmaceutically acceptable salts and formulations thereof. In
certain aspects, the invention pertains to methods of using such
compounds to treat infections such as those caused by Gram-negative
bacteria.
Inventors: |
AULAKH; Virender Singh;
(Whitehorse, CA) ; CASAREZ; Anthony; (San
Francisco, CA) ; LIN; Xiaodong; (Orinda, CA) ;
LINDVALL; Mika; (Oakland, CA) ; MCENROE; Glenn;
(San Mateo, CA) ; MOSER; Heinz Ernst; (San Mateo,
CA) ; RECK; Folkert; (Walnut Creek, CA) ;
TJANDRA; Meiliana; (Dublin, CA) ; SIMMONS; Robert
Lowell; (San Francisco, CA) ; YIFRU; Aregahegn;
(Pleasant Hill, CA) ; ZHU; Qingming; (Walnut
Creek, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Novartis AG |
Basel |
|
CH |
|
|
Family ID: |
1000004810649 |
Appl. No.: |
16/823485 |
Filed: |
March 19, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16380243 |
Apr 10, 2019 |
|
|
|
16823485 |
|
|
|
|
14861797 |
Sep 22, 2015 |
10369138 |
|
|
16380243 |
|
|
|
|
14665245 |
Mar 23, 2015 |
9174978 |
|
|
14861797 |
|
|
|
|
61969735 |
Mar 24, 2014 |
|
|
|
62088304 |
Dec 5, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/4545 20130101;
A61K 31/454 20130101; A61K 31/4439 20130101; C07D 417/14 20130101;
Y02A 50/30 20180101; A61K 31/433 20130101; C07D 487/04 20130101;
A61K 31/496 20130101; A61K 45/06 20130101; A61K 31/427
20130101 |
International
Class: |
A61K 31/427 20060101
A61K031/427; A61K 45/06 20060101 A61K045/06; C07D 487/04 20060101
C07D487/04; A61K 31/4545 20060101 A61K031/4545; A61K 31/496
20060101 A61K031/496; A61K 31/433 20060101 A61K031/433; A61K
31/4439 20060101 A61K031/4439; A61K 31/454 20060101 A61K031/454;
C07D 417/14 20060101 C07D417/14 |
Claims
1. A compound of Formula (IA): ##STR00374## or a pharmaceutically
acceptable salt thereof, wherein: Z is CH; the group
--O--CR.sup.1R.sup.2R.sup.3 is selected from ##STR00375## and Het
is selected from ##STR00376## ##STR00377## ##STR00378##
2. The compound of claim 1, wherein the group
--OCR.sup.1R.sup.2R.sup.3 is selected from: ##STR00379## or a
pharmaceutically acceptable salt thereof.
3. The compound of claim 1, wherein the group
--O--CR.sup.1R.sup.2R.sup.3 is ##STR00380## or a pharmaceutically
acceptable salt thereof.
4. The compound of claim 1, wherein Het is selected from:
##STR00381## or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1, wherein Het is selected from:
##STR00382## or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1, wherein Het is selected from:
##STR00383## or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1, wherein Het is selected from:
##STR00384## or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1, which is selected from:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2-oxoimidazolidin-1-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)a-
mino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-((3-(2-aminoethyl)ureido)methyl)-2-oxooxaz-
olidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4--
yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxoimidazo-
lidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopr-
opanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(((2-aminoethyl)amino)methyl)-2-oxooxazoli-
din-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-
-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)-cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazoli-
din-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cycloprop-
anecarboxylic acid; and
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-(guanidinomethyl)--
2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyli-
dene)amino)oxy)-cyclopropanecarboxylic acid, or a pharmaceutically
acceptable salt thereof.
9. The compound of claim 1, which is selected from:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(guanidinomethyl)-2H-1-
,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)cyclopropanecarboxylic acid;
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(2-aminoethyl)carbamimidoyl)phenoxy)propanoic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(((3-guanidinopropyl)a-
mino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amin-
o)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4,5-bis(aminomethyl)-2H--
1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylide-
ne)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-((4-((3-aminoazetidin-1-yl)methyl)-2H-1,2,3-triazo-
l-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-(((S)-pyrr-
olidin-3-ylamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazetidin-3-y-
l)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid;
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-((1R,5S,6s)-3-azabicyclo[3.1.0]hexan-6-yl)carbamimidoyl)phenoxy)propa-
noic acid; and
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(3-aminopropyl)carbamimidoyl)phenoxy)propanoic acid; or a
pharmaceutically acceptable salt thereof.
10. The compound of claim 1, which is selected from:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2-oxoimidazolidin-1-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)a-
mino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-((3-(2-aminoethyl)ureido)methyl)-2-oxooxaz-
olidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4--
yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid; and
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxoimidazo-
lidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopr-
opanecarboxylic acid; or a pharmaceutically acceptable salt
thereof.
11. The compound of claim 1, which is selected from:
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(((2-aminoethyl)amino)methyl)-2-oxooxazoli-
din-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-
-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)-cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazoli-
din-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cycloprop-
anecarboxylic acid; and
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-(guanidinomethyl)--
2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyli-
dene)amino)oxy)-cyclopropanecarboxylic acid, or a pharmaceutically
acceptable salt thereof.
12. The compound of claim 1, which is selected from:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(guanidinomethyl)-2H-1-
,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)cyclopropanecarboxylic acid;
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(2-aminoethyl)carbamimidoyl)phenoxy)propanoic acid; or a
pharmaceutically acceptable salt thereof.
13. The compound of claim 1, which is selected from:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(((3-guanidinopropyl)a-
mino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amin-
o)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4,5-bis(aminomethyl)-2H--
1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylide-
ne)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-((4-((3-aminoazetidin-1-yl)methyl)-2H-1,2,3-triazo-
l-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid; or a
pharmaceutically acceptable salt thereof.
14. The compound of claim 1, which is selected from:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-(((S)-pyrr-
olidin-3-ylamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazetidin-3-y-
l)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid;
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-((1R,5S,6s)-3-azabicyclo[3.1.0]hexan-6-yl)carbamimidoyl)phenoxy)propa-
noic acid; and
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(3-aminopropyl)carbamimidoyl)phenoxy)propanoic acid; or a
pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition comprising a compound of claim 1
and at least one pharmaceutically acceptable excipient.
16. The pharmaceutical composition of claim 15, wherein the
compound is selected from:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2-oxoimidazolidin-1-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)a-
mino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-((3-(2-aminoethyl)ureido)methyl)-2-oxooxaz-
olidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4--
yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxoimidazo-
lidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopr-
opanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(((2-aminoethyl)amino)methyl)-2-oxooxazoli-
din-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-
-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)-cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazoli-
din-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cycloprop-
anecarboxylic acid; and
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-(guanidinomethyl)--
2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyli-
dene)amino)oxy)-cyclopropanecarboxylic acid, or a pharmaceutically
acceptable salt thereof.
17. The pharmaceutical composition of claim 15, wherein the
compound is selected from:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(guanidinomethyl)-2H-1-
,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)cyclopropanecarboxylic acid;
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(2-aminoethyl)carbamimidoyl)phenoxy)propanoic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(((3-guanidinopropyl)a-
mino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amin-
o)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4,5-bis(aminomethyl)-2H--
1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylide-
ne)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-((4-((3-aminoazetidin-1-yl)methyl)-2H-1,2,3-triazo-
l-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-(((S)-pyrr-
olidin-3-ylamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazetidin-3-y-
l)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid;
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-((1R,5S,6s)-3-azabicyclo[3.1.0]hexan-6-yl)carbamimidoyl)phenoxy)propa-
noic acid; and
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(3-aminopropyl)carbamimidoyl)phenoxy)propanoic acid; or a
pharmaceutically acceptable salt thereof.
18. A method to treat a Gram-negative bacterial infection, which
comprises administering to a subject in need of such treatment a
compound of claim 1.
19. The method of claim 18, wherein the bacterial infection is
caused by a species of Burkholderia, Citrobacter, Enterobacter,
Eschirichia, Klebsiella, Meningitidis, Morganella, Pseudomonas,
Proteus, Salmonella, Serratia, Acinetobacter, Bacteroides,
Burkholderia, Campylobacter, Neisseria, or Stenotrophomonas
bacteria.
20. The method of claim 19, wherein the compound is selected from:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(guanidinomethyl)-2H-1-
,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)cyclopropanecarboxylic acid;
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(2-aminoethyl)carbamimidoyl)phenoxy)propanoic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(((3-guanidinopropyl)a-
mino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amin-
o)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4,5-bis(aminomethyl)-2H--
1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylide-
ne)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-((4-((3-aminoazetidin-1-yl)methyl)-2H-1,2,3-triazo-
l-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-(((S)-pyrr-
olidin-3-ylamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazetidin-3-y-
l)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid;
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-((1R,5S,6s)-3-azabicyclo[3.1.0]hexan-6-yl)carbamimidoyl)phenoxy)propa-
noic acid; and
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(3-aminopropyl)carbamimidoyl)phenoxy)propanoic acid; or a
pharmaceutically acceptable salt thereof.
21. The method of claim 19, wherein the compound is selected from:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2-oxoimidazolidin-1-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)a-
mino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-((3-(2-aminoethyl)ureido)methyl)-2-oxooxaz-
olidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4--
yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxoimidazo-
lidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopr-
opanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(((2-aminoethyl)amino)methyl)-2-oxooxazoli-
din-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-
-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)-cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazoli-
din-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cycloprop-
anecarboxylic acid; and
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-(guanidinomethyl)--
2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyli-
dene)amino)oxy)-cyclopropanecarboxylic acid, or a pharmaceutically
acceptable salt thereof.
22. The method of claim 19, wherein the bacterial infection is
caused by Eschirichia coli.
23. A pharmaceutical combination, comprising a compound of claim 1
and a second therapeutic agent.
24. The pharmaceutical combination of claim 23, wherein the second
therapeutic agent is a beta-lactamase inhibitor.
25. The pharmaceutical combination of claim 23, wherein the
compound is selected from:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2-oxoimidazolidin-1-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)a-
mino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-((3-(2-aminoethyl)ureido)methyl)-2-oxooxaz-
olidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4--
yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxoimidazo-
lidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopr-
opanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(((2-aminoethyl)amino)methyl)-2-oxooxazoli-
din-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-
-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)-cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazoli-
din-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cycloprop-
anecarboxylic acid; and
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-(guanidinomethyl)--
2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyli-
dene)amino)oxy)-cyclopropanecarboxylic acid, or a pharmaceutically
acceptable salt thereof.
26. The pharmaceutical combination of claim 23, wherein the
compound is selected from:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(guanidinomethyl)-2H-1-
,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-11-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)a-
mino)oxy)cyclopropanecarboxylic acid;
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(2-aminoethyl)carbamimidoyl)phenoxy)propanoic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(((3-guanidinopropyl)a-
mino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amin-
o)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4,5-bis(aminomethyl)-2H--
1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylide-
ne)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(2-(((2R,3S)-2-((4-((3-aminoazetidin-1-yl)methyl)-2H-1,2,3-triazo-
l-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylic acid;
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-(((S)-pyrr-
olidin-3-ylamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazetidin-3-y-
l)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid;
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-((1R,5S,6s)-3-azabicyclo[3.1.0]hexan-6-yl)carbamimidoyl)phenoxy)propa-
noic acid; and
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(3-aminopropyl)carbamimidoyl)phenoxy)propanoic acid; or a
pharmaceutically acceptable salt thereof.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims benefit of priority to U.S.
Provisional Application No. 61/969,735, filed 24 Mar. 2014, and
U.S. Provisional Application No. 62/088,304, filed 5 Dec. 2014; the
contents of these applications are incorporated herein by
reference.
FIELD OF THE INVENTION
[0002] This invention relates to novel .beta.-lactam compounds, and
their preparation and use. In particular, the invention relates to
novel .beta.-lactam compounds where the lactam ring is monocyclic,
and their uses to treat bacterial infections, especially those
caused by Gram-negative bacteria.
BACKGROUND
[0003] Over the past several decades, the frequency of
antimicrobial resistance and its association with serious
infectious diseases have increased at alarming rates. The
increasing prevalence of resistance among nosocomial pathogens is
particularly disconcerting. Of the over 2 million nosocomial
infections occuring each year in the United States, 50 to 60% are
caused by antimicrobial-resistant strains of bacteria. The high
rate of resistance to commonly used antibacterial agents increases
the morbidity, mortality, and costs associated with nosocomial
infections. In the United States, nosocomial infections are thought
to contribute to or cause more than 77,000 deaths per year and cost
approximately $5 to $10 billion annually.
[0004] Important causes of Gram-negative resistance include
extended-spectrum .beta.-lactamases (ESBLs), serine carbapenemases
(KPCs) and metallo-.beta.-lactamases (for example NDM-1) in
Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis,
high-level third-generation cephalosporin (AmpC) .beta.-lactamase
resistance among Enterobacter species and Citrobacter freundii, and
multidrug-resistance genes observed in Pseudomonas, Acinetobacter,
and Stenotrophomonas. The problem of antibacterial resistance is
compounded by the existence of bacterial strains resistant to
multiple antibacterials. For example, Klebsiella pneumonia
harboring NDM-1 metallo-.beta.-lactamase carries frequently
additional serine-.beta.-lactamases on the same plasmid that
carries the NDM-1.
[0005] Thus there is a need for new antibacterials, particularly
antibacterial compounds that are effective against existing
drug-resistant microbes, or are less susceptible to development of
new bacterial resistance. The current invention provides such
compounds.
SUMMARY
[0006] The invention includes novel compounds, pharmaceutical
formulations including the compounds, and methods of using such
compounds and compositions for treatment of patients with bacterial
infections. The compounds are monobactams, which comprise a
monocyclic beta-lactam ring, and which typically act by inhibition
of penicillin-binding proteins (PBPs), which are involved in
biosynthesis of peptidoglycans required for normal bacterial cell
walls. Some known members of this class include aztreonam and
carumonam. Other monobactam compounds are disclosed in
WO2013/110643 and WO2012/073138. The compounds are primarily
effective against Gram-negative bacteria.
[0007] The compounds of the invention can be used to treat
infection caused by Enterobacteriaceae, including Salmonella, E.
coli, Klebsiella pneumoniae, Proteus, Enterobacter, Serratia, and
Citrobacter, including pathogens such as KPC producing Klebsiella
pneumoniae that are less susceptible to previous monobactams like
aztreonam, as well as non-fermenting bacteria, including
Pseudomonas aeruginosa, Acinetobacter, Burkholderia, Moraxella and
Stenotrophomonas.
[0008] The compounds of the invention can be used alone or in
combination with other antibiotics, and can be used in combination
with compounds such as beta-lactamase inhibitors that potentiate
the activity of the compounds of the invention against certain
pathogens or reduce the frequency or extent of bacterial resistance
to the compounds of the invention against certain pathogens.
Suitable beta-lactamase inhibitors for use in combination with the
compounds of the invention include avibactam, tazobactam, sulbactam
and clavulanic acid.
[0009] In one aspect, the invention provides compounds of Formula
(I):
##STR00002##
or a pharmaceutically acceptable salt thereof, [0010] wherein:
[0011] Z is CR.sup.4 or N; [0012] R.sup.1 is H or C.sub.1-C.sub.4
alkyl; [0013] R.sup.2 is selected from the group consisting of H,
C.sub.1-C.sub.4 alkyl, and --COOH [0014] or R.sup.1 and R.sup.2
taken together with the carbon to which they are attached form a
ring selected from a C.sub.3-C.sub.6 cycloalkyl ring and a 4-6
membered heterocyclic ring containing up to two heteroatoms
selected from N, O and S as ring members; [0015] R.sup.3 is
selected from H, --COOH, and
-L.sup.1-W--(CH.sub.2).sub.0-2--X--R.sup.5; [0016] R.sup.4 is H or
halo; [0017] each L.sup.1 is independently a straight chain or
branched C.sub.1-4 alkylene; [0018] W is a bond, O, NH or S; [0019]
X is phenyl, or a 5-6 membered heteroaryl ring containing 1-3
heteroatoms selected from N, O and S as ring members; where the
phenyl and 5-6 membered heteroaryl are optionally substituted with
one or two groups selected from C.sub.1-4 alkyl, hydroxy, --CN, F,
C.sub.1-4 alkoxy, --NH.sub.2, --NH(C.sub.1-4 alkyl) and
--N(C.sub.1-4 alkyl).sub.2; [0020] R.sup.5 is selected from
[0020] ##STR00003## [0021] wherein R.sup.1b, R.sup.2b, and R.sup.3b
are independently hydrogen, hydroxy, CN, (C.sub.1-C.sub.4)alkyl,
(C.sub.1-C.sub.4)alkoxy, (C.sub.3-C.sub.6)cycloalkyl, or 4-, 5-, 6-
or 7-membered heterocyclyl containing N, O or S as a ring member,
wherein each (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy,
(C.sub.3-C.sub.6)cycloalkyl, or 4-, 5-, 6- or 7-membered
heterocyclyl containing N, O or S as a ring member may be
substituted with one, two or three substituents selected
independently from Y, [0022] and wherein R.sup.2b and R.sup.3b
together with the nitrogen atom to which they are bonded can
optionally form a 5- to 7-membered heterocyclyl including 0 or 1
further heteroatoms selected from N, O and S, said heterocyclyl
optionally substituted by Y; [0023] Y is selected from F, CN,
--NH.sub.2, Q, -L.sup.2-C(O)NR.sup.10-L.sup.2-Q,
-L.sup.2-NR.sup.10--C(O)-L.sup.2-Q, -L.sup.2-OR.sup.10,
-L.sup.2-N(R.sup.10).sub.2, -L.sup.2-N.sup.+(R.sup.11).sub.3,
-L.sup.2-NR.sup.10--C(O)R.sup.10,
-L.sup.2-NR.sup.10-L.sup.2-N(R.sup.10).sub.2,
-L.sup.2-O--C(O)OR.sup.10, -L.sup.2-O--C(O)--N(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(O)--N(R.sup.10).sub.2,
-L.sup.2-NR.sup.1--C(O)--OR.sup.11-L.sup.2-C(.dbd.NR.sup.10)--N(R.sup.10)-
.sub.2, CON(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--N(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--R.sup.10,
-L.sup.2-C(O)N(R.sup.10).sub.2, -L.sup.2-O--SO.sub.3R.sup.10;
[0024] L.sup.2 is independently at each occurrence a bond or a
straight chain or branched C.sub.1-4 alkylene, optionally
substituted with NH.sub.2, OH, or F; [0025] Het is a 4-6 membered
heteroaryl or heterocyclic ring, where the heteroaryl ring contains
1 to 4 heteroatoms selected from N, O and S as ring members and is
optionally substituted with one or two groups selected from Y, OH,
NH.sub.2, --C(O)NR.sup.10.sub.2, and C.sub.1-4 alkyl optionally
substituted with one or two Y; and the heterocyclic ring contains 1
or 2 heteroatoms selected from N, O and S as ring members and is
optionally substituted with up to three groups selected from halo,
Y, C.sub.1-4 alkyl optionally substituted with one or two groups
selected from Y, .dbd.NR.sup.10, .dbd.N--OR.sup.10, .dbd.N--CN, and
oxo; [0026] and Het is optionally fused to a 5 or 6 membered
heterocyclic or heteroaryl ring containing up to two heteroatoms
selected from N--R.sup.10, O and S as ring members, and optionally
substituted with one or two R.sup.16; [0027] R.sup.10 and R.sup.12
are independently H or C.sub.1-4 alkyl optionally substituted by
one or two groups selected from OH, NH.sub.2 or Q; [0028] Q is
selected from -L.sup.2-N(R.sup.13).sub.2,
-L.sup.2-N.sup.+(R.sup.14).sub.3,
-L.sup.2-NR.sup.13--C(.dbd.NR.sup.13)--N(R.sup.13).sub.2,
-L.sup.2-NR.sup.13--CR.sup.13(.dbd.NR.sup.13),
-L.sup.2-NR.sup.13-L.sup.2-Cy,
-L.sup.2-NR.sup.13--C(.dbd.NR.sup.13)--NR.sup.13-L.sup.2-Cy,
-L.sup.2-NR.sup.13--C(.dbd.NR.sup.13)-L.sup.2-Cy,
-L.sup.2-Cy-L.sup.2-R.sup.13,
-L.sup.2-Cy-L.sup.2-N(R.sup.13).sub.2,
-L.sup.2-NR.sup.13--SO.sub.2--N(R.sup.13).sub.2,
-L.sup.2-SO.sub.2--N(R.sup.13).sub.2,
-L.sup.2-NR.sup.13--SO.sub.2--R.sup.13, -
L.sup.2-NR.sup.13-L.sup.2-Ar, -L.sup.2-S-L.sup.2-Cy,
-L.sup.2-NR.sup.13--(C.dbd.O)--O--R.sup.13,
[0028] ##STR00004## [0029] each Cy is independently a 3-6 membered
cycloalkyl or 3-6 membered heterocyclyl containing one or two
heteroatoms selected from N, O and S as a ring member and
optionally fused to a 5-6 membered aryl or heteroaryl ring, wherein
each Cy is optionally substituted with one or two groups selected
from halo, C.sub.1-3 haloalkyl, R.sup.14, hydroxy, C.sub.1-4
alkoxy, --NH.sub.2, --NH(C.sub.1-4 alkyl) or --N(C.sub.1-4
alkyl).sub.2; [0030] Ar is phenyl, optionally substituted with one
or two groups selected from halo, C.sub.1-3 haloalkyl, R.sup.14,
hydroxy, C.sub.1-4 alkoxy, --NH.sub.2, --NH(C.sub.1-4 alkyl) or
--N(C.sub.1-4 alkyl).sub.2; [0031] R.sup.11 is independently at
each occurrence C.sub.1-4 alkyl; [0032] and two R.sup.10, or two
R.sup.11, or two R.sup.12 on the same N can cyclize to form a 4-6
membered heterocyclic ring optionally substituted with C.sub.1-4
alkyl, C.sub.1-4 alkoxy, hydroxy, or oxo; [0033] R.sup.13 is
independently at each occurrence H or C.sub.1-4 alkyl optionally
substituted with hydroxy, C.sub.1-4 alkoxy, --NH.sub.2,
--NH(C.sub.1-4 alkyl) or --N(C.sub.1-4 alkyl).sub.2; [0034]
R.sup.14 is independently at each occurrence C.sub.1-4 alkyl
optionally substituted with hydroxy, C.sub.1-4 alkoxy, --NH.sub.2,
--NH(C.sub.1-4 alkyl) or --N(C.sub.1-4 alkyl).sub.2; [0035] wherein
two R.sup.13 or two R.sup.14 on the same N can cyclize to form a
4-6 membered heterocyclic ring optionally substituted with
C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, amino or oxo; [0036]
R.sup.15 is H, halo, C.sub.1-4 alkyl, CN, or --O(C.sub.1-4 alkyl);
[0037] each R.sup.16 is independently halo, C.sub.1-4 alkyl,
--NH.sub.2, CN, or --O(C.sub.1-4 alkyl);
[0038] or a pharmaceutically acceptable salt thereof;
[0039] including variants of such compounds disclosed herein.
[0040] In another aspect, the invention provides a method of
inhibiting bacterial growth or modulating the virulence of a
bacterial infection, wherein the method comprises administering to
a patient in need of such inhibition a compound of formula (I).
[0041] In another aspect, the invention provides a method for
treating a subject having a Gram-negative bacterial infection,
which comprises administering to the subject in need thereof an
antibacterially effective amount of a compound of formula (I),
optionally in combination with a pharmaceutically acceptable
carrier. In certain embodiments, the subject is a mammal and in
some embodiments, the subject is a human.
[0042] The Gram-negative bacteria may be of a genus selected from
Citrobacter, Enterobacter, Escherichia, Klebsiella, Morganella,
Proteus, Salmonella, Serratia, Pseudomonas, Acinetobacter,
Bacteroides, Burkholderia, Campylobacter, Neisseria, and
Stenotrophomonas. In particular, a bacterial infection caused by a
species of Citrobacter, Enterobacter, Escherichia, Klebsiella,
Morganella, Proteus, Salmonella, Serratia, Pseudomonas, or
Acinetobacter is treatable. Particular bacterial species for such
treatment include Citrobacter freundii, Citrobacter koseri,
Enterobacter cloacae, Enterobacter faecalis, Enterobacter faecium,
Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca,
Morganella morganii, Proteus mirabilis, Salmonella species,
Serratia marcescens, Pseudomonas aeruginosa, and Acinetobacter
baumanii, as well as Bacteroides bivius, Bacteroides fragilis,
Burkholderia cepacia, Campylobacter jejuni, Neisseria gonorrhoeae,
and Stenotrophomonas maltophilia.
[0043] In another aspect, the invention provides a method of
administering an inhibitory amount of a compound of formula (I) to
fermenting or non-fermenting Gram-negative bacteria. In certain
embodiment of the method of administering an inhibitory amount of a
compound of formula (I) to fermenting or non-fermenting
Gram-negative bacteria, the Gram-negative bacteria are species of
Burkholderia, Citrobacter, Enterobacter, Escherichia, Klebsiella,
Morganella, Neisseria, Proteus, Salmonella, Serratia, Pseudomonas,
and Acinetobacter. Particular bacterial species for such methods
include Citrobacter freundii, Citrobacter koseri, Enterobacter
cloacae, Enterobacter faecalis, Enterobacter faecium, Escherichia
coli, Klebsiella pneumonia, Klebsiella oxytoca, Neisseria
meningiditis and Burkholderia cepacia, Morganella morganii, Proteus
mirabilis, Salmonella species, Serratia marcescens, Pseudomonas
aeruginosa, and Acinetobacter baumanii, as well as Bacteroides
bivius, Bacteroides fragilis, Burkholderia cepacia, Campylobacter
jejuni, Neisseria gonorrhoeae, and Stenotrophomonas
maltophilia.
[0044] In another embodiment, the invention provides a method of
administering an inhibitory amount of a compound of formula (I) to
Gram-negative bacteria, such as an Enterobacteriaceae; in some
embodiments the Gram-negative bacteria is selected from the group
consisting of species of Citrobacter, Enterobacter, Escherichia,
Klebsiella, Morganella, Proteus, Salmonella, Serratia, Pseudomonas,
and Acinetobacter.
[0045] Another embodiment of the invention provides a
pharmaceutical composition comprising an effective amount of a
compound of Formula (I) combined with a pharmaceutically acceptable
carrier or excipient. An `effective amount` as used here refers to
an amount sufficient to reduce the severity or symptoms of an
infection, or an amount effective to reduce bacteria load in the
patient.
[0046] Pharmaceutical compositions according to the present
invention are provided which include any of the compounds described
herein and a pharmaceutically acceptable carrier. In some
embodiments the composition includes an additional therapeutic
agent or a beta lactamase inhibitor.
[0047] In another aspect, the invention provides a pharmaceutical
combination comprising a compound of the invention and an
additional therapeutic agent or a beta lactamase inhibitor or
optionally both.
[0048] The present invention provides novel compounds, methods for
inhibiting survival and population growth of Gram-negative
bacteria, and novel methods and compositions for treating bacterial
infections in mammals, particularly in human subjects. The
compounds provided herein can be formulated into pharmaceutical
formulations and medicaments that are useful in methods to inhibit
bacterial growth or severity or duration of a bacterial infection,
or to treat a subject having a bacterial infection that is
susceptible to inhibition by the compounds of Formula (I). The
invention also provides for the use of the compounds in preparing
medicaments and pharmaceutical formulations, for use of the
compounds in inhibiting bacterial growth, and for use of the
compounds in treating bacterial infections in a subject in need of
such treatment, e.g., a subject infected with a Gram-negative
bacteria or at especially high risk for such infection.
[0049] Other aspects of the invention are discussed herein.
DETAILED DESCRIPTION
[0050] For purposes of interpreting this specification, the
following definitions apply unless specified otherwise or clearly
contradicted by context. Whenever appropriate, terms used in the
singular will also include the plural and vice versa.
Definitions
[0051] Terms used in the specification have the following
meanings:
[0052] As used herein, the term "subject" refers to an animal. In
certain aspects, the animal is a mammal. A subject also refers to
for example, primates (e.g., humans), cows, sheep, goats, horses,
dogs, cats, rabbits, rats, mice, fish, birds and the like. In
certain embodiments, the subject is a human.
[0053] As used herein, the term "inhibition" or "inhibiting" refers
to the reduction or suppression of a given condition, symptom, or
disorder, or disease, or a significant decrease in the baseline
activity of a biological activity or process, or decrease in the
viability, number or growth rate of a bacterial population.
[0054] As used herein, the term "treating" or "treatment" of any
disease or disorder refers in one embodiment, to ameliorating the
disease or disorder (i.e., slowing or arresting or reducing the
development of the disease or at least one of the clinical symptoms
thereof). In another embodiment "treating" or "treatment" refers to
alleviating or ameliorating at least one physical parameter
including those which may not be discernible by the patient. In yet
another embodiment, "treating" or "treatment" refers to modulating
the disease or disorder, either physically, (e.g., stabilization of
a discernible symptom), physiologically, (e.g., stabilization of a
physical parameter), or both. In yet another embodiment, "treating"
or "treatment" refers to preventing or delaying the onset or
development or progression of the disease or disorder.
[0055] As used herein, the term "a," "an," "the" and similar terms
used in the context of the present invention (especially in the
context of the claims) are to be construed to cover both the
singular and plural unless otherwise indicated herein or clearly
contradicted by the context.
[0056] All methods described herein can be performed in any
suitable order unless otherwise indicated herein or otherwise
clearly contradicted by context. The use of any and all examples,
or exemplary language (e.g. "such as") provided herein is intended
merely to better illuminate the invention and does not pose a
limitation on the scope of the invention otherwise claimed.
[0057] The term "antibacterial agent" refers to agents synthesized
or modified in the laboratory that have either bactericidal or
bacteriostatic activity. An "active" agent in this context will
inhibit the growth of P. aeruginosa and/or other Gram-negative
bacteria. The term "inhibiting the growth" indicates that the rate
of increase in the numbers of a population of a particular
bacterium is reduced. Thus, the term includes situations in which
the bacterial population increases but at a reduced rate, as well
as situations where the growth of the population is stopped, as
well as situations where the numbers of the bacteria in the
population are reduced or the population even eliminated.
[0058] "Optionally substituted" means the group referred to can be
substituted at one or more positions by any one or any combination
of the radicals listed thereafter. Such substitution involves the
replacement of a hydrogen atom of the unsubstituted group with
another moiety; thus the number of substituents that can be added
to any unsubstituted group is equal to the number of hydrogen atoms
on the unsubstituted group. If not otherwise specified, `optionally
substituted` means that up to three non-hydrogen substituent groups
can be added.
[0059] "Halo" or "halogen", as used herein, may be fluorine,
chlorine, bromine or iodine.
[0060] "C.sub.1-C.sub.6 alkyl", or "C.sub.1-6 alkyl" as used
herein, denotes straight chain or branched alkyl having 1-6 carbon
atoms. If a different number of carbon atoms is specified, such as
C.sub.8 or C.sub.3, then the definition is to be interpreted
accordingly, such as "C.sub.1-C.sub.4 alkyl" will include methyl,
ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and
tert-butyl.
[0061] "C.sub.1-C.sub.6 alkoxy", or "C.sub.1-6 alkoxy" as used
herein, denotes straight chain or branched alkoxy having 1-6 carbon
atoms. If a different number of carbon atoms is specified, such as
C.sub.8 or C.sub.3, then the definition is to be interpreted
accordingly, e.g., "C.sub.1-C.sub.4 alkoxy" will represent methoxy,
ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy and
tert-butoxy.
[0062] "C.sub.1-C.sub.4-Haloalkyl" or "C.sub.1-4 haloalkyl" as used
herein, denotes straight chain or branched alkyl having 1-4 carbon
atoms, wherein at least one hydrogen has been replaced by a
halogen. If a different number of carbon atoms is specified, such
as C.sub.6 or C.sub.3, then the definition is to be interpreted
accordingly, thus "C.sub.1-C.sub.4-Haloalkyl" will represent
methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and
tert-butyl that have at least one hydrogen substituted with
halogen, such as where the halogen is fluorine: CF.sub.3CF.sub.2--,
(CF.sub.3).sub.2CH--, CH.sub.3--CF.sub.2--, CF.sub.3CF.sub.2--,
CF.sub.3, CF.sub.2H--, CF.sub.3CF.sub.2CHCF.sub.3 or
CF.sub.3CF.sub.2CF.sub.2CF.sub.2--.
[0063] "C.sub.3-C.sub.8-cycloalkyl" or "C.sub.3-8 cycloalkyl" as
used herein refers to a saturated monocyclic hydrocarbon ring of 3
to 8 carbon atoms. Examples of such groups include cyclopropyl,
cyclobutyl, cyclopentyl and cyclohexyl. If a different number of
carbon atoms is specified, such as C.sub.3-C.sub.6, then the
definition is to be interpreted accordingly.
[0064] "4- to 8-Membered heterocyclyl", "5- to 6-membered
heterocyclyl", "3- to 10-membered heterocyclyl", "3- to 14-membered
heterocyclyl", "4- to 14-membered heterocyclyl" and "5- to
14-membered heterocyclyl", refer, respectively, to 4- to
8-membered, 5- to 6-membered, 3- to 10-membered, 3- to 14-membered,
4- to 14-membered and 5- to 14-membered heterocyclic rings
containing 1 to 7, 1 to 5 or 1 to 4 heteroatoms selected from the
group consisting of nitrogen, oxygen and sulphur, which may be
saturated, or partially saturated. "Heterocyclic" may be used
interchangeably with "heterocyclyl". The heterocyclic group can be
attached at a heteroatom or a carbon atom. The term "heterocyclyl"
includes single ring groups, fused ring groups and bridged groups.
Examples of such heterocyclyl include, but are not limited to
pyrrolidine, piperidine, piperazine, oxazolidine, pyrrolidinone,
morpholine, tetrahydrofuran, tetrahydrothiophene,
tetrahydrothiopyran, tetrahydropyran, 1,4-dioxane, 1,4-oxathiane,
8-aza-bicyclo[3.2.1]octane, 3,8-diazabicyclo[3.2.1]octane,
3-Oxa-8-aza-bicyclo[3.2.1]octane, 8-Oxa-3-aza-bicyclo[3.2.1]octane,
2-Oxa-5-aza-bicyclo[2.2.1]heptane, 2,5-Diaza-bicyclo[2.2.1]heptane,
azetidine, ethylenedioxo, oxtane and thiazolidine. Preferably, a
heterocyclic or heterocyclyl group is a saturated or partially
saturated monocyclic group unless otherwise specified, and contains
5-7 ring atoms with up to two heteroatoms selected from N, O and S
as ring members. In some embodiments, a heterocyclic group further
includes bicyclic ring systems containing 1 or 2 heteroatoms such
as N, O or S as ring members and comprising two fused 3-, 4-, 5-,
or 6-membered rings, such as 3-azabicyclo[3.1.0]hexane,
8-aza-bicyclo[3.2.1]octane, 3,8-diazabicyclo[3.2.1]octane,
3-Oxa-8-aza-bicyclo[3.2.1]octane, 8-Oxa-3-aza-bicyclo[3.2.1]octane,
2-Oxa-5-aza-bicyclo[2.2.1]heptane,
2,5-Diaza-bicyclo[2.2.1]heptane.
[0065] "Heteroaryl" is a completely unsaturated (aromatic) ring.
The term "heteroaryl" refers to a 5-14 membered monocyclic- or
bicyclic- or tricyclic-aromatic ring system, having 1 to 8
heteroatoms selected from N, O and S. Typically, the heteroaryl is
a 5-10 membered ring system (e.g., 5-6 membered monocycle or an
8-10 membered bicycle) or a 5-6 membered ring system. Unless
otherwise specified, a heteroaryl is preferably an isolated 5-6
membered ring containing up to 4 heteroatoms selected from N, O and
S as ring members. Typical heteroaryl groups include furan,
isothiazole, thiadiazole, oxadiazole, indazole, indole, quinoline,
2- or 3-thienyl; 2- or 3-furyl; 2- or 3-pyrrolyl; 1-, 2-, 4-, or
5-imidazolyl; 1, 3-, 4-, or 5-pyrazolyl; 2-, 4-, or 5-thiazolyl,
3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or
5-isoxazolyl, 3- or 5-(1,2,4-triazolyl), 4- or 5-(1,2,
3-triazolyl), tetrazolyl, triazine, pyrimidine, 2-, 3-, or
4-pyridyl, 3- or 4-pyridazinyl, 3-, 4-, or 5-pyrazinyl,
2-pyrazinyl, and 2-, 4-, or 5-pyrimidinyl.
[0066] The term "hydroxy" or "hydroxyl" refers to the group --OH,
or when used as part of a group name such as hydroxyalkyl, it
refers to the named group substituted with an --OH. Various
embodiments of the invention are described herein. It will be
recognized that features specified in each embodiment may be
combined with other specified features to provide further
embodiments. The following numbered embodiments are representative
of some aspects of the invention. [0067] 1. A compound of Formula
(I):
##STR00005##
[0067] or a pharmaceutically acceptable salt thereof, [0068]
wherein: [0069] Z is CR.sup.4 or N; [0070] R.sup.1 is H or
C.sub.1-C.sub.4 alkyl; [0071] R.sup.2 is selected from the group
consisting of H, C.sub.1-C.sub.4 alkyl, and --COOH [0072] or
R.sup.1 and R.sup.2 taken together with the carbon to which they
are attached form a ring selected from a C.sub.3-C.sub.6 cycloalkyl
ring and a 4-6 membered heterocyclic ring containing up to two
heteroatoms selected from N, O and S as ring members; [0073]
R.sup.3 is selected from H, --COOH, and
-L.sup.1-W--(CH.sub.2).sub.0-2--X--R.sup.5; [0074] R.sup.4 is H or
halo; [0075] each L.sup.1 is independently a straight chain or
branched C.sub.1-4 alkylene; [0076] W is a bond, O, NH or S; [0077]
X is phenyl, or a 5-6 membered heteroaryl ring containing 1-3
heteroatoms selected from N, O and S as ring members; where the
phenyl and 5-6 membered heteroaryl are optionally substituted with
one or two groups selected from C.sub.1-4 alkyl, hydroxy, --CN, F,
C.sub.1-4 alkoxy, --NH.sub.2, --NH(C.sub.1-4 alkyl) and
--N(C.sub.1-4 alkyl).sub.2; [0078] R.sup.5 is selected from
[0078] ##STR00006## [0079] wherein R.sup.b, R.sup.2b, and R.sup.3b
are independently hydrogen, hydroxy, CN, (C.sub.1-C.sub.4)alkyl,
(C.sub.1-C.sub.4)alkoxy, (C.sub.3-C.sub.6)cycloalkyl, or 4-, 5-, 6-
or 7-membered heterocyclyl containing N, O or S as a ring member,
wherein each (C.sub.1-C.sub.4)alkyl, (C.sub.1-C.sub.4)alkoxy,
(C.sub.3-C.sub.6)cycloalkyl, or 4-, 5-, 6- or 7-membered
heterocyclyl containing N, O or S as a ring member may be
substituted with one, two or three substituents selected
independently from Y, [0080] and wherein R.sup.2b and R.sup.3b
together with the nitrogen atom to which they are bonded can
optionally form a 5- to 7-membered heterocyclyl including 0 or 1
further heteroatoms selected from N, O and S, said heterocyclyl
optionally substituted by Y; [0081] Y is selected from F, CN,
--NH.sub.2, Q, -L.sup.2-C(O)NR.sup.10-L.sup.2-Q,
-L.sup.2-NR.sup.10--C(O)-L.sup.2-Q, -L.sup.2-OR.sup.10,
-L.sup.2-N(R.sup.10).sub.2, -L.sup.2-N.sup.+(R.sup.11).sub.3,
-L.sup.2-NR.sup.10--C(O)R.sup.10,
-L.sup.2-NR.sup.10-L.sup.2-N(R.sup.10).sub.2,
-L.sup.2-O--C(O)OR.sup.10, -L.sup.2-O--C(O)--N(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(O)--N(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(O)--OR.sup.11-L.sup.2-C(.dbd.NR.sup.10)--N(R.sup.10-
).sub.2, CON(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--N(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--R.sup.1,
-L.sup.2-C(O)N(R.sup.10).sub.2, -L.sup.2-O--SO.sub.3R.sup.10;
[0082] L.sup.2 is independently at each occurrence a bond or a
straight chain or branched C.sub.1-4 alkylene, optionally
substituted with NH.sub.2, OH, or F; [0083] Het is a 4-6 membered
heteroaryl or heterocyclic ring, where the heteroaryl ring contains
1 to 4 heteroatoms selected from N, O and S as ring members and is
optionally substituted with one or two groups selected from Y, OH,
NH.sub.2, --C(O)NR.sup.10.sub.2, and C.sub.1-4 alkyl optionally
substituted with one or two Y; and the heterocyclic ring contains 1
or 2 heteroatoms selected from N, O and S as ring members and is
optionally substituted with up to three groups selected from halo,
Y, C.sub.1-4 alkyl optionally substituted with one or two groups
selected from Y, .dbd.NR.sup.10, .dbd.N--OR.sup.10, .dbd.N--CN, and
oxo; [0084] and Het is optionally fused to a 5 or 6 membered
heterocyclic or heteroaryl ring containing up to two heteroatoms
selected from N--R.sup.10, O and S as ring members, and optionally
substituted with one or two R.sup.16; [0085] R.sup.10 and R.sup.12
are independently H or C.sub.1-4 alkyl optionally substituted by
one or two groups selected from OH, NH.sub.2 or Q; [0086] Q is
selected from -L.sup.2-N(R.sup.13).sub.2,
-L.sup.2-N.sup.+(R.sup.14).sub.3,
-L.sup.2-NR.sup.13--C(.dbd.NR.sup.13)--N(R.sup.13).sub.2,
-L.sup.2-NR.sup.13--CR.sup.13(.dbd.NR.sup.13),
-L.sup.2-NR.sup.13-L.sup.2-Cy,
-L.sup.2-NR.sup.13--C(.dbd.NR.sup.13)--NR.sup.13-L.sup.2-Cy,
-L.sup.2-NR.sup.13--C(.dbd.NR.sup.13)-L.sup.2-Cy,
-L.sup.2-Cy-L.sup.2-R.sup.13,
-L.sup.2-Cy-L.sup.2-N(R.sup.13).sub.2,
-L.sup.2-NR.sup.13--SO.sub.2--N(R.sup.13).sub.2,
-L.sup.2-SO.sub.2--N(R.sup.13).sub.2,
-L.sup.2-NR.sup.13--SO.sub.2--R.sup.13, -
L.sup.2-NR.sup.13-L.sup.2-Ar, -L.sup.2-S-L.sup.2-Cy,
-L.sup.2-NR.sup.13--(C.dbd.O)--O--R.sup.13,
[0086] ##STR00007## [0087] each Cy is independently a 3-6 membered
cycloalkyl or 3-6 membered heterocyclyl containing one or two
heteroatoms selected from N, O and S as a ring member and
optionally fused to a 5-6 membered aryl or heteroaryl ring, wherein
each Cy is optionally substituted with one or two groups selected
from halo, C.sub.1-3 haloalkyl, R.sup.14, hydroxy, C.sub.1-4
alkoxy, --NH.sub.2, --NH(C.sub.1-4 alkyl) or --N(C.sub.1-4
alkyl).sub.2; [0088] Ar is phenyl, optionally substituted with one
or two groups selected from halo, C.sub.1-3 haloalkyl, R.sup.14,
hydroxy, C.sub.1-4 alkoxy, --NH.sub.2, --NH(C.sub.1-4 alkyl) or
--N(C.sub.1-4 alkyl).sub.2; [0089] R.sup.11 is independently at
each occurrence C.sub.1-4 alkyl; [0090] and two R.sup.10, or two
R.sup.11, or two R.sup.12 on the same N can cyclize to form a 4-6
membered heterocyclic ring optionally substituted with C.sub.1-4
alkyl, C.sub.1-4 alkoxy, hydroxy, or oxo; [0091] R.sup.13 is
independently at each occurrence H or C.sub.1-4 alkyl optionally
substituted with hydroxy, C.sub.1-4 alkoxy, --NH.sub.2,
--NH(C.sub.1-4 alkyl) or --N(C.sub.1-4 alkyl).sub.2; optionally,
when R.sup.13 is O.sub.1-4 alkyl it can be substituted with
--OR.sup.14, --NHR.sup.14, hydroxy, C.sub.1-4 alkoxy, --NH.sub.2,
--NH(C.sub.1-4 alkyl) or --N(C.sub.1-4 alkyl).sub.2; [0092]
R.sup.14 is independently at each occurrence C.sub.1-4 alkyl
optionally substituted with hydroxy, C.sub.1-4 alkoxy, --NH.sub.2,
--NH(C.sub.1-4 alkyl) or --N(C.sub.1-4 alkyl).sub.2; [0093] wherein
two R.sup.13 or two R.sup.14 on the same N can cyclize to form a
4-6 membered heterocyclic ring optionally substituted with
C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, amino or oxo; [0094]
R.sup.15 is H, halo, C.sub.1-4 alkyl, CN, or --O(C.sub.1-4 alkyl);
[0095] each R.sup.16 is independently halo, C.sub.1-4 alkyl,
--NH.sub.2, CN, or --O(C.sub.1-4 alkyl); or a pharmaceutically
acceptable salt thereof.
[0096] It is understood that each of the compounds in Table B,
including compounds of Examples 1-152, is an embodiment of the
invention and is intended to fall within the scope of embodiment 1.
[0097] 2. A compound of Formula (IA):
##STR00008##
[0097] or a pharmaceutically acceptable salt thereof, [0098]
wherein: [0099] Z is CR.sup.4 or N; [0100] R.sup.1 is H or
C.sub.1-C.sub.4 alkyl; [0101] R.sup.2 is selected from the group
consisting of H, C.sub.1-C.sub.4 alkyl, and --COOH [0102] or
R.sup.1 and R.sup.2 taken together with the carbon to which they
are attached form a ring selected from a C.sub.3-C.sub.6 cycloalkyl
ring and a 4-6 membered heterocyclic ring containing up to two
heteroatoms selected from N, O and S as ring members; [0103]
R.sup.3 is selected from H, --COOH, and
-L.sup.1-W--(CH.sub.2).sub.0-2--X--R.sup.5; [0104] R.sup.4 is H or
halo; [0105] each L.sup.1 is independently a straight chain or
branched C.sub.1-4 alkylene; [0106] W is a bond, O, NH or S; [0107]
X is phenyl, or a 5-6 membered heteroaryl ring containing 1-3
heteroatoms selected from N, O and S as ring members; where the
phenyl and 5-6 membered heteroaryl are optionally substituted with
one or two groups selected from C.sub.1-4 alkyl, hydroxy, --CN, F,
C.sub.1-4 alkoxy, --NH.sub.2, --NH(C.sub.1-4 alkyl) and
--N(C.sub.1-4 alkyl).sub.2; [0108] R.sup.5 is selected from
[0108] ##STR00009## [0109] wherein R.sup.1b, R.sup.2b, and R.sup.3b
are independently hydrogen, hydroxy, CN, (C.sub.1-C.sub.4)alkyl,
(C.sub.1-C.sub.4)alkoxy, (C.sub.3-C.sub.6)cycloalkyl, or 4-, 5-, 6-
or 7-membered heterocyclyl, wherein each (C.sub.1-C.sub.4)alkyl,
(C.sub.1-C.sub.4)alkoxy, (C.sub.3-C.sub.6)cycloalkyl, or 4-, 5-, 6-
or 7-membered heterocyclyl may be substituted with one, two or
three substituents selected independently from Y, [0110] and
wherein R.sup.2b and R.sup.3b together with the nitrogen atom to
which they are bonded can optionally form a 5- to 7-membered
heterocyclyl including 0 or 1 further heteroatoms selected from N,
O and S, said heterocyclyl optionally substituted by Y; [0111] Y is
selected from F, CN, --NH.sub.2, Q,
-L.sup.2-C(O)NR.sup.10-L.sup.2-Q,
-L.sup.2-NR.sup.10--C(O)-L.sup.2-Q, -L.sup.2-OR.sup.10,
-L.sup.2-N(R.sup.10).sub.2, -L.sup.2-N.sup.+(R.sup.11).sub.3,
-L.sup.2-NR.sup.10--C(O)R.sup.10,
-L.sup.2-NR.sup.10-L.sup.2-N(R.sup.10).sub.2,
-L.sup.2-O--C(O)OR.sup.10, -L.sup.2-O--C(O)--N(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(O)--N(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(O)--OR.sup.11-L.sup.2-C(.dbd.NR.sup.10)--N(R.sup.10-
).sub.2, CON(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--N(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--R.sup.10,
-L.sup.2-C(O)N(R.sup.10).sub.2, -L.sup.2-O--SO.sub.3R.sup.10;
[0112] L.sup.2 is independently at each occurrence a bond or a
straight chain or branched C.sub.1-4 alkylene; [0113] Het is a 5-6
membered heteroaryl or heterocyclic ring, where the heteroaryl ring
contains 1 to 4 heteroatoms selected from N, O and S as ring
members and is optionally substituted with one or two groups
selected from Y, C.sub.1-4 alkyl optionally substituted with one or
two Y, NH.sub.2, and --C(O)NR.sup.102, and the heterocyclic ring
contains 1 or 2 heteroatoms selected from N, O and S as ring
members and is optionally substituted with up to three groups
selected from halo, Y, C.sub.1-4 alkyl optionally substituted with
one or two groups selected from Y, .dbd.NR.sup.10,
.dbd.N--OR.sup.10, .dbd.N--CN, and oxo; [0114] and Het is
optionally fused to a 5 or 6 membered heterocyclic or heteroaryl
ring containing up to two heteroatoms selected from N, O and S as
ring members, and optionally substituted with one or two R.sup.16;
[0115] R.sup.10 and R.sup.12 are independently H or C.sub.1-4 alkyl
optionally substituted by Q; [0116] Q is selected from
-L.sup.2-N(R.sup.13).sub.2, -L.sup.2-N.sup.+(R.sup.14).sub.3,
-L.sup.2-NH--C(.dbd.NH)--NH.sub.2,
-L.sup.2-C(.dbd.NH)--NH.sub.2,
[0116] ##STR00010## [0117] R.sup.11 is independently at each
occurrence C.sub.1-4 alkyl; [0118] and two R.sup.10, or two
R.sup.11, or two R.sup.12 on the same N can cyclize to form a 4-6
membered heterocyclic ring optionally substituted with C.sub.1-4
alkyl, C.sub.1-4 alkoxy, hydroxy, or oxo; [0119] R.sup.13 is
independently at each occurrence H or C.sub.1-4 alkyl optionally
substituted with hydroxy, C.sub.1-4 alkoxy, --NH.sub.2,
--NH(C.sub.1-4 alkyl) or --N(C.sub.1-4 alkyl).sub.2; [0120]
R.sup.14 is independently at each occurrence C.sub.1-4 alkyl
optionally substituted with hydroxy, C.sub.1-4 alkoxy, --NH.sub.2,
--NH(C.sub.1-4 alkyl) or --N(C.sub.1-4 alkyl).sub.2; [0121] wherein
two R.sup.13 or two R.sup.14 on the same N can cyclize to form a
4-6 membered heterocyclic ring optionally substituted with
C.sub.1-4 alkyl, C.sub.1-4 alkoxy, hydroxy, amino or oxo; [0122]
R.sup.15 is H, halo, C.sub.1-4 alkyl, CN, or --O(C.sub.1-4 alkyl);
[0123] each R.sup.16 is independently halo, C.sub.1-4 alkyl,
--NH.sub.2, CN, or --O(C.sub.1-4 alkyl);
[0124] or a pharmaceutically acceptable salt thereof.
[0125] In certain embodiments of the compounds of Formula (I) or
(IA), the group
##STR00011##
represented by --O--CR.sup.1R.sup.2R.sup.3 is selected from [0126]
3. The compound of embodiment 1 or embodiment 2, wherein R.sup.1
and R.sup.2 are each methyl and R.sup.3 is --COOH. [0127] 4. The
compound of embodiment 1 or embodiment 2, wherein R.sup.1 and
R.sup.2 together with the carbon to which they are both attached
form a cyclopropane ring and R.sup.3 is --COOH. [0128] 5. The
compound of embodiment 1 or embodiment 2, wherein R.sup.1 and
R.sup.2 are both H and R.sup.3 is --COOH. [0129] 6. The compound of
any of the preceding embodiments, wherein Z is CH. [0130] 7. The
compound of any of embodiments 1-6, wherein Z is N. [0131] 8. The
compound of any of the preceding embodiments, wherein Het is a
5-membered heteroaryl ring containing 1-4 nitrogen atoms as ring
members and is optionally substituted with Y. In some such
embodiments, Het is triazole optionally substituted with Y. [0132]
9. The compound of embodiment 8, wherein Het is selected from
pyrrole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, 1,3,4-triazole,
and 1,2,3,4-tetrazole and is optionally substituted as provided in
embodiment 8. [0133] 10. The compound of embodiment 8, wherein Het
is a 1,2,3-triazol-2-yl group that is optionally substituted with
-L.sup.2-N(R.sup.10).sub.2 or
L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--N(R.sup.10).sub.2. [0134] 11.
The compound of embodiment 8, which is of the formula:
##STR00012##
[0134] wherein R.sup.17 is selected from
--CH.sub.2-G.sup.1-(CH.sub.2).sub.1-4-G.sup.2 and
--CH.sub.2-G.sup.1-R.sup.x--(CH.sub.2).sub.0-2-G.sup.2, [0135]
G.sup.1 is selected from --NH--, --NMe-, --NH--C(.dbd.NH)--, and
--NH--C(.dbd.NH)--NH--, G.sup.2 is selected from --NH.sub.2,
--NHMe, --NH--C(.dbd.NH)--NH.sub.2, azetidine, and pyrrolidine; and
R.sup.x is a ring selected from cyclobutyl, azetidine, and
pyrrolidine. [0136] 12. The compound of embodiment 8, wherein Het
is a 1,2,3-triazol-1-yl group that is optionally substituted with
-L.sup.2-N(R.sup.10).sub.2 or
L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--N(R.sup.10).sub.2. [0137] 13.
The compound of embodiment 8, wherein Het is a 1,2,4-triazol-1-yl
group that is optionally substituted with
-L.sup.2-N(R.sup.10).sub.2 or
L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--N(R.sup.10).sub.2. [0138] 14.
The compound of any of embodiments 1-7, wherein Het is a saturated
ring substituted with oxo and optionally further substituted with
Y. [0139] 15. The compound of embodiment 14, wherein Het is
selected from pyrrolidine-2-one, oxazolidin-2-one, and
imidazolidin-2-one, and is optionally substituted with Y. In
particular embodiments of these compounds, Het is selected
from:
##STR00013##
[0139] where the dashed bond indicates the point of attachment of
Het to the remainder of Formula (I) or (IA), and (Y).sub.0-1
represents an optional substituent Y that can be attached at any
available position on the ring. [0140] 16. The compound of
embodiment 14, wherein Het is oxazolidin-2-one and is optionally
substituted with -L.sup.2-N(R.sup.10).sub.2 or
L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--N(R.sup.10).sub.2 [0141] 17.
The compound of embodiment 14, wherein Het is oxazolidin-2-one that
is substituted on the 5-position with -L.sup.2-N(R.sup.10).sub.2 or
L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--N(R.sup.10).sub.2 in the
R-configuration [0142] 18. The compound of any of the preceding
embodiments, having the structure of Formula (II):
##STR00014##
[0142] or a pharmaceutically acceptable salt thereof. [0143] 19.
The compound of embodiment 1 or embodiment 2, which is of the
formula (IIIa) or (IIIb):
##STR00015##
[0144] wherein R.sup.17 is Y or C.sub.1-4 alkyl optionally
substituted with one or two Y. [0145] 20. The compound of
embodiment 1 or embodiment 2, wherein --O--CR.sup.1R.sup.2R.sup.3
is selected from
[0145] ##STR00016## [0146] 21. The compound of embodiment 1 or
embodiment 20, wherein Het is selected from
[0146] ##STR00017## ##STR00018## ##STR00019## [0147] 22. The
compound of any of embodiments 1-16, wherein L.sup.2 is
--(CH.sub.2).sub.1-3--. [0148] 23. The compound of embodiment 18
wherein Het is selected from:
[0148] ##STR00020## [0149] 24. The compound of embodiment 18,
wherein Het is selected from
[0149] ##STR00021## [0150] 25. The compound of embodiment 19, 23,
or 25, wherein Y is selected from Q, -L.sup.2-OR.sup.10,
-L.sup.2-N(R.sup.10).sub.2, -L.sup.2-N.sup.+(R.sup.11).sub.3,
-L.sup.2-NR.sup.10--C(O)R.sup.10, -L.sup.2-O--C(O)OR.sup.10,
-L.sup.2-O--C(O)--N(R.sup.10).sub.2,
-L.sub.2-NR.sup.10--C(O)--N(R.sup.10).sub.2,
-L.sup.2-C(.dbd.NR.sup.10)--N(R.sup.10).sub.2,
--CON(R.sup.10).sub.2,
-L.sup.2-NR.sup.10--C(.dbd.NR.sup.10)--N(R.sup.10).sub.2, and
-L.sup.2-NR.sub.10--C(.dbd.NR.sup.10)--R.sup.10.
[0151] Alternatively, the compound of embodiment 19, 23 or 24
wherein Y is of the formula
-L.sup.2-NR.sup.10-L.sup.2-N(R.sup.10).sub.2, e.g. Y can be a group
such as
--CH.sub.2--NR.sup.10--(CH.sub.2).sub.2-3--N(R.sup.10).sub.2; in
particular embodiments of these compounds, R.sup.10 is H. [0152]
26. The compound of any of embodiments 6-25, wherein R.sup.3 is of
the formula
[0152] ##STR00022## [0153] 27. The compound of embodiment 26,
wherein R.sup.3 is
[0153] ##STR00023## [0154] where R.sup.3b is selected from H,
azetidine, pyrrolidine and piperidine. [0155] 28. The compound of
any of the preceding embodiments, which is a pharmaceutically
acceptable salt. [0156] 29. A pharmaceutical composition comprising
a compound of any of the preceding embodiments and at least one
pharmaceutically acceptable excipient. [0157] 30. A method to treat
a Gram-negative bacterial infection, which comprises administering
to a subject in need of such treatment a compound of any of
embodiments 1-27, or a pharmaceutical composition of embodiment 29.
[0158] 31. The method of embodiment 30, wherein the bacterial
infection is caused by a species of Burkholderia, Citrobacter,
Enterobacter, Escherichia, Klebsiella, Meningitidis, Morganella,
Pseudomonas, Proteus, Salmonella, Serratia, Acinetobacter,
Bacteroides, Campylobacter, Neisseria, or Stenotrophomonas
bacteria. [0159] 32. The method of embodiment 30, wherein the
bacterial infection is nosocomial pneumonia, an intraabdominal
infection, or a urinary tract infection caused by a species of
Enterobacteriaceae. [0160] 33. A compound according to any of
embodiments 1-27 for use as a medicament. [0161] 34. The compound
of embodiment 33, wherein the medicament is an antibacterial agent.
[0162] 35. The compound of embodiment 33, wherein the antibacterial
agent is for treatment of a Gram-negative bacterial infection
caused by a species of Citrobacter, Enterobacter, Escherichia,
Klebsiella, Morganella, Pseudomonas, Proteus, Salmonella, Serratia,
Acinetobacter, Bacteroides, Burkholderia, Campylobacter, Neisseria,
or Stenotrophomonas. [0163] 36. A pharmaceutical combination,
comprising a compound according to any of embodiments 1-27 and a
second therapeutic agent.
[0164] In compounds of Formula (I) and various embodiments
described above, the oxime is preferably of the configuration shown
here:
##STR00024##
[0165] In some instances of any of the embodiments described above,
unless otherwise specified, one but not both of R.sup.2 and R.sup.3
represent --COOH.
[0166] In many embodiments of the compounds described above, Het is
not pyridine. In preferred embodiments, Het is a 5-membered
heteroaryl or heterocyclic ring.
[0167] Where R.sup.3 in any of the above embodiments is of the
formula -L.sup.1-W--(CH.sub.2).sub.0-2--X--R.sup.5, X can be
phenyl. In some of these embodiments, L.sup.1 is CH.sub.2. In some
such embodiments, W is O. In some of these embodiments, R.sup.5 is
a group of the formula
##STR00025##
[0168] wherein R.sup.1b, R.sup.2b and R.sup.3b are as described for
embodiment 1 above. In certain of these embodiments, R.sup.5 is of
the formula
##STR00026##
wherein R.sup.1b and R.sup.2b each represent H, and R.sup.3b can be
H, or a heterocyclic group such as 4-piperidinyl. Suitably, in
these embodiments R.sup.1 is H and R.sup.2 is H or COOH.
[0169] In a further aspect, the invention provides: [0170] A
pharmaceutical combination comprising (a) a first therapeutic agent
which is a compound of the invention, e.g. a compound of formula
(I) or any subformula thereof described herein, and (b) a second
therapeutic agent as described above. [0171] A method as defined
above comprising co-administration, e.g. concomitantly or in
sequence, of a therapeutically effective amount of a compound of
the invention, e.g. a compound of formula (I) or any subformulae
thereof that is described herein, and a second therapeutic agent as
described above.
[0172] The terms "co-administration" or "combined administration"
or the like as utilized herein are meant to encompass
administration of the selected therapeutic agents to a single
patient, and are intended to include treatment regimens in which
the agents are not necessarily administered by the same route of
administration or at the same time. Fixed combinations are also
within the scope of the present invention. The administration of a
pharmaceutical combination of the invention results in a beneficial
effect, e.g. a synergistic therapeutic effect, compared to a
monotherapy applying only one of its pharmaceutically active
ingredients.
[0173] Each component of a combination according to this invention
may be administered separately, together, or in any combination
thereof.
[0174] The compound of the invention and any additional agent may
be formulated in separate dosage forms. Alternatively, to decrease
the number of dosage forms administered to a patient, the compound
of the invention and any additional agent may be formulated
together in any combination. For example, the compound of the
invention inhibitor may be formulated in one dosage form and the
additional agent may be formulated together in another dosage form.
Any separate dosage forms may be administered at the same time or
different times.
[0175] Alternatively, a composition of this invention comprises an
additional agent as described herein. Each component may be present
in individual compositions, combination compositions, or in a
single composition.
[0176] The compounds of the invention may be synthesized by the
general synthetic routes below, specific examples of which are
described in more detail in the Examples.
[0177] Compounds of the present invention and intermediates can
also be converted into each other according to methods generally
known to those skilled in the art.
[0178] Within the scope of this text, only a readily removable
group that is not a constituent of the particular desired end
product of the compounds of the present invention is designated a
"protecting group", unless the context indicates otherwise. The
protection of functional groups by such protecting groups, the
protecting groups themselves, and their cleavage reactions are
described for example in standard reference works, such as J. F. W.
McOmie, "Protective Groups in Organic Chemistry", Plenum Press,
London and New York 1973, in T. W. Greene and P. G. M. Wuts,
"Protective Groups in Organic Synthesis", Third edition, Wiley, New
York 1999, in "The Peptides"; Volume 3 (editors: E. Gross and J.
Meienhofer), Academic Press, London and New York 1981, in "Methoden
der organischen Chemie" (Methods of Organic Chemistry), Houben
Weyl, 4th edition, Volume 15/I, Georg Thieme Verlag, Stuttgart
1974, in H.-D. Jakubke and H. Jeschkeit, "Aminosauren, Peptide,
Proteine" (Amino acids, Peptides, Proteins), Verlag Chemie,
Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann,
"Chemie der Kohlenhydrate: Monosaccharide und Derivate" (Chemistry
of Carbohydrates: Monosaccharides and Derivatives), Georg Thieme
Verlag, Stuttgart 1974. A characteristic of protecting groups is
that they can be removed readily (i.e. without the occurrence of
undesired secondary reactions) for example by solvolysis,
reduction, photolysis or alternatively under physiological
conditions (e.g. by enzymatic cleavage).
[0179] Salts of compounds of the present invention having at least
one salt-forming group may be prepared in a manner known to those
skilled in the art. For example, salts of compounds of the present
invention having acid groups may be formed, for example, by
treating the compounds with metal compounds, such as alkali metal
salts of suitable organic carboxylic acids, e.g. the sodium salt of
2-ethylhexanoic acid, with organic alkali metal or alkaline earth
metal compounds, such as the corresponding hydroxides, carbonates
or hydrogen carbonates, such as sodium or potassium hydroxide,
carbonate or hydrogen carbonate, with corresponding calcium
compounds or with ammonia or a suitable organic amine,
stoichiometric amounts or only a small excess of the salt-forming
agent preferably being used. Acid addition salts of compounds of
the present invention are obtained in customary manner, e.g. by
treating the compounds with an acid or a suitable anion exchange
reagent. Internal salts of compounds of the present invention
containing acid and basic salt-forming groups, e.g. a free carboxy
group and a free amino group, may be formed, e.g. by the
neutralisation of salts, such as acid addition salts, to the
isoelectric point, e.g. with weak bases, or by treatment with ion
exchangers.
[0180] Salts can be converted into the free compounds in accordance
with methods known to those skilled in the art. Metal and ammonium
salts can be converted, for example, by treatment with suitable
acids, and acid addition salts, for example, by treatment with a
suitable basic agent.
[0181] Mixtures of isomers obtainable according to the invention
can generally be separated in a manner known to those skilled in
the art into the individual isomers; diastereoisomers can be
separated, for example, by partitioning between polyphasic solvent
mixtures, recrystallisation and/or chromatographic separation, for
example over silica gel or by e.g. medium pressure liquid
chromatography over a reversed phase column, and racemates can be
separated, for example, by the formation of salts with optically
pure salt-forming reagents and separation of the mixture of
diastereoisomers so obtainable, for example by means of fractional
crystallisation, or by chromatography over optically active column
materials.
[0182] Intermediates and final products can be worked up and/or
purified according to standard methods, e.g. using chromatographic
methods, distribution methods, (re-) crystallization, and the
like.
[0183] The following applies in general to all processes mentioned
herein before and hereinafter.
[0184] All process steps for making compounds of the invention can
be carried out under reaction conditions that are known to those
skilled in the art, including those mentioned specifically, in the
absence or, customarily, in the presence of solvents or diluents,
including, for example, solvents or diluents that are inert towards
the reagents used and dissolve them, in the absence or presence of
catalysts, condensation or neutralizing agents, for example ion
exchangers, such as cation exchangers, e.g. in the H+ form,
depending on the nature of the reaction and/or of the reactants at
reduced, normal or elevated temperature, for example in a
temperature range of from about -100.degree. C. to about
190.degree. C., including, for example, from approximately
-80.degree. C. to approximately 150.degree. C., for example at from
-80 to -60.degree. C., at room temperature, at from -20 to
40.degree. C. or at reflux temperature, under atmospheric pressure
or in a closed vessel, where appropriate under pressure, and/or in
an inert atmosphere, for example under an argon or nitrogen
atmosphere.
[0185] At all stages of the reactions, mixtures of isomers that are
formed can be separated into the individual isomers, for example
diastereoisomers or enantiomers, or into any desired mixtures of
isomers, for example racemates or mixtures of diastereoisomers
[0186] The solvents from which those solvents that are suitable for
any particular reaction may be selected include those mentioned
specifically or, for example, water, esters, such as lower
alkyl-lower alkanoates, for example ethyl acetate, ethers, such as
aliphatic ethers, for example diethyl ether, or cyclic ethers, for
example tetrahydrofuran or dioxane, liquid aromatic hydrocarbons,
such as benzene or toluene, alcohols, such as methanol, ethanol or
1- or 2-propanol, nitriles, such as acetonitrile, halogenated
hydrocarbons, such as methylene chloride or chloroform, acid
amides, such as dimethylformamide or dimethyl acetamide, bases,
such as heterocyclic nitrogen bases, for example pyridine or
N-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower
alkanoic acid anhydrides, for example acetic anhydride, cyclic,
linear or branched hydrocarbons, such as cyclohexane, hexane or
isopentane, methycyclohexane, or mixtures of those solvents, for
example aqueous solutions, unless otherwise indicated in the
description of the processes. Such solvent mixtures may also be
used in working up, for example by chromatography or
partitioning.
[0187] The compounds of the present invention, including their
salts, may also be obtained in the form of hydrates, or their
crystals may, for example, include the solvent used for
crystallization. Different crystalline forms may be present.
[0188] All starting materials, building blocks, reagents, acids,
bases, dehydrating agents, solvents and catalysts utilized to
synthesize the compounds of the present invention are either
commercially available or can be produced by organic synthesis
methods known to one of ordinary skill in the art.
[0189] The term "optical isomer" or "a stereoisomer" refers to any
of the various stereoisomeric configurations which may exist for a
given compound of the present invention and includes geometric
isomers. It is understood that a substituent may be attached at a
chiral center of a carbon atom. The term "chiral" refers to
molecules which have the property of non-superimposability on their
mirror image partner, while the term "achiral" refers to molecules
which are superimposable on their mirror image partner. Therefore,
the invention includes enantiomers, diastereomers or racemates of
the compound. "Enantiomers" are a pair of stereoisomers that are
non-superimposable mirror images of each other. A 1:1 mixture of a
pair of enantiomers is a "racemic" mixture. The term is used to
designate a racemic mixture where appropriate. "Diastereoisomers"
are stereoisomers that have at least two asymmetric atoms, but
which are not mirror-images of each other. The absolute
stereochemistry is specified according to the Cahn-Ingold-Prelog
R--S system. When a compound is a pure enantiomer the
stereochemistry at each chiral carbon may be specified by either R
or S. Resolved compounds whose absolute configuration is unknown
can be designated (+) or (-) depending on the direction (dextro- or
levorotatory) which they rotate plane polarized light at the
wavelength of the sodium D line. Certain compounds described herein
contain one or more asymmetric centers or axes and may thus give
rise to enantiomers, diastereomers, and other stereoisomeric forms
that may be defined, in terms of absolute stereochemistry, as (R)-
or (S)-.
[0190] Depending on the choice of the starting materials and
procedures, the compounds can be present in the form of one of the
possible isomers or as mixtures thereof, for example as pure
optical isomers, or as isomer mixtures, such as racemates and
diastereoisomer mixtures, depending on the number of asymmetric
carbon atoms. The present invention is meant to include all such
possible stereoisomers, including racemic mixtures, diasteriomeric
mixtures and optically pure forms. Optically active (R)- and
(S)-isomers may be prepared using chiral synthons or chiral
reagents, or resolved using conventional techniques. If the
compound contains a double bond, the substituent may be E or Z
configuration. If the compound contains a disubstituted cycloalkyl,
the cycloalkyl substituent may have a cis- or trans-configuration.
All tautomeric forms are also intended to be included.
[0191] Any resulting mixtures of isomers can be separated on the
basis of the physicochemical differences of the constituents, into
the pure or substantially pure geometric or optical isomers,
diastereomers, racemates, for example, by chromatography and/or
fractional crystallization.
[0192] Any resulting racemates of final products or intermediates
can be resolved into the optical antipodes by known methods, e.g.,
by separation of the diastereomeric salts thereof, obtained with an
optically active acid or base, and liberating the optically active
acidic or basic compound. In particular, a basic moiety may thus be
employed to resolve the compounds of the present invention into
their optical antipodes, e.g., by fractional crystallization of a
salt formed with an optically active acid, e.g., tartaric acid,
dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p-toluoyl
tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic
acid. Racemic products can also be resolved by chiral
chromatography, e.g., high pressure liquid chromatography (HPLC)
using a chiral adsorbent.
[0193] Furthermore, the compounds of the present invention,
including their salts, can also be obtained in the form of their
hydrates, or include other solvents used for their crystallization.
The compounds of the present invention may inherently or by design
form solvates with pharmaceutically acceptable solvents (including
water); therefore, it is intended that the invention embrace both
solvated and unsolvated forms. The term "solvate" refers to a
molecular complex of a compound of the present invention (including
pharmaceutically acceptable salts thereof) with one or more solvent
molecules. Such solvent molecules are those commonly used in the
pharmaceutical art, which are known to be innocuous to the
recipient, e.g., water, ethanol, and the like. The term "hydrate"
refers to the complex where the solvent molecule is water.
[0194] The compounds of the present invention, including salts,
hydrates and solvates thereof, may inherently or by design form
polymorphs.
[0195] As used herein, the terms "salt" or "salts" refers to an
acid addition or base addition salt of a compound of the present
invention. "Salts" include in particular "pharmaceutically
acceptable salts". The term "pharmaceutically acceptable salts"
refers to salts that retain the biological effectiveness and
properties of the compounds of this invention and, which typically
are not biologically or otherwise undesirable. In many cases, the
compounds of the present invention are capable of forming acid
and/or base salts by virtue of the presence of amino and/or
carboxyl groups or groups similar thereto.
[0196] Pharmaceutically acceptable acid addition salts can be
formed with inorganic acids and organic acids, e.g., acetate,
aspartate, benzoate, besylate, bromide/hydrobromide,
bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate,
chloride/hydrochloride, chlortheophyllonate, citrate,
ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate,
hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate,
laurylsulfate, malate, maleate, malonate, mandelate, mesylate,
methylsulphate, naphthoate, napsylate, nicotinate, nitrate,
octadecanoate, oleate, oxalate, palmitate, pamoate,
phosphate/hydrogen phosphate/dihydrogen phosphate,
polygalacturonate, propionate, stearate, succinate,
sulfosalicylate, tartrate, tosylate and trifluoroacetate salts.
[0197] Inorganic acids from which salts can be derived include, for
example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric
acid, phosphoric acid, and the like.
[0198] Organic acids from which salts can be derived include, for
example, acetic acid, propionic acid, glycolic acid, oxalic acid,
maleic acid, malonic acid, succinic acid, fumaric acid, tartaric
acid, citric acid, benzoic acid, mandelic acid, methanesulfonic
acid, ethanesulfonic acid, toluenesulfonic acid, sulfosalicylic
acid, and the like. Pharmaceutically acceptable base addition salts
can be formed with inorganic and organic bases.
[0199] Inorganic bases from which salts can be derived include, for
example, ammonium salts and metals from columns I to XII of the
periodic table. In certain embodiments, the salts are derived from
sodium, potassium, ammonium, calcium, magnesium, iron, silver,
zinc, and copper; particularly suitable salts include ammonium,
potassium, sodium, calcium and magnesium salts.
[0200] Organic bases from which salts can be derived include, for
example, primary, secondary, and tertiary amines, substituted
amines including naturally occurring substituted amines, cyclic
amines, basic ion exchange resins, and the like. Certain organic
amines include isopropylamine, benzathine, cholinate,
diethanolamine, diethylamine, lysine, meglumine, piperazine and
tromethamine.
[0201] The pharmaceutically acceptable salts of the present
invention can be synthesized from a basic or acidic moiety, by
conventional chemical methods. Generally, such salts can be
prepared by reacting free acid forms of these compounds with a
stoichiometric amount of the appropriate base (such as Na, Ca, Mg,
or K hydroxide, carbonate, bicarbonate or the like), or by reacting
free base forms of these compounds with a stoichiometric amount of
the appropriate acid. Such reactions are typically carried out in
water or in an organic solvent, or in a mixture of the two.
Generally, use of non-aqueous media like ether, ethyl acetate,
ethanol, isopropanol, or acetonitrile is desirable, where
practicable. Additional suitable salts can be found, e.g., in
"Remington's Pharmaceutical Sciences", 20th ed., Mack Publishing
Company, Easton, Pa., (1985); and in "Handbook of Pharmaceutical
Salts: Properties, Selection, and Use" by Stahl and Wermuth
(Wiley-VCH, Weinheim, Germany, 2002).
[0202] Any formula given herein is also intended to represent
unlabeled forms as well as isotopically labeled forms of the
compounds of the present invention. Isotopically labeled compounds
have structures depicted by the formulas given herein except that
one or more atoms are replaced by an atom having a selected atomic
mass or mass number. Examples of isotopes that can be incorporated
into compounds of the invention include isotopes of hydrogen,
carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such
as .sup.2H, .sup.3H, .sup.11C, .sup.13C, .sup.14C, .sup.15N,
.sup.18F .sup.31P, .sup.32P, 35S, .sup.36Cl, .sup.125I
respectively. The invention includes various isotopically labeled
compounds of the present invention, for example those into which
radioactive isotopes, such as .sup.3H and .sup.14C, or those into
which non-radioactive isotopes, such as .sup.2H and .sup.13C are
present. Such isotopically labelled compounds are useful in
metabolic studies (with .sup.14C), reaction kinetic studies (with,
for example .sup.2H or .sup.3H), detection or imaging techniques,
such as positron emission tomography (PET) or single-photon
emission computed tomography (SPECT) including drug or substrate
tissue distribution assays, or in radioactive treatment of
patients. In particular, an .sup.18F labeled compound of the
present invention may be particularly desirable for PET or SPECT
studies. Isotopically-labeled compounds of the present invention
can generally be prepared by conventional techniques known to those
skilled in the art or by processes analogous to those described in
the accompanying Examples and Preparations using an appropriate
isotopically-labeled reagent in place of the non-labeled reagent
previously employed.
[0203] Further, substitution with heavier isotopes, particularly
deuterium (i.e., .sup.2H or D) may afford certain therapeutic
advantages resulting from greater metabolic stability, for example
increased in vivo half-life or reduced dosage requirements or an
improvement in therapeutic index. It is understood that deuterium
in this context is regarded as a substituent of a compound of the
present invention. The concentration of such a heavier isotope,
specifically deuterium, may be defined by the isotopic enrichment
factor. The term "isotopic enrichment factor" as used herein means
the ratio between the isotopic abundance and the natural abundance
of a specified isotope. If a substituent in a compound of this
invention is denoted deuterium, such compound has an isotopic
enrichment factor for each designated deuterium atom of at least
3500 (52.5% deuterium incorporation at each designated deuterium
atom), at least 4000 (60% deuterium incorporation), at least 4500
(67.5% deuterium incorporation), at least 5000 (75% deuterium
incorporation), at least 5500 (82.5% deuterium incorporation), at
least 6000 (90% deuterium incorporation), at least 6333.3 (95%
deuterium incorporation), at least 6466.7 (97% deuterium
incorporation), at least 6600 (99% deuterium incorporation), or at
least 6633.3 (99.5% deuterium incorporation).
[0204] Pharmaceutically acceptable solvates in accordance with the
invention include those wherein the solvent of crystallization may
be isotopically substituted, e.g. D.sub.2O, d.sub.6-acetone,
d.sub.6-DMSO.
[0205] Compounds of the present invention that contain groups
capable of acting as donors and/or acceptors for hydrogen bonds may
be capable of forming co-crystals with suitable co-crystal formers.
These co-crystals may be prepared from compounds of the present
invention by known co-crystal forming procedures. Such procedures
include grinding, heating, co-subliming, co-melting, or contacting
in solution compounds of the present invention with the co-crystal
former under crystallization conditions and isolating co-crystals
thereby formed. Suitable co-crystal formers include those described
in WO 2004/078163. Hence the invention further provides co-crystals
comprising a compound of the present invention.
[0206] All methods described herein can be performed in any
suitable order unless otherwise indicated herein or otherwise
clearly contradicted by context. The use of any and all examples,
or exemplary language (e.g. "such as") provided herein is intended
merely to better illuminate the invention and does not pose a
limitation on the scope of the invention otherwise claimed.
[0207] The present invention provides novel compounds,
pharmaceutical formulations including the compounds, and methods of
treating Gram-negative bacterial infections. Particularly, the
compounds are suitable for use to treat infections caused by
Burkholderia, Citrobacter, Enterobacter, Escherichia, Klebsiella,
Meningitidis, Morganella, Pseudomonas, Proteus, Salmonella,
Serratia, Acinetobacter, Bacteroides, Campylobacter, Neisseria, or
Stenotrophomonas bacteria, including species named herein.
[0208] Substitution with heavier isotopes such as deuterium, i.e.
.sup.2H, may afford certain therapeutic advantages resulting from
greater metabolic stability, for example, increased in vivo
half-life or reduced dosage requirements, and hence may be
preferred in some circumstances. For example, deuterium
substitution at non-exchangeable hydrocarbon bonds (e.g., C--H) may
retard epimerization and/or metabolic oxidation in vivo.
[0209] Isotopically-labeled compounds of the invention, i.e.
compounds of formula (I), can generally be prepared by conventional
techniques known to those skilled in the art or by processes
analogous to those described in the accompanying Examples and
Preparations Sections using an appropriate isotopically-labeled
reagent in place of the non-labeled reagent previously.
[0210] In still another aspect, the invention provides a method for
treating a subject with a Gram-negative bacterial infection, the
method comprising the step of administering to the subject in need
thereof an antibacterially effective amount of a compound of the
invention, e.g., a compound of Formula I or salt thereof with a
pharmaceutically acceptable carrier.
[0211] The compounds of the invention also are useful in the
treatment of patients suffering from or susceptible to pneumonia,
sepsis, cystic fibrosis, wound, complicated diabetic foot or
complicated urinary tract infections and sexually transmitted
diseases caused by Gram-negative pathogens. The compounds of the
invention also are useful in the conditions that are caused by a
species of Citrobacter, Enterobacter, Escherichia, Klebsiella,
Morganella, Proteus, Salmonella, Serratia, Pseudomonas,
Acinetobacter, Bacteroides, Burkholderia, Campylobacter, Neisseria,
or Stenotrophomonas. In particular, a bacterial infection caused by
a species of Citrobacter, Enterobacter, Escherichia, Klebsiella,
Morganella, Proteus, Salmonella, Serratia, Pseudomonas, or
Acinetobacter is treatable by methods herein. Particular bacterial
species for such treatment include Citrobacter freundii,
Citrobacter koseri, Enterobacter cloacae, Enterobacter faecalis,
Enterobacter faecium, Escherichia coli, Klebsiella pneumonia,
Klebsiella oxytoca, Morganella morganii, Proteus mirabilis,
Salmonella species, Serratia marcescens, Pseudomonas aeruginosa,
and Acinetobacter baumanii, as well as Bacteroides bivius,
Bacteroides fragilis, Burkholderia cepacia, Campylobacter jejuni,
Neisseria gonorrhoeae, and Stenotrophomonas maltophilia.
[0212] A compound of the present invention may also be used in
combination with other agents, e.g., an additional antibiotic agent
that is or is not of the formula I, for treatment of a bacterial
infection in a subject, or a compound that enhances the
antibacterial activity of the compounds of the invention, including
potentiators such as beta-lactamase inhibitors (BLIs). Suitable
BLIs for use in combination with the compounds of the invention,
including compounds of Formula (I) and subgenera therof, include
avibactam, clavulanic acid, sulbactam, tazobactam, and other
compounds of the formula
##STR00027##
[0213] wherein M is H or a pharmaceutically acceptable cation, and
R represents CN, --C(O)NR.sup.1R.sup.2, or an optionally
substituted 5-6 membered heterocyclic or heteroaryl group. Suitable
amides include those where R.sup.1 is H or C.sub.1-4 alkyl, and
R.sup.2 is optionally substituted C.sub.1-4 alkyl, optionally
substituted C.sub.1-4 alkoxy, optionally substituted C.sub.1-4
alkylamino, an optionally substituted C.sub.5-6 heterocyclic group,
or --NH--C(O)--R.sup.3, where R.sup.3 is optionally substituted
C.sub.1-4 alkyl, optionally substituted C.sub.1-4 alkoxy,
optionally substituted C.sub.1-4 alkylamino, an optionally
substituted C.sub.5-6 heterocyclic group. Each heterocyclic or
heteroaryl group in these compounds contains 1-2 heteroatoms
selected from N, O and S as ring members, and each optionally
substituted group can be substituted by 1-2 groups selected from
CN, halo, --OH, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, amino, C.sub.1-4
alkylamino, di(C.sub.1-4 alkyl)amino, --COO(C.sub.1-4 alkyl), and
5-6 membered heterocyclic groups. Suitable compounds of this
formula are described in WO2008/039420, WO2009/091856,
WO2013/122888, WO2010/126820, WO2009/091856, WO2013/038330,
US2013/0225554, WO2013149121, WO2013149136, WO2014141132 and
WO2014/033560.
[0214] By the term "combination", is meant either a fixed
combination in one dosage unit form, or a kit or instructions for
the combined administration where a compound of the present
invention and a combination partner may be administered
independently at the same time or separately within time intervals
that especially allow that the combination partners show a
cooperative, e.g., synergistic, effect, or any combination
thereof.
[0215] An embodiment of the present invention provides compounds of
the present invention in a pharmaceutical combination with a second
therapeutic agent. In some embodiments, the second therapeutic
agent is an antibacterial agent. Non-limiting examples of
antibacterial agents for use in pharmaceutical combinations of the
invention may be selected from the following groups:
[0216] (1) Macrolides or ketolides such as erythromycin,
azithromycin, clarithromycin, and telithromycin;
[0217] (2) Beta-lactams including penicillin such as penicillin G,
penicillin V, methicillin, oxacillin, cloxacillin, dicloxacillin,
nafcillin, ampicillin, amoxicillin, carbenicillin, ticarcillin,
mezlocillin, piperacillin, azlocillin, temocillin, cephalosporin
such as cepalothin, cephapirin, cephradine, cephaloridine,
cefazolin, cefamandole, cefuroxime, cephalexin, cefprozil,
cefaclor, loracarbef, cefoxitin, cefinetazole, cefotaxime,
ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, cefixime,
cefpodoxime, ceftibuten, cefdinir, cefpirome, cefepime, and
carbapenems such as doripenem, imipenem, meropenem and PZ-601;
[0218] (3) Glycopeptides such as vancomycin and teicoplanin;
[0219] (4) Quinolones such asnalidixic acid, oxolinic acid,
norfloxacin, pefloxacin, enoxacin, ofloxacin, levofloxacin,
ciprofloxacin, temafloxacin, lomefloxacin, fleroxacin,
grepafloxacin, sparfloxacin, trovafloxacin, clinafloxacin,
gatifloxacin, moxifloxacin, sitafloxacin, ganefloxacin,
gemifloxacin and pazufloxacin;
[0220] (5) Antibacterial sulfonamides and antibacterial
sulphanilamides, including para-aminobenzoic acid, sulfadiazine,
sulfisoxazole, sulfamethoxazole and sulfathalidine;
[0221] (6) Aminoglycosides such as streptomycin, neomycin,
kanamycin, paromycin, gentamicin, tobramycin, amikacin, netilmicin,
spectinomycin, sisomicin, dibekalin and isepamicin;
[0222] (7) Tetracyclines such as tetracycline, chlortetracycline,
demeclocycline, minocycline, oxytetracycline, methacycline,
doxycycline, tigecycline;
[0223] (8) Rifamycins such as rifampicin (also called rifampin),
rifapentine, rifabutin, bezoxazinorifamycin and rifaximin;
[0224] (9) Lincosamides such as lincomycin and clindamycin;
[0225] (10) Streptogramins such as quinupristin and
daflopristin;
[0226] (11) Oxazolidinones such as linezolid or tedizolid;
[0227] (12) Polymyxin, colistin and colymycin;
[0228] (13) Trimethoprim and bacitracin;
[0229] (14) Efflux pump inhibitors;
[0230] (15) Beta-lactamase inhibitors, including avibactam and
analogs thereof, and those described above.
[0231] The second antibacterial agent may be administered in
combination with the compounds of the present inventions wherein
the second antibacterial agent is administered prior to,
simultaneously, or after the compound or compounds of the present
invention. When simultaneous administration of a compound of the
invention with a second agent is desired and the route of
administration is the same, then a compound of the invention may be
formulated with a second agent into the same dosage form. An
example of a dosage form containing a compound of the invention and
a second agent is an intravenous administration. An alternative
example is an intramuscular administration of a solution comprising
a compound of the invention and a second agent.
[0232] The compounds and compositions described herein can be used
or administered in combination with one or more therapeutic agents
that act as immunomodulators, e.g., an activator of a costimulatory
molecule, or an inhibitor of an immune-inhibitory molecule, or a
vaccine. The Programmed Death 1 (PD-1) protein is an inhibitory
member of the extended CD28/CTLA4 family of T cell regulators
(Okazaki et al. (2002) Curr Opin Immunol 14: 391779-82; Bennett et
al. (2003) J. Immunol. 170:711-8). PD-1 is expressed on activated B
cells, T cells, and monocytes. PD-1 is an immune-inhibitory protein
that negatively regulates TCR signals (Ishida, Y. et al. (1992)
EMBO J. 11:3887-3895; Blank, C. et al. (Epub 2006 Dec. 29) Immunol.
Immunother. 56(5):739-745), and is up-regulated in chronic
infections. The interaction between PD-1 and PD-L1 can act as an
immune checkpoint, which can lead to, e.g., a decrease in
infiltrating lymphocytes, a decrease in T-cell receptor mediated
proliferation, and/or immune evasion by cancerous or infected cells
(Dong et al. (2003) J. Mol. Med. 81:281-7; Blank et al. (2005)
Cancer Immunol. Immunother. 54:307-314; Konishi et al. (2004) Clin.
Cancer Res. 10:5094-100). Immune suppression can be reversed by
inhibiting the local interaction of PD-1 with PD-L1 or PD-L2; the
effect is additive when the interaction of PD-1 with PD-L2 is
blocked as well (Iwai et al. (2002) Proc. Nat'l. Acad. Sci. USA
99:12293-7; Brown et al. (2003) J. Immunol. 170:1257-66).
Immunomodulation can be achieved by binding to either the
immune-inhibitory protein (e.g., PD-1) or to binding proteins that
modulate the inhibitory protein (e.g., PD-L1, PD-L2).
[0233] In one embodiment, the combination therapies of the
invention include an immunomodulator that is an inhibitor or
antagonist of an inhibitory molecule of an immune checkpoint
molecule. In another embodiment the immunomodulator binds to a
protein that naturally inhibits the immuno-inhibitory checkpoint
molecule. When used in combination with antibacterial compounds,
these immunomodulators can enhance the antimicrobial response, and
thus enhance efficacy relative to treatment with the antibacterial
compound alone.
[0234] The term "immune checkpoints" refers to a group of molecules
on the cell surface of CD4 and CD8 T cells. These molecules can
effectively serve as "brakes" to down-modulate or inhibit an
adaptive immune response. Immune checkpoint molecules include, but
are not limited to, Programmed Death 1 (PD-1), Cytotoxic
T-Lymphocyte Antigen 4 (CTLA-4), B7H1, B7H4, OX-40, CD137, CD40,
and LAG3, which directly inhibit immune cells. Immunotherapeutic
agents which can act as immune checkpoint inhibitors useful in the
methods of the present invention, include, but are not limited to,
inhibitors of PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT,
LAIR1, CD160, 2B4 and/or TGFR beta. Inhibition of an inhibitory
molecule can be performed by inhibition at the DNA, RNA or protein
level. In some embodiments, an inhibitory nucleic acid (e.g., a
dsRNA, siRNA or shRNA), can be used to inhibit expression of an
inhibitory molecule. In other embodiments, the inhibitor of an
inhibitory signal is a polypeptide, e.g., a soluble ligand, or an
antibody or antigen-binding fragment thereof, that binds to the
inhibitory molecule.
[0235] By "in combination with," it is not intended to imply that
the therapy or the therapeutic agents must be administered at the
same time and/or formulated for delivery together, although these
methods of delivery are within the scope described herein. The
immunomodulator can be administered concurrently with, prior to, or
subsequent to, one or more compounds of the invention, and
optionally one or more additional therapies or therapeutic agents.
The therapeutic agents in the combination can be administered in
any order. In general, each agent will be administered at a dose
and/or on a time schedule determined for that agent. It will
further be appreciated that the therapeutic agents utilized in this
combination may be administered together in a single composition or
administered separately in different compositions. In general, it
is expected that each of the therapeutic agents utilized in
combination be utilized at levels that do not exceed the levels at
which they are utilized individually. In some embodiments, the
levels utilized in combination will be lower than those utilized
individually.
[0236] In certain embodiments, the antibacterial compounds
described herein are administered in combination with one or more
immunomodulators that are inhibitors of PD-1, PD-L1 and/or PD-L2.
Each such inhibitor may be an antibody, an antigen binding fragment
thereof, an immunoadhesin, a fusion protein, or an oligopeptide.
Examples of such immunomodulators are known in the art.
[0237] In some embodiments, the immunomodulator is an anti-PD-1
antibody chosen from MDX-1106, Merck 3475 or CT-011.
[0238] In some embodiments, the immunomodulator is an immunoadhesin
(e.g., an immunoadhesin comprising an extracellular or PD-1 binding
portion of PD-LI or PD-L2 fused to a constant region (e.g., an Fc
region of an immunoglobulin sequence).
[0239] In some embodiments, the immunomodulator is a PD-1 inhibitor
such as AMP-224.
[0240] In some embodiments, the the immunomodulator is a PD-LI
inhibitor such as anti-PD-LI antibody.
[0241] In some embodiments, the immunomodulator is an anti-PD-LI
binding antagonist chosen from YW243.55.S70, MPDL3280A, MEDI-4736,
MSB-0010718C, or MDX-1105. MDX-1105, also known as BMS-936559, is
an anti-PD-LI antibody described in WO2007/005874. Antibody
YW243.55.S70 is an anti-PD-LI described in WO 2010/077634.
[0242] In some embodiments, the immunomodulator is nivolumab (CAS
Registry Number: 946414-94-4). Alternative names for nivolumab
include MDX-1106, MDX-1106-04, ONO-4538, or BMS-936558. Nivolumab
is a fully human IgG4 monoclonal antibody which specifically blocks
PD-1. Nivolumab (clone 5C4) and other human monoclonal antibodies
that specifically bind to PD-1 are disclosed in U.S. Pat. No.
8,008,449, EP2161336 and WO2006/121168.
[0243] In some embodiments, the immunomodulator is an anti-PD-1
antibody Pembrolizumab. Pembrolizumab (also referred to as
Lambrolizumab, MK-3475, MK03475, SCH-900475 or KEYTRUDA.RTM.;
Merck) is a humanized IgG4 monoclonal antibody that binds to PD-1.
Pembrolizumab and other humanized anti-PD-1 antibodies are
disclosed in Hamid, O. et al. (2013) New England Journal of
Medicine 369 (2): 134-44, U.S. Pat. No. 8,354,509, WO2009/114335,
and WO2013/079174.
[0244] In some embodiments, the immunomodulator is Pidilizumab
(CT-011; Cure Tech), a humanized IgG1k monoclonal antibody that
binds to PD1. Pidilizumab and other humanized anti-PD-1 monoclonal
antibodies are disclosed in WO2009/101611.
[0245] Other anti-PD1 antibodies useful as immunomodulators for use
in the methods disclosed herein include AMP 514 (Amplimmune), and
anti-PD1 antibodies disclosed in U.S. Pat. No. 8,609,089, US
2010028330, and/or US 20120114649. In some embodiments, the
anti-PD-L1 antibody is MSB0010718C. MSB0010718C (also referred to
as A09-246-2; Merck Serono) is a monoclonal antibody that binds to
PD-L1.
[0246] In some embodiments, the immunomodulator is MDPL3280A
(Genentech/Roche), a human Fc optimized IgG1 monoclonal antibody
that binds to PD-L1. MDPL3280A and other human monoclonal
antibodies to PD-L1 are disclosed in U.S. Pat. No. 7,943,743 and
U.S Publication No.: 20120039906. Other anti-PD-L1 binding agents
useful as immunomodulators for methods of the invention include
YW243.55.S70 (see WO2010/077634), MDX-1105 (also referred to as
BMS-936559), and anti-PD-L1 binding agents disclosed in
WO2007/005874.
[0247] In some embodiments, the immunomodulator is AMP-224
(B7-DCIg; Amplimmune; e.g., disclosed in WO2010/027827 and
WO2011/066342), is a PD-L2 Fc fusion soluble receptor that blocks
the interaction between PD1 and B7-H1.
[0248] In some embodiments, the immunomodulator is an anti-LAG-3
antibody such as BMS-986016. BMS-986016 (also referred to as
BMS986016) is a monoclonal antibody that binds to LAG-3. BMS-986016
and other humanized anti-LAG-3 antibodies are disclosed in US
2011/0150892, WO2010/019570, and WO2014/008218 In certain
embodiments, the combination therapies disclosed herein include a
modulator of a costimulatory molecule or an inhibitory molecule,
e.g., a co-inhibitory ligand or receptor.
[0249] In one embodiment, the costimulatory modulator, e.g.,
agonist, of a costimulatory molecule is chosen from an agonist
(e.g., an agonistic antibody or antigen-binding fragment thereof,
or soluble fusion) of OX40, CD2, CD27, CDS, ICAM-1, LFA-1
(CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR,
HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83
ligand.
[0250] In another embodiment, the combination therapies disclosed
herein include an immunomodulator that is a costimulatory molecule,
e.g., an agonist associated with a positive signal that includes a
costimulatory domain of CD28, CD27, ICOS and/or GITR.
[0251] Exemplary GITR agonists include, e.g., GITR fusion proteins
and anti-GITR antibodies (e.g., bivalent anti-GITR antibodies),
such as, a GITR fusion protein described in U.S. Pat. No.
6,111,090, European Patent No.: 090505B1, U.S. Pat. No. 8,586,023,
PCT Publication Nos.: WO 2010/003118 and 2011/090754, or an
anti-GITR antibody described, e.g., in U.S. Pat. No. 7,025,962,
European Patent No.: 1947183B1, U.S. Pat. Nos. 7,812,135,
8,388,967, 8,591,886, European Patent No.: EP 1866339, PCT
Publication No.: WO 2011/028683, PCT Publication No.: WO
2013/039954, PCT Publication No.: WO2005/007190, PCT Publication
No.: WO 2007/133822, PCT Publication No.: WO2005/055808, PCT
Publication No.: WO 99/40196, PCT Publication No.: WO 2001/03720,
PCT Publication No.: WO99/20758, PCT Publication No.:
WO2006/083289, PCT Publication No.: WO 2005/115451, U.S. Pat. No.
7,618,632, and PCT Publication No.: WO 2011/051726.
[0252] In one embodiment, the immunomodulator used is a soluble
ligand (e.g., a CTLA-4-Ig), or an antibody or antibody fragment
that binds to PD-L1, PD-L2 or CTLA4. For example, the anti-PD-1
antibody molecule can be administered in combination with an
anti-CTLA-4 antibody, e.g., ipilimumab, for example. Exemplary
anti-CTLA4 antibodies include Tremelimumab (IgG2 monoclonal
antibody available from Pfizer, formerly known as ticilimumab,
CP-675,206); and Ipilimumab (CTLA-4 antibody, also known as
MDX-010, CAS No. 477202-00-9).
[0253] In one embodiment, an anti-PD-1 antibody molecule is
administered after treatment with a compound of the invention as
described herein.
[0254] In another embodiment, an anti-PD-1 or PD-L1 antibody
molecule is administered in combination with an anti-LAG-3 antibody
or an antigen-binding fragment thereof. In another embodiment, the
anti-PD-1 or PD-L1 antibody molecule is administered in combination
with an anti-TIM-3 antibody or antigen-binding fragment thereof. In
yet other embodiments, the anti-PD-1 or PD-L1 antibody molecule is
administered in combination with an anti-LAG-3 antibody and an
anti-TIM-3 antibody, or antigen-binding fragments thereof. The
combination of antibodies recited herein can be administered
separately, e.g., as separate antibodies, or linked, e.g., as a
bispecific or trispecific antibody molecule. In one embodiment, a
bispecific antibody that includes an anti-PD-1 or PD-L1 antibody
molecule and an anti-TIM-3 or anti-LAG-3 antibody, or
antigen-binding fragment thereof, is administered. In certain
embodiments, the combination of antibodies recited herein is used
to treat a cancer, e.g., a cancer as described herein (e.g., a
solid tumor). The efficacy of the aforesaid combinations can be
tested in animal models known in the art. For example, the animal
models to test the synergistic effect of anti-PD-1 and anti-LAG-3
are described, e.g., in Woo et al. (2012) Cancer Res.
72(4):917-27).
[0255] Exemplary immunomodulators that can be used in the
combination therapies include, but are not limited to, e.g.,
afutuzumab (available from Roche.RTM.); pegfilgrastim
(Neulasta.RTM.); lenalidomide (CC-5013, Revlimid.RTM.); thalidomide
(Thalomid.RTM.), actimid (CC4047); and cytokines, e.g., IL-21 or
IRX-2 (mixture of human cytokines including interleukin 1,
interleukin 2, and interferon .gamma., CAS 951209-71-5, available
from IRX Therapeutics).
[0256] Exemplary doses of such immunomodulators that can be used in
combination with the antibacterial compounds of the invention
include a dose of anti-PD-1 antibody molecule of about 1 to 10
mg/kg, e.g., 3 mg/kg, and a dose of an anti-CTLA-4 antibody, e.g.,
ipilimumab, of about 3 mg/kg.
[0257] Examples of embodiments of the methods of using the
antibacterial compounds of the invention in combination with an
immunomodulator include these:
[0258] i. A method to treat a bacterial infection in a subject,
comprising administering to the subject a compound of Formula (I)
as described herein, and an immunomodulator.
[0259] ii. The method of embodiment i, wherein the immunomodulator
is an activator of a costimulatory molecule or an inhibitor of an
immune checkpoint molecule.
[0260] iii. The method of either of embodiments i and ii, wherein
the activator of the costimulatory molecule is an agonist of one or
more of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS
(CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT,
NKG2C, SLAMF7, NKp80, CD160, B7-H3 and CD83 ligand.
[0261] iv. The method of any of embodiments i-iii above, wherein
the inhibitor of the immune checkpoint molecule is chosen from
PD-1, PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1,
CD160, 2B4 and TGFR beta.
[0262] v. The method of any of any of embodiments i-iii, wherein
the inhibitor of the immune checkpoint molecule is chosen from an
inhibitor of PD-1, PD-L1, LAG-3, TIM-3 or CTLA4, or any combination
thereof.
[0263] vi. The method of any of embodiments i-v, wherein the
inhibitor of the immune checkpoint molecule is a soluble ligand or
an antibody or antigen-binding fragment thereof, that binds to the
immune checkpoint molecule.
[0264] vii. The method of any of embodiments i-vi, wherein the
antibody or antigen-binding fragment thereof is from an IgG1 or
IgG4 (e.g., human IgG1 or IgG4).
[0265] viii. The method of any of embodiments i-vii, wherein the
antibody or antigen-binding fragment thereof is altered, e.g.,
mutated, to increase or decrease one or more of: Fc receptor
binding, antibody glycosylation, the number of cysteine residues,
effector cell function, or complement function.
[0266] ix. The method of any of embodiments i-viii, wherein the
antibody molecule is a bispecific or multispecific antibody
molecule that has a first binding specificity to PD-1 or PD-L1 and
a second binding specifity to TIM-3, LAG-3, or PD-L2.
[0267] x. The method of any of embodiments i-ix, wherein the
immunomodulator is an anti-PD-1 antibody chosen from Nivolumab,
Pembrolizumab or Pidilizumab.
[0268] xi. The method of any of embodiments i-x, wherein the
immunomodulator is an anti-PD-L1 antibody chosen from YW243.55.S70,
MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1105.
[0269] xii. The method of any of embodiments i-x, wherein the
immunomodulator is an anti-LAG-3 antibody molecule.
[0270] xiii. The method of embodiment xii, wherein the anti-LAG-3
antibody molecule is BMS-986016,
[0271] xiv. The method of any of embodiments i-x, wherein the
immunomodulator is an anti-PD-1 antibody molecule administered by
injection (e.g., subcutaneously or intravenously) at a dose of
about 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20
mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg., e.g., once a week to
once every 2, 3, or 4 weeks.
[0272] xv. The method of embodiment xiv, wherein the anti-PD-1
antibody molecule is administered at a dose from about 10 to 20
mg/kg every other week.
[0273] xvi. The method of embodiment xv, wherein the anti-PD-1
antibody molecule, e.g., nivolumab, is administered intravenously
at a dose from about 1 mg/kg to 3 mg/kg, e.g., about 1 mg/kg, 2
mg/kg or 3 mg/kg, every two weeks.
[0274] xvii. The method of embodiment xv, wherein the anti-PD-1
antibody molecule, e.g., nivolumab, is administered intravenously
at a dose of about 2 mg/kg at 3-week intervals.
[0275] The language "effective amount" of the compound is that
amount necessary or sufficient to treat or prevent a bacterial
infection and/or a disease or condition described herein. In an
example, an effective amount of the compound is an amount
sufficient to treat bacterial infection in a subject. In another
example, an effective amount of the compound is an amount
sufficient to treat a bacterial infection, such as, but not limited
to Pseudomonas aeruginosa and the like in a subject. The effective
amount can vary depending on such factors as the size and weight of
the subject, the type of illness, or the particular compound of the
invention. For example, the choice of the compound of the invention
can affect what constitutes an "effective amount." One of ordinary
skill in the art would be able to study the factors contained
herein and make the determination regarding the effective amount of
the compounds of the invention without undue experimentation.
[0276] The regimen of administration can affect what constitutes an
effective amount. The compound of the invention can be administered
to the subject either prior to or after the onset of a bacterial
infection. Typically, the compound is administered to a subject
diagnosed as having a bacterial infection and in need of treatment
therefor. Further, several divided dosages, as well as staggered
dosages, can be administered daily or sequentially, or the dose can
be continuously infused, or can be a bolus injection. Further, the
dosages of the compound(s) of the invention can be proportionally
increased or decreased as indicated by the exigencies of the
therapeutic or prophylactic situation. Typically, the compound of
the invention would be administered over a course of at least 5
days, more commonly at least 7 days or at least 10 days or at least
14 days.
[0277] Compounds of the invention may be used in the treatment of
states, disorders or diseases as described herein, or for the
manufacture of pharmaceutical compositions for use in the treatment
of these diseases. The invention provides methods of use of
compounds of the present invention in the treatment of these
diseases or pharmaceutical preparations having compounds of the
present invention for the treatment of these diseases.
[0278] The language "pharmaceutical composition" includes
preparations suitable for administration to mammals, e.g., humans.
When the compounds of the present invention are administered as
pharmaceuticals to mammals, e.g., humans, they can be given per se
or as a pharmaceutical composition containing, for example, 0.1 to
99.5% (more preferably, 0.5 to 90%) of active ingredient in
combination with a pharmaceutically acceptable carrier.
[0279] The phrase "pharmaceutically acceptable carrier" is art
recognized and includes a pharmaceutically acceptable material,
composition or vehicle, suitable for administering compounds of the
present invention to mammals. The carriers include liquid or solid
filler, diluent, excipient, solvent or encapsulating material,
involved in carrying or transporting the subject agent from one
organ, or portion of the body, to another organ, or portion of the
body. Each carrier must be "acceptable" in the sense of being
compatible with the other ingredients of the formulation and not
injurious to the patient. Some examples of materials which can
serve as pharmaceutically acceptable carriers include: sugars, such
as lactose, glucose and sucrose; starches, such as corn starch and
potato starch; cellulose, and its derivatives, such as sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa
butter and suppository waxes; oils, such as peanut oil, cottonseed
oil, safflower oil, sesame oil, olive oil, corn oil and soybean
oil; glycols, such as propylene glycol; polyols, such as glycerin,
sorbitol, mannitol and polyethylene glycol; esters, such as ethyl
oleate and ethyl laurate; agar; buffering agents, such as magnesium
hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water;
isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer
solutions; and other non-toxic compatible substances employed in
pharmaceutical formulations. In some embodiments, a
pharmaceutically acceptable carrier is sterilized before
combination with the compound of the invention.
[0280] In some embodiments, the pharmaceutical composition of the
invention comprises a compound of any of the numbered embodiments
and at least one pharmaceutically acceptable carrier or excipient.
In certain embodiments, the pharmaceutical composition of the
invention comprises a compound of any of the numbered embodiments
and at least two pharmaceutically acceptable carriers or
excipients.
[0281] Wetting agents, emulsifiers and lubricants, such as sodium
lauryl sulfate and magnesium stearate, as well as coloring agents,
release agents, coating agents, sweetening, flavoring and perfuming
agents, preservatives and antioxidants can also be present in the
compositions.
[0282] Examples of pharmaceutically acceptable antioxidants
include: water soluble antioxidants, such as ascorbic acid,
cysteine hydrochloride, sodium bisulfate, sodium metabisulfite,
sodium sulfite and the like; oil-soluble antioxidants, such as
ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated
hydroxytoluene (BHT), lecithin, propyl gallate, .alpha.-tocopherol,
and the like; and metal chelating agents, such as citric acid,
ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid,
phosphoric acid, and the like.
[0283] Formulations of the present invention include those suitable
for oral, nasal, inhalation, topical, transdermal, buccal,
sublingual, rectal, vaginal and/or parenteral administration.
Typically, compounds of the invention would be administered
intravenously, in the form of a solution that is often isotonic,
such as a saline or glucose solution. The formulations may
conveniently be presented in unit dosage form and may be prepared
by any methods well known in the art of pharmacy. The amount of
active ingredient that can be combined with a carrier material to
produce a single dosage form will generally be that amount of the
compound that produces a therapeutic effect. Generally, out of one
hundred percent, this amount will range from about 1 percent to
about ninety-nine percent of active ingredient, preferably from
about 5 percent to about 70 percent, most preferably from about 10
percent to about 30 percent.
[0284] Methods of preparing these formulations or compositions
include the step of bringing into association a compound of the
present invention with the carrier and, optionally, one or more
accessory ingredients. In general, the formulations are prepared by
uniformly and intimately bringing into association a compound of
the present invention with liquid carriers, or finely divided solid
carriers, or both, and then, if necessary, shaping the product.
[0285] Formulations of the invention suitable for oral
administration may be in the form of capsules, cachets, pills,
tablets, lozenges (using a flavored basis, usually sucrose and
acacia or tragacanth), powders, granules, or as a solution or a
suspension in an aqueous or non-aqueous liquid, or as an
oil-in-water or water-in-oil liquid emulsion, or as an elixir or
syrup, or as pastilles (using an inert base, such as gelatin and
glycerin, or sucrose and acacia) and/or as mouth washes and the
like, each containing a predetermined amount of a compound of the
present invention as an active ingredient. A compound of the
present invention may also be administered as a bolus, electuary or
paste.
[0286] In solid dosage forms of the invention for oral
administration (capsules, tablets, pills, dragees, powders,
granules and the like), the active ingredient is mixed with one or
more pharmaceutically acceptable carriers, such as sodium citrate
or dicalcium phosphate, and/or any of the following: fillers or
extenders, such as starches, lactose, sucrose, glucose, mannitol,
and/or silicic acid; binders, such as, for example,
carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone,
sucrose and/or acacia; humectants, such as glycerol; disintegrating
agents, such as agar-agar, calcium carbonate, potato or tapioca
starch, alginic acid, certain silicates, and sodium carbonate;
solution retarding agents, such as paraffin; absorption
accelerators, such as quaternary ammonium compounds; wetting
agents, such as, for example, cetyl alcohol and glycerol
monostearate; absorbents, such as kaolin and bentonite clay;
lubricants, such a talc, calcium stearate, magnesium stearate,
solid polyethylene glycols, sodium lauryl sulfate, and mixtures
thereof; and coloring agents. In the case of capsules, tablets and
pills, the pharmaceutical compositions may also comprise buffering
agents. Solid compositions of a similar type may also be employed
as fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugars, as well as high molecular
weight polyethylene glycols and the like.
[0287] A tablet may be made by compression or molding, optionally
with one or more accessory ingredients. Compressed tablets may be
prepared using binder (for example, gelatin or hydroxypropylmethyl
cellulose), lubricant, inert diluent, preservative, disintegrant
(for example, sodium starch glycolate or cross-linked sodium
carboxymethyl cellulose), surface-active or dispersing agent.
Molded tablets may be made by molding in a suitable machine a
mixture of the powdered compound moistened with an inert liquid
diluent.
[0288] The tablets, and other solid dosage forms of the
pharmaceutical compositions of the present invention, such as
dragees, capsules, pills and granules, may optionally be scored or
prepared with coatings and shells, such as enteric coatings and
other coatings well known in the pharmaceutical-formulating art.
They may also be formulated so as to provide slow or controlled
release of the active ingredient therein using, for example,
hydroxypropylmethyl cellulose in varying proportions to provide the
desired release profile, other polymer matrices, liposomes and/or
microspheres. They may be sterilized by, for example, filtration
through a bacteria-retaining filter, or by incorporating
sterilizing agents in the form of sterile solid compositions that
can be dissolved in sterile water, or some other sterile injectable
medium immediately before use. These compositions may also
optionally contain opacifying agents and may be of a composition
that they release the active ingredient(s) only, or preferentially,
in a certain portion of the gastrointestinal tract, optionally, in
a delayed manner. Examples of embedding compositions that can be
used include polymeric substances and waxes. The active ingredient
can also be in micro-encapsulated form, if appropriate, with one or
more of the above-described excipients.
[0289] Liquid dosage forms for oral administration of the compounds
of the invention include pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In
addition to the active ingredient, the liquid dosage forms may
contain inert diluent commonly used in the art, such as, for
example, water or other solvents, solubilizing agents and
emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, oils (in particular,
cottonseed, groundnut, corn, germ, olive, castor and sesame oils),
glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty
acid esters of sorbitan, and mixtures thereof.
[0290] Besides inert diluents, the oral compositions can also
include adjuvants such as wetting agents, emulsifying and
suspending agents, sweetening, flavoring, coloring, perfuming and
preservative agents.
[0291] Suspensions, in addition to the active compounds, may
contain suspending agents as, for example, ethoxylated isostearyl
alcohols, polyoxyethylene sorbitol and sorbitan esters,
microcrystalline cellulose, aluminum metahydroxide, bentonite,
agar-agar and tragacanth, and mixtures thereof.
[0292] Formulations of the pharmaceutical compositions of the
invention for rectal or vaginal administration may be presented as
a suppository, which may be prepared by mixing one or more
compounds of the invention with one or more suitable nonirritating
excipients or carriers comprising, for example, cocoa butter,
polyethylene glycol, a suppository wax or a salicylate, and which
is solid at room temperature, but liquid at body temperature and,
therefore, will melt in the rectum or vaginal cavity and release
the active compound.
[0293] Formulations of the present invention which are suitable for
vaginal administration also include pessaries, tampons, creams,
gels, pastes, foams or spray formulations containing such carriers
as are known in the art to be appropriate.
[0294] Dosage forms for the topical or transdermal administration
of a compound of this invention include powders, sprays, ointments,
pastes, creams, lotions, gels, solutions, patches and inhalants.
The active compound may be mixed under sterile conditions with a
pharmaceutically acceptable carrier, and with any preservatives,
buffers, or propellants that may be required.
[0295] The ointments, pastes, creams and gels may contain, in
addition to an active compound of this invention, excipients, such
as animal and vegetable fats, oils, waxes, paraffins, starch,
tragacanth, cellulose derivatives, polyethylene glycols, silicones,
bentonites, silicic acid, talc and zinc oxide, or mixtures
thereof.
[0296] Powders and sprays can contain, in addition to a compound of
this invention, excipients such as lactose, talc, silicic acid,
aluminum hydroxide, calcium silicates and polyamide powder, or
mixtures of these substances. Sprays can additionally contain
customary propellants, such as chlorofluorohydrocarbons and
volatile unsubstituted hydrocarbons, such as butane and
propane.
[0297] Transdermal patches have the added advantage of providing
controlled delivery of a compound of the present invention to the
body. Such dosage forms can be made by dissolving or dispersing the
compound in the proper medium. Absorption enhancers can also be
used to increase the flux of the compound across the skin. The rate
of such flux can be controlled by either providing a rate
controlling membrane or dispersing the active compound in a polymer
matrix or gel.
[0298] Ophthalmic formulations, eye ointments, powders, solutions
and the like, are also contemplated as being within the scope of
this invention.
[0299] Pharmaceutical compositions of this invention suitable for
parenteral administration comprise one or more compounds of the
invention in combination with one or more pharmaceutically
acceptable sterile isotonic aqueous or nonaqueous solutions,
dispersions, suspensions or emulsions, or sterile powders which may
be reconstituted into sterile injectable solutions or dispersions
just prior to use, which may contain antioxidants, buffers,
bacteriostats, solutes which render the formulation isotonic with
the blood of the intended recipient or suspending or thickening
agents.
[0300] Examples of suitable aqueous and nonaqueous carriers that
may be employed in the pharmaceutical compositions of the invention
include water, ethanol, polyols (such as glycerol, propylene
glycol, polyethylene glycol, and the like), and suitable mixtures
thereof, vegetable oils, such as olive oil, and injectable organic
esters, such as ethyl oleate. Proper fluidity can be maintained,
for example, by the use of coating materials, such as lecithin, by
the maintenance of the required particle size in the case of
dispersions, and by the use of surfactants.
[0301] These compositions may also contain adjuvants such as
preservatives, wetting agents, emulsifying agents and dispersing
agents. Prevention of the action of microorganisms may be ensured
by the inclusion of various antibacterial and antifungal agents,
for example, paraben, chlorobutanol, phenol sorbic acid, and the
like. It may also be desirable to include isotonic agents, such as
sugars, sodium chloride, and the like into the compositions. In
addition, prolonged absorption of the injectable pharmaceutical
form may be brought about by the inclusion of agents that delay
absorption such as aluminum monostearate and gelatin.
[0302] In some cases, in order to prolong the effect of a drug, it
is desirable to slow the absorption of the drug from subcutaneous
or intramuscular injection. This may be accomplished by the use of
a liquid suspension of crystalline or amorphous material having
poor water solubility. The rate of absorption of the drug then
depends upon its rate of dissolution which, in turn, may depend
upon crystal size and crystalline form. Alternatively, delayed
absorption of a parenterally-administered drug form is accomplished
by dissolving or suspending the drug in an oil vehicle.
[0303] Injectable depot forms are made by forming microencapsule
matrices of the subject compounds in biodegradable polymers such as
polylactide-polyglycolide. Depending on the ratio of drug to
polymer, and the nature of the particular polymer employed, the
rate of drug release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the drug in liposomes or microemulsions that are
compatible with body tissue.
[0304] The preparations of the present invention may be given
orally, parenterally, topically, or rectally. They are of course
given by forms suitable for each administration route. For example,
they are administered in tablets or capsule form, by injection,
inhalation, eye lotion, ointment, suppository, etc., administration
by injection, infusion or inhalation; topical by lotion or
ointment; and rectal by suppositories. Intravenous administration
is preferred.
[0305] The phrases "parenteral administration" and "administered
parenterally" as used herein means modes of administration other
than enteral and topical administration, usually by injection, and
includes, without limitation, intravenous, intramuscular,
intraarterial, intrathecal, intracapsular, intraorbital,
intracardiac, intradermal, intraperitoneal, transtracheal,
subcutaneous, subcuticular, intraarticular, subcapsular,
subarachnoid, intraspinal and intrasternal injection and
infusion.
[0306] The phrases "systemic administration," "administered
systemically," "peripheral administration" and "administered
peripherally" as used herein mean the administration of a compound,
drug or other material other than directly into the central nervous
system, such that it enters the patient's system and, thus, is
subject to metabolism and other like processes, for example,
subcutaneous administration.
[0307] These compounds may be administered to humans and other
animals for therapy by any suitable route of administration,
including orally, nasally, as by, for example, a spray, rectally,
intravaginally, parenterally, intracisternally and topically, as by
powders, ointments or drops, including buccally and
sublingually.
[0308] Regardless of the route of administration selected, the
compounds of the present invention, which may be used in a suitable
hydrated form, and/or the pharmaceutical compositions of the
present invention, are formulated into pharmaceutically acceptable
dosage forms by conventional methods known to those of skill in the
art.
[0309] Actual dosage levels of the active ingredients in the
pharmaceutical compositions of this invention may be varied so as
to obtain an amount of the active ingredient which is effective to
achieve the desired therapeutic response for a particular patient,
composition, and mode of administration, without being toxic to the
patient.
[0310] The selected dosage level will depend upon a variety of
factors including the activity of the particular compound of the
present invention employed, or the ester, salt or amide thereof,
the route of administration, the time of administration, the rate
of excretion of the particular compound being employed, the
duration of the treatment, other drugs, compounds and/or materials
used in combination with the particular compound employed, the age,
sex, weight, condition, general health and prior medical history of
the patient being treated, and like factors well known in the
medical arts.
[0311] In general, a suitable daily dose of a compound of the
invention will be that amount of the compound that is the dose
effective to produce a therapeutic effect. Such an effective dose
will generally depend upon the factors described above. Generally,
intravenous and subcutaneous doses of the compounds of this
invention for a patient, when used for the indicated antibacterial
effects, will range from about 5 to about 150 mg per kilogram of
body weight per day, more preferably from about 15 to about 115 mg
per kg per day, and still more preferably from about 20 to about 85
mg per kg per day. An effective amount is that amount treats a
bacterial infection.
[0312] If desired, the effective daily dose of the active compound
may be administered as two, three, four, five, six or more
sub-doses administered separately at appropriate intervals
throughout the day, optionally, in unit dosage forms, or as
continuous infusion.
[0313] While it is possible for a compound of the present invention
to be administered alone, it is preferable to administer the
compound as a pharmaceutical composition.
[0314] The compounds as defined in embodiments may be synthesized
by the general synthetic routes below, specific examples of which
are described in more detail in the Examples.
General Synthetic Schemes
[0315] One method for synthesizing compounds with formula (I) is
described in Scheme A. An alcohol A-1 can be converted into A-2
following the "Mitsunobu" protocol, provided the heterocycle is
sufficiently acidic to engage in a Misunobu reaction. Sulfonylation
of A-2 provides A-3, which can be deprotected with TFA or formic
acid to yield A-4.
##STR00028##
1-Linked 1,2,3 triazole analogs of the intermediate A-3 can
accessed as outlined in Scheme B. The alcohol in A-1 is converted
into a leaving group and the leaving group is replaced with azide
to give B-2, which can be sulfonylated and reacted with an alkyne
under "click chemistry" conditions according to the method by
Sharpless, to give B-4. Alternatively, "click chemistry" can be
performed with B-2, prior to sulfonylation.
##STR00029##
[0316] Heterocyclic intermediates A-2 could also be obtained as
outlined in Scheme C, by alkylation of an amine such as C-1.
Suitable alkylation reagents include alkyl halides or epoxides.
Alkylation of C-1 could also be effected by reductive amination
with an appropriately functionalized and protected aldehyde.
Cyclization of C-2 could be effected using a carbonylating agent
like CDI. Examples of the group Y in these compounds include oxygen
or NR.sup.5, e.g., NH.
##STR00030##
[0317] The functionalized amines C-2 were alternatively obtained
from B-1 by alkylation with a functionalized amine. A lactam
heterocycle may analogously be obtained by alkylation of C-1 with
brominated carboxylic esters, followed by base catalyzed
cyclization.
A heterocycle may be introduced to yield Intermediate A-2, by
substitution of a leaving group in an appropriately protected
azetidinone intermediate. Suitable protection groups include Cbz
for the amine and DMB for the azetidinone. Deprotection of the Cbz
group followed by acylation with appropriately functionalized and
protected acids D-6 gave A-2, as outlined in Scheme D.
##STR00031##
Protected intermediates such as D-1 were also used for introduction
of the heterocycle under Mitsunobu conditions, as outlined in
Scheme A. D-1 was also converted to the corresponding azide, which
was used for "click chemistry" to introduce 1-linked 1,2,3
triazoles following a similar sequence as outlined in Scheme B. D-1
can also be used to yield functionalized amine derivatives that can
be converted to heterocycles, as described in Scheme C.
[0318] Intermediates of the type A-3 may also be assembled by the
sequence outlined in Scheme E, whereby the oxime moiety is
introduced after the coupling step.
##STR00032##
Compounds of the Formula (I) are prepared from commonly available
compounds using these general schemes and procedures known to those
skilled in the art along with the methods and examples provided
herein.
Examples
[0319] The invention is further illustrated by the following
examples, which should not be construed as further limiting. The
assays used throughout the Examples are accepted. Demonstration of
efficacy in these assays is predictive of efficacy in subjects.
[0320] General Conditions
[0321] Mass spectra were acquired on LC-MS, SFC-MS, or GC-MS
systems using electrospray, chemical and electron impact ionization
methods from a range of instruments of the following
configurations: Waters ACQUITY UPLC system and equipped with a ZQ
2000 or SQD MS system where (M+1) refers to the protonated
molecular ion of the chemical species, (M+) refers to the
unprotonated quaternary ammonium cation, (M+Na) refers to the
sodium-incorporated ion and (M-1) refers to the deprotonated
molecular ion of the chemical species.
[0322] NMR spectra were run on Bruker AVANCE 500 MHz or Varian 400
MHz NMR spectrometers using ICON-NMR, under TopSpin program
control. Spectra were measured at 298K, unless indicated otherwise,
and were referenced relative to the solvent resonance.
[0323] Instrumentation
[0324] MS Methods: Using Agilent 1100 HPLC systems with an Agilent
6110 Mass Spectrometer
[0325] Method 2m_acidic:
TABLE-US-00001 Column Kinetex C18 50 .times. 2.1 mm, 2.6 .mu.m
Column Temperature 50.degree. C. Eluents A: H.sub.2O, B:
acetonitrile, both containing 0.1% TFA Flow Rate 1.2 mL/min
Gradient 2% to 88% B in 1.30 min, 0.15 min 95% B
[0326] Method 2m_Acidic_Polar:
TABLE-US-00002 Column Kinetex C18 50 .times. 2.1 mm, 2.6 .mu.m
Column Temperature 50.degree. C. Eluents A: H.sub.2O, B:
acetonitrile, both containing 0.1% TFA Flow Rate 1.2 mL/min
Gradient 1% to 30% B in 1.30 min, 0.15 min 98% B
Abbreviations
[0327] ACN acetonitrile [0328] aq aqueous [0329] app apparent
[0330] ATP adenosine 5'-triphosphate [0331] BINAP racemic
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl [0332] Boc tertiary
butyl carboxy [0333] br broad [0334] brs broad singlet [0335] BSA
bovine serum albumin [0336] CDI 1,1'-carbonyldiimidazole [0337] d
doublet [0338] dd doublet of doublets [0339] DCM dichloromethane
[0340] DCE 1,2-dichloroethane [0341] DIAD
diisopropylazodicarboxylate [0342] DIPEA diisopropylethylamine
[0343] DME 1,4-dimethoxyethane [0344] DMF N,N-dimethylformamide
[0345] DMSO dimethylsulfoxide [0346] EDTA ethylenediamine
tetraacetic acid [0347] ESI electrospray ionization [0348] EtOAc
ethyl acetate [0349] g gram [0350] h hour(s) [0351] HATU
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b] [0352]
pyridinium 3-oxid hexafluorophosphate [0353] HBTU
1-[bis(dimethylamino)methylene]-1H-benzotriazoliumhexafluorophosphate(1-)
3-oxide [0354] HCl hydrochloric acid [0355] HOBt
1-hydroxybenzotriazole [0356] HPLC high performance liquid
chromatography [0357] LCMS liquid chromatography and mass
spectrometry [0358] m multiplet [0359] m-CPBA 3-chloroperbenzoic
acid [0360] MeOH methanol [0361] MS mass spectrometry [0362] mg
milligram [0363] min minutes [0364] mL milliliter [0365] mmol
millimol [0366] m/z mass to charge ratio [0367] NMR nuclear
magnetic resonance [0368] p pentet [0369]
PdCl.sub.2(dppf)-CH.sub.2Cl.sub.2
1,1'-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride
dichloromethane complex [0370] PPh.sub.3 triphenylphosphine [0371]
ppm parts per million [0372] PyBOP
benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate
[0373] q quartet [0374] rac racemic [0375] rt room temperature
[0376] R.sub.t retention time [0377] s singlet [0378] satd
saturated [0379] t triplet [0380] TBAF tetrabutylammonium fluoride
[0381] TBME methyl tert-butyl ether [0382] TFA trifluoroacetic acid
[0383] THF tetrahydrofuran [0384] Tris-HCl
aminotris(hydroxymethyl)methane hydrochloride
Preparation of Intermediates
Intermediate A:
((2S,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-oxoazet-
idin-2-yl)methyl Methanesulfonate
##STR00033##
[0386] To a solution of benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)car-
bamate (5.37 g, 13.41 mmol) and TEA (3.72 mL, 26.8 mmol) in DCM at
0.degree. C. was added MsCl (1.15 mL, 14.75 mmol). After stirring
at 0.degree. C. for 1 h, it was diluted with water/DCM and the
layers were separated. The aqueous layer was extracted with DCM
(2.times.) and the combined organic layers were washed with brine,
dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude
residue was taken up in toluene and concentrated (2.times.),
affording the title compound as an off white solid. It was used as
such in subsequent reactions. LCMS: R.sub.t=0.86 min, m/z=479.2
(M+1) Method 2m_acidic.
Intermediate B: tert-Butyl ((2H-tetrazol-5-yl)methyl)carbamate
##STR00034##
[0388] To a flask charged with (2H-tetrazol-5-yl)methylamine (1.67
g, 16.85 mmol), Boc anhydride (3.86, 17.70 mmol) and water (16.85
mL) was added NaOH (4 N, 4.42 mL, 17.70 mmol). The resulting
suspension was stirred at rt for 12 h then cooled to 0.degree. C.,
whereupon HCl (1 N) was added until pH=4-5. The precipitate was
collected by filtration and the mother liquor was cooled to
0.degree. C. and reacidified with HCl (1 N) until pH=4-5. More of
the precipitate was collected and combined with the first batch,
washing the lot with heptane to afford the title compound (2.74 g,
82%) as a white solid. LCMS: R.sub.t=0.38 min, m/z=200.2 (M+1)
Method 2m_acidic.
Intermediate C: tert-Butyl
((1H-1,2,4-triazol-3-yl)methyl)carbamate
##STR00035##
[0390] To a solution of 2H-[1,2,4]triazole-3-yl-methylamine
hydrochloride (583 mg, 4.33 mmol) and Boc-anhydride (993 mg, 4.55
mmol) in water (5.78 mL) was added NaOH (4N, 1.137 mL, 4.55 mmol).
After stirring for 48 h the white precipitate was collected by
filtration. The solid was suspended in heptane, sonicated then
filtered, washing the filter cake with heptane. LCMS: R.sub.t=0.41
min, m/z=199.2 (M+1) Method 2m_acidic.
Intermediate D:
3-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)oxazolidin-2-one
##STR00036##
[0391] Step 1: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-(((2-hydroxyethyl)amino)methyl)-4-oxoa-
zetidin-3-yl)carbamate
[0392] To a solution of
((2S,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-oxoazet-
idin-2-yl)methyl methanesulfonate (6.43 g, 13.4 mmol) in
Acetonitrile (44.8 ml) was added ethanolamine (8.13 ml, 134 mmol)
followed by DIPEA (7.0 ml, 40 mmol). The solution was heated to
80.degree. C. for 20 h, whereupon it was cooled to rt, diluted with
EtOAc, washed with water, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo, afford the title compound (4.47 g, 75%) as a
white solid. LCMS: R.sub.t=0.60 min, m/z=444.2 (M+1).
Step 2: Benzyl
((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)az-
etidin-3-yl)carbamate
[0393] To a solution of benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-(((2-hydroxyethyl)amino)methyl)-4-oxoa-
zetidin-3-yl)carbamate (4.47 g, 10.08 mmol) in chloroform (50 ml)
was added CDI (4.90 g, 30.2 mmol). After stirring at rt for 30 min
it was concentrated in vacuo. The crude residue was purified via
silica gel chromatography (MeOH-DCM, 0-5%), affording the title
compound (3.84 g, 81%) as a white foam. LCMS: R.sub.t=0.76 min,
m/z=470.1 (M+1).
Step 3: Benzyl
((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3-yl)carbamate
[0394] Prepared in an analogous manner to example 4, step 2 using
benzyl
((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)az-
etidin-3-yl)carbamate (3.84 g, 8.18 mmol), K.sub.2S.sub.2O.sub.8
(3.10 g, 11.5 mmol) and K.sub.2HPO.sub.4 (1.852 g, 10.6 mmol) in
ACN:water (2:1, 136 mL) while heating for 40 min at 90.degree. C.
More K.sub.2S.sub.2O.sub.8 (663 g, 2.45 mmol) and K.sub.2HPO.sub.4
(370 mg, 2.13 mmol) were added and it was heated for another 3 h.
More K.sub.2S.sub.2O.sub.8 (332 mg, 1.23 mmol) and K.sub.2HPO.sub.4
(185 mg, 1.06 mmol) were added, and it was heated for an additional
2 h, whereupon it was concentrated in vacuo, removing most of the
ACN. The mixture was diluted with brine/EtOAc and the layers were
separated. The aqueous layer was extracted with EtOAc (3.times.)
and the combined organic layers were dried over Na.sub.2SO.sub.4.
The crude residue was purified via silica gel chromatography
(EtOAc-Heptane, 0-100% then MeOH-DCM, 10%) to afford the title
compound (1.61 g, 62%) as a beige foam. LCMS: R.sub.t=0.51 min,
m/z=320.0 (M+1) Method 2m_acidic.
Step 4:
3-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)oxazolidin-2-one
[0395] Prepared in an analogous manner to example 4, step 3 using
benzyl
((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3-yl)carbamate
(96 mg, 0.30 mmol) and Pd/C 10% Degussa type 101 (10%, 64 mg) in
EtOH:MeOH (4:1, 1.5 mL) for 1 h. The crude residue was used as such
in following step. LCMS: R.sub.t=0.11 min, m/z=186.0 (M+1) Method
2m_acidic.
Intermediate E: tert-Butyl
(4-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amin-
o)-2-oxoacetyl)thiazol-2-yl)carbamate
##STR00037##
[0397] To a slurry of
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoacetic acid
(2.72 g, 9.99 mmol) and HATU (3.80, 10.0 mmol) in DCM:DMF (3:1,
33.3 mL) at 0.degree. C. was added DIPEA (2.91 mL, 16.7 mmol). A
soln of
(3S,4R)-4-((1H-1,2,4-triazol-1-yl)methyl)-3-aminoazetidin-2-one
(1.39 g, 8.33 mmol) in DCM:DMF (1:1, 32 mL) was added followed by a
DMF (3 mL) wash. After stirring for 48 h the dark solution was
diluted with EtOAc (150 mL)/brine (140 mL) and the layers were
separated. The aqueous was extracted with EtOAc (3.times.) and the
combined organic layers were washed with brine (70 mL). The brine
layer wash was re-extracted with EtOAc. The combined organic layers
were dried over Na.sub.2SO.sub.4 and concd in vacuo. The crude
residue was purified via silica gel chromatography (MeOH-DCM,
0-10%), affording the title compound (2.38 g, 68%) as a red solid.
LCMS: R.sub.t=0.59 min, m/z=422.0 (M+1) Method 2m_acidic; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.85 (s, 1H), 9.70 (d, J=9.3
Hz, 1H), 8.52 (d, J=1.6 Hz, 1H), 8.48 (s, 1H), 8.44 (s, 1H), 7.96
(s, 1H), 5.28 (ddd, J=9.3, 5.2, 1.5 Hz, 1H), 4.45 (dd, J=14.2, 5.3
Hz, 1H), 4.36 (dd, J=14.1, 7.6 Hz, 1H), 4.18 (dt, J=7.6, 5.3 Hz,
1H), 1.47 (s, 9H).
Intermediate F:
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-(2-(2-((tert-butoxycarbonyl)a-
mino)thiazol-4-yl)-2-oxoacetamido)-4-oxoazetidine-1-sulfonic
acid
##STR00038##
[0399] To a soln of tert-Butyl
(4-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amin-
o)-2-oxoacetyl)thiazol-2-yl)carbamate (200 mg, 0.475 mmol) in DMF
(4.75 mL) at 0.degree. C. was added SO.sub.3.DMF (367 mg, 2.40
mmol). After 16 h of stirring it was concentrated in vacuo and
purified with HP21 resin (ACN-water, 0-50%), affording the title
compound (110 mg, 46%) as a pale yellow solid. LCMS: R.sub.t=0.54
min, m/z=501.9 (M+1) Method 2m_acidic; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.87 (s, 1H), 9.75 (d, J=9.2 Hz, 1H), 8.94
(s, 1H), 8.44 (s, 1H), 8.34 (s, 1H), 5.25 (dd, J=9.1, 5.4 Hz, 1H),
4.75 (dd, J=14.3, 4.9 Hz, 1H), 4.61 (dd, J=14.4, 7.6 Hz, 1H), 4.43
(dt, J=7.6, 5.2 Hz, 1H), 1.49 (s, 9H).
Intermediate G: Benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)car-
bamate
##STR00039## ##STR00040##
[0400] Step 1:
(R,E)-1-(2,4-dimethoxyphenyl)-N-((2,2-dimethyl-1,3-dioxolan-4-yl)methylen-
e)methanamine
[0401] Prepared according to the procedure described by
Hubschwerlen, C. and Schmid, G. Helv. Chim. Acta 1983, 66,
2206-2209 with the addition of MgSO.sub.4. To a suspension of
(S)-2,2-dimethyl-1,3-dioxolane-4-carbaldehyde (Carbosynth LLC, 346
g, 43% in DCM, 1.143 mol) and MgSO.sub.4 (278 g) in DCM (1.5 L) at
0.degree. C. was added 2,4-dimethoxybenzylamine (193 g, 1.154 mol)
over 20 min. After stirring at rt for 2 h it was filtered, washing
the filter cake with DCM (2.times.250 mL). The mother liquor was
used directly in step 2.
Step 2:
2-((2S,3S)-1-(2,4-dimethoxybenzyl)-2-((R)-2,2-dimethyl-1,3-dioxola-
n-4-yl)-4-oxoazetidin-3-yl)isoindoline-1,3-dione
[0402] Prepared according to the procedure described by
Hubschwerlen, C. and Schmid, G. Helv. Chim. Acta 1983, 66,
2206-2209. After addition of TEA (322 mL, 2.31 mol) to the crude
mother liquor from step 1, it was cooled to 0.degree. C. followed
by addition of a solution of 2-(1,3-dioxoisoindolin-2-yl)acetyl
chloride (284.3 g, 1.272 mol) in DCM (1 L) over a period of 30 min.
The mixture was allowed to warm to rt and stirred for an additional
16 h, whereupon it was washed with water (2.times.1 L), saturated
NaHCO.sub.3 (aq, 1 L), brine (1 L), dried over Na.sub.2SO.sub.4 and
concentrated in vacuo, affording the crude title compound (631 g,
assumed quantitative) as a pale yellow solid. The .sup.1H NMR of a
purified sample (EtOAc-Heptane, 40-60%) was an identical match to
literature reported data.
Step 3:
(3S,4S)-3-amino-1-(2,4-dimethoxybenzyl)-4-((R)-2,2-dimethyl-1,3-di-
oxolan-4-yl)azetidin-2-one
[0403] To a solution of crude
2-((2S,3S)-1-(2,4-dimethoxybenzyl)-2-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-
-4-oxoazetidin-3-yl)isoindoline-1,3-dione (631 g, 1.143 mol,
assumed quantitative conversion from step 2) in EtOH (8.2 L) was
added hydrazine hydrate (235 mL, 50-60%, .about.4 mol) over 20 min.
The resulting mixture was heated to reflux for 3 h, cooled to rt,
filtered, washed with EtOH and concentrated in vacuo. The residue
was slurried in EtOAc (4 L), filtered and washed with water
(2.times.1 L).
Step 4: Benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-
-oxoazetidin-3-yl)carbamate
[0404] To the crude organic solution from step 3 (EtOAc, 4 L)
cooled to 0.degree. C. was added saturated NaHCO.sub.3 (aq, 2.05 L)
followed by benzyl chloroformate (205 mL, 1.43 mol), drop-wise over
1 h. After stirring at rt for 2 h the layers were separated and the
aqueous layer was extracted with EtOAc (2.times.50 mL). The
combined organic layers were washed with water, brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
treated with MeOH (2 L), filtered and washed with MeOH (2.times.200
mL) to afford pure title compound (155 g) as a white solid. The
mother liquor was cooled to -20.degree. C. for 12 h and the
resulting precipitate was collected by filtration, affording
additional title compound (90 g) for a combined 45% yield over 4
steps. LCMS: m/z=471.1 (M+1).
Step 5: Benzyl
((2S,3S)-2-((R)-1,2-dihydroxyethyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-
-3-yl)carbamate
[0405] To a solution of benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-
-oxoazetidin-3-yl)carbamate (267 g, 0.567 mol) in THF (3 L) was
added a solution of TsOH.H.sub.2O (43.6 g, 0.229 mol) in water
(0.75 L). The bilayer was heated to 70.degree. C. for 16 h then
cooled to rt, neutralized to pH=7 with saturated NaHCO.sub.3 (aq)
and concentrated in vacuo. The resulting mixture was filtered,
washed with water and dried to afford the title compound (240 g,
98%) as a pale yellow solid. LCMS: m/z=431.1 (M+1).
Step 6: Benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-formyl-4-oxoazetidin-3-yl)carbamate
[0406] To a solution of benzyl
((2S,3S)-2-((R)-1,2-dihydroxyethyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-
-3-yl)carbamate (240 g, 0.557 mol) in EtOAc (4.5 L) was added a
solution of sodium periodate (132 g, 0.617 mol) in water (1.125 L)
and the bilayer was heated to 50.degree. C. for 2 h, whereupon it
was cooled to rt and the layers were separated. The aqueous layer
was extracted with EtOAc (500 mL) and the combined organic layers
were washed with water, brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo to afford the title compound (218 g, 98%) as
a pale yellow solid. LCMS: m/z=399.0 (M+1). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.32 (d, J=3.2 Hz, 1H), 8.19 (d, J=8.5 Hz,
1H), 7.39-7.23 (m, 5H), 7.16 (d, J=8.3 Hz, 1H), 6.53 (d, J=2.4 Hz,
1H), 6.47 (dd, J=8.3, 2.4 Hz, 1H), 5.00-4.96 (m, 2H), 4.90 (dd,
J=8.5, 5.8 Hz, 1H), 4.38 (d, J=14.5 Hz, 1H), 4.29 (d, J=14.5 Hz,
1H), 4.05 (dd, J=5.9, 3.3 Hz, 1H), 3.73 (s, 3H), 3.70 (s, 3H).
Step 7: Benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)car-
bamate
[0407] To a solution of benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-formyl-4-oxoazetidin-3-yl)carbamate
(218 g, 0.546 mol) in a mixture of DCM:MeOH (4:1, 2.25 L) at
0.degree. C. was added sodium borohydride (41.3 g, 1.09 mol),
portion-wise. The resulting mixture was stirred at 0.degree. C. for
2 h, whereupon it was quenched with cold water (1 L) for 30 min and
the layers were separated. The aqueous layer was extracted with DCM
(3.times.200 mL) and the combined organic layers were washed with
water, brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo
to afford the title compound (208 g, 95%) as an off white solid.
LCMS: m/z=401.2 (M+1); .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
7.37-7.29 (m, 5H), 7.21-7.18 (m, 1H), 6.46-6.49 (m, 2H), 5.82 (bd,
J=9.6 Hz, 1H), 5.18-5.08 (m, 3H), 4.45 (d, J=14.4 Hz, 1H), 4.28 (d,
J=14.4 Hz, 1H), 3.83 (s, 3H), 3.79 (s, 3H), 3.76-3.72 (m, 1H),
3.63-3.52 (m, 2H), 1.87 (dd, J=9.6, 4.0 Hz, 1H).
Intermediate H: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(hy-
droxymethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-
propanoate
##STR00041##
[0408] Step 1: Benzyl
((2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate
[0409] Prepared according to Mastalerz et al. J. Med. Chem. 1988,
31, 1190. To a solution of intermediate G (208 g, 0.529 mol) in ACN
(4 L) was added potassium persulfate (243 g, 0.899 mol) followed by
a solution of dipotassium phosphate (147.4 g, 0.846 mol) in water
(2 L). The resulting mixture was heated to 90.degree. C. for 4 h
then cooled to rt and concentrated in vacuo, removing most of the
ACN. The mixture was extracted with EtOAc (1 L, 2.times.200 mL) and
the combined organic layers were washed with water, brine, dried
over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue
was purified via silica gel chromatography (EtOAc-Hexanes,
50-100%), affording the title compound (86 g, 65%) as a white
solid. Analytical data was an identical match to that reported in
the literature.
Step 2: (2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-ammonium
Acetate
[0410] To a solution of benzyl
((2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)carbamate (25 g, 100
mmol) in MeOH (350 mL) was added Pd on C (10% wet, 2.5 g) followed
by AcOH (11.4 mL, 200 mmol). The mixture was evacuated and
recharged with H.sub.2 (3.times.), bringing the final pressure to
50 psi. It was stirred at rt for 2 h, then discharged, filtered
over celite and concentrated in vacuo, affording the crude title
compound (22 g) as a light brown oil, which was used directly in
step 3.
Step 3: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(hy-
droxymethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-
propanoate
[0411] To a solution of (Z)-tert-butyl
2-(((2-(benzo[d]thiazol-2-ylthio)-1-(2-((tert-butoxycarbonyl)amino)-thiaz-
ol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (85 g, 116.4
mmol) in DMF (200 mL) at 0.degree. C. was added a solution of
(2S,3S)-2-(hydroxymethyl)-4-oxoazetidin-3-ammonium acetate (22 g,
100 mmol, assumed quantitative from step 2) in DMF (100 mL)
followed by DIPEA (52.2 mL, 300 mmol). The mixture was allowed to
warm to rt and stirred for an additional 16 h, whereupon it was
concentrated in vacuo and purified via silica gel chromatography
(EtOAc-Hexanes, 25-100%), affording the crude title compound (44 g,
83%) as a pale yellow solid. LCMS: m/z=526.1 (M-1); .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta. 8.94 (s, 1H), 8.02 (d, J=7.8 Hz,
1H), 7.30 (s, 1H), 6.48 (s, 1H), 5.43 (dd, J=7.4, 4.7 Hz, 1H), 4.25
(m, 1H), 4.02 (dd, J=8.6, 4.3 Hz, 1H), 3.86 (m, 2H), 1.56 (s, 3H),
1.55 (s, 3H), 1.52 (s, 9H), 1.44 (9H, s).
Intermediate I: (Z)-tert-Butyl
2-(((2-(benzo[d]thiazol-2-ylthio)-1-(2-((tert-butoxycarbonyl)amino)thiazo-
l-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0412] To a suspension of
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (50 g, 116.4 mmol)
and 2,2'-dibenzothiazolyl disulfide (54.2 g, 163 mmol) in DCM (1 L)
was added triphenylphosphine (44.3 g, 168.8 mmol) followed by
drop-wise addition of TEA (22.7 mL, 163 mmol). After stirring for
16 h, the mixture was concentrated and used directly in the
preparation of intermediate H. LCMS: m/z=579.0 (M+1).
Intermediate J: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-(azidomethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpr-
opanoate
##STR00042##
[0413] Step 1: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(io-
domethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpro-
panoate
[0414] To a solution of intermediate H (44.0 g, 83.4 mmol),
triphenylphosphine (43.7 g, 166.8 mmol) and imidazole (11.4 g,
166.8 mmol) in DCM was added iodine (42.3 g, 166.8 mmol)
portion-wise over 5 min. After stirring at rt for 16 h it was
diluted with DCM (300 mL), washed with saturated
Na.sub.2S.sub.2O.sub.3 (aq, 200 mL), water, brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via column chromatography (EtOAc-Hexanes, 25-75%),
affording the title compound (33 g, 62%) as a yellow solid. LCMS:
m/z=638.0 (M-1). .sup.1H NMR data was an identical match to that
described in WO2012073138(A1).
Step 2: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-(azidomethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpr-
opanoate
[0415] To a solution of tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(io-
domethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpro-
panoate (24.0 g, 37.6 mmol) in THF (200 mL) at 0.degree. C. was
added TEA (10.5 mL, 75.2 mmol) followed by tetrabutylammonium azide
(13.9 g, 48.9 mmol). The mixture was allowed to warm to rt and
stirred for an additional 16 h, whereupon it was poured into
ice-water (200 mL) and extracted with EtOAc (3.times.100 mL). The
combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography, affording the title
compound (17.0 g, 82%) as a pale yellow solid. LCMS: m/z=551.0
(M-1). .sup.1H NMR data was an identical match to that described in
WO2012073138(A1).
Intermediate K:
(2R,3S)-2-(azidomethyl)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan--
2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-
-oxoazetidine-1-sulfonic Acid
##STR00043##
[0417] To a solution of intermediate J (500 mg, 0.905 mmol) in DMF
(8 mL) was added SO.sub.3.DMF (1.38 g, 9.05 mmol). After stirring
at rt for 4 h, it was diluted with EtOAc (50 mL) and washed with
water, followed by brine until pH=7. The organic layer was dried
over Na.sub.2SO.sub.4 and concentrated in vacuo, affording the
title compound (500 mg, 87%) as a light yellow solid. LCMS:
m/z=629.85 (M-1); .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.85
(s, 1H), 9.10 (d, J=8.9 Hz, 1H), 8.63 (s, 1H), 7.27 (d, J=11.1 Hz,
1H), 6.55 (s, 1H), 5.37-5.13 (m, 1H), 3.83-3.54 (m, 2H), 1.46-1.41
(m, 4H), 1.43-1.35 (m, 7H).
Intermediate L: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-(aminomethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpr-
opanoate
##STR00044##
[0419] To a solution of intermediate J (17.0 g, 30.8 mmol) in EtOH
(300 mL) was added Pd on C (10%, wet, 2.0 g) under nitrogen. The
mixture was evacuated and recharged with H.sub.2 (3.times.),
bringing the final pressure to 50 psi. It was stirred at rt for 2
h, then discharged, filtered over celite and concentrated in vacuo,
affording the crude title compound (15.5 g, 96%) as a pale yellow
solid. LCMS: m/z=527.1 (M-1). .sup.1H NMR data was an identical
match to that described in WO2012073138(A1).
Intermediate M: tert-Butyl
4-(but-3-yn-1-yl)piperazine-1-carboxylate
##STR00045##
[0421] To a solution of 1-Boc-piperazine (0.5 g, 2.68 mmol) in
acetonitrile (2.5 mL) was added K.sub.2CO.sub.3 (0.55 g, 4.02 mmol)
followed by 4-bromo-1-butyne (0.39 g, 2.95 mmol). The mixture was
heated at 60.degree. C. for 6 h, allowed to come to room
temperature, diluted with water and extracted with EtOAc
(2.times.15 mL). The combined organic layers washed with water,
brine, dried over Na.sub.2SO.sub.4 and concentrated under vacuo to
afford the title compound (0.55 g, 86%); LCMS: m/z=239.10 (M+1).
Method 2minLowp.
Intermediate N:
N,N,N-Trimethyl-2-oxo-2-(prop-2-yn-1-ylamino)ethanaminium
Bromide
##STR00046##
[0422] Step 1: 2-Bromo-N-(prop-2-yn-1-yl)acetamide
[0423] To a solution of bromoacetyl bromide (2.1 g, 10.34 mmol) and
triethylamine (1.5 mL, 10.34 mmol) in DCM (20 mL) cooled to
0.degree. C., was added a solution of propargylamine (0.57 g, 10.34
mmol) in DCM (10 mL) drop-wise over a period of 5 min, maintaining
stirring throughout. The mixture was stirred at 0.degree. C. for 2
h, whereupon the solids were filtered and the filtrate was
concentrated in vacuo. The crude residue was purified via column
chromatography (60-120 mesh silica, 50% EtOAc:Hexane), affording
the title compound (1.3 g, 72%) as an off white solid; LCMS:
m/z=176.2 (M+1); .sup.1H NMR (300 MHz, CDCl.sub.3) 6.68 (brs, 1H),
4.09 (dd, J=5.4, 2.6 Hz, 2H), 3.90 (s, 2H), 2.28 (t, J=2.6 Hz,
1H).
Step 2: N,N,N-Trimethyl-2-oxo-2-(prop-2-yn-1-ylamino)ethanaminium
bromide
[0424] To a solution of 2-bromo-N-(prop-2-yn-1-yl)acetamide (0.6 g,
3.4 mmol) in acetonitrile (5 mL) was added trimethylamine (30% in
MeOH, 5 mL). The mixture was stirred at room temperature for 16 h
and concentrated in vacuo. The resulting residue was triturated
with ether, resulting in the title compound (780 mg, 97%); LCMS:
m/z=155.1 (M+1); .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 9.03
(t, J=5.3 Hz, 1H), 4.17 (s, 2H), 3.95 (dd, J=5.4, 2.6 Hz, 2H), 3.23
(s, 9H), 2.09 (s, 1H).
Intermediate O:
2-(4-methylpiperazin-1-yl)-N-(prop-2-yn-1-yl)acetamide
##STR00047##
[0426] To a solution of 2-bromo-N-(prop-2-yn-1-yl)acetamide (0.7 g,
3.98 mmol) in DCM (10 mL) added N-methyl piperazine (0.66 mL, 5.96
mmol) drop wise. Reaction mixture stirred at rt for 16 h, diluted
with DCM and washed with water and brine. The organic layer was
dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude
residue was triturated with ether-pentane, affording the title
compound (0.38 g, 49%); LCMS: m/z=196.15 (M+1); .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 8.06 (d, J=6.1 Hz, 1H), 3.86 (dd, J=5.9,
2.5 Hz, 2H), 3.07 (t, J=2.5 Hz, 1H), 2.91 (s, 2H), 2.47-2.25 (m,
8H), 2.15 (s, 3H).
Intermediate P: 4-Ethynyl-1-methylpyridin-1-ium
Trifluoromethanesulfonate
##STR00048##
[0428] Prepared according to Rubinsztajn et al. Tetrahedron Lett.
1992, 33, 14, 1821-1824. To a suspension of 4-ethynylpyridine
hydrochloride (500 mg, 3.58 mmol) in DCM (50 mL) at 0.degree. C.
was slowly added NaHCO.sub.3 solution (aq, satd, 10 mL). After
stirring for 5 min, the layers were separated and the aqueous was
extracted with DCM (2.times.10 mL). The combined organic layers
were dried over Na.sub.2SO.sub.4, concentrated in vacuo and
subjected to high vacuum for 10 min. The crude residue was
dissolved in DCM (10 mL), cooled to 0.degree. C. and methyl
triflate (450 .mu.L, 3.94 mmol) was added drop-wise. After stirring
for 30 min at 0.degree. C., ether was added and the precipitate was
collected and dried, affording the title compound (870 mg, 91%) as
a light brown solid. Analytical data was identical to literature
reported values.
Intermediate Q: 4-Ethynyl-1,3-dimethylpyridin-1-ium
Trifluoromethanesulfonate
##STR00049##
[0430] Step 1: 3-Methyl-4-((trimethylsilyl)ethynyl)pyridine.
[0431] To a solution of 4-bromo-3-methyl pyridine hydrochloride
(5.0 g, 24.0 mmol) in THF (degassed, 80 mL) was added copper iodide
(450 mg, 2.40 mmol) and triethylamine (20.0 mL, 143.9 mmol). After
degassing for 15 min, palladium tetrakis triphenylphosphine (830
mg, 0.72 mmol) and trimethylsilylacetylene (6.10 mL, 43.16 mmol)
were added. The mixture was heated at 50.degree. C. for 16 h then
cooled to rt and filtered. The crude residue was purified via
silica gel chromatography (EtOAc-Hexanes, 10%) to afford the title
compound (3.95 g, 87%) as clear but dark oil.
Step 2: 4-Ethynyl-3-methylpyridine
[0432] Prepared according to the method described in WO2013/028590.
To a solution of 4-ethynyl-3-methylpyridine (3.79 g, 20 mmol) in
THF (50 mL) was added TBAF (1M in THF, 40 mL, 40 mmol). After
stirring at rt for 1 h, the solution was concentrated in vacuo. The
crude residue was purified via silica gel chromatography
(EtOAc-Hexanes, 20-40%) affording the title compound (1.70 g, 72%)
as an off white solid.
Step 3: 4-Ethynyl-1,3-dimethylpyridin-1-ium
Trifluoromethanesulfonate
[0433] Prepared according to Rubinsztajn et al. Tetrahedron Lett.
1992, 33, 14, 1821-1824. To a solution of
4-ethynyl-3-methylpyridine (420 mg, 3.58 mmol) in DCM (10 mL) at
0.degree. C. was added methyl triflate (450 .mu.L, 3.94 mmol),
drop-wise. After stirring for 30 min at 0.degree. C., ether was
added and the precipitate was collected and dried, affording the
title compound (863 mg, 86%) as a light brown solid.
Intermediate R: tert-Butyl
((2H-1,2,3-triazol-4-yl)methyl)carbamate
##STR00050##
[0435] To a solution of N-Boc-propargyl amine (1.60 g, 10.3 mmol)
in a mixture of DMF:MeOH (4:1, 10 mL) was added trimethylsilylazide
(2.0 mL, 15.2 mmol) and CuI (95 mg, 0.50 mmol). The resulting
mixture was heated to 100.degree. C. for 16 h, whereupon it was
concentrated in vacuo and purified via silica gel chromatography,
affording the title compound (2.0 g, 99%) as a light yellow oil;
LCMS: m/z=196.9 (M-1).
Intermediate S
##STR00051##
[0436] Step 1: Benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(iodomethyl)-4-oxoazetidin-3-yl)carbam-
ate
[0437] To a solution of intermediate G (10 g, 25 mmol),
triphenylphosphine (19.6 g, 75 mmol) and imidazole (5.1 g, 75 mmol)
in DCM (150 mL) at 0.degree. C. was added iodine (19 g, 75 mmol)
portion-wise over 10 min. After stirring at rt for 4 h, it was
washed with saturated Na.sub.2S.sub.2O.sub.3 (aq) solution, water,
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The
crude residue was suspended in EtOAc (150 mL) and stirred for 16 h
whereupon it was filtered then washed with acetone and MeOH,
affording the title compound (9.8 g, 77%) as a white solid. LCMS:
m/z=510.8 (M+1).
Step 2: Benzyl
((2R,3S)-2-(azidomethyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carba-
mate
[0438] To a solution of benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(iodomethyl)-4-oxoazetidin-3-yl)carbam-
ate (5.00 g, 9.80 mmol) in THF (100 mL) at 0.degree. C. was added
TEA (2.73 g, 19.6 mmol) followed by a solution of
tetrabutylammonium azide (3.62 g, 12.7 mmol) in THF. After stirring
at rt for 16 h, it was filtered and concentrated in vacuo. The
crude residue was purified via silica gel chromatography (MeOH-DCM,
2%), affording the title compound (3.4 g, 81%) as a white
solid.
Step 3
[0439] To a solution of benzyl
((2R,3S)-2-(azidomethyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carba-
mate (3.00 g, 7.06 mmol) in DCM (6 mL) was added
DMSO:water:tert-butanol (1:1:1, 6 mL) tert-butyl
but-3-yn-1-ylcarbamate (2.19 g, 14.1 mmol), CuSO.sub.4 (56 mg, 0.35
mmol) and sodium L-ascorbate (2.01 mg, 10.6 mmol). After stirring
at rt for 3 h the mixture was partially concentrated and water was
added, whereupon the solids were collected by filtration. The
filter cake was suspended in DCM, filtered and the filtrate
concentrated, affording the title compound (assumed quantitative)
as a light yellow solid.
Step 4
[0440] To a solution of the product from step 3 (7.06 mmol) in ACN
(50 mL) was added potassium persulfate (3.82 g, 14.1 mmol) followed
by a solution of dipotassium phosphate (3.08 g, 17.7 mmol) in water
(25 mL). The resulting mixture was heated to 90.degree. C. for 4 h
then cooled to rt, filtered and concentrated in vacuo, removing
most of the ACN. The filtrate was extracted with EtOAc and
concentrated in vacuo. The crude residue washed with hexanes and
acetone, affording the title compound (1.72 g, 57% over 2-steps) as
a white solid. LCMS: m/z=431.1 (M+1).
Intermediate T
##STR00052##
[0441] Step 1
[0442] The general procedure for the Mitsunobu reaction was
followed. To a solution of intermediate G (5.00 g, 12.5 mmol),
tert-butyl ((2H-1,2,3-triazol-4-yl)methyl)carbamate (2.97 mg, 15.0
mmol), triphenylphosphine (3.93 mg, 15.0 mmol) and DIAD (3.0 mL, 15
mmol) in THF (100 mL). Purified via silica gel chromatography
(MeOH-DCM, 2-5%), affording the title compound (12.6 g,
contaminated with triphenylphosphine oxide) as a white foam.
Step 2
[0443] To a solution of the product from step 1 (12.5 mmol) in ACN
(150 mL) was added a solution of potassium persulfate (6.76 g, 25.0
mmol) and dipotassium phosphate (5.44 g, 31.2 mmol) in water (75
mL). The resulting mixture was heated to 90.degree. C. for 4 h then
cooled to rt, diluted with water and extracted with EtOAc. The
organic layer was concentrated in vacuo and the crude residue was
purified via silica gel chromatography, affording the title
compound (2.23 g, 41% over 2-steps) as a white solid. LCMS:
m/z=428.9 (M-1).
Intermediate U
##STR00053##
[0444] Step 1: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((1,3-dioxoisoindolin-2-yl)methyl)-4-o-
xoazetidin-3-yl)carbamate
[0445] The general procedure for the Mitsunobu reaction was
followed using intermediate G (5.00 g, 12.5 mmol), phthalimide
(1.83 g, 12.5 mmol), triphenylphosphine (3.93 g, 15.0 mmol), DIAD
(3.03 g, 15.0 mmol) and THF (150 mL). After stirring for 16 h, the
formed precipitate was filtered, affording title compound (5.67 g,
85%) as a white solid.
Step 2: Benzyl
((2R,3S)-2-(aminomethyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carba-
mate
[0446] To a solution of benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((1,3-dioxoisoindolin-2-yl)methyl)-4-o-
xoazetidin-3-yl)carbamate (4.40 g, 8.31 mmol) in DCM:MeOH (5:1, 60
mL) was added hydrazine hydrate (1.50 g, 25.0 mmol). After stirring
for 16 h the precipitate was filtered off and the filtrate was
concentrated, affording title compound (quantitative) as a white
solid.
Step 3
[0447] To a solution of benzyl
((2R,3S)-2-(aminomethyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carba-
mate (8.31 mmol) in DCM:MeOH (13:1.43 mL) was added (R)-tert-butyl
(oxiran-2-ylmethyl)carbamate. After stirring for 16 h it was
concentrated in vacuo and purified via silica gel chromatography
(MeOH-DCM, 2-10%), affording the title compound (2.2 g, 46%) as a
white foam.
Step 4
[0448] To a solution of the product from step 3 (2.20 g, 3.85 mmol)
in DCM (100 mL) at 0.degree. C. was added CDI (1.12 g, 6.92 mmol).
After stirring at 15.degree. C. for 2 h the solution was
concentrated in vacuo. The crude residue was purified via silica
gel chromatography (MeOH-DCM, 1-5%) to afford the title compound
(2.10 g, 91%) as a white foam.
Step 5
[0449] To a solution of the product from step 4 (2.10 g, 3.51 mmol)
in ACN (40 mL) was added a solution of potassium persulfate (1.89
g, 7.02 mmol) and dipotassium phosphate (1.52 g, 8.75 mmol) in
water (20 mL). The resulting mixture was heated to 90.degree. C.
for 4 h then cooled to rt and filtered. The filtrate was
concentrated, extracted with EtOAc and the organic layer was
concentrated. The crude residue was purified via silica gel
chromatography (MeOH-DCM, 2-5%), affording the title compound (660
mg, 42%) as a pale yellow solid. LCMS: m/z=449.09 (M+1).
Intermediate V
##STR00054##
[0450] Step 1: (1H-1,2,3-triazol-4-yl)methanol
[0451] To a solution of propargyl alcohol (11.2 g, 200 mmol) in DMF
(160 mL) and MeOH (40 mL) was added CuI (1.9 g, 10 mmol) and
trimethylsilyl azide (34.6 g, 300 mmol). After heating to
100.degree. C. for 16 h, the reaction mixture was cooled to rt and
filtered through celite. The filtrate was concentrated in vacuo to
afford the title compound (assume quantitative). The crude compound
was used as such in the following step.
Step 2:
4-(((tert-butyldimethylsilyl)oxy)methyl)-1H-1,2,3-triazole
[0452] To a solution of (1H-1,2,3-triazol-4-yl)methanol (30 g, 200
mmol) in DCM (160 mL) was added imidazole (20.4 g, 300 mmol)
followed by TBDMS-Cl (33.3 g, 220 mmol) as a solid in portions.
After stirring at rt for 16 h, the reaction mixture was filtered
through celite, and the filtrate was concentrated in vacuo. The
residue was dissolved in EtOAc (500 mL) and washed with water,
brine, dried over Na.sub.2SO.sub.4, and concentrated in vacuo. The
crude residue was purified via silica gel chromatography
(EtOAc-hexanes, 5-30%) to afford the title compound (30.2 g, 71%)
as a pale yellow solid.
Step 3: Benzyl
((2R,3S)-2-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2H-1,2,3-triazol-2--
yl)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carbamate
[0453] To a solution of benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)car-
bamate (0.94 g, 2.34 mmol),
4-(((tert-butyldimethylsilyl)oxy)methyl)-1H-1,2,3-triazole (0.5 g,
2.34 mmol), and PPh.sub.3 (0.74 g, 2.81 mmol) in THF (20 mL) at
0.degree. C. was added DIAD (0.57 g, 2.81 mmol) slowly. After
stirring at rt for 16 h, the reaction mixture was concentrated in
vacuo. The crude residue was purified via silica gel chromatography
(EtOAc-hexanes, 20-30%) to afford the title compound (1.25 g, 89%)
as a pale yellow solid. LCMS: m/z=594.3 (M-1).
Step 4: Benzyl
((2R,3S)-2-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2H-1,2,3-triazol-2--
yl)methyl)-4-oxoazetidin-3-yl)carbamate
[0454] To a solution of benzyl
((2R,3S)-2-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2H-1,2,3-triazol-2--
yl)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carbamate
(1.25 g, 2.1 mmol) in CH.sub.3CN (20 mL) was added
K.sub.2S.sub.2O.sub.8 (0.73 g, 2.7 mmol) followed by a solution of
K.sub.2HPO.sub.4 (0.84 g, 4.8 mmol) in water (10 mL). After
stirring at 90.degree. C. for 1 h, more K.sub.2S.sub.2O.sub.8 (0.23
g, 0.84 mmol) was added. After heating at 90.degree. C. for
additional 2 h, the reaction mixture was concentrated in vacuo. The
residue was extracted with EtOAc (2.times.30 mL). Combined organic
layers were washed with water, brine, dried with Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The crude residue was purified
via silica gel chromatography (MeOH-DCM, 1-3%) to afford the title
compound (0.44 g, 47%) as a pale yellow solid. LCMS: m/z=446.2
(M+1).
Step 5: Benzyl
((2R,3S)-2-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidi-
n-3-yl)carbamate
[0455] To a solution of benzyl
((2R,3S)-2-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2H-1,2,3-triazol-2--
yl)methyl)-4-oxoazetidin-3-yl)carbamate (10.8 g, 24.4 mmol) in THF
(100 mL) was added TBAF (1 M in THF, 26.6 mL, 26.6 mmol) slowly
over a period of 15 min. After stirring at rt for 1.5 h, the
reaction mixture was concentrated in vacuo. The crude residue was
purified via silica gel chromatography (MeOH-DCM, 1-5%) to afford
the title compound (6.8 g, 85%) as a pale yellow solid. LCMS:
m/z=330.0 (M+1).
Step 6:
(3S,4R)-3-amino-4-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl-
)azetidin-2-one
[0456] To a solution of benzyl
((2R,3S)-2-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidi-
n-3-yl)carbamate (1.54 g, 4.65 mmol) in EtOH (50 mL) and EtOH (25
mL) was added Pd/C (10%, 0.51 g, 4.65 mmol). After stirring at rt
for 4 h, the reaction mixture was filtered through a celite pad,
and the filtrate was concentrated in vacuo to afford the title
compound (assume quantitative). The crude was used as such in the
following step. LCMS: R.sub.t=0.12 min, m/z=198.0 (M+1) Method
2m_acidic.
Intermediate W: 3-(ammoniomethyl)-1-methylpyridin-1-ium
Chloride
##STR00055##
[0457] Step 1: N-(pyridin-3-ylmethyl)acetamide
[0458] Prepared according to Plater et al. Org. Biomol. Chem. 2009,
7, 1633. To a solution of pyridin-3-ylmethanamine (9.42 ml, 92
mmol) in water (103 ml) at 10.degree. C. was added acetic anhydride
(10.47 ml, 111 mmol), stirred at a rate where the internal
temperature did not rise above 25.degree. C. After an additional 18
h of stirring, the solution was concentrated in vacuo then
co-evaporated with toluene (3.times.) to afford the title compound
(14.22 g, quantitative) as a clear oil. LCMS: R.sub.t=0.12 min,
m/z=151.1 (M+1) Method 2m_acidic. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 8.49 (d, J=2.4 Hz, 2H) 7.65 (dd, J=7.8, 1.6 Hz, 1H)
7.30-7.24-(m, 1H) 6.59-6.49 (m, 1H) 4.43 (d, J=6.0 Hz, 2H) 2.02 (s,
3H).
Step 2: 3-(acetamidomethyl)-1-methylpyridin-1-ium Iodide
[0459] To a solution of N-(pyridin-3-ylmethyl)acetamide (13.89 g,
92 mmol) in DCM at 0.degree. C. was added methyl iodide (8.10 mL,
129 mmol). The cooling bath was removed after 10 min and the
solution was stirred at rt for 19 h, whereupon it was concentrated
in vacuo and used as crude in step 3. LCMS: R.sub.t=0.18 min,
m/z=164.9 (M+) Method 2m_acidic. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.91-8.87 (m, 2H) 8.58 (brs, 1H) 8.42 (d,
J=8.0 Hz, 1H) 8.09 (t, J=7.0 Hz, 1H) 4.43 (d, J=5.9 Hz, 2H) 4.35
(s, 3H) 1.92 (s, 3H)
Step 3: 3-(ammoniomethyl)-1-methylpyridin-1-ium Chloride
[0460] A suspension of 3-(acetamidomethyl)-1-methylpyridin-1-ium
iodide (26.9 g, 92 mmol) in HCl (6N, 307 mL, 1.84 mol) was heated
to 100.degree. C. for 3 h. The solution was concentrated under
reduced pressure (bath temp 80.degree. C.). The resulting red oil
solidified overnight and was triturated with MeOH and filtered to
afford the title compound (8.76 g, 49%) as an off white solid. The
filtrate was concentrated to a red oil, which after standing for 4
days, the formed solid was collected and washed with cold MeOH,
affording a second crop (6.5 g, 36%). LCMS: R.sub.t=0.11 min,
m/z=123.0 (M+) Method 2m_acidic. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.18 (s, 1H) 9.03 (d, J=6.0 Hz, 1H) 8.66
(d, J=8.1 Hz, 1H) 8.45 (brs, 3H) 8.24 (t, J=7.0 Hz, 1H) 4.38 (s,
3H) 4.30 (s, 2H).
The Intermediates described above, and similar compounds made by
the same methods, can be used to prepare compounds of Formula (I)
by the synthesis schemes provided herein. The following Examples
illustrate synthesis of selected compounds of Formula (I) and
provide methods that can be adapted to synthesis of other compounds
of Formula (I).
Example 1.
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2--
oxopyrrolidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy-
)-2-methylpropanoic acid
Step 1: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxopyrrolidin-1-yl)methyl)azetidin-3-yl)amino)ethylidene)amin-
o)oxy)-2-methylpropanoate
[0461] A solution of Intermediate L (100 mg, 0.190 mmol),
methyl-4-bromobutyrate (25 .mu.L, 0.194 mmol) and TEA (27 .mu.L,
0.194 mmol) in DMF (1.3 mL) was heated to 70.degree. C. for 16 h
while stirring, whereupon the heat was then raised to 90.degree. C.
After 6 h of additional heating it was diluted with HCl (1N) and
EtOAc. The aqueous layer was extracted with EtOAc (2.times.) and
the combined organic layers were washed with LiCl soln (5% aq),
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The
crude residue was purified via silica gel chromatography
(EtOAc-Heptane, 50-100% then MeOH-EtOAc, 0-7%), affording the title
compound (21 mg, 18%) as a foam. LCMS: R.sub.t=0.88 min, m/z=595.4
(M+1) Method 2m_acidic.
Step 2:
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((-
2-oxopyrrolidin-1-yl)methyl)azetidine-1-sulfonic Acid
[0462] tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxopyrrolidin-1-yl)methyl)azetidin-3-yl)amino)ethylidene)amin-
o)oxy)-2-methylpropanoate (43 mg, 0.072 mmol) in DMF (725 .mu.L)
was treated with SO.sub.3.DMF (111 mg, 0.725 mmol). The solution
was stirred at rt for 30 min then diluted with EtOAc and poured
into LiCl solution (5% aq). The aqueous was extracted with EtOAc
(2.times.) and the combined organic layers were washed with brine,
dried over Na.sub.2SO.sub.4 and concentrated in vacuo, affording
the crude title compound (55 mg) as a white solid. LCMS: Rt=0.77
min, m/z=675.3 (M+1) Method 2m_acidic. It was used in step 3
without further purification.
Step 3:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxo-
pyrrolidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2-
-methylpropanoic Acid
##STR00056##
[0464] Followed the general procedure for the acid mediated
deprotection using
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-
-oxopyrrolidin-1-yl)methyl)azetidine-1-sulfonic acid (55 mg, 0.072
mmol), DCM (720 .mu.L) and TFA (333 .mu.L, 4.32 mmol). The crude
residue was purified by reverse phase preparative HPLC (XSelect
CSH, 19.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1%
formic acid modifier, 24 mL/min), affording the title compound (6
mg, 16%) as a white solid. LCMS: R.sub.t=0.35 min, m/z=519.0 (M+1)
Method 2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O): .delta.7.17 (s,
1H), 5.46 (d, J=5.8 Hz, 1H), 4.71-4.64 (m, 1H), 3.92 (dd, J=14.7,
8.7 Hz, 1H), 3.71-3.55 (m, 2H), 3.49 (dd, J=14.7, 4.1 Hz, 1H), 2.42
(td, J=8.0, 4.8 Hz, 2H), 2.08 (p, J=7.6 Hz, 2H), 1.55 (s, 3H), 1.54
(s, 3H).
Example 2:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2--
oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy-
)-2-methylpropanoic Acid
Step 1: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(((-
2-(((tert-butyldimethylsilyl)oxy)ethyl)amino)methyl)-4-oxoazetidin-3-yl)am-
ino)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0465] A solution of Intermediate L (500 mg, 0.949 mmol) and
(2-bromoethoxy)(tert-butyl)dimethylsilane (204 .mu.l, 0.949 mmol)
in ACN (3.2 mL) was heated at 80.degree. C. in a microwave for 30
min then kept at rt for 12 h. It was reheated to 100.degree. C. for
45 min in the microwave then kept at rt for 12 h, whereupon it was
diluted with EtOAc and washed with sodium carbonate (2 M, aq),
dried over sodium sulfate and concentrated in vacuo. The crude
residue was purified via silica gel chromatography (EtOAc-Heptane,
0-100% then MeOH-DCM, 10%) to afford the title compound (111 mg,
17%). LCMS: R.sub.t=1.03 min, m/z=685.4 (M+1) Method 2m_acidic;
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.17 (d, J=8.4 Hz, 1H),
7.30 (s, 1H), 6.30 (br s, 1H) 5.57-5.50 (m, 1H) 4.09-4.01 (m, 1H)
3.77-3.61 (m, 3H) 3.09 (dd, J=12.6, 3.7 Hz, 1H) 2.87-2.71 (m, 3H)
1.56 (s, 6H) 1.53 (s, 9H) 1.44 (s, 9H) 0.86 (s, 9H) 0.03 (s, 3H),
0.03 (s, 3H).
Step 2: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(((-
2-hydroxyethyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoate
[0466] Prepared according to Seki et al. Synlett 1995, 609-611. To
a solution of tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(((-
2-((tert-butyldimethylsilyl)oxy)ethyl)amino)methyl)-4-oxoazetidin-3-yl)ami-
no)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (111 mg, 0.162
mmol) in DMF:NMP (2.7:1, 1.62 mL) was added ammonium fluoride
hydrofluoride (37.0 mg, 0.648 mmol). After stirring for 65 h, the
solution was diluted with water and extracted with EtOAc. The
organic layer was dried over sodium sulfate and concentrated in
vacuo to afford crude title compound (92 mg, 99%). The crude
material was used directly in step 3. LCMS: R.sub.t=0.76 min, m/z
571.3 (M+1) Method 2m_acidic.
Step 3: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3-yl)amino)ethylidene)amin-
o)oxy)-2-methylpropanoate
[0467] Prepared according to PCT Int. Appl. 2011061760. A solution
of tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(((-
2-hydroxyethyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoate (92 mg, 0.161 mmol) in Chloroform (806
.mu.l) was treated with CDI (131 mg, 0.806 mmol) After stirring at
rt for 3 h it was diluted with EtOAc, washed with water, brine,
dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude
residue was purified by silica gel chromatography (MeOH-DCM,
0-10%), affording the title compound (91 mg, 95%) as an orange oil.
LCMS: R.sub.t=0.86 min, m/z=597.2 (M+1) Method 2m_acidic.
Step 4:
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((-
2-oxooxazolidin-3-yl)methyl)azetidine-1-sulfonic Acid
[0468] A solution of tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3-yl)amino)ethylidene)amin-
o)oxy)-2-methylpropanoate (91 mg, 0.153 mmol) in DMF (Volume: 763
.mu.l) was treated with SO.sub.3.DMF (234 mg, 1.525 mmol). After
stirring at rt for 1 h it was diluted with EtOAc, washed with brine
(3.times.), dried over Na.sub.2SO.sub.4 and concentrated in vacuo,
affording the title compound (100 mg, 97%) as an orange solid.
LCMS: R.sub.t=0.78 min, m/z=677.3 (M+1) Method 2m_acidic.
Step 5:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxo-
oxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2-
-methylpropanoic Acid
##STR00057##
[0470] Followed the general procedure for the acid mediated
deprotection using
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-
-oxooxazolidin-3-yl)methyl)azetidine-1-sulfonic acid (100 mg, 0.148
mmol), DCM (1.5 mL) and TFA (569 .mu.l, 7.39 mmol). The crude
residue was purified by reverse phase prep HPLC (XSelect CSH,
19.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 24 mL/min), affording the title compound (10 mg,
12%) as a white solid. LCMS: R.sub.t=0.32 min, m/z=521.0 (M+1)
Method 2m_acidic; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.33
(d, J=8.8 Hz, 1H), 6.89 (s, 1H), 5.22 (dd, J=8.8, 5.7 Hz, 1H),
4.23-4.11 (m, 3H), 3.75-3.62 (m, 2H assumed; obscured by water),
3.60-3.51 (m, 1H assumed; obscured by water), 3.34 (dd, J=14.6, 5.5
Hz, 1H), 1.44 (s, 3H), 1.40 (s, 3H).
Example 3:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2--
oxoimidazolidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)o-
xy)-2-methylpropanoic Acid
Step 1: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-(((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)et-
hyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0471] A solution of Intermediate L (650 mg, 1.234 mmol) and
(9H-fluoren-9-yl)methyl (2-oxoethyl)carbamate (365 mg, 1.234 mmol)
in DCE (12.3 ml) was treated with sodium triacetoxyborohydride
(1.377 g, 6.17 mmol). After stirring at rt for 18 h it was quenched
with saturated NaHCO.sub.3 (aq) and extracted with EtOAc. The
organic layer was washed with brine, dried over Na.sub.2SO.sub.4
and concentrated in vacuo. The crude residue was purified via
silica gel chromatography (MeOH-DCM, 0-10%), affording the title
compound (435 mg, 45%) as a white solid. LCMS: R.sub.t=1.00 min,
m/z=792.3 (M+1) Method 2m_acidic; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.11 (d, J=9.0 Hz, 1H), 8.35 (s, 1H), 7.89
(d, J=7.7 Hz, 2H), 7.67 (d, J=7.5 Hz, 2H), 7.41 (t, J=7.2 Hz, 2H),
7.32 (td, J=7.4, 1.2 Hz, 2H), 7.27 (s, 1H), 7.19 (t, J=5.7 Hz, 1H),
5.20 (dd, J=9.1, 5.0 Hz, 1H), 4.30 (d, J=6.8 Hz, 2H), 4.24-4.17 (m,
1H), 3.76 (ddd, J=8.8, 5.3, 3.7 Hz, 1H), 3.11-2.97 (m, 2H), 2.76
(dd, J=12.5, 3.7 Hz, 1H), 2.63-2.52 (m, 3H), 1.45 (s, 9H), 1.42 (s,
3H), 1.39 (s, 3H), 1.38 (s, 9H).
Step 2: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-(((2-aminoethyl)amino)methyl)-4-oxoazetidin-3-yl)a-
mino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino-
)oxy)-2-methylpropanoate
[0472] A solution of tert-butyl
2-(((Z)-(2-(((2R,3S)-2-(((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)et-
hyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (435
mg, 0.549 mmol) in DMF (2.75 mL) was treated with piperidine (1.1
mL, 11 mmol). After stirring at rt for 1 h it was diluted with
toluene and concentrated (3.times.). The crude residue was purified
by reverse phase prep HPLC (XSelect CSH, 19.times.100 mm, 5 .mu.m,
C18 column; ACN-water with 0.1% formic acid modifier, 24 mL/min),
affording the title compound (238 mg, 64%) as a white powder. LCMS:
R.sub.t=0.68 min, m/z=570.3 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.12 (d, J=8.9 Hz, 1H), 8.38 (s,
1H), 8.31 (s, 1H), 7.21 (s, 1H), 5.17 (dd, J=8.3, 4.9 Hz, 1H), 3.76
(dt, J=8.7, 4.7 Hz, 1H), 2.81-2.51 (m, 6H), 1.44 (s, 9H), 1.41 (s,
3H), 1.39 (s, 3H), 1.38 (s, 9H).
Step 3: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxoimidazolidin-1-yl)methyl)azetidin-3-yl)amino)ethylidene)am-
ino)oxy)-2-methylpropanoate
[0473] To a solution of tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-(((2-aminoethyl)amino)methyl)-4-oxoazetidin-3-yl)a-
mino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino-
)oxy)-2-methylpropanoate (100 mg, 0.151 mmol) in chloroform (756
.mu.l) was added CDI (98 mg, 0.604 mmol) followed by TEA (105
.mu.l, 0.756 mmol). After stirring at rt for 1 h it was diluted
with EtOAc, washed with water, brine, dried over Na.sub.2SO.sub.4
and concentrated in vacuo to afford the title compound (73 mg, 81%)
as a white solid. It was used as crude in step 4. LCMS:
R.sub.t=0.70 min, m/z=596.2 (M+1) Method 2m_acidic.
Step 4:
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((-
2-oxoimidazolidin-1-yl)methyl)azetidine-1-sulfonic Acid
[0474] A solution of tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxoimidazolidin-1-yl)methyl)azetidin-3-yl)amino)ethylidene)am-
ino)oxy)-2-methylpropanoate (73 mg, 0.123 mmol) in DMF (613 .mu.l)
was treated with SO.sub.3.DMF (94 mg, 0.613 mmol). After stirring
at rt for 2 h it was diluted with EtOAc, washed with brine
(3.times.), dried over Na.sub.2SO.sub.4 and concentrated in vacuo
to afford the title compound (99 mg) as a white solid. LCMS:
R.sub.t=0.74 min, m/z=676.3 (M+1) Method 2m_acidic.
Step 5:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxo-
imidazolidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-
-2-methylpropanoic Acid
##STR00058##
[0476] Followed the general procedure for the acid mediated
deprotection using
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-
-oxoimidazolidin-1-yl)methyl)azetidine-1-sulfonic acid (99 mg,
0.147 mmol), DCM (1.47 mL) and TFA (566 .mu.l, 7.35 mmol). The
crude residue purified by reverse phase prep HPLC (XSelect CSH,
19.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 24 mL/min), affording the title compound (4.8 mg) as
a white powder. LCMS: R.sub.t=0.31 min, m/z=520.0 (M+1) Method
2m_acidic; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 9.25 (dd,
J=9.0, 5.0 Hz, 1H), 6.83 (s, 1H), 5.21 (dd, J=9.0, 5.8 Hz, 1H),
4.06-4.00 (m, 1H), 3.65 (dd, J=14.5, 4.7 Hz, 1H), 3.33-3.30 (m, 1H
assumed; obscured by water), 3.25 (dd, J=14.5, 6.9 Hz, 2H assumed;
obscured by water), 3.17 (ddd, J=16.7, 8.6, 6.7 Hz, 2H), 1.43 (s,
3H), 1.42 (s, 3H).
Example 4:
2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)-2H-tetrazol-2-yl)methy-
l)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylide-
ne)amino)oxy)-2-methylpropanoic Acid
Step 1
[0477] A 75 mL pressure vessel was charged with Intermediate A
(1.50 g, 3.13 mmol), intermediate B (1.108 g, 4.70 mmol),
K.sub.2CO.sub.3 (1.733 g, 12.54 mmol), NaI (564 mg, 3.76 mmol) and
DMF (10 mL) then heated to 70.degree. C. with stirring. After 3 h,
more intermediate B (1.108 g, 4.70 mmol), K.sub.2CO.sub.3 (1.733 g,
12.54 mmol) and NaI (394 mg, 2.63 mmol) were added and heating was
continued. After 8 h of total heating it was cooled to rt, diluted
with EtOAc/brine and the layers were separated. The aqueous layer
was extracted with EtOAc (2.times.) and the combined organic layers
were washed with brine (3.times.), dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude residue was combined with another
sample of identical scale and procedure and purified via silica gel
chromatography (Acetone-DCM, 0-30%), affording the 2H-tetrazole
isomer (2.15 g, 60%) and 1H-tetrazole isomer (443 mg, 12%) as white
solids. A-LCMS: R.sub.t=0.97 min, m/z=582.3 (M+1) Method 2m_acidic;
B-LCMS: R.sub.t=0.93 min, m/z=582.3 (M+1) Method 2m_acidic.
Step 2
[0478] Prepared according to Mastalerz et al. J. Med. Chem. 1988,
31, 1190. To a solution of 2H-tetrazole isomer (2.15 g, 3.70 mmol)
from step 1 in ACN:water (2:1, 61.5 mL) was added
K.sub.2S.sub.2O.sub.8 (1.40 g, 5.18 mmol) followed by
K.sub.2HPO.sub.4 (837 mg, 4.81 mmol). The resulting mixture was
heated to 90.degree. C. for 1.5 h, whereupon more
K.sub.2S.sub.2O.sub.8 (300 mg, 1.11 mmol) and K.sub.2HPO.sub.4 (167
mg, 0.961 mmol) were added. After 3.5 h of additional heating at
90.degree. C., it was diluted with ACN and concentrated in vacuo,
removing most of the ACN. The mixture was diluted with water/EtOAc
and the layers separated. The aqueous layer was extracted with
EtOAc (5.times.) and the combined organic layers were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (Acetone-DCM, 50%), to
afford the title compound (785 mg, 49%). LCMS: R.sub.t=0.77 min,
m/z=432.3 (M+1) Method 2m_acidic; .sup.1H NMR (500 MHz,
ACN-d.sub.3) 7.49-7.30 (m, 5H), 6.76 (br s, 1H), 6.55-6.41 (m, 1H),
5.85 (br s, 1H), 5.03-5.21 (m, 3H), 4.88-4.71 (m, 2H), 4.52-4.43
(m, 3H), 4.39-4.24 (m, 1H), 1.50-1.35 (m, 9H).
Step 3: tert-Butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-tetrazol-5-yl)methyl)-
carbamate
[0479] Prepared according to the procedure described in Malmstrom
et al. Bioorg. Med. Chem. Lett. 2012, 22, 5293. A solution of
compound from step 2 (785 mg, 1.819 mmol) in EtOAc:MeOH (5:1, 65
mL) was evacuated and backfilled with argon (2.times.) followed by
addition of Pd on C (10%, 581 mg). The system was evacuated and
backfilled with H.sub.2 (3.times.). After 21 h of stirring, the
mixture was filtered over celite, washing with MeOH, concentrated
in vacuo, taken up on toluene and reconcentrated (3.times.). The
crude residue was used as such in following step. LCMS:
R.sub.t=0.37 min, m/z=298.3 (M+1) Method 2m_acidic.
Step 4: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((5-(((tert-butoxycarbonyl)amino)methyl)-2H-tetraz-
ol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino-
)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0480] To a solution of
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (938 mg, 2.18 mmol)
in DCM:DMF (5:1, 8.5 mL) at 0.degree. C. was added DIPEA (953
.mu.L, 5.46 mmol) followed by HATU (830 mg, 2.18 mmol). To the
resulting solution was added a solution of tert-butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-tetrazol-5-yl)methyl)-
carbamate (541 mg, 1.82 mmol) in DCM:DMF (5:1, 8.5 mL). The
solution was stirred at rt for 1 h then concentrated in vacuo,
dissolved in EtOAc and washed with brine. The aqueous layer was
extracted with EtOAc and the combined organic layers were washed
with brine (3.times.), dried over Na.sub.2SO.sub.4 and concentrated
in vacuo. The crude residue was purified via silica gel
chromatography (Acetone-DCM, 30-50%), affording the title compound
(897 mg, 70%) as a purple solid. LCMS: R.sub.t=1.01 min, m/z=709.3
(M+1) Method 2m_acidic.
Step 5:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(((t-
ert-butoxycarbonyl)amino)methyl)-2H-tetrazol-2-yl)methyl)-4-oxoazetidine-1-
-sulfonic Acid
[0481] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((5-(((tert-butoxycarbonyl)amino)methyl)-2H-tetraz-
ol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino-
)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (200
mg, 0.282 mmol) in DMF (2 mL) was treated with SO.sub.3.DMF (432
mg, 2.82 mmol). The purple solution immediately became green. After
20 min of stirring, more SO.sub.3.DMF (432 mg, 2.82 mmol) was
added. After an additional 20 min, more SO.sub.3.DMF (432 mg, 2.82
mmol) was added. After 20 min the solution was diluted with
EtOAc/brine and the layers were separated. The aqueous layer was
extracted with EtOAc (3.times.) and the combined organic layers
were dried over Na.sub.2SO.sub.4 and concentrated in vacuo to
afford the title compound (185 mg, 83%). LCMS: R.sub.t=0.91 min,
m/z=789.1 (M+1) Method 2m_acidic.
Step 6:
2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)-2H-tetrazol-2-yl)methyl)--
4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)-
amino)oxy)-2-methylpropanoic Acid
##STR00059##
[0483] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(((te-
rt-butoxycarbonyl)amino)methyl)-2H-tetrazol-2-yl)methyl)-4-oxoazetidine-1--
sulfonic acid (185 mg, 0.234 mmol), DCM (2.34 mL) and TFA (1.08 mL,
14.06 mmol) for 1.5 h. The crude residue purified by reverse phase
prep HPLC (XSelect CSH, 19.times.100 mm, 5 .mu.m, C18 column;
ACN-water with 0.1% formic acid modifier, 24 mL/min), affording the
title compound (55.5 mg, 45%) as a white powder. LCMS: R.sub.t=0.30
min, m/z=533.0 (M+1) Method 2m_acidic; .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. 9.34 (d, J=8.8 Hz, 1H), 8.55 (br s, 3H), 7.34
(br s, 2H), 6.73 (s, 1H), 5.37 (dd, J=8.7, 5.5 Hz, 1H), 5.19-5.13
(m, 1H), 5.01-4.94 (m, 1H), 4.62-4.57 (m, 1H), 4.43-4.37 (m, 2H),
1.38 (s, 3H) 1.34 (s, 3H).
Example 5:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((5-(guanidinome-
thyl)-2H-tetrazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethy-
lidene)amino)oxy)-2-methylpropanoic Acid
##STR00060##
[0485] To a solution of
2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)-2H-tetrazol-2-yl)methyl)-4-oxo-1-
-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)o-
xy)-2-methylpropanoic acid (20 mg, 0.038 mmol) and
pyrazole-1-carboxamidine hydrochloride (11.6 mg, 0.079 mmol). in
DMF (376 .mu.L) was added DIPEA (26.2 .mu.L, 0.150 mmol). After
stirring at rt for 12h the solution was concentrated in vacuo.
Toluene was added and it was reconcentrated (3.times.). The crude
residue was purified by reverse phase prep HPLC (XSelect CSH,
19.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 24 mL/min), affording the title compound (11 mg,
45%) as a white powder. LCMS: R.sub.t=0.31 min, m/z=575.2 (M+1)
Method 2m_acidic; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.
7.49-7.04 (m, 5H), 6.74 (br s, 1H), 5.26 (br s, 1H), 5.14-5.07 (m,
1H), 4.98-4.90 (m, 1H), 4.65 (br s, 2H), 4.59-4.52 (m, 1H), 1.36
(s, 3H), 1.34 (s, 3H).
Example 6:
2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)-1H-tetrazol-1-yl)methy-
l)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylide-
ne)amino)oxy)-2-methylpropanoic Acid
Step 1
[0486] Prepared in an analogous manner to Example 4, step 2 using
the appropriate 1H-tetrazole isomer obtained in Step 1 in Example 4
(442 mg, 0.760 mmol), K.sub.2S.sub.2O.sub.8 (288 mg, 1.064 mmol)
and K.sub.2HPO.sub.4 (172 mg, 0.988 mmol) in ACN:water (2:1, 12.6
mL) at 90.degree. C. for 1.5 h. More K.sub.2S.sub.2O.sub.8 (62 mg,
0.228 mmol) and K.sub.2HPO.sub.4 (42 mg, 0.198 mmol) were added and
it was heated for an additional 3.5 h then cooled to rt, diluted
with ACN and concentrated in vacuo, removing most of the ACN. The
mixture was diluted with water/EtOAc and the layers separated. The
aqueous layer was extracted with EtOAc (5.times.) and the combined
organic layers were dried over Na.sub.2SO.sub.4. The crude residue
was purified via silica gel chromatography (Acetone-DCM, 50%), to
afford the title compound (179 mg, 54%). LCMS: R.sub.t=0.72 min,
m/z=432.3 (M+1) Method 2m_acidic.
Step 2: tert-Butyl
((1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-tetrazol-5-yl)methyl)-
carbamate
[0487] Prepared in an analogous manner to example 4, step 3, using
the product of Step 1 (179 mg, 0.415 mmol) and Pd on C (10%, 132
mg) in EtOAc:MeOH (10:1, 13.8 mL) for 21 h. The crude residue was
used as such in following step. LCMS: R.sub.t=0.37 min, m/z=298.3
(M+1) Method 2m_acidic.
Step 3: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((5-(((tert-butoxycarbonyl)amino)methyl)-1H-tetraz-
ol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino-
)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0488] Prepared in an analogous manner to example 4, step 3 using
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (214 mg, 0.498
mmol), DIPEA (953 .mu.L, 5.46 mmol) and HATU (830 mg, 2.18 mmol) in
DCM:DMF (5:1, 3.6 mL) at 0.degree. C. followed by a solution of
tert-butyl
((1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-tetrazol-5-yl)methyl)-
carbamate (123 mg, 0.415 mmol) in DCM:DMF (4.3:1, 3.7 mL). After
stirring at rt for 1 h it was subjected to an identical workup then
purified via silica gel chromatography (Acetone-DCM), affording the
title compound (174 mg, 59%) as a light purple solid. LCMS:
R.sub.t=1.03 min, m/z=709.2 (M+1) Method 2m_acidic.
Step 4:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(((t-
ert-butoxycarbonyl)amino)methyl)-1H-tetrazol-1-yl)methyl)-4-oxoazetidine-1-
-sulfonic Acid
[0489] Prepared in an analogous manner to example 4, step 4 using
tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((5-(((tert-butoxycarbonyl)amino)methyl)-1H-tetraz-
ol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino-
)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (100
mg, 0.141 mmol) and SO.sub.3.DMF (216 mg, 1.41 mmol) in DMF (1.4
mL) for 20 min at rt. Subjected to identical workup to afford the
title compound (100 mg, 89%). LCMS: R.sub.t=0.91 min, m/z=789.1
(M+1) Method 2m_acidic.
Step 5:
2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)-1H-tetrazol-1-yl)methyl)--
4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)-
amino)oxy)-2-methylpropanoic Acid
##STR00061##
[0491] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(((te-
rt-butoxycarbonyl)amino)methyl)-1H-tetrazol-1-yl)methyl)-4-oxoazetidine-1--
sulfonic acid (100 mg, 0.126 mmol), DCM (1.26 mL) and TFA (584
.mu.L, 7.58 mmol) for 1.5 h. The crude residue purified by reverse
phase prep HPLC (XSelect CSH, 19.times.100 mm, 5 .mu.m, C18 column;
ACN-water with 0.1% formic acid modifier, 24 mL/min), affording the
title compound (18.7 mg, 28%) as a white powder. LCMS: R.sub.t=0.31
min, m/z=533.2 (M+1) Method 2m_acidic; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.21 (d, J=8.8 Hz, 1H), 7.28 (s, 2H), 6.79
(s, 1H), 5.35 (dd, J=8.8, 5.8 Hz, 1H), 4.79-4.61 (m, 2H), 4.59-4.53
(m, 1H), 4.47-4.35 (m, 2H), 1.36 (br s, 6H).
Example 7:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((5-methyl-2H-te-
trazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amin-
o)oxy)-2-methylpropanoic acid
Step 1, Compound 1: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((5-methyl-2H-tetrazol-2-yl)methyl)-4--
oxoazetidin-3-yl)carbamate
Step 1, Compound 2: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((5-methyl-1H-tetrazol-1-yl)methyl)-4--
oxoazetidin-3-yl)carbamate
[0492] Prepared in an analogous manner to example 4, step 1 using
Intermediate A (1.0 g, 2.1 mmol), 5-methyl-2H-tetrazole (527 mg,
6.27 mmol), K.sub.2CO.sub.3 (1.44 g, 10.5 mmol), NaI (470 mg, 3.13
mmol) in DMF (10 mL) at 70.degree. C. for 4 h. No further reagent
addition was necessary. After cooling to rt it was diluted with
EtOAc, washed with brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude residue was purified via silica
gel chromatography (Acetone-DCM), affording the title compound 1
(680 mg, 70%) and title compound 2 (221 mg, 23%) as solids. 1-LCMS:
R.sub.t=0.87 min, m/z=467.2 (M+1) Method 2m_acidic; 2-LCMS:
R.sub.t=0.80 min, m/z=467.2 (M+1) Method 2m_acidic.
Step 2: Benzyl
((2R,3S)-2-((5-methyl-2H-tetrazol-2-yl)methyl)-4-oxoazetidin-3-yl)carbama-
te
[0493] Prepared in an analogous manner to example 4, step 2 using
benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((5-methyl-2H-tetrazol-1-yl)methyl)-4--
oxoazetidin-3-yl)carbamate (202 mg, 0.433 mmol),
K.sub.2S.sub.2O.sub.8 (164 mg, 0.606 mmol) and K.sub.2HPO.sub.4 (98
mg, 0.563 mmol) in ACN:water (2:1, 7.4 mL) at 90.degree. C. for 1.5
h. More K.sub.2S.sub.2O.sub.8 (35 mg, 0.13 mmol) and
K.sub.2HPO.sub.4 (20 mg, 0.11 mmol) were added and it was heated
for an additional 30 min then cooled to rt then concentrated in
vacuo. The mixture was diluted with EtOAc, washed with brine, dried
over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue
was purified via silica gel chromatography (MeOH-DCM, 0-10%), to
afford the title compound (111 mg, 81%). LCMS: R.sub.t=0.58 min,
m/z=317.2 (M+1) Method 2m_acidic; .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.43-7.30 (m, 5H), 6.34 (br s, 1H), 6.01 (br s, 1H),
5.28-5.21 (m, 1H), 5.20-5.12 (m, 3H), 4.92 (dd, J=14.3, 3.9 Hz,
1H), 4.68 (dd, J=14.2, 7.9 Hz, 1H), 4.48-4.27 (m, 2H), 2.53 (s,
3H).
Step 3:
(3S,4R)-3-amino-4-((5-methyl-2H-tetrazol-2-yl)methyl)azetidin-2-on-
e
[0494] Prepared in an analogous manner to example 4, step 3 using
benzyl
((2R,3S)-2-((5-methyl-2H-tetrazol-2-yl)methyl)-4-oxoazetidin-3-yl)carbama-
te (111 mg, 0.351 mmol) and Pd on C (10%, 50 mg) in EtOAc:MeOH
(5:1, 7.0 mL) for 3 h. The crude residue was used as such in
following step. LCMS: R.sub.t=0.14 min, m/z=183.2 (M+1) Method
2m_acidic.
Step 4: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((5-
-methyl-2H-tetrazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene-
)amino)oxy)-2-methylpropanoate
[0495] Prepared in an analogous manner to example 4, step 3 using
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (130 mg, 0.302
mmol), DIPEA (158 .mu.L, 0.906 mmol) and HATU (138 mg, 0.362 mmol)
in DCM:DMF (2:1, 3.0 mL) at 0.degree. C. followed by a solution of
(3S,4R)-3-amino-4-((5-methyl-2H-tetrazol-2-yl)methyl)azetidin-2-one
(55 mg, 0.30 mmol) in DCM:DMF (2:1, 3.0 mL). After stirring at rt
for 1 h it was concentrated in vacuo, dissolved in EtOAc, washed
with water then brine, dried over Na.sub.2SO.sub.4 and concentrated
in vacuo. The crude residue was purified via silica gel
chromatography (Acetone-DCM), affording the title compound (179 mg,
99%) as a solid. LCMS: R.sub.t=0.93 min, m/z=594.3 (M+1) Method
2m_acidic.
Step 5:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-meth-
yl-2H-tetrazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic Acid
[0496] Prepared in an analogous manner to example 4, step 4 using
tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((5-
-methyl-2H-tetrazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene-
)amino)oxy)-2-methylpropanoate (179 mg, 0.302 mmol) and
SO.sub.3.DMF (462 mg, 3.02 mmol) in DMF (3.0 mL) for 1 h at rt. The
solution was diluted with EtOAc, washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to afford the title
compound (assumed quantitative). LCMS: R.sub.t=0.80 min, m/z=674.1
(M+1) Method 2m_acidic.
Step 6:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((5-methyl-2H-tetra-
zol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)o-
xy)-2-methylpropanoic Acid
[0497] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-methy-
l-2H-tetrazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic acid (203 mg,
0.302 mmol), DCM (3.0 mL) and TFA (1.39 mL, 18.1 mmol) for 2 h. The
crude residue purified by reverse phase prep HPLC (XSelect CSH,
19.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 24 mL/min), affording the title compound (37 mg,
24%) as a white powder. LCMS: R.sub.t=0.35 min, m/z=518.1 (M+1)
Method 2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.03 (s,
1H), 5.37 (d, J=5.5 Hz, 1H), 5.08-4.97 (m, 1H), 4.90-4.80 (m, 2H),
2.35 (s, 3H), 1.32 (s, 3H), 1.31 (s, 3H).
Example 8:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((5-methyl-1H-te-
trazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amin-
o)oxy)-2-methylpropanoic Acid
Step 1: Benzyl
((2R,3S)-2-((5-methyl-1H-tetrazol-1-yl)methyl)-4-oxoazetidin-3-yl)carbama-
te
[0498] Prepared in an analogous manner to example 4, step 2 using
benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((5-methyl-1H-tetrazol-1-yl)methyl)-4--
oxoazetidin-3-yl)carbamate (221 mg, 0.474 mmol),
K.sub.2S.sub.2O.sub.8 (179 mg, 0.663 mmol) and K.sub.2HPO.sub.4
(107 mg, 0.616 mmol) in ACN:water (2:1, 7.9 mL) at 90.degree. C.
for 1.5 h. More K.sub.2S.sub.2O.sub.8 (38.4 mg, 0.142 mmol) and
K.sub.2HPO.sub.4 (21.5 mg, 0.123 mmol) were added and it was heated
for an additional 30 min then cooled to rt then concentrated in
vacuo. The mixture was diluted with EtOAc, washed with brine, dried
over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue
was purified via silica gel chromatography (MeOH-DCM, 0-10%), to
afford the title compound (97 mg, 65%). LCMS: R.sub.t=1.00 min,
m/z=317.3 (M+1) Method 2m_acidic.
Step 2:
(3S,4R)-3-amino-4-((5-methyl-1H-tetrazol-1-yl)methyl)azetidin-2-on-
e
[0499] Prepared in an analogous manner to example 4, step 3 using
benzyl
((2R,3S)-2-((5-methyl-1H-tetrazol-1-yl)methyl)-4-oxoazetidin-3-yl)carbama-
te (97 mg, 0.31 mmol) and Pd on C (10%, 50 mg) in EtOH:MeOH (5:1,
3.0 mL) for 3 h. The crude residue was used as such in following
step. LCMS: R.sub.t=0.11 min, m/z=183.2 (M+1) Method 2m_acidic.
Step 3: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((5-
-methyl-1H-tetrazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene-
)amino)oxy)-2-methylpropanoate
[0500] Prepared in an analogous manner to example 4, step 3 using
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (130 mg, 0.302
mmol), DIPEA (158 .mu.L, 0.906 mmol) and HATU (115 mg, 0.302 mmol)
in DCM:DMF (2:1, 3.0 mL) at 0.degree. C. followed by a solution of
(3S,4R)-3-amino-4-((5-methyl-1H-tetrazol-1-yl)methyl)azetidin-2-one
(55 mg, 0.30 mmol) in DCM:DMF (2:1, 3.0 mL). After stirring at rt
for 1 h it was concentrated in vacuo, dissolved in EtOAc, washed
with water then brine, dried over Na.sub.2SO.sub.4 and concentrated
in vacuo. The crude residue was purified via silica gel
chromatography (Acetone-DCM), affording the title compound (133 mg,
74%) as a solid. LCMS: R.sub.t=0.92 min, m/z=594.2 (M+1) Method
2m_acidic.
Step 4:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-meth-
yl-1H-tetrazol-1-yl)methyl)-4-oxoazetidine-1-sulfonic Acid
[0501] Prepared in an analogous manner to example 4, step 4 using
tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((5-
-methyl-1H-tetrazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene-
)amino)oxy)-2-methylpropanoate (133 mg, 0.224 mmol) and
SO.sub.3.DMF (343 mg, 2.24 mmol) in DMF (2.24 mL) for 1 h at rt.
The solution was diluted with EtOAc, washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to afford the title
compound (assumed quantitative). LCMS: R.sub.t=0.85 min, m/z=674.2
(M+1) Method 2m_acidic.
Step 5:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((5-methyl-1H-tetra-
zol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)o-
xy)-2-methylpropanoic Acid
##STR00062##
[0503] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-methy-
l-1H-tetrazol-1-yl)methyl)-4-oxoazetidine-1-sulfonic acid (151 mg,
0.224 mmol), DCM (2.24 mL) and TFA (1.04 mL, 13.45 mmol) for 2 h.
The crude residue purified by reverse phase prep HPLC (XSelect CSH,
19.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 24 mL/min), affording the title compound (14.4 mg,
11%) as a white powder. LCMS: R.sub.t=0.55 min, m/z=518.1 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta.
7.04 (s, 1H), 5.37 (d, J=5.5 Hz, 1H), 4.83-4.77 (m, 1H), 4.76-4.54
(m, 2H assumed; obscured by solvent), 2.48 (s, 3H), 1.35 (s, 3H),
1.33 (s, 3H).
Example 9:
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1--
sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)ox-
y)-2-methylpropanoic acid
Step 1: benzyl
((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoa-
zetidin-3-yl)carbamate
[0504] A 20 mL microwave vial was charged with Intermediate A (250
mg, 0.0522 mmol), 1,2,4-triazole (54 mg, 0.784 mmol),
K.sub.2CO.sub.3 (215 mg, 1.56 mmol), NaI (94 mg, 0.63 mmol) and DMF
(2 mL) then heated to 70.degree. C. with stirring. After 4 h, more
1,2,4-triazole (54 mg, 0.784 mmol), K.sub.2CO.sub.3 (215 mg, 1.56
mmol) and NaI (94 mg, 0.63 mmol) were added and heating was
continued. After 7 h of total heating it was cooled to rt, diluted
with DCM/brine and the layers were separated. The aqueous layer was
extracted with DCM and the combined organic layers were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. Toluene was added and
it was concentrated in vacuo (40.degree. C. bath). The crude
residue was purified via silica gel chromatography
(Acetone-Heptane, 50%) to afford the title compound (156 mg, 66%).
LCMS: Rt=0.77 min, m/z=452.3 (M+1) Method 2m_acidic.
Step 2: Benzyl
((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)carbamate
[0505] Prepared in an analogous manner to example 4, step 2 using
benzyl
((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoa-
zetidin-3-yl)carbamate (101 mg, 0.224 mmol), K.sub.2S.sub.2O.sub.8
(85 mg, 0.313 mmol) and K.sub.2HPO.sub.4 (50.7 mg, 0.291 mmol) in
ACN:water (2:1, 61.5 mL) while heating for 2 h at 90.degree. C.
More K.sub.2S.sub.2O.sub.8 (18.1 mg, 0.067 mmol) and
K.sub.2HPO.sub.4 (10.1 mg, 0.058 mmol) were added and heated for
another 1.5 h. More K.sub.2S.sub.2O.sub.8 (18.1 mg, 0.067 mmol) and
K.sub.2HPO.sub.4 (10.1 mg, 0.058 mmol) were added and heated for
another hour. It was diluted with ACN and concentrated in vacuo,
removing most of the ACN. The mixture was diluted with water/DCM
then added EtOAc and the layers separated. The aqueous layer was
extracted with EtOAc (5.times.) and the combined organic layers
were dried over Na.sub.2SO.sub.4. The crude residue was purified
via silica gel chromatography (MeOH-DCM, 10%) to afford the title
compound (38 mg, 56%). LCMS: R.sub.t=0.50 min, m/z=302.2 (M+1)
Method 2m_acidic; .sup.1H NMR (500 MHz, ACN-d.sub.3) .delta. 8.17
(s, 1H), 7.92 (s, 1H), 7.49-7.31 (m, 4H), 6.82-6.74 (m, 1H), 6.67
(br s, 1H), 5.18-5.01 (m, 3H), 4.49-4.42 (m, 1H), 4.37-4.30 (m,
1H), 4.21 (q, J=5.4 Hz, 1H).
Step 3:
(3S,4R)-4-((1H-1,2,4-triazol-1-yl)methyl)-3-aminoazetidin-2-one
[0506] To a solution of benzyl
((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)carbamate
(38 mg, 0.126 mmol) in MeOH (5 mL) was added Pd black (6.7 mg,
0.063 mmol) followed by formic acid (339 .mu.L, 8.83 mmol). After 1
h of stirring, the mixture was filtered over celite, washing with
MeOH, and the filtrate was concentrated in vacuo. The solution was
lyophilized and the crude material was used directly in the
subsequent step. LCMS: R.sub.t=0.14 min, m/z=168.1 (M+1) Method
2m_acidic.
Step 4: tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoate
[0507] To a slurry of
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (81 mg, 0.19 mmol)
in DCM (800 .mu.L) at 0.degree. C. was added DIPEA (88 .mu.L, 0.504
mmol) followed by HATU (72 mg, 0.190 mmol). A few drops of DMF were
added to homogenize the mixture. To the resulting solution was
added a solution of
(3S,4R)-4-((1H-1,2,4-triazol-1-yl)methyl)-3-aminoazetidin-2-one (21
mg, 0.126 mmol) in DCM (1 mL). After 1.5 h of stirring it was
diluted with water/DCM and the layers separated. The aqueous layer
was extracted with DCM and the combined organic layers were dried
over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue
was purified via silica gel chromatography (Acetone-DCM) to afford
the title compound (47 mg, 65%). LCMS: R.sub.t=0.88 min, m/z=579.3
(M+1) Method 2m_acidic.
Step 5:
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-(((1-(tert-buto-
xy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)-
thiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic Acid
[0508] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoate (44 mg, 0.076 mmol) in DMF (760 .mu.L)
was treated with SO3.DMF (116 mg, 0.760 mmol). After 1 h of
stirring, the solution was diluted with EtOAc/brine and the layers
were separated. The aqueous layer was extracted with EtOAc
(3.times.) and the combined organic layers were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to afford the title
compound (assumed quantitative) as a white solid. LCMS: Rt=0.81
min, m/z=659.3 (M+1) Method 2m_acidic.
Step 6:
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sul-
foazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)--
2-methylpropanoic Acid
##STR00063##
[0510] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-(((1-(tert-butox-
y)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)t-
hiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic acid (50.1 mg,
0.076 mmol), DCM (760 .mu.L) and TFA (351 .mu.l, 4.56 mmol). The
crude residue purified by reverse phase prep HPLC (XSelect CSH,
19.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 24 mL/min), affording the title compound (14.8 mg,
34%) as a white powder. LCMS: R.sub.t=0.31 min, m/z=503.1 (M+1)
Method 2m_acidic; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 9.39
(d, J=8.83 Hz, 1H), 8.52 (s, 1H), 8.02 (s, 1H), 6.74 (s, 1H), 5.28
(dd, J=8.8, 5.4 Hz, 1H), 4.74-4.64 (m, 1H), 4.58 (d, J=6.9 Hz, 1H),
4.32 (d, J=5.7 Hz, 1H), 1.37 (s, 3H) 1.41 (s, 3H).
Example 10:
2-(((Z)-(2-(((2R,3S)-2-((3-(aminomethyl)-1H-1,2,4-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic Acid
Step 1
[0511]
((2S,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-o-
xoazetidin-2-yl)methyl methanesulfonate (3.10 g, 6.48 mmol),
tert-butyl ((1H-1,2,4-triazol-3-yl)methyl)carbamate (1.926 g, 9.72
mmol), K.sub.2CO.sub.3 (1.35 g, 9.72 mmol) and NaI (1.165 g, 7.78
mmol) were slurried in DMF (20 mL) and heated to 70.degree. C. with
stirring. After 3 h, more tert-butyl
((1H-1,2,4-triazol-3-yl)methyl)carbamate (1.926 g, 9.72 mmol),
K.sub.2CO.sub.3 (1.35 g, 9.72 mmol) and NaI (777 mg, 8.10 mmol)
were added and it was heated an additional 4 h, whereupon it was
diluted with EtOAc/water and the layers were separated. The aqueous
layer was extracted with EtOAc (2.times.) and the combined organic
layers were washed with brine (3.times.), dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (Acetone-Heptane, 0-70%) to
afford the 3-substituted isomer (1.16 g, 31%) along with the
5-substituted isomer (375 mg, 10%). A-LCMS: R.sub.t=0.87 min,
m/z=581.2 (M+1) Method 2m_acidic; B-LCMS: R.sub.t=0.94 min,
m/z=581.2 (M+1) Method 2m_acidic; B-.sup.1H NMR (500 MHz,
CDCl.sub.3) .delta. 7.86 (s, 1H), 7.44-7.31 (m, 4H), 7.29 (s, 3H),
6.90 (d, J=8.2 Hz, 1H), 6.49-6.37 (m, 2H), 5.25-5.04 (m, 3H),
4.54-4.43 (m, 2H), 4.43-4.22 (m, 3H), 4.13 (d, J=5.4 Hz, 1H),
3.90-3.71 (m, 7H), 1.36-1.51 (m, 9H).
Step 2
[0512] Prepared in an analogous manner to Example 4, step 2 using
the 3-substituted isomer from Step 1 (1.16 g, 2.00 mmol),
K.sub.2S.sub.2O.sub.8 (756 mg, 2.80 mmol) and K.sub.2HPO.sub.4 (452
mg, 2.60 mmol) in ACN:water (2:1, 33.3 mL) while heating for 1.5 h
at 90.degree. C. More K.sub.2S.sub.2O.sub.8 (162 mg, 0.599 mmol)
and K.sub.2HPO.sub.4 (90 mg, 0.52 mmol) were added and heated for
another 3.5 h, whereupon it was concentrated in vacuo, removing
most of the ACN. The mixture was diluted with water/EtOAc and the
layers were separated. The aqueous layer was extracted with EtOAc
(5.times.) and the combined organic layers were dried over
Na.sub.2SO.sub.4. The crude residue was purified via silica gel
chromatography (Acetone-DCM, 0-100%) to afford the title compound
(416 mg, 48%). LCMS: R.sub.t=0.71 min, m/z=431.3 (M+1) Method
2m_acidic; .sup.1H NMR (500 MHz, ACN-d.sub.3) .delta. 8.08 (s, 1H),
7.49-7.25 (m, 5H), 6.82-6.60 (m, 2H), 5.81-5.62 (m, 1H), 5.21-5.03
(m, 3H), 4.48-4.07 (m, 6H), 1.46-1.33 (m, 9H).
Step 3: tert-butyl
((1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-1,2,4-triazol-3-yl)me-
thyl)carbamate
[0513] Prepared according to the procedure described in Malmstrom
et al. Bioorg. Med. Chem. Lett. 2012, 22, 5293. A solution of the
product of Step 2 (416 mg, 0.966 mmol) in EtOAc:MeOH (5:1, 32.2 mL)
was evacuated and backfilled with argon (2.times.) followed by
addition of Pd on C (10%, 103 mg). The system was evacuated and
backfilled with H.sub.2 (3.times.). After 21 h of stirring MeOH
(282 .mu.L) was added. After an additional 4 h of stirring the
mixture was filtered over celite, washing with MeOH, concentrated
in vacuo, taken up on toluene and reconcentrated (3.times.). The
crude residue was used as such in following step. LCMS:
R.sub.t=0.33 min, m/z=297.2 (M+1) Method 2m_acidic.
Step 4: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((3-(((tert-butoxycarbonyl)amino)methyl)-1H-1,2,4--
triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)-
amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0514] To a slurry of
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (47 mg, 0.109 mmol)
in DCM:DMF (12:1, 6.5 mL) at 0.degree. C. was added DIPEA (505
.mu.L, 2.89 mmol) followed by HATU (440 mg, 1.16 mmol). To the
resulting solution was added a solution of tert-butyl
((1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-1,2,4-triazol-3-yl)me-
thyl)carbamate (286 mg, 0.964 mmol) in DCM:DMF (14:1, 7.5 mL).
After 1 h of stirring it was diluted with water/EtOAc and the
layers separated. The aqueous layer was extracted with EtOAc and
the combined organic layers were washed with brine (3.times.),
dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude
residue was purified via silica gel chromatography (Acetone-DCM,
70%) to afford the title compound (428 mg, 63%). LCMS: R.sub.t=0.99
min, m/z=708.2 (M+1) Method 2m_acidic.
Step 5:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((3-(((t-
ert-butoxycarbonyl)amino)methyl)-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetid-
ine-1-sulfonic Acid
[0515] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((3-(((tert-butoxycarbonyl)amino)methyl)-1H-1,2,4--
triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)-
amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
(200 mg, 0.283 mmol) in DMF (2.0 mL) was treated with SO3.DMF (433
mg, 2.83 mmol). After 20 min of stirring, the solution was diluted
with EtOAc/brine and the layers were separated. The aqueous layer
was extracted with EtOAc (3.times.) and the combined organic layers
were dried over Na.sub.2SO.sub.4 and concentrated in vacuo to
afford the title compound (assumed quantitatie) as a white solid.
LCMS: R.sub.t=0.91 min, m/z=788.4 (M+1) Method 2m_acidic.
Step 6:
2-(((Z)-(2-(((2R,3S)-2-((3-(aminomethyl)-1H-1,2,4-triazol-1-yl)met-
hyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyli-
dene)amino)oxy)-2-methylpropanoic Acid
##STR00064##
[0517] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((3-(((te-
rt-butoxycarbonyl)amino)methyl)-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidi-
ne-1-sulfonic acid (223 mg, 0.283 mmol), DCM (2.89 mL) and TFA
(1.31 ml, 16.98 mmol). The crude residue purified by reverse phase
prep HPLC (XSelect CSH, 19.times.100 mm, 5 .mu.m, C18 column;
ACN-water with 0.1% formic acid modifier, 24 mL/min), affording the
title compound (99 mg, 65%) as a white powder. LCMS: R.sub.t=0.31
min, m/z=532.2 (M+1) Method 2m_acidic; .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. 9.45 (d, J=8.5 Hz, 1H), 8.53 (s, 1H), 8.39
(br s, 3H), 7.32 (s, 2H), 6.74 (s, 1H), 5.23 (dd, J=8.5, 5.7 Hz,
1H), 4.76-4.65 (m, 1H), 4.62-4.55 (m, 1H), 4.32-4.27 (m, 1H),
4.16-4.08 (m, 2H), 1.36 (s, 3H) 1.43 (s, 3H).
Example 11:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((3-(guanidinomethyl)-1H-1-
,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-2-methylpropanoic Acid
##STR00065##
[0519] To a solution
2-(((Z)-(2-(((2R,3S)-2-((3-(aminomethyl)-1H-1,2,4-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic acid (25 mg, 0.047 mmol) and
pyrazole-1-carboxamidine hydrochloride (10.9 mg, 0.099 mmol) in DMF
(470 .mu.L) was added DIPEA (33 .mu.L, 0.188 mmol). After stirring
at rt for 12 h the solution was concentrated in vacuo. Toluene was
added and it was reconcentrated (3.times.). The crude residue was
purified by reverse phase prep HPLC (XSelect CSH, 19.times.100 mm,
5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier, 24
mL/min), affording the title compound (16 mg, 52%) as a white
powder. LCMS: R.sub.t=0.31 min, m/z=574.3 (M+1) Method 2m_acidic;
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 9.45 (br s, 1H), 8.47
(s, 1H), 7.86 (br s, 1H), 7.31 (br s, 3H), 6.74 (br s, 1H), 6.55
(s, 1H), 5.22 (br s, 1H), 4.69-4.59 (m, 1H), 4.60-4.50 (m, 1H),
4.45-4.36 (m, 2H), 4.34-4.26 (m, 1H), 1.35 (s, 3H) 1.41 (s,
3H).
Example 12:
2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)-1H-1,2,4-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic Acid
Step 1
[0520] Prepared in an analogous manner to Example 4, step 2 using
the 5-substituted isomer from Step 1 in Example 10 (361 mg, 0.622
mmol), K.sub.2S.sub.2O.sub.8 (235 mg, 0.870 mmol) and
K.sub.2HPO.sub.4 (115 mg, 0.808 mmol) in ACN:water (2:1, 10.4 mL)
while heating for 1.5 h at 90.degree. C. More K.sub.2S.sub.2O.sub.8
(50 mg, 0.187 mmol) and K.sub.2HPO.sub.4 (23 mg, 0.162 mmol) were
added and heated for another 3.5 h, whereupon it was concentrated
in vacuo, removing most of the ACN. The mixture was diluted with
water/EtOAc and the layers were separated. The aqueous layer was
extracted with EtOAc (5.times.) and the combined organic layers
were dried over Na.sub.2SO.sub.4. The crude residue was purified
via silica gel chromatography (Acetone-DCM, 0-100%) to afford the
title compound (155 mg, 58%). LCMS: R.sub.t=0.71 min, m/z=431.2
(M+1) Method 2m_acidic.
Step 2: tert-Butyl
((1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-1,2,4-triazol-5-yl)me-
thyl)carbamate
[0521] Prepared according to Example 7, step 3. A solution of the
product of Step 1 (134 mg, 0.311 mmol) in EtOAc:MeOH (5:1, 10.4 mL)
was evacuated and backfilled with argon (2.times.) followed by
addition of Pd on C (10%, 33 mg). The system was evacuated and
backfilled with H.sub.2 (3.times.). After 21 h of stirring MeOH
(282 .mu.L) was added. After an additional 4 h of stirring the
mixture was filtered over celite, washing with MeOH, concentrated
in vacuo, taken up on toluene and reconcentrated (3.times.). The
crude residue was used as such in following step. LCMS:
R.sub.t=0.38 min, m/z=297.2 (M+1) Method 2m_acidic.
Step 3: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((5-(((tert-butoxycarbonyl)amino)methyl)-1H-1,2,4--
triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)-
amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0522] To a slurry of
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (160 mg, 0.373 mmol)
in DCM:DMF (30:1, 3.1 mL) at 0.degree. C. was added DIPEA (163
.mu.L, 0.933 mmol) followed by HATU (142 mg, 0.373 mmol). To the
resulting solution was added a solution of tert-butyl
((1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-1,2,4-triazol-5-yl)me-
thyl)carbamate (92 mg, 0.311 mmol) in DCM:DMF (30:1, 3.1 mL). After
1 h of stirring it was concentrated in vacuo and taken up in
EtOAc/brine. The layers separated and the aqueous layer was
extracted with EtOAc. The combined organic layers were washed with
brine (3.times.), dried over Na.sub.2SO.sub.4 and concentrated in
vacuo. The crude residue was purified via silica gel chromatography
(Acetone-DCM, 70%) to afford the title compound (128 mg, 58%).
LCMS: R.sub.t=0.97 min, m/z=708.2 (M+1) Method 2m_acidic.
Step 4:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(((t-
ert-butoxycarbonyl)amino)methyl)-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetid-
ine-1-sulfonic Acid
[0523] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((5-(((tert-butoxycarbonyl)amino)methyl)-1H-1,2,4--
triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)-
amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
(128 mg, 0.181 mmol) in DMF (1.3 mL) was treated with SO3.DMF (277
mg, 1.81 mmol). After 20 min of stirring, the solution was diluted
with EtOAc/brine and the layers were separated. The aqueous layer
was extracted with EtOAc (3.times.) and the combined organic layers
were dried over Na.sub.2SO.sub.4 and concentrated in vacuo to
afford the title compound (assumed quantitatie) as a white solid.
LCMS: Rt=0.90 min, m/z=788.3 (M+1) Method 2m_acidic.
Step 5:
2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)-1H-1,2,4-triazol-1-yl)met-
hyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyli-
dene)amino)oxy)-2-methylpropanoic Acid
##STR00066##
[0525] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(((te-
rt-butoxycarbonyl)amino)methyl)-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidi-
ne-1-sulfonic acid (143 mg, 0.181 mmol), DCM (1.81 mL) and TFA (837
.mu.l, 10.9 mmol). The crude residue purified by reverse phase prep
HPLC (XSelect CSH, 19.times.100 mm, 5 .mu.m, C18 column; ACN-water
with 0.1% formic acid modifier, 24 mL/min), affording the title
compound (60 mg, 62%) as a white powder. LCMS: R.sub.t=0.28 min,
m/z=532.2 (M+1) Method 2m_acidic; .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. 9.23 (d, J=9.1 Hz, 1H), 8.40 (br s, 3H), 8.06
(s, 1H), 7.59-7.27 (m, 2H), 6.84 (s, 1H), 5.37 (dd, J=9.0, 5.5 Hz,
1H), 4.61-4.51 (m, 1H), 4.49-4.34 (m, 3H), 4.25 (dd, J=15.3, 5.8
Hz, 1H), 1.37 (s, 6H).
Example 13:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((5-(guanidinomethyl)-1H-1-
,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-2-methylpropanoic Acid
##STR00067##
[0527] To a solution
2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)-1H-1,2,4-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic acid (25 mg, 0.047 mmol) and
pyrazole-1-carboxamidine hydrochloride (10.9 mg, 0.099 mmol) in DMF
(470 .mu.L) was added DIPEA (33 .mu.L, 0.188 mmol). After stirring
at rt for 12 h the solution was concentrated in vacuo. Toluene was
added and it was reconcentrated (3.times.). The crude residue was
purified by reverse phase prep HPLC (XSelect CSH, 19.times.100 mm,
5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier, 24
mL/min), affording the title compound (13 mg, 42%) as a white
powder. LCMS: R.sub.t=0.29 min, m/z=574.2 (M+1) Method 2m_acidic;
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 7.96-7.78 (m, 1H),
7.41-6.96 (m, 5H), 6.80-6.71 (m, 1H), 6.55 (s, 1H), 5.42-5.32 (m,
1H), 4.75-4.63 (m, 1H), 4.62-4.42 (m, 1H), 4.39-4.28 (m, 1H), 1.38
(s, 3H) 1.34 (s, 3H).
Example 14:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxopiperid-
in-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2-methylp-
ropanoic Acid
Step 1: Benzyl
((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-((2-oxopyridin-1
(2H)-yl)methyl)azetidin-3-yl)carbamate
[0528]
((2S,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-o-
xoazetidin-2-yl)methyl methanesulfonate (860 mg, 1.80 mmol),
pyridin-2(1H)-one (855 mg, 8.99 mmol), K.sub.2CO.sub.3 (1.74 g,
12.6 mmol) and NaI (746 mg, 4.49 mmol) were slurried in DMF (6.9
mL) and heated to 80.degree. C. with stirring. After 4 h, it was
cooled to rt, diluted with EtOAc and washed with brine. The organic
layer was dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
The crude residue was purified via silica gel chromatography
(Acetone-DCM) to afford title compound (304 mg, 35%). LCMS:
R.sub.t=0.79 min, m/z=478.2 (M+1) Method 2m_acidic; .sup.1H NMR
(500 MHz, CDCl.sub.3) .delta. 7.39-7.28 (m, 6H), 7.07 (d, J=5.9 Hz,
1H), 6.93-6.85 (m, 1H), 6.55 (d, J=9.0 Hz, 1H), 6.40 (d, J=2.4 Hz,
1H), 6.35 (dd, J=8.2, 2.4 Hz, 1H), 6.10-6.02 (m, 1H), 5.87 (d,
J=7.8 Hz, 1H), 5.10 (s, 2H), 4.93 (br s, 1H), 4.63 (d, J=14.5 Hz,
1H), 4.27-4.10 (m, 1H), 3.97 (d, J=9.0 Hz, 2H), 3.88 (d, J=14.5 Hz,
1H), 3.78 (s, 3H), 3.76 (s, 3H).
Step 2: Benzyl
((3S,4R)-2-oxo-4-((2-oxopyridin-1(2H)-yl)methyl)azetidin-3-yl)carbamate
[0529] Prepared in an analogous manner to example 4, step 2 using
Benzyl ((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-((2-oxopyridin-1
(2H)-yl)methyl)azetidin-3-yl)carbamate (361 mg, 0.622 mmol),
K.sub.2S.sub.2O.sub.8 (225 mg, 0.833 mmol) and K.sub.2HPO.sub.4
(135 mg, 0.773 mmol) in ACN:water (2:1, 9.9 mL) while heating for
1.5 h at 90.degree. C. More K.sub.2S.sub.2O.sub.8 (45 mg, 0.17
mmol) and K.sub.2HPO.sub.4 (26.9 mg, 0.155 mmol) were added and
heated for another 30 min, whereupon it was concentrated,
redissolved in EtOAc, washed with brine, dried over
Na.sub.2SO.sub.4, and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (MeOH-DCM, 0-10%) to afford
the title compound (157 mg, 81%). LCMS: R.sub.t=0.56 min, m/z=328.2
(M+1) Method 2m_acidic.
Step 3, Compound 1:
1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)pyridin-2(1H)-one
Step 3, Compound 2:
1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)piperidin-2-one
[0530] Prepared according to example 7, step 3. A solution of
benzyl
((3S,4R)-2-oxo-4-((2-oxopyridin-1(2H)-yl)methyl)azetidin-3-yl)carbamate
(157 mg, 0.480 mmol) in EtOH:MeOH (5:1, 4.8 mL) was evacuated and
backfilled with argon (2.times.) followed by addition of Pd on C
(10%, 33 mg). The system was evacuated and backfilled with H.sub.2
(3.times.). After 3 h of stirring the mixture was filtered over
celite, washing with MeOH and concentrated in vacuo. The crude
residue was used as such in following step.
Step 4, Compound 1: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S4R)--
2-oxo-4-((2-oxopyridin-1(2H)-yl)methyl)azetidin-3-yl)amino)ethylidene)amin-
o)oxy)-2-methylpropanoate
Step 4, Compound 2: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl(3S,4R)-2-oxo-4-((2-
-oxopiperidin-1-yl)methyl)azetidin-3-yl)amino)ethylidene)amino)oxy)-2-meth-
ylpropanoate
[0531] To a slurry of
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (60 mg, 0.14 mmol)
in DCM:DMF (1:1, 1.4 mL) at 0.degree. C. was added DIPEA (73 .mu.L,
0.42 mmol) followed by HATU (63.7 mg, 0.168 mmol). To the resulting
solution, after 20 min, was added a mixture solution of
1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)pyridin-2(1H)-one and
1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)piperidin-2-one (90
mg, .about.0.46 mmol) in DCM (200 .mu.L). After 1 h of stirring it
was concntrated in vacuo and taken up in EtOAc, washed with water,
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The
crude residue was purified via silica gel chromatography
(Acetone-DCM) to afford title compound 1 (54 mg) and title compound
2 (30 mg). 1-LCMS: R.sub.t=0.88 min, m/z=605.2 (M+1) Method
2m_acidic; 2-LCMS: R.sub.t=0.90 min, m/z=609.2 (M+1) Method
2m_acidic.
Step 5:
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((-
2-oxopiperidin-1-yl)methyl)azetidine-1-sulfonic Acid
[0532] tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxopiperidin-1-yl)methyl)azetidin-3-yl)amino)ethylidene)amino-
)oxy)-2-methylpropanoate (30 mg, 0.049 mmol) in DMF (493 .mu.L) was
treated with SO.sub.3.DMF (151 mg, 0.986 mmol). After 1 h of
stirring, the solution was diluted with EtOAc, washed with brine,
dried over Na.sub.2SO.sub.4 and concentrated in vacuo to afford the
title compound (assumed quantitative) as a white solid. LCMS:
Rt=0.78 min, m/z=689.1 (M+1) Method 2m_acidic.
Step 6:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxo-
piperidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2--
methylpropanoic Acid
##STR00068##
[0534] Followed the general procedure for the acid mediated
deprotection using
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-
-oxopiperidin-1-yl)methyl)azetidine-1-sulfonic acid (34 mg, 0.049
mmol), DCM (494 .mu.L) and TFA (228 .mu.l, 2.96 mmol). The crude
residue purified by reverse phase prep HPLC (XSelect CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min), affording the title compound (5.2 mg,
17%) as a white powder. LCMS: R.sub.t=0.63 min, m/z=533.1 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta.
7.02 (s, 1H), 5.27 (d, J=5.5 Hz, 1H), 4.59-4.48 (m, 1H), 3.61 (d,
J=4.7 Hz, 2H), 3.48-3.37 (m, 1H), 3.32 (d, J=5.9 Hz, 1H), 2.34-2.13
(m, 2H), 1.78-1.57 (m, 4H), 1.39 (br s, 6H).
Example 15:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxopyridin-
-1(2H)-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2-methy-
lpropanoic Acid
##STR00069##
[0535] Step 1:
(3S,4R)-3-((Z)-2-(((1-(ter-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxopyr-
idin-1(2H)-yl)methyl)azetidine-1-sulfonic Acid
[0536] tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxopyridin-1
(2H)-yl)methyl)azetidin-3-yl)amino)ethylidene)amino)oxy)-2-methylpropanoa-
te (54 mg, 0.089 mmol) in DMF (893 .mu.L) was treated with
SO.sub.3.DMF (205 mg, 1.34 mmol). After 1 h of stirring, the
solution was diluted with EtOAc, washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to afford the title
compound (assumed quantitative) as a white solid. LCMS: Rt=0.76
min, m/z=685.1 (M+1) Method 2m_acidic.
Step 2:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxo-
pyridin-1(2H)-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)--
2-methylpropanoic Acid
[0537] Followed the general procedure for the acid mediated
deprotection using
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-
-oxopyridin-1 (2H)-yl)methyl)azetidine-1-sulfonic acid (61 mg,
0.089 mmol), DCM (891 .mu.L) and TFA (412 .mu.l, 5.35 mmol). The
crude residue purified by reverse phase prep HPLC (XSelect CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min), affording the title compound (9.6 mg,
19%) as a white powder. LCMS: R.sub.t=0.57 min, m/z=529.1 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta.
7.59 (d, J=6.7 Hz, 1H), 7.56-7.48 (m, 1H), 7.05 (s, 1H), 6.50 (d,
J=9.0 Hz, 1H), 6.39 (t, J=6.7 Hz, 1H), 5.30 (d, J=5.9 Hz, 1H), 4.47
(dd, J=14.5, 2.7 Hz, 1H), 4.07 (dd, J=14.5, 8.6 Hz, 1H), 1.37 (s,
3H), 1.36 (s, 3H).
Example 16:
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoazeti-
din-3-yl)amino)-1-(5-amino-1,2,4-thiadiazol-3-yl)-2-oxoethylidene)amino)ox-
y)-2-methylpropanoic Acid
Step 1:
(3S,4R)-4-((1H-1,2,4-triazol-1-yl)methyl)-3-aminoazetidin-2-one
[0538] Prepared in an analogous manner to example 4, step 3 using
benzyl
((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)carbamate
(250 mg, 0.830 mmol) and Pd on C (10%, 125 mg) in EtOH:MeOH (4:1,
8.3 mL) for 3 h. The crude residue was used as such in following
step. LCMS: R.sub.t=0.13 min, m/z=168.1 (M+1) Method 2m_acidic.
Step 2: tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(5-((tert-butoxycarbonyl)amino)-1,2,4-thiadiazol-3-yl)-2-oxoethy-
lidene)amino)oxy)-2-methylpropanoate
[0539] To a slurry of
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(5-((tert-
-butoxycarbonyl)amino)-1,2,4-thiadiazol-3-yl)acetic acid (129 mg,
0.299 mmol) in DCM:DMF (1:1, 3 mL) at 0.degree. C. was added DIPEA
(157 .mu.L, 0.897 mmol) followed by HATU (136 mg, 0.359 mmol). To
the resulting solution, after 20 min, was added a solution of
(3S,4R)-4-((1H-1,2,4-triazol-1-yl)methyl)-3-aminoazetidin-2-one (50
mg, 0.299 mmol) in DCM. After 2 h of stirring it was concntrated in
vacuo and taken up in EtOAc, washed with water, brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (Acetone-DCM) to afford the
title compound (100 mg, 58%). LCMS: R.sub.t=0.82 min, m/z=580.2
(M+1) Method 2m_acidic.
Step 3:
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-(((1-(tert-buto-
xy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(5-((tert-butoxycarbonyl)amino)-
-1,2,4-thiadiazol-3-yl)acetamido)-4-oxoazetidine-1-sulfonic
Acid
[0540] tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(5-((tert-butoxycarbonyl)amino)-1,2,4-thiadiazol-3-yl)-2-oxoethy-
lidene)amino)oxy)-2-methylpropanoate (100 mg, 0.173 mmol) in DMF
(1.7 mL) was treated with SO.sub.3.DMF (396 mg, 2.59 mmol). After 1
h of stirring, the solution was diluted with EtOAc, washed with
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo to
afford the title compound (assumed quantitative) as a white solid.
LCMS: Rt=0.74 min, m/z=660.2 (M+1) Method 2m_acidic.
Step
4:2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulf-
oazetidin-3-yl)amino)-1-(5-amino-1,2,4-thiadiazol-3-yl)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic Acid
##STR00070##
[0542] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-(((1-(tert-butox-
y)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(5-((tert-butoxycarbonyl)amino)--
1,2,4-thiadiazol-3-yl)acetamido)-4-oxoazetidine-1-sulfonic acid
(114 mg, 0.173 mmol), DCM (1.7 mL) and TFA (800 .mu.l, 10.4 mmol).
The crude residue purified by reverse phase prep HPLC (XSelect CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min), affording the title compound (46 mg,
46%) as a white powder. LCMS: R.sub.t=0.42 min, m/z=504.0 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.42 (d, J=8.6 Hz, 1H), 8.65 (s, 1H), 8.21 (br s, 2H), 8.10 (s,
1H), 5.22 (dd, J=8.6, 5.5 Hz, 1H), 4.67-4.58 (m, 1H), 4.56-4.47 (m,
1H), 4.28 (q, J=5.5 Hz, 1H), 1.39 (s, 3H), 1.34 (s, 3H).
Example 17:
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoazeti-
din-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)acetic
Acid
Step 1: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)acetate
[0543] To a solution of
(Z)-2-((2-(tert-butoxy)-2-oxoethoxy)imino)-2-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)acetic acid (108 mg, 0.269 mmol) in DCM (2.7 mL) at
0.degree. C. was added DIPEA (141 .mu.L, 0.808 mmol) followed by
HATU (113 mg, 0.296 mmol). To the resulting solution, after 20 min,
was added a solution of
(3S,4R)-4-((1H-1,2,4-triazol-1-yl)methyl)-3-aminoazetidin-2-one (50
mg, 0.299 mmol) in DCM. After 1 h of stirring it was diluted with
EtOAc, washed with water, brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude residue was purified via silica
gel chromatography (Acetone-DCM) to afford the title compound (106
mg, 72%). LCMS: R.sub.t=0.78 min, m/z=551.2 (M+1) Method
2m_acidic.
Step 2:
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((2-(tert-butox-
y)-2-oxoethoxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetam-
ido)-4-oxoazetidine-1-sulfonic Acid
[0544] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)acetate (100 mg, 0.182 mmol) in DMF (1.8 mL) was treated
with SO.sub.3.DMF (278 mg, 1.82 mmol). After 1 h of stirring, the
solution was diluted with EtOAc, washed with ice-cold water, brine,
dried over Na.sub.2SO.sub.4 and concd in vacuo, affording the title
compound (assumed quantitative) as a white solid. LCMS: Rt=0.71
min, m/z=631.1 (M+1) Method 2m_acidic.
Step 3:
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sul-
foazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)a-
cetic Acid
##STR00071##
[0546] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((2-(tert-butoxy-
)-2-oxoethoxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetami-
do)-4-oxoazetidine-1-sulfonic acid (97 mg, 0.154 mmol), DCM (1.54
mL) and TFA (711 .mu.l, 9.23 mmol). The crude residue purified by
reverse phase prep HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18
column; ACN-water with 0.1% formic acid modifier, 60 mL/min),
affording the title compound (22.7 mg, 22%) as a white powder.
LCMS: R.sub.t=0.28 min, m/z=475.0 (M+1) Method 2m_acidic; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta.9.50 (d, J=9.0 Hz, 1H), 8.56 (s,
1H), 8.07 (s, 1H), 6.80 (s, 1H), 5.25 (dd, J=9.0, 5.9 Hz, 1H),
4.69-4.49 (m, 4H), 4.36 (dt, J=7.4, 4.9 Hz, 1H).
Example 18:
1-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoazeti-
din-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopro-
panecarboxylic Acid
[0547] Step 1: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)cyclopropanecarboxylate.
[0548] To a solution of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (prepared according to
Yamawaki et al. Bioorg. Med. Chem. Lett. 2007, 15, 6716-6732) (150
mg, 0.279 mmol) in DCM:DMF (1:1, 2.8 mL) at 0.degree. C. was added
DIPEA (146 .mu.L, 0.837 mmol) followed by HATU (127 mg, 0.335
mmol). To the resulting solution, after 20 min, was added a
solution of
(3S,4R)-4-((1H-1,2,4-triazol-1-yl)methyl)-3-aminoazetidin-2-one (51
mg, 0.31 mmol) in DCM. After 1 h of stirring it was diluted with
EtOAc, washed with water, brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude residue was purified via silica
gel chromatography (Acetone-DCM) to afford the title compound (147
mg, 77%). LCMS: R.sub.t=0.98 min, m/z=687.1 (M+1) Method
2m_acidic.
Step 2:
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((1-((benzhydry-
loxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-
-4-yl)acetamido)-4-oxoazetidine-1-sulfonic Acid
[0549] Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)cyclopropanecarboxylate (147 mg, 0.214 mmol) in DMF (2.14
mL) was treated with SO.sub.3.DMF (328 mg, 2.14 mmol). After 1 h of
stirring, the solution was diluted with EtOAc, washed with ice cold
water, brine, dried over Na.sub.2SO.sub.4 and concd in vacuo,
affording the title compound (assumed quantitative) as a white
solid. LCMS: Rt=0.89 min, m/z=767.0 (M+1) Method 2m_acidic.
Step 3:
1-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sul-
foazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)c-
yclopropanecarboxylic Acid
##STR00072##
[0551] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((1-((benzhydryl-
oxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol--
4-yl)acetamido)-4-oxoazetidine-1-sulfonic acid (164 mg, 0.214
mmol), DCM (2.14 mL) and TFA (989 .mu.l, 12.8 mmol). The crude
residue purified by reverse phase prep HPLC (XSelect CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min), affording the title compound (50 mg,
41%) as a white powder. LCMS: R.sub.t=0.29 min, m/z=501.1 (M+1)
Method 2m_acidic; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.31
(d, J=9.0 Hz, 1H), 8.59 (s, 1H), 8.09 (s, 1H), 6.83 (s, 1H), 5.26
(dd, J=9.0, 5.5 Hz, 1H), 4.67 (dd, J=14.5, 4.3 Hz, 1H), 4.49-4.39
(m, 1H), 4.33 (ddd, J=7.4, 5.5, 4.3 Hz, 1H), 1.34-1.27 (m, 4H).
Example 19:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)cyclopropanecarboxylic Acid
Step 1: tert-Butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)me-
thyl)carbamate
[0552] Prepared in an analogous manner to example 4, step 3 using
Intermediate T (1.20 g, 2.79 mmol) and Pd on C (10%, 830 mg) in
EtOAc:MeOH (5:1, 24 mL) for 19 h. The crude residue was used as
such in following step. LCMS: R.sub.t=0.41 min, m/z=297.0 (M+1)
Method 2m_acidic.
Step 2: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(((tert-butoxycarbonyl)amino)methyl)-2H-1,2,3--
triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)-
amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
[0553] To a solution of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (prepared according to
Yamawaki et al. Bioorg. Med. Chem. Lett. 2007, 15, 6716-6732) (1.50
g, 2.79 mmol) in DCM (15 mL) at 0.degree. C. was added DIPEA (1.22
mL, 6.98 mmol) and HATU (1.11 g, 2.93 mmol). After warming to rt, a
solution of tert-butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)me-
thyl)carbamate (827 mg, 2.79 mmol) in DCM:DMF (1.7:1, 12.7 mL).
After 1 h of stirring it was diluted with DCM and washed with
water, brine, dried over Na.sub.2SO.sub.4 and concentrated in
vacuo. The crude residue was purified via silica gel chromatography
(EtOAc-Heptane, 0-90%), to afford the title compound (1.92 g, 84%)
as a purple oil. LCMS: R.sub.t=1.08 min, m/z=816.5 (M+1) Method
2m_acidic.
Step 3:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-but-
oxycarbonyl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-s-
ulfonic Acid
[0554] Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(((tert-butoxycarbonyl)amino)methyl)-2H-1,2,3--
triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)-
amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
(1.92 g, 2.35 mmol) in DMF (20 mL) was treated with SO.sub.3.DMF
(3.60 g, 23.5 mmol). After 30 min of stirring, the solution was
diluted with EtOAc/water and the layers were separated. The aqueous
was extracted with EtOAc and the combined organic layers were
washed with brine, dried over Na.sub.2SO.sub.4 and concd in vacuo,
affording the title compound (1.98 g, 94%) as a purple foam. LCMS:
Rt=0.99 min, m/z=896.4 (M+1) Method 2m_acidic.
Step 4:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)met-
hyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyli-
dene)amino)oxy)-cyclopropanecarboxylic Acid
##STR00073##
[0556] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-buto-
xycarbonyl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-su-
lfonic acid (1.98 g, 2.21 mmol), DCM (18.4 mL) and TFA (10.2 mL,
133 mmol). Half of the crude residue purified by reverse phase prep
HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water
with 0.1% formic acid modifier, 60 mL/min), affording the title
compound (300 mg, ca 50%) as an off-white powder. LCMS:
R.sub.t=0.29 min, m/z=530.1 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, D.sub.2O) .delta. 7.69 (s, 1H), 7.04 (br s, 1H), 5.43 (d,
J=5.5 Hz, 1H), 4.93-4.78 (m, 2H), 4.74-4.67 (m, 1H), 4.22-4.12 (m,
2H), 1.36-1.20 (m, 2H), 1.20-1.00 (m, 2H).
Example 20:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(guanidinomethyl)-2H-1-
,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-cyclopropanecarboxylic Acid
##STR00074##
[0558] To a solution of
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-cyclopropanecarboxylic acid (582 mg, 1.10 mmol) in DMF (12
mL) at 0.degree. C. was added pyrazole-1-carboxamidine
hydrochloride (322 mg, 2.20 mmol) and DIPEA (1.54 mL, 8.80 mmol).
After 16 h of stirring at rt, the solution was diluted with toluene
(60 mL), causing a dense oil to separate out. The top layer was
decanted and the remaining oil was purified by reverse phase prep
HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water
with 0.1% formic acid modifier, 60 mL/min), affording the title
compound (240 mg, 37%) as an off-white powder. LCMS: R.sub.t=0.31
min, m/z=572.2 (M+H) Method 2m_acidic; .sup.1H NMR (400 MHz,
D.sub.2O) .delta. 7.59 (s, 1H), 6.99 (br s, 1H), 5.43 (d, J=5.5 Hz,
1H), 4.91-4.75 (m, 2H assumed; obscured by solvent residual peak),
4.70 (dd, J=8.2, 6.3 Hz, 1H), 4.41-4.34 (m, 2H), 1.20 (br s, 2H),
1.05 (br s, 2H). E-isomer was also obtained. LCMS: R.sub.t=0.33
min, m/z=572.2 (M+H) Method 2m_acidic; .sup.1H NMR (400 MHz,
D.sub.2O) .delta. 7.58 (s, 1H), 7.46 (br. s., 1H), 5.45 (br. s.,
1H), 4.84 (s, 3H), 4.37 (s, 2H), 1.33-1.08 (m, 4H).
Example 21:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazoli-
din-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)acetic
Acid
Step 1: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3-yl)amino)ethylidene)amin-
o)oxy)acetate
[0559] To a solution of
(Z)-2-((2-(tert-butoxy)-2-oxoethoxy)imino)-2-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)acetic acid (100 mg, 0.249 mmol), Intermediate D
(51 mg, 0.27 mmol) and HATU (123 mg, 0.324 mmol) in DMF (1.25 mL)
was added DIPEA (131 .mu.L, 0.747 mmol). After 4 h of stirring it
was diluted with EtOAc, washed with water, brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (0-10% MeOH-DCM) to afford
the title compound (118 mg, 83%). LCMS: R.sub.t=0.81 min, m/z=569.1
(M+1) Method 2m_acidic.
Step 2:
(3S,4R)-3-((Z)-2-((2-(tert-butoxy)-2-oxoethoxy)imino)-2-(2-((tert--
butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxooxazolidin-3-y-
l)methyl)azetidine-1-sulfonic Acid
[0560] tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3-yl)amino)ethylidene)amin-
o)oxy)acetate (118 mg, 0.208 mmol) in DMF (2.14 mL) was treated
with SO.sub.3.DMF (159 mg, 1.04 mmol). After 30 min of stirring,
the solution was diluted with EtOAc, washed with ice-cold brine,
dried over Na.sub.2SO.sub.4 and concd in vacuo, affording the title
compound (assumed quantitative) as a white solid. LCMS: Rt=0.72
min, m/z=649.1 (M+1) Method 2m_acidic.
Step 3:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxo-
oxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)ac-
etic Acid
##STR00075##
[0562] Followed the general procedure for the acid mediated
deprotection using
(3S,4R)-3-((Z)-2-((2-(tert-butoxy)-2-oxoethoxy)imino)-2-(2-((tert-b-
utoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxooxazolidin-3-yl-
)methyl)azetidine-1-sulfonic acid (135 mg, 0.208 mmol), DCM (1.04
mL) and TFA (801 .mu.l, 10.4 mmol). The crude residue purified by
reverse phase prep HPLC (XSelect CSH, 19.times.100 mm, 5 .mu.m, C18
column; ACN-water with 0.1% formic acid modifier, 24 mL/min),
affording the title compound (25 mg, 23%) as a white powder. LCMS:
R.sub.t=0.25 min, m/z=493.0 (M+1) Method 2m_acidic; .sup.1H NMR
(500 MHz, DMSO-d.sub.6) .delta. 9.41 (d, J=9.1 Hz, 1H) 6.86 (s, 1H)
5.24 (dd, J=9.0, 5.8 Hz, 1H) 4.62 (s, 2H) 4.20-4.11 (m, 3H)
3.72-3.63 (m, 2H) 3.40-3.31 (m, 2H assumed; obscured by water).
Example 22:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazoli-
din-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cycloprop-
anecarboxylic Acid
Step 1: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3-yl)amino)ethylidene)amin-
o)oxy)cyclopropanecarboxylate
[0563] To a solution of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (854 mg, 1.59 mmol),
Intermediate D (324 mg, 1.75 mmol) and HATU (785 mg, 2.07 mmol) in
DMF (7.9 mL) was added DIPEA (832 .mu.L, 4.77 mmol). After 1 h of
stirring, it was poured into water and extracted with EtOAc. Brine
was added to the aqueous layer, and it was further extracted with
EtOAc (3.times.). The combined organic layers were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (0-10% MeOH-DCM) to afford
the title compound (1.09 g, 97%) as a beige foam. LCMS:
R.sub.t=0.97 min, m/z=705.3 (M+1) Method 2m_acidic.
Step 2:
(3S,4R)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxoox-
azolidin-3-yl)methyl)azetidine-1-sulfonic Acid
[0564] Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3-yl)amino)ethylidene)amin-
o)oxy)cyclopropanecarboxylate (1.00 g, 1.42 mmol) in DMF (7.0 mL)
at 0.degree. C. was treated with SO.sub.3.DMF (448 mg, 2.84 mmol).
After 2 h of stirring at rt, the solution was poured into ice-cold
brine and extracted with EtOAc (3.times.). The combined organic
layers were dried over Na.sub.2SO.sub.4 and concd in vacuo,
affording the title compound (assumed quantitative) as a white
solid. LCMS: Rt=0.90 min, m/z=785.2 (M+1) Method 2m_acidic.
Step 3:
l-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxo-
oxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cy-
clopropanecarboxylic Acid
##STR00076##
[0566] Followed the general procedure for the acid mediated
deprotection using
(3S,4R)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxooxa-
zolidin-3-yl)methyl)azetidine-1-sulfonic acid (1.10 g, 1.40 mmol),
DCM (7.0 mL) and TFA (5.39 mL, 70.0 mmol). Additional TFA (3.24 mL,
42.0 mmol) was added after 1 h at rt and the solution was diluted
with DCM and concentrated in vacuo after an additional 30 min. The
crude residue purified by reverse phase prep HPLC (XSelect CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min), affording the title compound (178 mg,
23%) as a white powder. LCMS: R.sub.t=0.30 min, m/z=518.9 (M+1)
Method 2m_acidic; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.27
(d, J=9.0 Hz, 1H) 6.92 (s, 1H) 5.23 (dd, J=9.1, 5.7 Hz, 1H)
4.12-4.23 (m, 3H) 3.72-3.62 (m, 2H assumed; obscured by water)
3.61-3.52 (m, 1H assumed; obscured by water) 3.26 (dd, J=14.5, 5.9
Hz, 1H) 1.36 (s, 4H). .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.23
(s, 1H), 5.48 (d, J=5.8 Hz, 1H), 4.71-4.65 (m, 1H), 4.44 (t, J=8.2
Hz, 2H), 3.89-3.73 (m, 3H), 3.54 (dd, J=14.9, 4.9 Hz, 1H),
1.65-1.56 (m, 2H), 1.56-1.46 (m, 2H).
Example 23:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-methyl-2-oxooxazol-
idin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)-
oxy)-2-methylpropanoic Acid
Step 1: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(((-
(R)-2-hydroxypropyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-2-methylpropanoate
[0567] A solution of Intermediate L (500 mg, 0.949 mmol) and
(R)-propylene oxide (996 .mu.l, 14.2 mmol) in DCM (1.9 ml) was
stirred at rt for 16 h whereupon precipitation was observed. More
(R)-propylene oxide (332 .mu.l, 4.75 mmol) was added. After an
additional 3 h, more (R)-propylene oxide (500 .mu.l, 7.14 mmol) was
added. After another 24 h of stirring it was concentrated in vacuo
and the crude residue purified by reverse phase prep HPLC (XSelect
CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1%
formic acid modifier, 60 mL/min), affording the title compound (185
mg, 33%) as a white powder. LCMS: R.sub.t=0.82 min, m/z=585.2 (M+1)
Method 2m_acidic.
Step 2: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(((-
R)-5-methyl-2-oxooxazolidin-3-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoet-
hylidene)amino)oxy)-2-methylpropanoate
[0568] To a solution of tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(((-
(R)-2-hydroxypropyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-2-methylpropanoate (185 mg, 0.316 mmol) in chloroform
(3.16 mL) was added CDI (257 mg, 1.58 mmol). After stirring at rt
for 20 min the solution was diluted with EtOAc/water and the layers
separated. The aqueous layer was extracted with EtOAc and the
combined organic layers were dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude residue was purified via silica
gel chromatography (Acetone-DCM, 0-100%) to afford the title
compound (81 mg, 42%). LCMS: R.sub.t=0.92 min, m/z=611.2 (M+1)
Method 2m_acidic.
Step 3:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-(((R)-5--
methyl-2-oxooxazolidin-3-yl)methyl)-4-oxoazetidine-1-sulfonic
acid
[0569] tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(((-
R)-5-methyl-2-oxooxazolidin-3-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoet-
hylidene)amino)oxy)-2-methylpropanoate (81 mg, 0.133 mmol) in DMF
(1.33 mL) was treated with SO.sub.3.DMF (203 mg, 1.33 mmol). After
20 min of stirring at rt, the solution was diluted with EtOAc/brine
and the layers separated. The aqueous layer was extracted with
EtOAc (3.times.) and the combined organic layers were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo, affording the title
compound (assumed quantitative) as a solid. LCMS: Rt=0.84 min,
m/z=691.0 (M+1) Method 2m_acidic.
Step
4:2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-methyl-2-oxo-
oxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)-
amino)oxy)-2-methylpropanoic Acid
##STR00077##
[0571] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-(((R)-5-m-
ethyl-2-oxooxazolidin-3-yl)methyl)-4-oxoazetidine-1-sulfonic acid
(92 mg, 0.133 mmol), DCM (1.33 mL) and TFA (615 .mu.L, 7.98 mmol).
The crude residue purified by reverse phase prep HPLC (XSelect CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min), affording the title compound (18.6 mg,
23%) as a white powder. LCMS: R.sub.t=0.39 min, m/z=535.1 (M+1)
Method 2m_acidic; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 9.29
(d, J=8.8 Hz, 1H), 6.85 (s, 1H), 5.22 (dd, J=8.8, 5.7 Hz, 1H), 4.55
(dt, J=13.5, 6.5 Hz, 1H), 4.15 (q, J=6.0 Hz, 1H), 3.72-3.63 (m,
2H), 3.34-3.27 (m, 2H), 1.46 (s, 3H), 1.42 (s, 3H), 1.28 (d, J=6.3
Hz, 3H).
Example 24:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-(guanidinomethyl)--
2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyli-
dene)amino)oxy)-2-methylpropanoic Acid
##STR00078##
[0573] To a solution of
2-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)-2-methylpropanoic acid (30.1 mg, 0.055 mmol) and
Pyrazole-1-carboxamidine hydrochloride (16.1 mg, 0.110 mmol) in DMF
(548 .mu.l) was added DIPEA (38.3 .mu.l, 0.219 mmol). After 5 h of
stirring at rt, the solution was concentrated in vacuo and purified
by reverse phase prep HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m,
C18 column; ACN-water with 0.1% formic acid modifier, 60 mL/min),
affording the title compound (17.5 mg, 49%) as a white powder.
LCMS: R.sub.t=0.30 min, m/z=592.2 (M+1) Method 2m_acidic; .sup.1H
NMR (400 MHz, D.sub.2O) .delta. 6.97 (s, 1H), 5.31 (d, J=5.9 Hz,
1H), 4.74 (dtd, J=9.3, 5.9, 3.2 Hz, 1H), 4.55 (ddd, J=9.2, 5.9, 3.1
Hz, 1H), 3.86 (t, J=9.3 Hz, 1H), 3.66 (dd, J=15.0, 9.5 Hz, 1H),
3.53 (dd, J=15.5, 3.2 Hz, 1H), 3.47-3.34 (m, 3H), 1.39 (s, 3H),
1.37 (s, 3H).
Example 25:
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)-cyclopropanecarboxylic Acid
Step 1: tert-Butyl
(((R)-3-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2-oxooxazolidin-5-yl-
)methyl)carbamate
[0574] Prepared in an analogous manner to example 4, step 3 using
Intermediate U (1.16 g, 2.28 mmol) and Pd on C (10%, 246 mg) in
EtOH:MeOH (5:1, 3 mL) for 19 h. The crude residue was used as such
in following step.
Step 2: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(((tert-butoxycarbonyl)amino)methyl)-2-oxo-
oxazolidin-3-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbon-
yl)amino)-thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
[0575] To a solution of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (1.29 g, 2.28 mmol) and
HATU (909 mg, 2.39 mmol) in DMF:DCM (3:1, 9.0 mL) at 0.degree. C.
was added DIPEA (1.0 mL, 5.72 mmol). After 15 min of stirring at
0.degree. C. tert-butyl
(((R)-3-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2-oxooxazolidin-5-yl-
)methyl)carbamate (715 mg, 2.28 mmol) was added as a solution in
DMF:DCM (1:1, 9 mL) followed by a DMF (1.5 mL) wash. After 1.2 h at
rt it was diluted with EtOAc and washed with LiCl (5% aq). The
aqueous layer was extracted with EtOAc (3.times.) and the combined
organic layers were washed with LiCl (5% aq), NaHCO.sub.3 (aq
satd), brine, dried over Na.sub.2SO.sub.4 and concentrated in
vacuo. The crude residue was purified via silica gel chromatography
(EtOAc-Heptane, 5-90%) to afford the title compound (1.357 g, 72%)
as a white solid. LCMS: R.sub.t=1.04 min, m/z=834.4 (M+1) Method
2m_acidic.
Step 3:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-(((R)-5-(((tert-
-butoxycarbonyl)amino)-methyl)-2-oxooxazolidin-3-yl)methyl)-4-oxoazetidine-
-1-sulfonic acid
[0576] Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(((tert-butoxycarbonyl)amino)methyl)-2-oxo-
oxazolidin-3-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbon-
yl)amino)-thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
(1.357 g, 1.627 mmol) in DMF (8.1 mL) at 0.degree. C. was treated
with SO.sub.3.DMF (748 mg, 4.88 mmol). After 2 h of stirring at rt,
the solution was diluted with EtOAc/LiCl (5% aq) and the layers
separated. The aqueous layer was extracted with EtOAc (3.times.)
and the combined organic layers were washed with LiCl (5% aq),
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo,
affording the title compound (assumed quantitative) as a solid.
LCMS: Rt=0.96 min, m/z=914.4 (M+1) Method 2m_acidic.
Step 4:
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)-
methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoeth-
ylidene)amino)oxy)-cyclopropanecarboxylic Acid
##STR00079##
[0578] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-(((R)-5-(((tert--
butoxycarbonyl)amino)-methyl)-2-oxooxazolidin-3-yl)methyl)-4-oxoazetidine--
1-sulfonic acid (725 mg, 0.794 mmol), DCM (8.0 mL) and TFA (3.7 mL,
48.0 mmol). The crude residue purified by reverse phase prep HPLC
(XSelect CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water with
0.1% formic acid modifier, 60 mL/min), affording the title compound
(231 mg, 52%) as a white powder. LCMS: R.sub.t=0.41 min, m/z=548.1
(M+1) Method 2m_acidic_polar; .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta.9.18 (d, J=8.8 Hz, 1H), 8.00 (t, J=5.8 Hz, 3H), 6.83 (s,
1H), 5.22 (dd, J=8.8, 5.9 Hz, 1H), 4.68 (tdd, J=9.0, 5.8, 3.4 Hz,
1H), 4.24 (ddd, J=9.3, 5.9, 3.6 Hz, 1H), 3.75 (t, J=8.8 Hz, 1H
assumed; obscured by water), 3.61 (dd, J=8.7, 5.8 Hz, 1H assumed;
obscured by water), 3.41 (dd, J=14.7, 9.0 Hz, 1H), 3.30 (dd,
J=14.7, 3.7 Hz, 1H), 3.25-3.05 (m, 2H), 1.40-1.27 (m, 4H). 1H NMR
(400 MHz, D.sub.2O) .delta. 7.18 (d, J=2.4 Hz, 1H), 5.45 (d, J=5.8
Hz, 1H), 5.02-4.93 (m, 1H), 4.70 (ddd, J=9.2, 5.8, 3.7 Hz, 1H),
4.04 (t, J=9.2 Hz, 1H), 3.78 (dd, J=15.0, 9.0 Hz, 1H), 3.60-3.56
(m, 1H), 3.54 (dd, J=11.3, 3.6 Hz, 1H), 3.40 (s, 1H), 3.38 (d,
J=2.0 Hz, 1H), 1.57-1.49 (m, 2H), 1.49-1.40 (m, 2H).
Example 26:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-(guanidinomethyl)--
2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyli-
dene)amino)oxy)-cyclopropanecarboxylic Acid
##STR00080##
[0580] To a solution of
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)cyclopropane-carboxylic acid (0.795 mmol) and
Pyrazole-1-carboxamidine hydrochloride (234.8 mg, 1.602 mmol) in
DMF (7.0 mL) was added DIPEA (1.20 mL, 8.06 mmol). After 19 h of
stirring at rt, the solution was concd in vacuo and purified by
reverse phase prep HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18
column; ACN-water with 0.1% formic acid modifier, 60 mL/min),
affording the title compound (177 mg, 37%) as a white powder. LCMS:
R.sub.t=0.47 min, m/z=590.1 (M+H) Method 2m_acidic_polar; .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 9.15 (d, J=8.9 Hz, 1H), 7.62
(br s, 1H), 7.24 (s, 3H), 6.81 (s, 1H), 5.23 (dd, J=8.9, 5.9 Hz,
1H), 4.60-4.51 (m, 1H), 4.23 (ddd, J=9.0, 5.8, 3.7 Hz, 1H), 3.70
(t, J=8.8 Hz, 1H), 3.52 (dd, J=8.8, 5.4 Hz, 1H), 3.49-3.44 (m, 1H),
3.43-3.34 (m, 3H), 1.38-1.24 (m, 4H).
Example 27:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)cyclopropanecarboxylic Acid
Step 1: tert-Butyl
((1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)me-
thyl)carbamate
[0581] To a suspension of palladium on carbon (823 mg, 0.774 mmol)
in EtOAc/MeOH (5:1, 16.8 mL) was added Intermediate S (1.11 g, 2.58
mmol) in one portion. The system was evacuated and backfilled with
H.sub.2 (3.times.). After stirring for 19 h the mixture was diluted
with EtOAc, filtered through celite, washing with MeOH-EtOAc (20%,
100 mL.times.3) and concentrated in vacuo, affording crude title
compound (730 mg) as an off-white powder. LCMS: R.sub.t=0.37 min,
m/z=297.0 (M+1) Method 2m_acidic.
Step 2: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(((tert-butoxycarbonyl)amino)methyl)-1H-1,2,3--
triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)-
amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
[0582] To a slurry of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (1.32 g, 2.46 mmol) in DCM
(12 mL) at 0.degree. C. was added DIPEA (1.08 mL, 6.16 mmol)
followed by HATU (0.984 g, 2.59 mmol). The reaction mixture was
warmed to room temperature and tert-butyl
((1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)me-
thyl)carbamate (0.73 g, 2.5 mmol) was added as a solution in
DCM:DMF (1.7:1, 9.6 mL). After stirring for 1.3 h, a color change
from yellow to dark purple was observed, whereupon it was diluted
with DCM, washed with water, brine, dried over sodium sulfate and
concentrated in vacuo. The crude residue was purified by silica gel
chromatography (EtOAc-Heptane, 0-90%), affording the title compound
(1.62 g, 81%) as a purple foam. LCMS: R.sub.t=1.05 min, m/z=816.5
(M+1) Method 2m_acidic.
Step 3:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-but-
oxycarbonyl)amino)methyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1-s-
ulfonic acid
[0583] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(((tert-butoxycarbonyl)amino)methyl)-1H-1,2,3--
triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)-
amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
(1.58 g, 1.94 mmol) in DMF (15 mL) was added SO.sub.3.DMF complex
(2.97 g, 19.4 mmol). After 45 min of stirring it was diluted with
EtOAc (120 mL), brine (80 mL), water (40 mL) and the layers were
separated. The aqueous layer was extracted with EtOAc (2.times.20
mL) and the combined organic layers were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo to afford the title
compound (assumed quantitative) as a purple foam. LCMS:
R.sub.t=0.96 min, m/z=896.4 (M+1) Method 2m_acidic.
Step 4:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-1-yl)met-
hyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyli-
dene)amino)oxy)-cyclopropanecarboxylic Acid
##STR00081##
[0585] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-buto-
xycarbonyl)amino)methyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1-su-
lfonic acid (1.74 g, 1.94 mmol), DCM (19.4 mL) and TFA (8.95 mL,
116 mmol). After 3 h at rt, it was cooled to 0.degree. C. and more
TFA (200 .mu.L, 2.6 mmol) was added whereupon it was allowed to
warm to rt. After another 1 h at rt, it was cooled to 0.degree. C.
and more TFA (200 .mu.L, 2.6 mmol) was added, again allowing to
warm to rt. After an additional 1 h at rt it was diluted with DCM
and concentrated in vacuo. Half of the the crude residue was
purified by reverse phase prep HPLC (XSelect CSH, 30.times.100 mm,
5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier, 60
mL/min), affording the title compound (140 mg, ca 23%) as a white
powder. LCMS: R.sub.t=0.27 min, m/z=530.1 (M+1) Method 2m_acidic;
.sup.1H NMR (400 MHz, D.sub.2O) .delta. 8.07 (s, 1H), 7.08-6.99 (m,
1H) 5.42-5.31 (m, 1H), 4.88-4.74 (m, 2H assumed; partially obscured
by solvent residual peak), 4.74-4.68 (m, 1H), 4.20 (s, 2H),
1.36-1.23 (m, 2H), 1.23-1.07 (m, 2H).
Example 28:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(guanidinomethyl)-1H-1-
,2,3-triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-cyclopropanecarboxylic Acid
##STR00082##
[0587] To a solution of
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2
oxoethylidene)amino)oxy)cyclopropane-carboxylic acid (559 mg, 1.06
mmol) and Pyrazole-1-carboxamidine hydrochloride (310 mg, 2.12
mmol) in DMF (12 mL) was added DIPEA (1.48 mL, 8.45 mmol). After 16
h of stirring at rt, the solution was diluted with toluene (20 mL),
causing a dense oil to separate out. The top layer was decanted and
the remaining oil was purified by reverse phase prep HPLC (XSelect
CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1%
formic acid modifier, 60 mL/min), affording the title compound (240
mg, 39%) as a white powder. LCMS: R.sub.t=0.28 min, m/z=572.0 (M+H)
Method 2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 8.09 (s,
1H), 7.18 (s, 1H), 5.52 (d, J=5.4 Hz, 1H), 4.97 (dd, J=14.1, 5.5
Hz, 1H), 4.91 (q, J=5.5 Hz, 1H), 4.84-4.76 (m, 1H assumed;
partially obscured by solvent residual peak), 4.55 (s, 2H),
1.49-1.36 (m, 2H), 1.34-1.23 (m, 2H). E-isomer was also obtained.
LCMS: R.sub.t=0.32 min, m/z=572.0 (M+H) Method 2m_acidic. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 9.37 (d, J=9.6 Hz, 1H), 8.11
(s, 1H), 7.41 (s, 1H), 7.13 (s, 2H), 6.50 (s, 1H), 5.18 (dd, J=9.6,
5.3 Hz, 1H), 4.97 (d, J=13.5 Hz, 1H), 4.76-4.58 (m, 1H), 4.52 (dd,
J=16.11, 7.70 Hz, 1H), 4.26-4.05 (m, 2H), 1.86-2.08 (m, 1H),
1.34-1.07 (m, 6H).
Example 29:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)prop-
anoic Acid
Step 1: (R)-tert-Butyl 2-chloropropanoate
[0588] Prepared according to Wright et al. Tetrahedron Lett. 1997,
38, 7345. A 500 mL glass bomb was charged with magnesium sulfate
(4.21 g, 35.0 mmol) and DCM (43.8 mL). To this suspension was added
sulfuric acid (486 .mu.L, 8.75 mmol), drop-wise with vigorus
stirring. After 15 min of stirring, (R)-2-chloropropanoic acid (950
mg, 8.75 mmol) was added followed by tert-butanol (4.20 ml, 43.8
mmol). The bomb was sealed and stirred at rt for 19 h, whereupon
sodium bicarbonate (aq satd, 100 mL) was carefully added, at which
point all solids had dissolved. The layers were separated and the
aqueous layer was extracted with DCM (2.times.). The combined
organics layers were washed with brine, dried over Na.sub.2SO.sub.4
and concentrated in vacuo (20.degree. C. bath, 50 mBar) to afford
the title compound (1.36 g, 94%) as a light pink oil. .sup.1H NMR
(500 MHz, CDCl.sub.3) .delta. 4.29 (q, J=6.9 Hz, 1H) 1.65 (d, J=6.9
Hz, 3H) 1.49 (s, 9H).
Step 2: (S)-tert-butyl
2-((1,3-dioxoisoindolin-2-yl)oxy)propanoate
[0589] Prepared according to Yamawaki et al. Bioorg. Med. Chem.
2007, 15, 6716. To a slurry of N-hydroxyphthalimide (517 mg, 3.17
mmol) and potassium carbonate (657 mg, 4.76 mmol) in DMF (4.5 mL)
was added (R)-tert-butyl 2-chloropropanoate (522 mg, 3.17 mmol).
Additional DMF (4.5 mL) was added after the slurry became viscous.
After stirring for 5 d it was diluted with EtOAc and poured into
LiCl soln (5% aq, 90 mL). The aqueous layer was extracted with
EtOAc (3.times.) and the combined organic layers were washed with
LiCl (5% aq), brine, dried over Na.sub.2SO.sub.4 and concd in
vacuo. The crude residue was purified by silica gel chromatography
(EtOAc-Heptane, 0-50%), affording the title compound (348 mg, 38%)
as a white solid. LCMS: R.sub.t=0.89 min, m/z=314.0 (M+23) Method
2m_acidic; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 7.87-7.81 (m,
2H), 7.75 (dd, J=5.5, 3.1 Hz, 2H), 4.79 (q, J=6.8 Hz, 1H), 1.61 (s,
3H), 1.46 (s, 9H).
Step 3: (S)-tert-butyl 2-(aminooxy)propanoate
[0590] To a solution of (S)-tert-butyl
2-((1,3-dioxoisoindolin-2-yl)oxy)propanoate (73.3 mg, 0.252 mmol)
in DCM (Volume: 500 .mu.L) at 0.degree. C. was added methyl
hydrazine (13.5 .mu.L, 0.252 mmol). After stirring for 3 h at
0.degree. C., the solids were filtered off and the filtrate was
concentrated in vacuo, affording the title compound (assumed
quantitative) as a clear oil.
Step 4: (S)-tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-propanoate
[0591] To a soln of Intermediate E (62.2 mg, 0.148 mmol) in MeOH (1
mL) at 0.degree. C. was added a soln of (S)-tert-butyl
2-(aminooxy)propanoate (24 mg, 0.15 mmol) in DCM (300 .mu.L). After
stirring for 6 d acetic acid (8.5 .mu.l, 0.15 mmol) was added.
After 4 d more acetic acid (8.5 .mu.l, 0.15 mmol) was added. After
an additional 24 h, it was partially concentrated in vacuo then
diluted with EtOAc/water. The layers were separated and the organic
layer was washed with brine, dried over Na.sub.2SO.sub.4 and concd
in vacuo. The crude residue was purified by silica gel
chromatography (MeOH-DCM, 0-10%), affording the title compound
(20.2 mg, 24%) as a white solid. LCMS: R.sub.t=0.81 min, m/z=565.1
(M+1) Method 2m_acidic.
Step 5:
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((((S)-1-(tert--
butoxy)-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiaz-
ol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic Acid
[0592] To a soln of (S)-tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)propanoate (20.2 mg, 0.036 mmol) in DMF (400 .mu.l) was
added SO.sub.3.DMF (54.8 mg, 0.358 mmol). After 2.5 h of stirring
it was diluted with EtOAc/LiCl (5% aq) and the layers were
separated. The aqueous layer was extracted with EtOAc (3.times.)
and the combined organic layers were washed with LiCl (5% aq),
brine, dried over Na.sub.2SO.sub.4 and concd in vacuo, affording
the title compound (assumed quantitative) as a white solid. LCMS:
R.sub.t=0.74 min, m/z=645.3 (M+1) Method 2m_acidic.
Step 6:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-
-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)o-
xy)propanoic Acid
##STR00083##
[0594] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((((S)-1-(tert-b-
utoxy)-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazo-
l-4-yl)acetamido)-4-oxoazetidine-1-sulfonic acid (23 mg, 0.036
mmol), DCM (357 .mu.L) and TFA (165 .mu.L, 2.14 mmol). The crude
residue was purified by reverse phase prep HPLC (XSelect CSH,
19.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 24 mL/min), affording the title compound (7.9 mg,
36%) as a white powder. LCMS: R.sub.t=0.40 min, m/z=489.0 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta.
8.69 (s, 1H), 8.18 (s, 1H), 7.20 (s, 1H), 5.54 (d, J=5.7 Hz, 1H),
4.96-4.67 (m, 4H assumed; partially obscured by solvent residual
peak), 1.44 (d, J=7.0 Hz, 3H).
Example 30:
(R)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)prop-
anoic Acid
Step 1: (S)-tert-Butyl 2-chloropropanoate
[0595] Prepared according to Wright et al. Tetrahedron Lett. 1997,
38, 7345. A 500 mL glass bomb was charged with magnesium sulfate
(21.7 g, 181 mmol) and DCM (182 mL). To this suspension was added
sulfuric acid (2.5 mL, 45 mmol), drop-wise with vigorous stirring.
After 15 min of stirring, (S)-2-chloropropanoic acid (5.0 g, 45
mmol) was added followed by tert-butanol (21.6 ml, 226 mmol). The
bomb was sealed and stirred at rt for 19 h, whereupon it was cooled
to 0.degree. C. and sodium bicarbonate (aq satd, 350 mL) was
carefully added, at which point all solids had dissolved. The
layers were separated and the aqueous layer was extracted with DCM
(2.times.). The combined organics layers were washed with brine,
dried over Na.sub.2SO.sub.4 and concentrated in vacuo (20.degree.
C. bath, 50 mBar) to afford the title compound (7.64 g, 96%) as a
light yellow oil (93% purity). .sup.1H NMR data was an identical
match to the previously prepared enantiomer.
Step 2: (R)-tert-butyl
2-((1,3-dioxoisoindolin-2-yl)oxy)propanoate
[0596] To a slurry of N-hydroxyphthalimide (3.71 g, 22.1 mmol) and
potassium carbonate (4.58 g, 33.1 mmol) in DMF (55 mL) was added
(S)-tert-butyl 2-chloropropanoate (4.30 g, 24.3 mmol). After 72 h
of stirring, the slurry was heated to 40.degree. C. for an
additional 16 h, at which point it was diluted with EtOAc/LiCl (5%
aq) and the layers were separated. The aqueous layer was extracted
with EtOAc (2.times.) and the combined organic layers were washed
with LiCl (5% aq), brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo, affording the title compound (5.45 g, 85%)
as an off-white solid. LCMS: R.sub.t=0.88 min, m/z=313.9 (M+23)
Method 2m_acidic.
Step 3: (R)-tert-butyl 2-(aminooxy)propanoate
[0597] To a solution of (R)-tert-butyl
2-((1,3-dioxoisoindolin-2-yl)oxy)propanoate (69.6 mg, 0.239 mmol)
in DCM (478 .mu.L) at 0.degree. C. was added methyl hydrazine (12.8
.mu.L, 0.239 mmol). After stirring for 3 h at 0.degree. C., the
solids were filtered off and the filtrate was concentrated in
vacuo, affording the title compound (assumed quantitative) as a
clear oil.
Step 4:
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((((R)-1-(tert--
butoxy)-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiaz-
ol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic Acid
[0598] To a soln of Intermediate F (110 mg, 0.219 mmol) in MeOH (2
mL) at 0.degree. C. was added a soln of (R)-tert-butyl
2-(aminooxy)propanoate (38.5 mg, 0.239 mmol) in DCM:MeOH (2:1, 600
.mu.L) followed by a DCM (400 .mu.L) wash. After stirring for 16 h
it was partially concentrated in vacuo then diluted with
EtOAc/water and the layers were separated. The aqueous layer was
extracted with EtOAc (2.times.) and the combined organic layers
were dried over Na.sub.2SO.sub.4 and concd in vacuo, affording the
title compound (assumed quantitative) as a white solid. LCMS:
R.sub.t=0.74 min, m/z=645.3 (M+1) Method 2m_acidic.
Step 5:
(R)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-
-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)o-
xy)propanoic Acid
##STR00084##
[0600] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((((R)-1-(tert-b-
utoxy)-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazo-
l-4-yl)acetamido)-4-oxoazetidine-1-sulfonic acid (141 mg, 0.219
mmol), DCM (2.19 mL) and TFA (1.0 mL, 13 mmol). The crude residue
was purified by reverse phase prep HPLC (XSelect CSH, 30.times.100
mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier,
60 mL/min), affording the title compound (35.5 mg, 29%) as a white
powder. LCMS: R.sub.t=0.42 min, m/z=489.0 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 8.58 (s,
1H), 8.06 (s, 1H), 7.06 (s, 1H), 5.41 (d, J=5.6 Hz, 1H), 4.81-4.52
(m, 4H assumed; partly obscured by solvent peak), 1.29 (d, J=7.0
Hz, 3H).
Example 31:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(piperidin-4-yl)carbamimidoyl)-phenoxy)propanoic Acid
Step 1: tert-Butyl
4-(4-((S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoaze-
tidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethy-
lidene)amino)oxy)-3-(benzhydryloxy)-3-oxopropoxy)benzimidamido)piperidine--
1-carboxylate
[0601] To a solution of
(S,Z)-2-(((1-(benzhydryloxy)-3-(4-(N-(1-(tert-butoxycarbonyl)piperidin-4--
yl)carbamimidoyl)phenoxy)-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxyca-
rbonyl)amino)thiazol-4-yl)acetic acid (Prepared according to
WO2013110643, 72 mg, 0.085 mmol),
(3S,4R)-4-((1H-1,2,4-triazol-1-yl)methyl)-3-aminoazetidin-2-one
(15.7 mg, 0.094 mmol) and HATU (42.2 mg, 0.111 mmol) in DMF (854
.mu.L) was added DIPEA (44.8 .mu.L, 0.256 mmol). After stirring at
for 3 h it was diluted with EtOAc, washed with water, NaHCO.sub.3
(aq satd), brine, dried over Na.sub.2SO.sub.4 and concentrated in
vacuo, affording the title compound (82 mg, 87%) as an olive film.
LCMS: R.sub.t=0.97 min, m/z=992.5 (M+1) Method 2m_acidic.
Step 2:
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((((S)-1-(benzh-
ydryloxy)-3-(4-(N-(1-(tert-butoxycarbonyl)piperidin-4-yl)carbamimidoyl)phe-
noxy)-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-
-4-yl)acetamido)-4-oxoazetidine-1-sulfonic Acid
[0602] tert-Butyl
4-(4-((S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxoaze-
tidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethy-
lidene)amino)oxy)-3-(benzhydryloxy)-3-oxopropoxy)benzimidamido)piperidine--
1-carboxylate (99 mg, 0.10 mmol) in DMF (500 .mu.L) was treated
with SO.sub.3.DMF (45.9 mg, 0.299 mmol). After stirring for 40 min
more SO.sub.3.DMF (45.9 mg, 0.299 mmol) was added. After 1.3 h more
SO.sub.3.DMF (45.9 mg, 0.299 mmol) was added. After stirring for an
additional 30 min the solution was poured into ice-cold brine and
extracted with EtOAc. The layers were separated and the organic
layer was dried over Na.sub.2SO.sub.4 and concentrated in vacuo,
affording the title compound (assumed quantitative) as an off white
solid. LCMS: R.sub.t=0.97 min, m/z=1073.1 (M+1) Method
2m_acidic.
Step 3:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-
-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)o-
xy)-3-(4-(N-(piperidin-4-yl)carbamimidoyl)-phenoxy)propanoic
Acid
##STR00085##
[0604] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-3-((Z)-2-((((S)-1-(benzhy-
dryloxy)-3-(4-(N-(1-(tert-butoxycarbonyl)piperidin-4-yl)carbamimidoyl)phen-
oxy)-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol--
4-yl)acetamido)-4-oxoazetidine-1-sulfonic acid (0.085 mmol), DCM
(850 .mu.L) and TFA (327 .mu.L, 4.25 mmol). The crude residue was
purified by reverse phase prep HPLC (XSelect CSH, 19.times.100 mm,
5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier, 24
mL/min), affording the title compound (12 mg, 17%) as a white
powder. LCMS: R.sub.t=0.41 min, m/z=706.2 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.55
(d, J=7.4 Hz, 1H) 9.40 (br s, 1H) 9.01 (br s, 1H) 8.53-8.71 (m, 1H)
8.41 (s, 1H) 7.92 (s, 1H) 7.67 (d, J=9.0 Hz, 2H) 7.21 (br s, 2H)
7.03 (d, J=7.8 Hz, 1H) 6.76 (s, 1H) 5.17-5.24 (m, 1H) 4.94 (d,
J=3.9 Hz, 1H) 4.46-4.53 (m, 2H) 4.37-4.45 (m, 1H) 4.25-4.32 (m, 1H)
3.88 (br s, 1H) 3.39 (br s, 4H) 2.92 (t, J=11.5 Hz, 2H) 2.05-2.14
(m, 2H) 1.79 (d, J=11.0 Hz, 2H).
Example 32:
1-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoazeti-
din-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclobut-
anecarboxylic Acid
##STR00086##
[0606] LCMS: R.sub.t=0.58 min, m/z=515.0 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 8.75 (s,
1H), 8.22 (s, 1H), 7.23 (s, 1H), 5.56 (d, J=5.6 Hz, 1H), 4.95-4.85
(m, 2H), 4.86-4.82 (m, 1H assumed; partially obscured by solvent
residual peak), 4.78-4.70 (m, 1H assumed; partially obscured by
solvent residual peak), 2.61-2.46 (m, 2H), 2.38-2.27 (m, 2H),
2.00-1.89 (m, 2H).
Example 33:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(cyanomethyl)-2H-1,2,3-
-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic Acid
##STR00087##
[0608] LCMS: R.sub.t=0.57 min, m/z=542.1 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.19
(d, J=9.0 Hz, 1H), 7.71 (s, 1H), 6.65 (s, 1H), 5.43-5.23 (m, 1H),
4.93-4.84 (m, 1H), 4.76-4.67 (m, 1H), 4.47 (ddd, J=8.71, 5.4, 3.5
Hz, 1H), 4.07 (d, J=1.6 Hz, 2H), 1.35 (s, 6H).
Example 34:
2-(((Z)-(2-(((2R,3S)-2-((3-amino-1H-pyrazol-1-yl)methyl)-4-oxo-1-sulfoaze-
tidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-met-
hylpropanoic Acid
##STR00088##
[0610] LCMS: R.sub.t=0.50 min, m/z=517.3 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.54 (d,
J=2.5 Hz, 1H), 6.97 (s, 1H), 6.00 (d, J=2.4 Hz, 1H), 5.40 (d, J=5.8
Hz, 1H), 4.69 (q, J=5.5 Hz, 1H), 4.43 (d, J=5.4 Hz, 2H), 1.31 (d,
J=1.8 Hz, 6H).
Example 35:
2-(((Z)-(2-(((2R,3S)-2-((4-amino-1H-pyrazol-1-yl)methyl)-4-oxo-1-sulfoaze-
tidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-met-
hylpropanoic Acid
##STR00089##
[0612] LCMS: R.sub.t=0.39 min, m/z=517.1 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.86 (s,
1H), 7.56 (s, 1H), 6.90 (s, 1H), 5.35 (d, J=5.9 Hz, 1H), 4.72-4.67
(m, 1H), 4.54-4.49 (m, 2H), 1.28 (s, 3H), 1.27 (s, 3H).
Example 36:
(2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imin-
o)acetamido)-2-((4-((1-methylpyrrolidin-1-ium-1-yl)methyl)-2H-1,2,3-triazo-
l-2-yl)methyl)-4-oxoazetidine-1-sulfonate
##STR00090##
[0614] LCMS: R.sub.t=0.55 min, m/z=600.3 (M+) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 12.50
(s, 1H), 9.34 (s, 1H), 7.94 (s, 1H), 7.27 (s, 2H), 6.72 (s, 1H),
5.33 (dd, J=8.6, 5.6 Hz, 1H), 4.82 (dd, J=15.1, 9.2 Hz, 1H),
4.69-4.53 (m, 4H), 3.60-3.50 (m, 2H), 3.46-3.33 (m, 2H), 2.95 (s,
3H), 2.14-2.00 (m, 4H), 1.35 (s, 3H), 1.29 (s, 3H).
Example 37:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((carbamoyloxy)methyl)-
-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethy-
lidene)amino)oxy)-2-methylpropanoic Acid
##STR00091##
[0616] LCMS: R.sub.t=0.53 min, m/z=576.0 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.23
(d, J=9.3 Hz, 1H), 7.70 (s, 1H), 6.74 (s, 1H), 6.59 (br s, 2H),
5.31 (dd, J=9.2, 5.4 Hz, 1H), 4.94 (s, 2H), 4.91 (dd, J=14.3, 3.2
Hz, 1H), 4.72 (dd, J=14.2, 9.0 Hz, 1H), 4.42 (ddd, J=8.8, 5.5, 3.1
Hz, 1H), 1.38 (s, 3H), 1.37 (s, 3H).
Example 38:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-1-sulfo-4-((4-((-
sulfooxy)methyl)-2H-1,2,3-triazol-2-yl)methyl)azetidin-3-yl)amino)ethylide-
ne)amino)oxy)-2-methylpropanoic Acid
##STR00092##
[0618] LCMS: R.sub.t=0.43 min, m/z=612.9 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.71 (s,
1H), 6.96-7.11 (m, 1H), 5.40 (d, J=5.5 Hz, 1H), 4.98 (s, 2H),
4.93-4.65 (m 3H assumed; partially obscured by solvent residual
peak), 1.34 (s, 6H).
Example 39:
2-(((Z)-(2-(((2R,3S)-2-((2-amino-4,5-dihydro-1H-imidazol-1-yl)methyl)-4-o-
xo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoic Acid
##STR00093##
[0620] LCMS: R.sub.t=0.30 min, m/z=520.1 (M+1) Method 2m_acidic;
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 12.63 (br s, 1H) 9.12
(d, J=8.6 Hz, 1H) 7.74 (d, J=15.3 Hz, 3H) 7.31-7.49 (m, 2H) 6.77
(s, 1H) 5.22 (dd, J=8.5, 5.8 Hz, 1H) 4.24 (dt, J=7.1, 5.3 Hz, 1H)
3.76-3.85 (m, 1H) 3.59-3.73 (m, 2H) 3.43-3.55 (m, 3H) 1.43 (s, 3H)
1.41, (s, 3H).
Example 40:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((E)-2-(cyanoimino)imidaz-
olidin-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amin-
o)oxy)-2-methylpropanoic Acid
##STR00094##
[0622] LCMS: R.sub.t=0.33 min, m/z=544.0 (M+1) Method 2m_acidic;
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 9.29 (d, J=9.1 Hz, 1H)
7.74 (br s, 1H) 6.85 (s, 1H) 5.20 (dd, J=8.8, 5.7 Hz, 1H) 4.10-4.17
(m, 1H) 3.72-3.81 (m, 1H) 3.62 (dd, J=14.7, 6.8 Hz, 1H) 3.48-3.56
(m, 1H) 3.31-3.42 (m, 3H) 1.43 (s, 3H) 1.41, (s, 3H).
Example 41:
2-(((Z)-(2-(((2R,3S)-2-((4-(2-aminoethyl)-1H-1,2,3-triazol-1-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)a-
mino)oxy)-2-methylpropanoic Acid
##STR00095##
[0624] Step 1:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(2-((tert-b-
utoxycarbonyl)amino)ethyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1--
sulfonic Acid.
[0625] To a mixture of Intermediate K (100 mg, 0.158 mmol) and
tert-butyl but-3-yn-1-ylcarbamate (54 mg, 0.32 mmol) in
DMSO:water:tert-butanol (1:1:1, 3 mL) was added CuSO.sub.4 (13 mg,
0.079 mmol) and sodium L-ascorbate (32 mg, 0.16 mmol). After
overnight stirring the mixture was diluted with EtOAc and water.
The layers were separated and aqueous layer was extracted with
EtOAc (3.times.). The combined organic layers were washed with
water, brine, dried over Na.sub.2SO.sub.4 and concentrated in
vacuo. The crude residue was washed with diethyl ether/pentane,
affording the title compound (80 mg, 63%) as a white solid. LCMS:
m/z=799.8 (M-1).
Step 2:
2-(((Z)-(2-(((2R,3S)-2-((4-(2-aminoethyl)-1H-1,2,3-triazol-1-yl)me-
thyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoic Acid
[0626] To a solution of
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(2-((tert-b-
utoxycarbonyl)amino)ethyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1--
sulfonic acid (110 mg, 0.137 mmol) in DCM (1.4 mL) at 0.degree. C.
added TFA:DCM (1:1, 4.2 mL) followed by triethylsilane (65 .mu.L,
0.411 mmol). The reaction mixture was stirred at 0.degree. C. for
30 min and slowly warmed to room temperature. After 2 h at rt it
was concentrated in vacuo and triturated with MTBE:Heptane (1:2)
whereupon a solid was observed. The crude solid was purified by
reverse phase prep HPLC (C18 column, acetonitrile:water solvent
system with 0.1% formic acid modifier) to afford the title compound
(5 mg, 7%); LCMS: m/z=543.9 (M-1); .sup.1H NMR (400 MHz,
MeOH-d.sub.4) .delta. 8.06 (s, 1H), 6.95 (s, 1H), 5.44 (d, J=5.8
Hz, 1H), 4.66 (q, J=6.0 Hz, 1H), 4.95-4.83 (m, 2H assumed; obscured
by water), 3.29-3.24 (m, 2H), 3.07 (t, J=6.5 Hz, 2H), 1.54 (s, 3H),
1.52 (s, 3H).
Example 42:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-(2-(pipera-
zin-1-yl)ethyl)-1H-1,2,3-triazol-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)e-
thylidene)amino)oxy)-2-methylpropanoic Acid
[0627] Step 1:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(2-(4-(tert-
-butoxycarbonyl)piperazin-1-yl)ethyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoa-
zetidine-1-sulfonic acid. To a solution of Intermediate K (90 mg,
0.142 mmol) and tert-butyl
4-(but-3-yn-1-yl)piperazine-1-carboxylate (34 mg, 0.14 mmol) in a
mixture of DMSO:water:tert-butanol (1:1:1, 2.16 mL) was added
CuSO.sub.4 (2.5 mg, 0.016 mmol) and sodium L-ascorbate (5 mg, 0.15
mmol). After overnight stirring the mixture was diluted with EtOAc
and water. The layers were separated and aqueous layer was
extracted with EtOAc (3.times.). The combined organic layers were
washed with water, brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude residue was washed with diethyl
ether/pentane, affording the title compound (120 mg, crude); LCMS:
m/z=871.4 (M+1).
Step 2:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-(2--
(piperazin-1-yl)ethyl)-1H-1,2,3-triazol-1-yl)methyl)-1-sulfoazetidin-3-yl)-
amino)ethylidene)amino)oxy)-2-methylpropanoic Acid
##STR00096##
[0629] To a solution of
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(2-(4-(tert-
-butoxycarbonyl)piperazin-1-yl)ethyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoa-
zetidine-1-sulfonic acid (120 mg, 0.138 mmol) in DCM (1.4 mL) at
0.degree. C. added TFA:DCM (1:1, 4.2 mL) followed by triethylsilane
(65 .mu.L, 0.411 mmol). The reaction mixture was stirred at
0.degree. C. for 30 min and slowly warmed to room temperature.
After 2 h at rt it was concentrated in vacuo and triturated with
MTBE:Heptane (1:2) whereupon a solid was observed. The crude solid
was purified by reverse phase prep HPLC (C18 column,
acetonitrile:water solvent system with 0.1% formic acid modifier)
to afford the title compound (9.3 mg, 11%); LCMS: m/z=612.8 (M-1);
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.67 (s, 1H), 7.99 (s,
1H), 7.30 (s, 2H), 6.66 (s, 1H), 5.27 (dd, J=8.8, 5.5 Hz, 1H), 4.82
(dd, J=14.7, 4.0 Hz, 1H), 4.68 (dd, J=14.7, 6.6 Hz, 1H), 4.24 (td,
J=5.9, 4.2 Hz, 1H), 3.10 (t, J=5.2 Hz, 4H), 2.76 (t, J=7.0 Hz, 2H),
2.64-2.54 (m, 6H), 1.37 (s, 3H), 1.30 (s, 3H).
Example 43:
(3S,4R)-3-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imin-
o)acetamido)-2-oxo-4-((4-((2-(trimethylammonio)acetamido)methyl)-1H-1,2,3--
triazol-1-yl)methyl)azetidine-1-sulfonate
Step 1:
2-(((1-(((2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan--
2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-
-oxo-1-sulfoazetidin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-N,N,-
N-trimethyl-2-oxoethanammonium Bromide
[0630] To a solution of Intermediate K (100 mg, 0.158 mmol) and
N,N,N-trimethyl-2-oxo-2-(prop-2-yn-1-ylamino)ethanammonium bromide
(50 mg, 0.212 mmol) in a mixture of DMSO:water:tert-butanol (1:1:1,
3 mL) was added CuSO.sub.4 (2.5 mg, 0.016 mmol) and sodium
L-ascorbate (5 mg, 0.15 mmol). The mixture was stirred overnight
and quenched with ice-cold water, whereupon the resulting solids
were filtered and dried in vacuo to afford crude title compound (50
mg, 40%); LCMS: m/z=784.85 (M-1).
Step 2:
(3S,4R)-3-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)o-
xy)imino)acetamido)-2-oxo-4-((4-((2-(trimethylammonio)acetamido)methyl)-1H-
-1,2,3-triazol-1-yl)methyl)azetidine-1-sulfonate
##STR00097##
[0632] To a slurry of
2-(((1-(((2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)ox-
y)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxo-1--
sulfoazetidin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)methyl)amino)-N,N,N-trime-
thyl-2-oxoethanaminium bromide (50 mg, 0.0635 mmol) In DCM (640
.mu.L) at 0.degree. C. was added TFA:DCM (1:1, 1.92 mL) followed by
triethylsilane (31 .mu.L, 0.19 mmol). The reaction mixture was
stirred at 0.degree. C. for 30 min and slowly warmed to room
temperature. After 2 h at rt, it was concentrated in vacuo and
triturated with MTBE:Heptane (1:2) whereupon a solid was observed.
The crude solid was purified by reverse phase prep HPLC (C18
column, acetonitrile:water solvent system with 0.1% formic acid
modifier) to afford the title compound (11 mg, 27%). LCMS:
m/z=630.9 (M-1); .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.40
(d, J=8.6 Hz, 1H), 9.06 (t, J=5.6 Hz, 1H), 8.06 (s, 1H), 7.32 (s,
2H), 6.71 (s, 1H), 5.28 (dd, J=8.6, 5.5 Hz, 1H), 4.89-4.64 (m, 2H),
4.38 (t, J=5.1 Hz, 2H), 4.22 (q, J=5.3 Hz, 1H), 4.08 (s, 2H), 3.22
(s, 9H), 1.33 (s, 3H), 1.26 (s, 3H).
Example 44:
2-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic Acid
Step 1:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((t-
ert-butoxycarbonyl)amino)methyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetid-
ine-1-sulfonic Acid
[0633] To a solution of Intermediate K (100 mg, 0.158 mmol) in a
mixture of DMSO:water:tert-butanol (1:1:1, 1.5 mL) at 0.degree. C.
was added N-Boc-propargyl amine (50 mg, 0.321 mmol), CuSO.sub.4 (13
mg, 0.079 mmol) and sodium L-ascorbate (48 mg, 0.237 mmol). The
resulting mixture was gradually brought to rt and stirred for 3 h.
It was then diluted with EtOAc and brine and the layers were
separated. The aqueous layer was extracted with EtOAc (3.times.)
and the combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4 then concentrated in vacuo to afford crude title
compound (120 mg, 96%); LCMS: m/z=787.95 (M+1).
Step 2:
2-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-1-yl)met-
hyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyli-
dene)amino)oxy)-2-methylpropanoic Acid
##STR00098##
[0635] To a slurry of
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-but-
oxycarbonyl)amino)methyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1-s-
ulfonic acid (120 mg, 0.15 mmol) In DCM (1.5 mL) at 0.degree. C.
was added TFA:DCM (1:1, 4.5 mL) followed by triethylsilane (72
.mu.L, 0.45 mmol). The reaction mixture was stirred at 0.degree. C.
for 30 min and slowly warmed to room temperature. After 2 h at rt
it was concentrated in vacuo and triturated with MTBE:Heptane (1:2)
whereupon a solid was observed. The crude solid was purified by
reverse phase prep HPLC (C18 column, acetonitrile:water solvent
system with 0.1% formic acid modifier) to afford the title compound
(11.3 mg, 14%). LCMS: m/z=528.9 (M-1); .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.47 (d, J=8.5 Hz, 1H), 8.25 (s, 1H), 7.30
(s, 2H), 6.75 (s, 1H), 5.27 (dd, J=8.6, 5.6 Hz, 1H), 4.82 (qd,
J=14.9, 5.0 Hz, 2H), 4.23 (q, J=5.1 Hz, 1H), 4.09 (s, 2H), 1.37 (s,
3H), 1.32 (s, 3H).
Example 45:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(guanidinomethyl)-1H-1-
,2,3-triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-2-methylpropanoic Acid
##STR00099##
[0636] Step 1:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((2,3-bis(tert-butoxyc-
arbonyl)guanidino)methyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxo-1-sulfoazeti-
din-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic
Acid
[0637] To a solution of
2-(((Z)-(2-(((2R,3S)-2-((4-(ammoniomethyl)-1H-1,2,3-triazol-1-yl)methyl)--
4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)-
amino)oxy)-2-methylpropanoic acid trifluoroacetate (150 mg, 0.122
mmol) In DCM (10 mL) was added DIPEA (100 .mu.L, 0.610 mmol)
followed N,N-di-Boc-1H-pyrazole-1-carboxamidine (42 mg, 0.134
mmol). The solution was stirred at RT overnight whereupon it was
concentrated in vacuo, water was added and it was lyophilized for
72 h to afford crude title compound (210 mg, assumed quantitative
conversion). LCMS: m/z=772.1 (M-1).
Step 2:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(guanidinomethy-
l)-1H-1,2,3-triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoet-
hylidene)amino)oxy)-2-methylpropanoic Acid
[0638] General Procedure for Acid Mediated Deprotection.
[0639] To a solution of
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((2,3-bis(tert-butoxyc-
arbonyl)guanidino)methyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxo-1-sulfoazeti-
din-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic acid
(0.15 mmol, assumed quantitative conversion) In DCM (1.5 mL) at
0.degree. C. was added TFA (689 .mu.L, 9 mmol). The cold bath was
removed after 10 min. After 4 h at rt it was diluted with DCM (1.5
mL) and concentrated in vacuo. The crude residue was purified by
reverse phase prep HPLC (X-Bridge, 30.times.100 mm, 5 .mu.m, C18
column; acetonitrile-water with 0.1% formic acid modifier, 1
mL/min) to afford the title compound (2.7 mg, 3%). LCMS: m/z=572.0
(M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta. .sup.1H NMR (400
MHz, D.sub.2O): .delta. 7.91 (s, 1H), 6.80 (s, 1H), 5.31 (d, J=5.2
Hz, 1H), 4.54 (s, 1H), 4.35 (s, 2H), 3.50-3.35 (m, 2H), 1.19 (s,
3H), 1.18 (s, 3H).
Example 46:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((2-(4-methylpiperazin-
-1-yl)acetamido)methyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxo-1-sulfoazetidi-
n-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic Acid
Step 1:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((2--
(4-methylpiperazin-1-yl)acetamido)methyl)-1H-1,2,3-triazol-1-yl)methyl)-4--
oxoazetidine-1-sulfonic Acid
[0640] To a solution of Intermediate K (100 mg, 0.158 mmol) in a
mixture of DMSO:water:tert-butanol (1:1:1, 1 mL) at 0.degree. C.
was added 2-(4-methylpiperazin-1-yl)-N-(prop-2-yn-1-yl)acetamide
(47 mg, 0.24 mmol), CuSO.sub.4 (13 mg, 0.079 mmol) and sodium
L-ascorbate (48 mg, 0.237 mmol). The resulting mixture was
gradually brought to room temperature and stirred for 3 h. It was
then diluted with EtOAc and brine and the layers were separated.
The aqueous layer was extracted with EtOAc (3.times.) and the
combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4 then concentrated in vacuo to afford crude title
compound (110 mg, 84%); LCMS: m/z=829.1 (M+1).
Step 2:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((2-(4-methylpi-
perazin-1-yl)acetamido)methyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxo-1-sulfo-
azetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoic
Acid
##STR00100##
[0642] To a slurry of
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((2-(4-meth-
ylpiperazin-1-yl)acetamido)methyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazet-
idine-1-sulfonic acid (120 mg, 0.13 mmol) In DCM (1.3 mL) at
0.degree. C. was added TFA:DCM (1:1, 3.9 mL) followed by
triethylsilane (62 .mu.L, 0.39 mmol). The reaction mixture was
stirred at 0.degree. C. for 30 min and slowly warmed to room
temperature. After 2 h at rt it was concentrated in vacuo and
triturated with MTBE:Heptane (1:2) whereupon a solid was observed.
The crude solid was purified by reverse phase prep HPLC (C18
column, ACN-water solvent system with 0.1% formic acid modifier) to
afford the title compound (9 mg). LCMS: m/z=669.75 (M-1); .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 9.40 (d, J=8.7 Hz, 1H), 8.25
(s, 1H), 8.00 (s, 1H), 7.33 (s, 2H), 6.71 (s, 1H), 5.29 (dd, J=8.7,
5.6 Hz, 1H), 4.88-4.60 (m, 2H), 4.34 (d, J=5.7 Hz, 2H), 4.24 (q,
J=5.3 Hz, 1H), 3.20-2.87 (m, 8H), 2.77 (s, 3H), 1.34 (s, 3H), 1.30
(s, 3H).
Example 47:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(hydroxymethyl)-1H-1,2-
,3-triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)-
amino)oxy)-2-methylpropanoic Acid
Step 1:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(hyd-
roxymethyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1-sulfonic
Acid
[0643] To a solution of Intermediate K (126 mg, 0.20 mmol) in a
mixture of DMSO:water:tert-butanol (1:1:1, 1.5 mL) at 0.degree. C.
was added propargyl alcohol (24 .mu.L, 0.40 mmol), CuSO.sub.4 (16
mg, 0.10 mmol) and sodium L-ascorbate (59 mg, 0.30 mmol). The
resulting mixture was gradually brought to rt and stirred for 3 h.
It was then frozen and lyophilized. The crude residue was purified
with HP21 resin (ACN-water, 10-100%) to afford the title compound
as a light brown solid (100 mg, 73%); LCMS: m/z=687.1 (M-1).
Step 2:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(hydroxymethyl)-
-1H-1,2,3-triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethy-
lidene)amino)oxy)-2-methylpropanoic Acid
##STR00101##
[0645] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(hydr-
oxymethyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1-sulfonic
acid (100 mg, 0.145 mmol), DCM (4 mL) and TFA (1 mL, 13 mmol). The
crude residue was purified by reverse phase prep HPLC (T3,
30.times.100 mm, 5 .mu.m, C18 column; acetonitrile-water with 0.1%
formic acid modifier, 1 mL/min), affording the title compound (22
mg, 29%) as a white solid. LCMS: m/z=530.9 (M-1); .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 12.50 (br s, 1H), 9.36 (d, J=9.2 Hz,
1H), 7.97 (s, 1H), 7.50 (br s, 2H), 6.70 (s, 1H), 5.28 (dd, J=8.8,
5.2, Hz, 1H), 4.86 (dd, J=14.4, 4.0 Hz, 1H), 4.69 (dd, J=14.8, 7.2
Hz, 1H), 4.48 (s, 2H), 4.27-4.21 (m, 1H), 1.35 (s, 3H), 1.34 (s,
3H).
Example 48:
(2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imin-
o)acetamido)-2-((4-(1-methylpyridin-1-ium-4-yl)-1H-1,2,3-triazol-1-yl)meth-
yl)-4-oxoazetidine-1-sulfonate
Step 1:
4-(1-(((2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2--
yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-o-
xoazetidin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)-1-methylpyridin-1-ium
trifluoromethanesulfonate
[0646] To a solution of Intermediate K (85 mg, 0.134 mmol) in a
mixture of DMSO:water:tert-butanol (1:1:1, 1.0 mL) at 0.degree. C.
was added 4-ethynyl-1-methylpyridin-1-ium trifluoromethanesulfonate
(72 .mu.L, 0.27 mmol), CuSO.sub.4 (11 mg, 0.067 mmol) and sodium
L-ascorbate (40 mg, 0.201 mmol). The resulting mixture was
gradually brought to rt and stirred for 3 h whereupon it was
diluted with water (5 mL). The resulting precipitate was washed
with water (2 mL) and dried via N.sub.2 stream, affording the title
compound (80 mg) as a mixture with its N-sulfonylated azetidinone
analog as a light brown solid; LCMS: m/z=748.1 (M-1).
Step 2:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(1-m-
ethylpyridin-1-ium-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1-su-
lfonate
[0647]
4-(1-(((2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-y-
l)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-ox-
oazetidin-2-yl)methyl)-1H-1,2,3-triazol-4-yl)-1-methylpyridin-1-ium
trifluoromethanesulfonate (70 mg, 0.10 mmol) in DMF (1 mL) was
treated with SO.sub.3.DMF (80 mg, 0.52 mmol). The reaction mixture
was stirred at rt for 16 h then concentrated in vacuo and purified
by HP21 resin (ACN-water, 10-100%), affording the title compound
(24 mg, 31%) as a beige solid. LCMS: m/z=748.1 (M-1).
Step 3:
(2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)o-
xy)imino)acetamido)-2-((4-(1-methylpyridin-1-ium-4-yl)-1H-1,2,3-triazol-1--
yl)methyl)-4-oxoazetidine-1-sulfonate
##STR00102##
[0649] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(1-me-
thylpyridin-1-ium-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1-sul-
fonate (24 mg, 0.032 mmol), DCM (1.2 mL) and TFA (0.3 mL, 3.9
mmol). The crude residue was purified by reverse phase prep HPLC
(XBridge, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1%
formic acid modifier, 1 mL/min), affording the title compound (7.9
mg, 41%) as a white solid. LCMS: m/z=592.0 (M-1); .sup.1H NMR (400
MHz, D.sub.2O): .delta. 8.76 (s, 1H), 8.62 (d, J=6.8 Hz, 2H), 8.19
(d, J=6.4 Hz, 2H), 6.76 (s, 1H), 5.42 (d, J=5.2 Hz, 1H), 4.98-4.81
(m, 2H; partially obscured by residual solvent peak), 4.66-4.54 (m,
1H assumed: obscured by residual solvent peak), 4.22 (s, 3H), 1.30
(s, 3H), 1.27 (s, 3H).
Example 49:
(2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)imin-
o)acetamido)-2-((4-(1,3-dimethylpyridin-1-ium-4-yl)-1H-1,2,3-triazol-1-yl)-
methyl)-4-oxoazetidine-1-sulfonate
Step 1:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(1,3-
-dimethylpyridin-1-ium-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine--
1-sulfonate
[0650] To a solution of intermediate K (120 mg, 0.19 mmol) in a
mixture of DMSO:water:tert-butanol (1:1:1, 1.5 mL) at 0.degree. C.
was added 4-ethynyl-1,3-dimethylpyridin-1-ium
trifluoromethanesulfonate (107 mg, 0.38 mmol), CuSO.sub.4 (15 mg,
0.095 mmol) and sodium L-ascorbate (56 mg, 0.285 mmol). The
resulting mixture was gradually brought to rt and stirred for 3 h
whereupon it was diluted with water (10 mL). The resulting
precipitate was washed with water (5 mL) and dried. The crude
residue was purified with HP21 resin (ACN-water, 10-100%),
affording the title compound (80 mg, 55%) as a light brown solid;
LCMS: m/z=762.2 (M-1).
Step 2:
(2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)o-
xy)imino)acetamido)-2-((4-(1,3-dimethylpyridin-1-ium-4-yl)-1H-1,2,3-triazo-
l-1-yl)methyl)-4-oxoazetidine-1-sulfonate
##STR00103##
[0652] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(1,3--
dimethylpyridin-1-ium-4-yl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1-
-sulfonate (24 mg, 0.032 mmol), DCM (1.2 mL) and TFA (0.3 mL, 3.9
mmol). The crude residue was purified by reverse phase prep HPLC
(T3, 30.times.150 mm, 5 .mu.m, C18 column; ACN-water with 0.1%
formic acid modifier, 1 mL/min), affording the title compound (12
mg, 62%) as a white solid. LCMS: m/z=606.1 (M-1); .sup.1H NMR (400
MHz, D.sub.2O): .delta. 8.65 (s, 1H), 8.57 (s, 1H), 8.49 (d, J=5.6
Hz, 1H), 8.27 (d, J=6.8 Hz, 1H), 6.74 (br s, 1H), 5.47 (d, J=5.2
Hz, 1H), 4.97-4.88 (m, 3H), 4.21 (s, 3H), 2.46 (s, 3H), 1.30 (s,
3H), 1.28 (s, 3H).
Example 50:
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-oxo-1-sulfoazeti-
din-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methy-
lpropanoic Acid
Step 1: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)methyl)azetidin-3-yl)a-
mino)ethylidene)amino)oxy)-2-methylpropanoate
[0653] To a solution of Intermediate J (120 mg, 0.19 mmol) in a
mixture of DMSO:water:tert-butanol (1:1:1, 2.0 mL) at 0.degree. C.
was added trimethylsilylacetylene (100 .mu.L, 0.724 mmol),
CuSO.sub.4 (29 mg, 0.181 mmol) and sodium L-ascorbate (108 mg,
0.543 mmol). The resulting mixture was gradually brought to rt and
stirred for 4 h, whereupon it was diluted with brine (5 mL) and
extracted with EtOAc (3.times.10 mL). The combined organic layers
were dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The
crude residue was purified via silica gel chromatoraphy (MeOH-DCM,
7%), affording the title compound (170 mg, 72%) as a light brown
solid; LCMS: m/z=651.2 (M+1).
Step 2: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoate
[0654] Prepared according to the method described in WO2013/028590.
To a solution of tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)methyl)azetidin-3-yl)a-
mino)ethylidene)amino)oxy)-2-methylpropanoate (140 mg, 0.261 mmol)
in THF (4 mL) was added TBAF (1M in THF, 860 .mu.L, 0.86 mmol).
After stirring at rt for 16 h, additional TBAF (1M in THF, 1.0 mL,
1.0 mmol) was added. After stirring for an another 48 h, the
solution was concentrated in vacuo. The crude residue was purified
via silica gel chromatography (MeOH-DCM, 7%) affording the title
compound (84 mg, 68%) as an off white solid. LCMS: m/z=579.2
(M+1).
Step 3:
(2R,3S)-2-((1H-1,2,3-triazol-1-yl)methyl)-3-((Z)-2-(((1-(tert-buto-
xy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)-
thiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic Acid
[0655] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoate (84 mg, 0.145 mmol) in DMF (2 mL) was
treated with SO.sub.3.DMF (222 mg, 1.45 mmol). The reaction mixture
was stirred at rt for 16 h then diluted with EtOAc (50 mL) and
water. The layers were separated and the organic layer was washed
with brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo,
affording the crude title compound as a light yellow solid (84 mg,
88%). LCMS: m/z=657.1 (M-1).
Step 4:
2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,3-triazol-1-yl)methyl)-4-oxo-1-sul-
foazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)--
2-methylpropanoic Acid
##STR00104##
[0657] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-2-((1H-1,2,3-triazol-1-yl)methyl)-3-((Z)-2-(((1-(tert-butox-
y)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)t-
hiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic acid (80 mg, 0.121
mmol), DCM (4 mL) and TFA (1 mL, 13 mmol). The crude residue was
purified by reverse phase prep HPLC (T3, 30.times.150 mm, 5 .mu.m,
C18 column; ACN-water with 0.1% formic acid modifier, 1 mL/min),
affording the title compound (12 mg, 20%) as a white solid. LCMS:
m/z=500.9 (M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta. 7.95 (s,
1H), 7.67 (s, 1H), 7.04 (s, 1H), 5.38 (d, J=5.6 Hz, 1H), 4.88-4.80
(m, 1H), 4.78-4.70 (m, 2H assumed; obscured by solvent residual
peak), 1.34 (s, 6H).
Example 51:
1-(((2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2-yl)oxy)-
imino)acetamido)-4-oxo-1-sulfoazetidin-2-yl)methyl)-1H-1,2,3-triazole-4-ca-
rboxylic Acid
Step 1:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(ter-
t-butoxycarbonyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1-sulfonic
Acid
[0658] To a solution of Intermediate K (157 mg, 0.248 mmol) in a
mixture of DMSO:water:tert-butanol (1:1:1, 2.0 mL) at 0.degree. C.
was added tert-butyl propiolate (68 .mu.L, 0.496 mmol), CuSO.sub.4
(20 mg, 0.124 mmol) and sodium L-ascorbate (198 mg, 0.372 mmol).
The resulting mixture was gradually brought to room temperature and
stirred for 3 h, whereupon it was diluted with water (20 mL) and
extracted with EtOAc (3.times.50 mL). The combined oganic layers
were dried over Na.sub.2SO.sub.4, concentrated in vacuo dissolved
in water and lyophilized, affording the title compound (180 mg,
96%) as a light yellow solid; LCMS: m/z=759.3 (M+1).
Step 2:
1-(((2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-(((2-carboxypropan-2--
yl)oxy)imino)acetamido)-4-oxo-1-sulfoazetidin-2-yl)methyl)-1H-11,2,3-triaz-
ole-4-carboxylic Acid
##STR00105##
[0660] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(tert-
-butoxycarbonyl)-1H-1,2,3-triazol-1-yl)methyl)-4-oxoazetidine-1-sulfonic
acid (180 mg, 0.237 mmol), DCM (8 mL) and TFA (2 mL, 26 mmol). The
crude residue was purified by reverse phase prep HPLC (T3,
30.times.150 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 1 mL/min), affording the title compound (35 mg, 27%)
as a white solid. LCMS: m/z=544.9 (M-1); .sup.1H NMR (400 MHz,
D.sub.2O): .delta. 8.43 (s, 1H), 6.99 (s, 1H), 5.38 (d, J=5.2 Hz,
1H), 4.92-4.71 (m, 3H; partially obscured by solvent residual
peak), 1.33 (s, 6H).
Example 52:
2-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic Acid
Step 1: tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((4-(((tert-butoxycarbonyl)amino)methyl)-2H-1,2,3--
triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)-
amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0661] General Procedure for the Mitsunobu Reaction.
[0662] To a solution of Intermediate H (300 mg, 0.569 mmol),
tert-butyl ((2H-1,2,3-triazol-4-yl)methyl)carbamate (135 mg, 0.682
mmol) and triphenylphosphine (178 mg, 0.682 mmol) in THF (10 mL) at
0.degree. C. was added DIAD (145 mg, 0.682 mmol), drop-wise. After
stirring at rt for 16 h, the solution was concentrated and purified
silica gel chromatography (MeOH-DCM, 2-5%), affording the title
compound (300 mg, 75%) as a yellow foam. LCMS: m/z=706.2 (M+1).
Step 2:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((t-
ert-butoxycarbonyl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetid-
ine-1-sulfonic Acid
[0663] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((4-(((tert-butoxycarbonyl)amino)methyl)-2H-1,2,3--
triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)-
amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
(220 mg, 0.311 mmol) in DMF (5 mL) was treated with SO.sub.3.DMF
(476 mg, 3.11 mmol). The solution was stirred at rt for 48 h then
then concentrated in vacuo and purified with HP21 resin (ACN-water,
10-50%), affording the title compound (82 mg, 33%). LCMS: m/z=786.2
(M-1).
Step 3:
2-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)met-
hyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyli-
dene)amino)oxy)-2-methylpropanoic Acid
##STR00106##
[0665]
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((te-
rt-butoxycarbonyl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidi-
ne-1-sulfonic acid (82 mg, 0.104 mmol) was stirred with formic acid
(2.0 mL) at rt for 5 h, which removed both Boc groups. After
concentration in vacuo, the material was dissolved in DCM (1.5 mL),
cooled to 0.degree. C. and treated with TFA (0.5 mL, 6.5 mmol) for
1 h, whereupon it was concentrated in vacuo. The crude residue was
purified by reverse phase prep HPLC (T3, 30.times.150 mm, 5 .mu.m,
C18 column; ACN-water with 0.1% formic acid modifier, 1 mL/min),
affording the title compound (17.2 mg, 31%) as a white solid. LCMS:
m/z=529.9 (M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta. 7.67 (s,
1H), 6.92 (s, 1H), 5.39 (d, J=5.6 Hz, 1H), 4.86-4.74 (m, 3H
assumed; obscured by solvent residual peak), 4.16 (s, 2H), 1.25 (s,
3H), 1.23 (3H, s).
Example 53:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(guanidinomethyl)-2H-1-
,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-2-methylpropanoic Acid
##STR00107##
[0667] To a solution of
2-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic acid (60 mg, 0.089 mmol) and
pyrazole-1-carboxamide hydrochloride (16 mg, 0.11 mmol) in DMF (3
mL) was added DIPEA (45 .mu.L, 0.27 mmol). After stirring for 16 h,
the solution was concentrated and washed with ether. The crude
residue was purified by reverse phase prep HPLC (XBridge,
30.times.150 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 1 mL/min), affording the title compound (7.5 mg,
15%) as a white solid. LCMS: m/z=571.9 (M-1); .sup.1H NMR (400 MHz,
D.sub.2O): .delta. 7.55 (s, 1H), 6.78 (s, 1H), 5.38 (d, J=5.2 Hz,
1H), 4.82-4.76 (m, 1H assumed; obscured by solvent residual peak),
4.76-4.72 (m, 2H assumed; obscured by solvent residual peak), 4.32
(s, 2H), 1.15 (s, 3H), 1.14 (s, 3H).
Example 54:
2-(((Z)-(2-(((2R,3S)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazeti-
din-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methy-
lpropanoic acid
Step 1: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoate
[0668] The general procedure for the Mitsunobu reaction was
followed using Intermediate H (300 mg, 0.569 mmol), 1,2,3-triazole
(47 mg, 0.682 mmol), triphenylphosphine (178 mg, 0.682 mmol), DIAD
(145 mg, 0.682 mmol) and THF (10 mL). Purified via silica gel
chromatography (MeOH-DCM, 2-5%), affording the title compound (320
mg, 97%) as a yellow foam. LCMS: m/z=579.2 (M+1).
Step 2:
(2R,3S)-2-((2H-1,2,3-triazol-2-yl)methyl)-3-((Z)-2-(((1-(tert-buto-
xy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)-
thiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic Acid
[0669] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoate (320 mg, 0.553 mmol) in DMF (5 mL) was
treated with SO.sub.3.DMF (846 mg, 5.53 mmol). The solution was
stirred at rt for 24 h then then concentrated in vacuo and purified
with HP21 resin (ACN-water, 10-50%), affording the title compound
(70 mg, 19%). LCMS: m/z=657.1 (M-1).
Step 3:
2-(((Z)-(2-(((2R,3S)-2-((2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sul-
foazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)--
2-methylpropanoic Acid
##STR00108##
[0671]
(2R,3S)-2-((2H-1,2,3-triazol-2-yl)methyl)-3-((Z)-2-(((1-(tert-butox-
y)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)t-
hiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic acid (70 mg, 0.11
mmol) was stirred with formic acid (2.0 mL) at rt for 4 h then
concentrated in vacuo. The crude residue was purified by reverse
phase prep HPLC (XBridge, 30.times.100 mm, 5 .mu.m, C18 column;
ACN-water with 0.1% formic acid modifier, 1 mL/min), affording the
title compound (8.1 mg, 15%) as a white solid. LCMS: m/z=500.9
(M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta. 7.60 (s, 2H), 6.94
(s, 1H), 5.39 (d, J=5.2 Hz, 1H), 4.83-4.78 (m, 2H), 4.78-4.68 (m,
1H assumed; obscured by solvent residual peak), 1.26 (s, 3H), 1.25
(s, 3H).
Example 55:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-methyl-2H-1,2,3-triazo-
l-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy-
)-2-methylpropanoic Acid
Step 1: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-methyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoate
[0672] The general procedure for the Mitsunobu reaction was
followed using Intermediate H (300 mg, 0.569 mmol),
4-methyl-1,2,3-triazole (83 mg, 0.683 mmol), triphenylphosphine
(179 mg, 0.683 mmol), DIAD (138 mg, 0.648 mmol) and THF (8 mL).
Purified via silica gel chromatography (MeOH-DCM, 2-4%), affording
the title compound (160 mg, 47%) as a yellow foam. LCMS: m/z=591
(M-1).
Step 2:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-meth-
yl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic Acid
[0673] tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-methyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoate (160 mg, 0.270 mmol) in DMF (5
mL) was treated with SO.sub.3.DMF (413 mg, 2.70 mmol). The solution
was stirred at rt for 16 h then then concentrated in vacuo and
purified with HP21 resin (ACN-water, 10-50%), affording the title
compound (77 mg, 43%). LCMS: m/z=671.1 (M-1).
Step 3:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-methyl-2H-1,2,3-
-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic Acid
##STR00109##
[0675]
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-methy-
l-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic acid (67
mg, 0.10 mmol) was stirred with formic acid (1.5 mL) at rt for 3.5
h then concentrated in vacuo. The crude residue was purified by
reverse phase prep HPLC (XBridge, 30.times.100 mm, 5 .mu.m, C18
column; ACN-water with 0.1% formic acid modifier, 1 mL/min),
affording the title compound (13.7 mg, 27%) as a white solid. LCMS:
m/z=514.9 (M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta. 7.39 (s,
1H), 6.94 (s, 1H), 5.38 (d, J=5.6 Hz, 1H), 4.80-4.60 (m, 3H
assumed; obscured by solvent residual peak), 2.10 (s, 3H), 1.26 (s,
3H), 1.25 (s, 3H).
Example 56:
2-(((Z)-(2-(((2R,3S)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-oxo-1-sulfoazeti-
din-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methy-
lpropanoic Acid
Step 1: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoate
[0676] A solution of formic acid hydrazide (27.4 mg, 0.456 mmol)
and triethyl orthoformate (67.6 mg, 0.456 mmol) in MeOH (5 mL) was
heated to reflux for 4 h. After cooling to 40.degree. C.,
Intermediate L (120 mg, 0.228 mmol) was added and the mixture was
heated to reflux for an additional 20 h. Upon cooling to rt the
solvent was evaporated in vacuo and the resulting residue was
dissolved in EtOAc, washed with water, brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (0-10% MeOH-EtOAc),
affording the title compound (95 mg, 72%) as a foam. LCMS:
m/z=529.1 (M+1).
Step 2: (2R,3S)-2-((4H-1,2,4-triazol-4-yl)
methyl)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidine-1--
sulfonic Acid
[0677] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-oxoazetidin-3-yl-
)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoate (95 mg, 0.16 mmol) in DMF (2 mL) was
treated with SO.sub.3.DMF (251 mg, 1.64 mmol). The solution was
stirred at rt for 24 h whereupon more SO.sub.3.DMF (502 mg, 3.28
mmol) was added and the solution stirred for an additional 72 h. It
was diluted with water and extracted with EtOAc (2.times.). The
combined organic layers were washed with brine (2.times.), dried
over Na.sub.2SO.sub.4 and concentrated in vacuo, affording the
title compound (77 mg) as a solid. LCMS: m/z=657.1 (M-1).
Step 3:
2-(((Z)-(2-(((2R,3S)-2-((4H-1,2,4-triazol-4-yl)methyl)-4-oxo-1-sul-
foazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)--
2-methylpropanoic Acid
##STR00110##
[0679] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-2-((4H-1,2,4-triazol-4-yl)methyl)-3-((Z)-2-(((1-(tert-butox-
y)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)t-
hiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonic acid (77 mg, 0.117
mmol), DCM (3 mL) and TFA (1 mL, 13.0 mmol) for 2 h. The crude
residue purified by reverse phase prep HPLC (XBridge, 30.times.100
mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier,
1 mL/min, affording the title compound (5.6 mg, 10%) as a white
powder. LCMS: m/z=500.8 (M-1); .sup.1H NMR (400 MHz, D.sub.2O):
.delta. 8.52 (s, 2H), 6.90 (s, 1H), 5.30 (d, J=5.6 Hz, 1H), 4.56
(m, 2H), 4.42 (q, 1H), 1.30 (s, 6H).
Example 57:
2-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)-2-methylpropanoic Acid
Step 1: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((((S)-3-((tert-butoxycarbonyl)amino)-2-hydroxypro-
pyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0680] A solution of Intermediate L (250 mg, 0.475 mmol) and
(R)-tert-butyl (oxiran-2-ylmethyl)carbamate (410 mg, 2.38 mmol) in
DCM (3 ml) was stirred at rt for 16 h then concentrated in vacuo.
The crude residue was purified by silica gel chromatography
(MeOH-DCM, 4-10%), affording the title compound (250 mg, 75%) as a
white solid. LCMS: m/z=698.1 (M-1).
Step 2: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-(((R)-5-(((tert-butoxycarbonyl)amino)methyl)-2-oxo-
oxazolidin-3-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbon-
yl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0681] To a solution of tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(((-
(R)-2-hydroxypropyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyliden-
e)amino)oxy)-2-methylpropanoate (250 mg, 0.357 mmol) in DCM (10 mL)
at 0.degree. C. was added CDI (104 mg, 0.643 mmol). After stirring
at 15.degree. C. for 2 h the solution was concentrated in vacuo.
The crude residue was purified via silica gel chromatography
(MeOH-DCM, 3-5%) to afford the title compound (155 mg, 60%). LCMS:
m/z=724.0 (M-1).
Step 3:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-(((R)-5--
(((tert-butoxycarbonyl)amino)methyl)-2-oxooxazolidin-3-yl)methyl)-4-oxoaze-
tidine-1-sulfonic Acid
[0682] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-(((R)-5-(((tert-butoxycarbonyl)amino)methyl)-2-oxo-
oxazolidin-3-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbon-
yl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
(155 mg, 0.213 mmol) in DMF (1 mL) was treated with SO.sub.3.DMF
(130 mg, 0.854 mmol). The solution was stirred at rt for 2 h
whereupon it was concentrated in vacuo and purified with HP21 resin
(ACN-water, 10-50%), affording the title affording the title
compound (160 mg, 93%) as a white solid. LCMS: m/z=804.0 (M-1).
Step 4:
2-(((Z)-(2-(((2R,3S)-2-(((R)-5-(aminomethyl)-2-oxooxazolidin-3-yl)-
methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoeth-
ylidene)amino)oxy)-2-methylpropanoic Acid
##STR00111##
[0684] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-(((R)-5-(-
((tert-butoxycarbonyl)amino)methyl)-2-oxooxazolidin-3-yl)methyl)-4-oxoazet-
idine-1-sulfonic acid (160 mg, 0.199 mmol), DCM (1.5 mL) and TFA
(500 .mu.L, 6.49 mmol). The crude residue purified by reverse phase
prep HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18 column;
ACN-water with 0.1% formic acid modifier, 60 mL/min), affording the
title compound (85.8 mg, 78%) as a white powder. LCMS: m/z=548.0
(M+1); .sup.1H NMR (400 MHz, D.sub.2O) 6 ppm 6.93 (s, 1H), 5.23 (d,
J=5.6 Hz, 1H), 4.76-4.69 (m, 1H), 4.54-4.49 (m, 1H), 3.84 (t, J=9.6
Hz, 1H), 3.56 (dd, J=14.8, 9.6 Hz, 1H), 3.41-3.34 (m, 2H),
3.21-3.11 (m, 2H), 1.34 (s, 3H), 1.32 (s, 3H).
Example 58:
2-(((Z)-(2-(((2R,3S)-2-(((S)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)-2-methylpropanoic Acid
Step 1: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((((R)-3-((tert-butoxycarbonyl)amino)-2-hydroxypro-
pyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0685] A solution of Intermediate L (400 mg, 0.760 mmol) and
(S)-tert-butyl (oxiran-2-ylmethyl)carbamate (658 mg, 3.80 mmol) in
DCM (4 ml) was stirred at rt for 16 h then concentrated in vacuo.
The crude residue was purified by silica gel chromatography
(MeOH-DCM, 4-10%), affording the title compound (390 mg, 73%) as a
white solid. LCMS: m/z=700.1 (M+1).
Step 2: tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-(((S)-5-(((tert-butoxycarbonyl)amino)methyl)-2-oxo-
oxazolidin-3-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbon-
yl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0686] To a solution of tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-((((R)-3-((tert-butoxycarbonyl)amino)-2-hydroxypro-
pyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (390
mg, 0.557 mmol) in DCM (20 mL) at 0.degree. C. was added CDI (162
mg, 1.00 mmol). After stirring at 15.degree. C. for 2 h the
solution was concentrated in vacuo. The crude residue was purified
via silica gel chromatography (MeOH-DCM, 3-5%) to afford the title
compound (168 mg, 41%). LCMS: m/z=726.1 (M+1).
Step 3:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-(((S)-5--
(((tert-butoxycarbonyl)amino)methyl)-2-oxooxazolidin-3-yl)methyl)-4-oxoaze-
tidine-1-sulfonic Acid
[0687] tert-Butyl
2-(((Z)-(2-(((2R,3S)-2-(((S)-5-(((tert-butoxycarbonyl)amino)methyl)-2-oxo-
oxazolidin-3-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbon-
yl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
(168 mg, 0.231 mmol) in DMF (1 mL) was treated with SO.sub.3.DMF
(142 mg, 0.926 mmol). The solution was stirred at rt for 2 h
whereupon it was concentrated in vacuo and purified with HP21 resin
(ACN-water, 10-50%), affording the title compound (155 mg, 83%) as
a white solid. LCMS: m/z=804.0 (M-1).
Step 4:
2-(((Z)-(2-(((2R,3S)-2-(((S)-5-(aminomethyl)-2-oxooxazolidin-3-yl)-
methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoeth-
ylidene)amino)oxy)-2-methylpropanoic Acid
##STR00112##
[0689] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-(((S)-5-(-
((tert-butoxycarbonyl)amino)methyl)-2-oxooxazolidin-3-yl)methyl)-4-oxoazet-
idine-1-sulfonic acid (155 mg, 0.192 mmol), DCM (1.5 mL) and TFA
(500 .mu.L, 6.49 mmol). Half of the crude residue was purified by
reverse phase prep HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18
column; ACN-water with 0.1% formic acid modifier, 60 mL/min),
affording the title compound (21.8 mg, ca 82%) as a white powder.
LCMS: m/z=547.8 (M-1); .sup.1H NMR (400 MHz, D.sub.2O) .delta. ppm
6.96 (s, 1H), 5.27 (d, J=6.0 Hz, 1H), 4.80-4.78 (m, 1H), 4.52-4.47
(m, 1H), 3.75-3.66 (m, 2H), 3.49-3.45 (m, 1H), 3.32-3.16 (m, 3H),
1.37 (s, 3H), 1.35 (s, 3H).
Example 59:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((S)-5-(guanidinomethyl)--
2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyli-
dene)amino)oxy)-2-methylpropanoic Acid
##STR00113##
[0691] To a solution of
2-(((Z)-(2-(((2R,3S)-2-(((S)-5-(aminomethyl)-2-oxooxazolidin-3-yl)methyl)-
-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene-
)amino)oxy)-2-methylpropanoic acid (0.096 mmol) and
Pyrazole-1-carboxamidine hydrochloride (21 mg, 0.144 mmol) in DMF
(3 mL) was added DIPEA (100 .mu.L, 0.576 mmol). After 16 h of
stirring at rt, the solution was concentrated in vacuo and washed
with ether. The crude residue was purified by reverse phase prep
HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water
with 0.1% formic acid modifier, 60 mL/min), affording the title
compound (29 mg, 51%) as a white solid. LCMS m/z=589.8 (M-1);
.sup.1H NMR (400 MHz, D.sub.2O) .delta. ppm 6.93 (s, 1H), 5.26 (d,
J=6.0 Hz, 1H), 4.65-4.55 (m, 1H), 4.52-4.45 (m, 1H), 3.69-3.61 (m,
2H), 3.44-3.30 (m, 4H), 1.34 (s, 3H), 1.32 (s, 3H).
Example 60:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((3-methyl-1H-1,2,4-triazo-
l-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy-
)-2-methylpropanoic Acid
Step 1, Compound A: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((3-methyl-1H-1,2,4-triazol-1-yl)methy-
l)-4-oxoazetidin-3-yl)carbamate
Step 1, Compound B: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((5-methyl-1H-1,2,4-triazol-1-yl)methy-
l)-4-oxoazetidin-3-yl)carbamate
[0692]
((2S,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-o-
xoazetidin-2-yl)methyl methanesulfonate (3.74 g, 8.0 mmol),
3-methyl-1H-1,2,4-triazole (2.00 g, 24.0 mmol), K.sub.2CO.sub.3
(6.64 g, 48.0 mmol) and NaI (2.88 g, 17.2 mmol) were slurried in
DMF (16 mL) and heated to 70.degree. C. with stirring. After 24 h
the mixture was concentrated in vacuo. The crude residue was
purified via silica gel chromatography (MeOH-DCM, 2%) to afford
title compounds (1.64 g, 44% combined) as an off-white solid
(unseperable mixture). LCMS: m/z=466.2 (M+1).
Step 2, Compound A: Benzyl
((2R,3S)-2-((3-methyl-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)ca-
rbamate
Step 2, Compound B: Benzyl
((2R,3S)-2-((5-methyl-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)ca-
rbamate
[0693] Prepared according to Mastalerz et al. J. Med. Chem. 1988,
31, 1190. To a solution of compounds A/B, step 1 (1.60 g, 3.44
mmol) in ACN:water (2:1, 45 mL) was added K.sub.2S.sub.2O.sub.8
(1.86 g, 6.88 mmol) followed by K.sub.2HPO.sub.4 (1.50 g, 8.60
mmol). The resulting mixture was heated to 90.degree. C. for 4 h,
whereupon it was cooled to rt then diluted with EtOAc and the
layers separated. The aqueous layer was extracted with EtOAc
(3.times.) and the combined organic layers were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (MeOH-DCM, 10%), to afford
the title compounds (mixture, 670 mg, 62%) as a white solid. The
mixture was further purified via chiral HPLC (Chiralcel-OJ,
2.times.25 cm, EtOH-Hexanes, 18%), affording compound A (250 mg)
and compound B (240 mg).
Step 3:
(3S,4R)-3-amino-4-((3-methyl-1H-1,2,4-triazol-1-yl)methyl)azetidin-
-2-one
[0694] A slurry of benzyl
((2R,3S)-2-((3-methyl-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)ca-
rbamate (250 mg, 0.79 mmol) and Pd on C (10%, 100 mg) in MeOH (20
mL) was evacuated and backfilled with H.sub.2 (3.times.), bringing
the final pressure to 35 psi. After 2 h of stirring the mixture was
filtered over celite, washing with MeOH and the filtrate was
concentrated in vacuo. The crude residue was used as such in the
following step.
Step 4: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((3-
-methyl-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoate
[0695] To a solution of
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (310 mg, 0.72 mmol),
(3S,4R)-3-amino-4-((3-methyl-1H-1,2,4-triazol-1-yl)methyl)azetidin-2-one
(130 mg, 0.72 mmol) and EDCl (150 mg, 0.79 mmol) in DMF (5 mL) at
0.degree. C. was added pyridine (64 .mu.L, 0.79 mmol). After
stirring at rt for 24 h, more
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (310 mg, 0.72 mmol)
and EDCl (150 mg, 0.79 mmol) were added, along with HOBt (110 mg,
0.79 mmol) and DIPEA (250 .mu.L, 1.44 mmol). After an additional 16
h of stirring it was concentrated in vacuo. The crude residue was
purified via silica gel chromatography (MeOH-DCM, 5%), affording
the title compound (230 mg, 54%) as a white solid. LCMS: m/z=593.0
(M+1).
Step 5:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((3-meth-
yl-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidine-1-sulfonic Acid
[0696] tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((3-
-methyl-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoate (230 mg, 0.388 mmol) in DMF (4
mL) was treated with SO.sub.3.DMF (594 mg, 3.88 mmol). After 24 h
of stirring the solution was concentrated in vacuo. The crude
residue was purified with HP21 resin (ACN-water, 5-50%), affording
the title compound (100 mg, 38%) as a pale yellow solid. LCMS:
m/z=673.1 (M+1).
Step
6:2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((3-methyl-1H-1,2,4--
triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoic Acid
##STR00114##
[0698] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((3-methy-
l-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidine-1-sulfonic acid (100
mg, 0.149 mmol), DCM (4.0 mL) and TFA (1.0 mL, 13.0 mmol) for 3 h.
The crude residue purified by reverse phase prep HPLC (XSelect CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min), affording the title compound (50 mg,
65%) as a white powder. LCMS: m/z=514.7 (M-1); .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 9.40 (d, J=8.4 Hz, 1H), 8.72 (br s, 1H),
6.78 (s, 1H), 5.25 (dd, J=8.8, 5.6 Hz, 1H), 4.61 (dd, J=14.4, 5.2
Hz, 1H), 4.47 (dd, J=14.4, 6.0 Hz, 1H), 4.33 (dd, J=6.0, 5.2 Hz,
1H), 2.30 (s, 3H), 1.42 (s, 3H), 1.38 (s, 3H).
Example 61:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((5-methyl-1H-1,2,4-triazo-
l-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy-
)-2-methylpropanoic Acid
Step 1:
(3S,4R)-3-amino-4-((5-methyl-1H-1,2,4-triazol-1-yl)methyl)azetidin-
-2-one
[0699] A slurry of benzyl
((2R,3S)-2-((5-methyl-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)ca-
rbamate (240 mg, 0.76 mmol) and Pd on C (10%, 100 mg) in MeOH (20
mL) was evacuated and backfilled with H.sub.2 (3.times.), bringing
the final pressure to 35 psi. After 2 h of stirring the mixture was
filtered over celite, washing with MeOH and the filtrate was
concentrated in vacuo. The crude residue was used as such in the
following step.
Step 2: tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((5-
-methyl-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoate
[0700] To a solution of
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (310 mg, 0.72 mmol),
(3S,4R)-3-amino-4-((5-methyl-1H-1,2,4-triazol-1-yl)methyl)azetidin-2-one
(130 mg, 0.72 mmol) and EDCl (150 mg, 0.79 mmol) in DMF (5 mL) at
0.degree. C. was added pyridine (64 .mu.L, 0.79 mmol). After
stirring at rt for 24 h it was concentrated in vacuo. The crude
residue was purified via silica gel chromatography (MeOH-DCM, 10%),
affording the title compound (190 mg, 45%) as a white solid. LCMS:
m/z=593.0 (M+1).
Step 3:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-meth-
yl-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidine-1-sulfonic Acid
[0701] tert-Butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((5-
-methyl-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoate (180 mg, 0.304 mmol) in DMF (4
mL) was treated with SO.sub.3.DMF (466 mg, 3.04 mmol). After 24 h
of stirring the solution was concentrated in vacuo. The crude
residue was purified with HP21 resin (ACN-water, 0-50%), affording
the title compound (80 mg, 39%) as a white solid. LCMS: m/z=671.0
(M+1).
Step 4:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((5-methyl-1H-1,2,4-
-triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic Acid
##STR00115##
[0703] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-methy-
l-1H-1,2,4-triazol-1-yl)methyl)-4-oxoazetidine-1-sulfonic acid (80
mg, 0.119 mmol), DCM (4.0 mL) and TFA (1.0 mL, 13.0 mmol) for 3 h.
The crude residue purified by reverse phase prep HPLC (XSelect CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min), affording the title compound (15 mg,
24%) as a white powder. LCMS: m/z=514.8 (M-1); .sup.1H NMR (400
MHz, D.sub.2O) .delta. 7.86 (s, 1H), 6.89 (s, 1H), 5.36-5.28 (m,
1H), 4.78-4.66 (m, 1H assumed; obscured by solvent residual peak),
4.54-4.44 (m, 1H), 4.42-4.30 (m, 1H), 2.35 (s, 3H), 1.25 (s,
6H).
Example 62:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(formimidamidomethyl)--
2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoic Acid
##STR00116##
[0705] To a solution of
2-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic acid (100 mg, 0.159 mmol) and
ethylformamidate hydrochloride (17.4 mg, 0.159 mmol) in DMF (1 mL)
was added DIPEA (41 mg, 0.32 mmol). After 2 h of stirring, more
ethylformamidate hydrochloride (9.0 mg, 0.082 mmol) and DIPEA (20
mg, 0.16 mmol) was added. After an additional 4 h the solution was
concentrated and washed with ether. The crude residue was purified
by reverse phase prep HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m,
C18 column; ACN-water with 0.1% formic acid modifier, 60 mL/min),
affording the title compound (15.5 mg, 18%) as mixture of amidine
tautomers. LCMS: m/z=556.8 (M-1); .sup.1H NMR (400 MHz, D.sub.2O):
.delta. 7.73 (s, 0.4H), 7.65 (s, 0.6H), 7.57 (m, 1H), 6.83 (s, 1H),
5.37 (d, J=5.6 Hz, 1H), 4.80-4.61 (m, 3H assumed; obscured by
solvent residual peak) 4.48 (s, 0.4H), 4.45 (s, 0.6H), 1.17 (s,
3H), 1.15 (s, 3H).
Example 63:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((S)-5-(hydroxymethyl)-2--
oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylide-
ne)amino)oxy)-2-methylpropanoic Acid
Step 1: Tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((S-
)-9-hydroxy-2,2-dimethyl-5,7-dioxa-11-aza-2-siladodecan-12-yl)-4-oxoazetid-
in-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0706] To a solution of tert-butyl
2-(((Z)-(2-(((2R,3S)-2-(aminomethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpr-
opanoate (500 mg, 0.95 mmol) in DCM (5 mL) was added
(S)-trimethyl(2-((oxiran-2-ylmethoxy)methoxy)ethyl)silane (485 mg,
2.38 mmol). After stirring at rt for 12 h, another 2.5 equiv of
(S)-trimethyl(2-((oxiran-2-ylmethoxy)methoxy)ethyl)silane was
added. After stirring at rt for additional 12 h, the reaction
mixture was concentrated in vacuo. The crude residue was purified
via silica gel chromatography (MeOH-DCM, 2-10%) to afford the title
compound (155 mg, 22%). LCMS: m/z=731.4 (M+1).
Step 2: Tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-(((S)-2-oxo-5-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)oxazolid-
in-3-yl)methyl)azetidin-3-yl)amino)ethylidene)amino)oxy)-2-methylpropanoat-
e
[0707] To a solution of tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((S-
)-9-hydroxy-2,2-dimethyl-5,7-dioxa-11-aza-2-siladodecan-12-yl)-4-oxoazetid-
in-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (155
mg, 0.21 mmol) in DCM (10 mL) at 0.degree. C. was added CDI (62 mg,
0.38 mmol). After stirring at <15.degree. C. for 2 h, the
reaction mixture was concentrated in vacuo. The crude residue was
purified via silica gel chromatography (MeOH-DCM, 3-5%) to afford
the title compound (130 mg, 81%). LCMS: m/z=755.3 (M-1).
Step 3:
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((-
(S)-2-oxo-5-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)oxazolidin-3-yl)met-
hyl)azetidine-1-sulfonic Acid
[0708] To a solution of tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-(((S)-2-oxo-5-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)oxazolid-
in-3-yl)methyl)azetidin-3-yl)amino)ethylidene)amino)oxy)-2-methylpropanoat-
e (130 mg, 0.17 mmol) in DMF (1 mL) was added SO.sub.3.DMF (105 mg,
0.69 mmol). After stirring at rt for 2 h, the reaction mixture was
concentrated in vacuo. The crude mixture was purified via HP21
resin (ACN-water, 10-50%) to afford the title compound (140 mg,
97%). LCMS: m/z=705.42 (M-SEM).
Step
4:2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((S)-5-(hydroxymeth-
yl)-2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoet-
hylidene)amino)oxy)-2-methylpropanoic Acid
##STR00117##
[0710] Followed the general procedure for the acid mediated
deprotection using
(3S,4R)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-(((-
S)-2-oxo-5-(((2-(trimethylsilyl)ethoxy)methoxy)methyl)oxazolidin-3-yl)meth-
yl)azetidine-1-sulfonic acid (140 mg, 0.17 mmol), DCM (2 mL) and
TFA (1 mL) for 3 h. The crude residue was purified by reverse phase
prep HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18 column;
ACN-water with 0.1% formic acid modifier, 60 mL/min), affording the
title compound (28 mg, 30%) LCMS: m/z=549.0 (M-1); .sup.1H NMR (400
MHz, D.sub.2O): .delta. 7.00 (s, 1H), 5.23 (d, J=5.2 Hz, 1H),
4.80-4.70 (m, 1H), 4.45-4.40 (m, 1H), 4.10-3.95 (m, 2H), 3.77 (t,
J=9.2 Hz, 1H), 3.49 (t, J=7.6 Hz, 2H), 3.39 (m, 1H), 1.39 (s, 3H),
1.38 (s, 3H).
Example 64:
(S)-2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxa-
zolidin-3-yl)methyl)azetidin-3-yl)amino)ethylidene)amino)oxy)-3-(4-(N-(pip-
eridin-4-yl)carbamimidoyl)phenoxy)propanoic Acid
Step 1: tert-Butyl
(4-(2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3-yl-
)amino)acetyl)thiazol-2-yl)carbamate
[0711] Prepared in an analogous manner to intermediate E, using
intermediate D (0.776 g, 4.19 mmol),
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoacetic acid
(1.141 g, 4.19 mmol), HATU (3.071 g, 8.08 mmol) in DMF (20 mL)
followed by DIPEA (3.66 mL, 20.95 mmol). LCMS: R.sub.t=0.60 min,
m/z=440.1 (M+1) Method 2m_acidic.
Step 2:
(3S,4R)-3-(2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoace-
tamido)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidine-1-sulfonic
Acid
[0712] Prepared in an analogous manner to intermediate F, using
tert-butyl
(4-(2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidin-3-yl-
)amino)acetyl)thiazol-2-yl)carbamate (500 mg, 1.138 mmol),
SO.sub.3.DMF (523 mg, 3.41 mmol) in DMF (5.7 mL). LC/MS: Rt=0.54
min; m/z=520.0 (M+1) Method 2m_acidic.
Step 3:
(3S,4R)-3-((Z)-2-((((S)-1-(benzhydryloxy)-3-(4-(N-(1-(tert-butoxyc-
arbonyl)piperidin-4-yl)carbamimidoyl)phenoxy)-1-oxopropan-2-yl)oxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxoox-
azolidin-3-yl)methyl)azetidine-1-sulfonic Acid
[0713] To a soln of
(3S,4R)-3-(2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoacetamido)-
-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidine-1-sulfonic acid
(170 mg, 0.328 mmol) in CHCl.sub.3 (2 mL, ratio: 1) and EtOH (6 mL,
ratio: 3) was added (S)-tert-butyl
4-(4-(2-(aminooxy)-3-(benzhydryloxy)-3-oxopropoxy)benzimidamido)piperidin-
e-1-carboxylate (prepared according to WO2013110643, 193 mg, 0.328
mmol). After stirring for 2 h, AcOH (19 .mu.L, 0.328 mmol) was
added. After 12 h, more solution of
(3S,4R)-3-(2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoacetamido)-
-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)azetidine-1-sulfonic acid
(170 mg, 0.328 mmol) in 3:1 CHCl.sub.3:EtOH was added. After
stirring for 45 h, it was concentrated in vacuo, and the crude
residue was purified with HP21 resin (10-100% ACN-water), affording
the title compound (117 mg, 33%) as an off white solid. LCMS:
Rt=0.96 min, m/z=1091.1 (M+1) Method 2m_acidic.
Step 4:
(S)-2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-
-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)ox-
y)-3-(4-(N-(piperidin-4-yl)carbamimidoyl)phenoxy)propanoic Acid
##STR00118##
[0715] Followed the general procedure for the acid mediated
deprotection using
(3S,4R)-3-((Z)-2-((((S)-1-(benzhydryloxy)-3-(4-(N-(1-(tert-butoxyca-
rbonyl)piperidin-4-yl)carbamimidoyl)phenoxy)-1-oxopropan-2-yl)oxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxooxa-
zolidin-3-yl)methyl)azetidine-1-sulfonic acid (117 mg, 0.107 mmol),
DCM (5.3 mL) and TFA (0.413 mL, 5.37 mmol). The crude residue was
purified by reverse phase prep HPLC (Xselect CSH, 30.times.100 mm,
5 .mu.M, C18 column; ACN-water with 0.1% formic acid modifier, 60
mL/min), affording the title compound (23 mg, 28%) as a white
powder. LC/MS: R.sub.t=0.42 min, m/z=724.5 (M+1) Method
2m_acidic_polar; .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 9.53
(d, J=7.57 Hz, 1H), 9.43-9.36 (m, 2H), 9.01 (br s, 1H), 8.53-8.36
(m, 2H), 7.72 (d, J=8.5 Hz, 3H), 7.26 (br s, 2H), 7.15 (d, J=8.8
Hz, 2H), 6.82 (s, 1H), 5.19 (dd, J=8.7, 5.8 Hz, 1H), 5.02 (t, J=3.8
Hz, 1H), 4.51-4.42 (m, 2H), 4.12-3.96 (m, 3H), 3.90-3.81 (m, 1H),
3.73 (d, J=7.3 Hz, 1H), 3.69-3.62 (m, 1H), 3.58-3.53 (m, 1H),
3.20-3.16 (m, 1H), 2.98-2.85 (m, 1H) 2.13-2.04 (m, 1H), 1.85-1.72
(m, 1H).
Example 65:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-((sulfamoy-
lamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazetidin-3-yl)amino)et-
hylidene)amino)oxy)-2-methylpropanoic Acid
##STR00119##
[0717] Prepared in an analogous manner to example 53, using
2-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-2-methylpropanoic acid TFA salt, crude compound (200 mg,
0.318 mmol), tert-butyl chlorosulfonylcarbamate (68 mg, 0.318
mmol), DIPEA (113 mL, 0.636 mmol) and DMF (1 mL). LCMS: m/z=609.1
(M-1). .sup.1H NMR (400 MHz, D.sub.2O): .delta. 7.65 (s, 1H), 6.98
(s, 1H), 5.40 (d, J=6.0 Hz, 1H), 4.85-4.83 (m, 1H), 4.76-4.74 (m,
2H), 4.13 (s, 2H), 1.26 (s, 3H), 1.25 (s, 3H).
[0718] Preparation of tert-butyl chlorosulfonylcarbamate: To a
solution of tert-butanol (3.2 g, 36.9 mmol) in benzene (13 mL) was
added sulfurisocyanatidoyl chloride (3.5 mL, 36.6 mmol). After
stirring at rt for 2 h, the reaction mixture was quenched with
hexane. The mixture was cooled in an ice-bath, resulted in white
solid precipitation. The solid was filtered, washed with hexane,
dried and used in the next step immediately (3.2 g, 41%).
Example 66:
(S)-3-(4-(N-(2-aminoethyl)carbamimidoyl)phenoxy)-2-(((Z)-(2-(((2R,3S)-2-(-
(4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)-
amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)propanoic
Acid
##STR00120##
[0720] Prepared in analogous manner to example 31, using tert-butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)me-
thyl)carbamate and
(S,Z)-2-(((1-(benzhydryloxy)-3-(4-(N-(2-((tert-butoxycarbonyl)amino)ethyl-
)carbamimidoyl)phenoxy)-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-butoxycarb-
onyl)amino)thiazol-4-yl)acetic acid (prepared according to
WO2013110643). The crude residue was purified by reverse phase prep
HPLC (Xselect CSH, 30.times.100 mm, 5 .mu.M, C18 column; ACN-water
with 0.1% formic acid modifier, 60 mL/min). LCMS: R.sub.t=0.25 min,
m/z=695.2 (M+1) Method 2m_acidic; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.48 (s, 3H), 8.99 (s, 1H), 8.21 (s, 4H),
7.89 (s, 4H), 7.82-7.77 (m, 2H), 7.71 (s, 1H), 7.22 (dd, J=10.5,
8.2 Hz, 4H), 6.72 (s, 1H), 5.33 (dd, J=9.3, 5.5 Hz, 1H), 4.99 (dd,
J=5.7, 3.3 Hz, 1H), 4.90 (ddd, J=12.8, 8.0, 3.9 Hz, 1H), 4.78-4.68
(m, 2H), 4.51-4.36 (m, 3H), 4.08 (s, 3H), 3.13 (s, 2H).
Example 67:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(2-aminoethyl)carbamimidoyl)phenoxy)propanoic Acid
##STR00121##
[0722] Prepared in analogous manner to example 66, using
(3S,4R)-4-((1H-1,2,4-triazol-1-yl)methyl)-3-aminoazetidin-2-one.
The crude residue was purified by reverse phase prep HPLC (Xselect
CSH, 30.times.100 mm, 5 .mu.M, C18 column; ACN-water with 0.1%
formic acid modifier, 60 mL/min). LCMS: R.sub.t=0.25 min, m/z=666.1
(M+1) Method 2m_acidic.
Example 68:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(azetidin-3-yl)carbamimidoyl)phenoxy)propanoic Acid
##STR00122##
[0724] Prepared in analogous manner to example 64, using
intermediate F and (S)-tert-butyl
3-(4-(2-(aminooxy)-3-(benzhydryloxy)-3-oxopropoxy)benzimidamido)azetidine-
-1-carboxylate (prepared according to WO2013110643). The crude
residue was purified by reverse phase prep HPLC (Xselect CSH,
30.times.100 mm, 5 .mu.M, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min). LCMS: R.sub.t=0.35 min, m/z=678.2 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (500 MHz, DMSO-d.sub.6):
.delta. 13.68-13.03 (m, 1H), 10.02 (d, J=5.9 Hz, 1H), 9.57-9.51 (m,
2H), 9.05 (br s, 1H), 8.91-8.76 (m, 2H), 8.39 (s, 1H), 7.91 (s,
1H), 7.69 (d, J=8.5 Hz, 2H), 7.30 (br s, 2H), 6.92 (d, J=8.8 Hz,
2H), 6.80 (s, 1H), 5.12-5.04 (m, 2H), 4.74-4.66 (m, 1H), 4.54 (d,
J=8.8 Hz, 1H), 4.49-4.35 (m, 3H), 4.31-4.16 (m, 5H).
Example 69:
1-(((Z)-(2-(((2R,3S)-2-((4-(((3-aminopropyl)amino)methyl)-1H-1,2,3-triazo-
l-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid Compound with
Formic Acid (1:1)
##STR00123##
[0726] Prepared in analogous manner to example 28, using
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-1H-1,2,3-triazol-1-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)cyclopropanecarboxylic acid (20 mg, 0.038 mmol), tert-butyl
(3 bromopropyl)carbamate (60 mg, 0.252 mmol), DIPEA (0.1 mL, 0.572
mmol), and DMF (0.5 mL). The crude residue was purified by reverse
phase prep HPLC (Xselect CSH, 19.times.100 mm, 5 .mu.M, C18 column;
ACN-water with 0.1% formic acid modifier, 24 mL/min). LCMS:
R.sub.t=0.29 min, m/z=587.1 (M+1) Method 2m_acidic. .sup.1H NMR
(500 MHz, D.sub.2O) .delta. 8.31 (s, 1H), 8.14 (s, 1H), 6.93 (s,
1H), 5.32 (d, J=5.1 Hz, 1H), 4.86-4.78 (m, 2H), 4.73-4.66 (m, 1H
assumed; obscured by solvent residual peak), 4.29 (s, 2H),
3.04-3.01 (m, 2H), 2.97-2.92 (m, 2H), 1.96 (p, J=7.9 Hz, 2H),
1.22-1.11 (m, 2H), 1.10-0.96 (m, 2H).
Example 70:
2-(((Z)-(2-(((2R,3S)-2-((3-(2-aminoethyl)-2-oxoimidazolidin-1-yl)methyl)--
4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)-
amino)oxy)-2-methylpropanoic Acid
[0727] Step 1: Tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(11-
,11-dimethyl-9-oxo-10-oxa-2,5,8-triazadodecyl)-4-oxoazetidin-3-yl)amino)-2-
-oxoethylidene)amino)oxy)-2-methylpropanoate.
[0728] To a solution of tert-butyl
2-(((Z)-(2-(((2R,3S)-2-(((2-aminoethyl)amino)methyl)-4-oxoazetidin-3-yl)a-
mino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino-
)oxy)-2-methylpropanoate (100 mg, 0.176 mmol) in DCE (1.8 mL) was
added tert-butyl (2-oxoethyl)carbamate (27.9 mg, 0.176 mmol). After
stirring for 2 h, sodium triacetoxyborohydride (112 mg, 0.527 mmol)
was added. After 12 h, the reaction mixture was quenched with
saturated NaHCO.sub.3 (aq) and extracted with EtOAc. The organic
layer was washed with brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. It was used as crude in step 2.
Step 2: Tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((3-(2-((tert-butoxycarbonyl)amino)ethyl)-2-oxoimi-
dazolidin-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbony-
l)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0729] Prepared in analogous manner to example 3 step 3, using
tert-butyl
2-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-(11-
,11-dimethyl-9-oxo-10-oxa-2,5,8-triazadodecyl)-4-oxoazetidin-3-yl)amino)-2-
-oxoethylidene)amino)oxy)-2-methylpropanoate (135 mg, 0.189 mmol),
CDI (46.1 mg, 0.284 mmol), TEA (132 .mu.l, 0.947 mmol) and
chloroform (1.9 mL). The crude residue was used as such in the
following step. LC/MS: R.sub.t=1.02 min, m/z=739.4 (M+1) Method
2m_acidic.
Step 3:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((3-(2-(-
(tert-butoxycarbonyl)amino)ethyl)-2-oxoimidazolidin-1-yl)methyl)-4-oxoazet-
idine-1-sulfonic Acid
[0730] Prepared in analogous manner to example 3, step 4, using
tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((3-(2-((tert-butoxycarbonyl)amino)ethyl)-2-oxoimi-
dazolidin-1-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbony-
l)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
(60 mg, 0.081 mmol), SO.sub.3.DMF (124 mg, 0.812 mmol), DMF (812
.mu.l). The crude residue was used as such in the following step.
LC/MS: R.sub.t=0.94 min, m/z=819.2 (M+1) Method 2m_acidic.
Step
4:2-(((Z)-(2-(((2R,3S)-2-((3-(2-aminoethyl)-2-oxoimidazolidin-1-yl)me-
thyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoic Acid
##STR00124##
[0732] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((3-(2-((-
tert-butoxycarbonyl)amino)ethyl)-2-oxoimidazolidin-1-yl)methyl)-4-oxoazeti-
dine-1-sulfonic acid (42 mg, 0.051 mmol), TFA (237 .mu.l, 3.08
mmol) in DCM (500 .mu.L). The crude residue was purified by reverse
phase prep HPLC (Xselect CSH, 30.times.100 mm, 5 .mu.M, C18 column;
ACN-water with 0.1% formic acid modifier, 60 mL/min) to afford the
title compound (1.2 mg, 4%). LC/MS: R.sub.t=0.35 min, m/z=563.2
(M+1) Method 2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O): .delta.
.sup.1H NMR 6.99 (s, 1H), 5.32 (d, J=5.9 Hz, 1H), 4.56-4.50 (m,
1H), 3.70 (dd, J=15.1, 9.6 Hz, 1H), 3.59-3.49 (m, 1H), 3.46 3.30
(m, 4H), 3.29-3.20 (m, 2H), 3.08-3.02 (m, 2H), 1.40 (s, 3H), 1.38
(s, 3H).
Example 71:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N--((S)-pyrrolidin-3-yl)carbamimidoyl)phenoxy)propanoic Acid
##STR00125##
[0734] Prepared in analogous manner to example 64, using
intermediate F and (R)-tert-butyl
3-(4-((S)-2-(aminooxy)-3-(benzhydryloxy)-3-oxopropoxy)benzimidamido)pyrro-
lidine-1-carboxylate (prepared according to WO2013110643). The
crude residue was purified by reverse phase prep HPLC (Xselect CSH,
30.times.100 mm, 5 .mu.M, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min). LCMS: R.sub.t=0.39 min, m/z=692.3 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (500 MHz, DMSO-d.sub.6):
.delta. 9.52 (d, J=7.6 Hz, 3H), 9.11 (br s, 1H), 8.92-8.78 (m, 2H),
8.40 (s, 1H), 7.92 (s, 1H), 7.67 (d, J=8.8 Hz, 2H), 7.30 (br s,
2H), 6.90 (d, J=9.1 Hz, 2H), 6.80 (s, 1H), 5.11-5.04 (m, 2H),
4.58-4.51 (m, 1H), 4.48-4.35 (m, 4H), 4.25-4.20 (m, 1H), 3.53-3.44
(m, 1H), 2.35-2.25 (m, 1H), 2.20-2.11 (m, 1H).
Example 72:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-(hydroxymethyl)-2--
oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylide-
ne)amino)oxy)-2-methylpropanoic Acid
Step 1: Tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((((R)-3-(benzyloxy)-2-hydroxypropyl)amino)methyl)-
-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)--
2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0735] Prepared in analogous manner to example 63 step 1, using
tert-butyl
2-(((Z)-(2-(((2R,3S)-2-(aminomethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpr-
opanoate (200 mg, 0.38 mmol), (R)-2-((benzyloxy)methyl)oxirane (623
mg, 3.8 mmol), DCM (2 mL). The crude residue was purified via
silica gel chromatography (MeOH-DCM, 4-10%) to afford the title
compound (126 mg, 48%). LCMS: m/z=691.3 (M+1).
Step 2: Tert-butyl
2-(((Z)-(2-(((2R,3S)-2-(((R)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)m-
ethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol--
4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0736] Prepared in analogous manner to example 63 step 2, using
tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((((R)-3-(benzyloxy)-2-hydroxypropyl)amino)methyl)-
-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)--
2-oxoethylidene)amino)oxy)-2-methylpropanoate (126 mg, 0.182 mmol),
CDI (53 mg, 0.33 mmol), DCM (5 mL). The crude residue was purified
via silica gel chromatography (MeOH-DCM, 3-5%) to afford the title
compound (76 mg, 58%). LCMS: m/z=715.3 (M-1).
Step 3: Tert-butyl
2-(((Z)-(2-(((2R,3S)-2-(((R)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)m-
ethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol--
4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
(2R,3S)-2-(((R)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)methyl)-3-((Z)-
-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-but-
oxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonate
[0737] Prepared in analogous manner to example 63 step 3, using
tert-butyl
2-(((Z)-(2-(((2R,3S)-2-(((R)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)m-
ethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol--
4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (76 mg, 0.11
mmol), SO.sub.3.DMF (65 mg, 0.42 mmol), DMF (1 mL). The crude
residue was purified via HP21 resin (CH.sub.3CN-water, 10-50%) to
afford the title compound (80 mg, 95%). LCMS: m/z=797.3 (M+1).
Step
4:2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-(hydroxymeth-
yl)-2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoet-
hylidene)amino)oxy)-2-methylpropanoic Acid
##STR00126##
[0739] To a solution of tert-butyl
2-(((Z)-(2-(((2R,3S)-2-(((R)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)m-
ethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol--
4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
(2R,3S)-2-(((R)-5-((benzyloxy)methyl)-2-oxooxazolidin-3-yl)methyl)-3-((Z)-
-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-but-
oxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidine-1-sulfonate
(80 mg, 0.1 mmol) in DCM (10 mL) was added BC13 (1 M in DCM, 0.6
mL). After stirring at rt for 15 min, the reaction mixture was
quenched with EtOH and concentrated in vacuo. The crude residue was
purified by reverse phase prep HPLC (XSelect CSH, 30.times.100 mm,
5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier, 60
mL/min), affording the title compound (1.1 mg, 2%). LCMS: m/z=549.0
(M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta. 6.96 (s, 1H), 5.29
(d, J=5.2 Hz, 1H), 4.48 (m, 2H), 3.73-3.35 (m, 6H), 1.36 (s, 3H),
1.35 (s, 3H).
Example 73:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N--((R)-pyrrolidin-3-yl)carbamimidoyl)phenoxy)propanoic Acid
##STR00127##
[0741] Prepared in analogous manner to example 64, using
intermediate F and (S)-tert-butyl
3-(4-((S)-2-(aminooxy)-3-(benzhydryloxy)-3-oxopropoxy)benzimidamido)pyrro-
lidine-1-carboxylate (prepared according to WO2013110643). The
crude residue was purified by reverse phase prep HPLC (Xselect CSH,
30.times.100 mm, 5 .mu.M, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min). LCMS: R.sub.t=0.39 min, m/z=692.3 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (500 MHz, DMSO-d.sub.6):
.delta. 9.52 (d, J=7.6 Hz, 3H), 9.11 (br s, 1H), 8.92-8.78 (m, 2H),
8.40 (s, 1H), 7.92 (s, 1H) 7.67 (d, J=8.8 Hz, 2H), 7.30 (br s, 2H),
6.90 (d, J=9.1 Hz, 2H), 6.80 (s, 1H), 5.11-5.04 (m, 2H), 4.51-4.58
(m, 1H), 4.48-4.35 (m, 4H), 4.25-4.19 (m, 1H), 3.53-3.44 (m, 1H),
2.35-2.26 (m, 1H), 2.29-2.11 (m, 1H).
Example 74:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((3-carbamoyl-1H-1,2,4-tri-
azol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)-
oxy)-2-methylpropanoic Acid
##STR00128##
[0743] Prepared in analogous manner to example 4, using tert-butyl
(1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-1,2,4-triazole-3-carbo-
nyl)carbamate. LCMS: m/z=544.0 (M-1); .sup.1H NMR (400 MHz,
D.sub.2O): .delta. 8.41 (s, 1H), 6.94 (s, 1H), 5.36-5.32 (m, 1H),
4.75-4.50 (m, 3H, partially obscured by solvent residual peak),
1.23 (s, 6H).
Example 75:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(5-amino-1,2,4-thiadiazol-3-yl)-2-oxoethylidene)amin-
o)oxy)-3-(4-(N-(piperidin-4-yl)carbamimidoyl)phenoxy)propanoic
Acid
##STR00129##
[0745] Prepared in analogous manner to example 31, using
2-(5-((tert-butoxycarbonyl)amino)-1,2,4-thiadiazol-3-yl)-2-oxoacetic
acid. LCMS: R.sub.t=0.305 min, m/z=707.4 (M+1) Method 2m_acidic;
.sup.1H NMR (500 MHz, D.sub.2O): .delta. 8.02 (s, 1H), 7.66 (s,
1H), 7.43 (d, J=8.8 Hz, 2H), 6.77 (d, J=9.1 Hz, 2H), 5.24 (d, J=5.9
Hz, 1H), 5.10-5.06 (m, 1H), 4.44-4.29 (m, 4H), 4.01-3.88 (m, 1H),
3.49 (d, J=13.6 Hz, 2H), 3.21-2.99 (m, 2H), 2.33-2.23 (m, 2H),
1.92-1.80 (m, 2H).
Example 76:
2-(((Z)-(2-(((2R,3S)-2-(((S)-3-amino-2-oxopyrrolidin-1-yl)methyl)-4-oxo-1-
-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)o-
xy)-2-methylpropanoic Acid
##STR00130##
[0747] Prepared in analogous manner to example 1, using (S)-methyl
4-bromo-2-((tert-butoxycarbonyl)amino)butanoate. LCMS: m/z=532.0
(M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta. 6.99 (s, 1H), 5.31
(d, J=6.0 Hz, 1H), 4.70-4.58 (m, 1H), 4.02 (t, J=9.6, 9.2 Hz, 1H),
3.85 (dd, J=9.6, 9.2 Hz, 1H), 3.59 (m, 1H), 3.47 (m, 1H), 3.34 (dd,
J=14.8, 2.4 Hz, 1H), 2.48 (m, 1H), 2.01 (m, 1H), 1.39 (s, 3H), 1.37
(s, 3H).
Example 77:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-((1r,3S)-3-aminocyclobutyl)carbamimidoyl)phenoxy)propanoic
Acid
##STR00131##
[0749] Prepared in analogous manner to example 31, using
(S)-benzhydryl 2-(aminooxy)-3-(4-(N-((1
r,3S)-3-((tert-butoxycarbonyl)amino)cyclobutyl)carbamimidoyl)phenoxy)prop-
anoate LCMS: R.sub.t=0.39 min, m/z=692.1 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
9.83-9.76 (m, 1H), 9.51 (d, J=8.1 Hz, 1H), 9.33 (br s, 1H), 8.71
(br s, 1H), 8.39 (s, 1H), 8.05-7.97 (m, 3H), 7.91 (s, 1H), 7.66 (d,
J=8.5 Hz, 2H), 7.30 (br s, 2H), 6.89 (d, J=9.2 Hz, 2H), 6.80 (s,
1H), 5.13-5.04 (m, 2H), 4.55-4.49 (m, 1H), 4.47-4.33 (m, 3H),
4.24-4.16 (m, 2H), 3.97-3.86 (m, 1H), 2.69-2.52 (m, 4H).
Example 78:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-(3-aminopropyl)carbamimidoyl)phenoxy)propanoic Acid
##STR00132##
[0751] Prepared in analogous manner to example 67, using
(S)-benzhydryl
2-(aminooxy)-3-(4-(N-(3-((tert-butoxycarbonyl)amino)propyl)carbamimidoyl)-
phenoxy)propanoate (prepared according to WO2013110643). LCMS:
R.sub.t=0.38 min, m/z=680.2 (M+1) Method 2m_acidic_polar; .sup.1H
NMR (400 MHz, DMSO-d.sub.6).sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 9.59-9.47 (m, 2H), 9.34 (s, 1H), 8.88 (s, 1H), 8.37 (s,
1H), 7.90 (s, 1H), 7.79-7.67 (m, 3H), 7.66-7.62 (m, 2H), 7.29 (s,
2H), 6.94-6.88 (m, 2H), 6.80 (s, 1H), 5.10 (dd, J=8.1, 5.5 Hz, 1H),
5.06 (dd, J=5.0, 2.7 Hz, 1H), 4.56-4.48 (m, 1H), 4.48-4.35 (m, 3H),
4.26-4.19 (m, 1H), 2.90 (dd, J=8.9, 5.5 Hz, 3H), 1.96-1.83 (m,
2H).
Example 79:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
(6-(N-(piperidin-4-yl)carbamimidoyl)pyridin-3-yl)oxy)propanoic
Acid
##STR00133##
[0753] Prepared in analogous manner to example 68, using
intermediate F and (R)-tert-butyl
4-(5-(2-(aminooxy)-3-(benzhydryloxy)-3-oxopropoxy)picolinimidamido)piperi-
dine-1-carboxylate (prepared according to WO2013110643). LCMS:
R.sub.t=0.29 min, m/z=707.0 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 9.71 (d, J=7.8 Hz, 1H), 9.58 (br
s, 1H), 9.24 (br s, 1H), 8.45-8.40 (m, 1H), 8.36 (s, 1H), 8.27-8.21
(m, 1H), 8.12 (d, J=8.6 Hz, 1H), 7.84 (s, 1H), 7.65-7.59 (m, 1H),
7.24 (br s, 2H), 6.77 (s, 1H), 6.50 (s, 1H), 5.18-5.11 (m, 1H),
5.09-5.03 (m, 1H), 4.64-4.58 (m, 1H), 4.55-4.49 (m, 1H), 4.48-4.42
(m, 1H), 4.23 (q, J=5.5 Hz, 1H), 3.96-3.85 (m, 1H), 3.45-3.40 (m,
2H), 2.94-2.83 (m, 2H), 2.10-2.02 (m, 2H), 1.92-1.81 (m, 2H).
Example 80:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((S)-3-guanidino-2-oxopyr-
rolidin-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoic Acid
##STR00134##
[0755] Prepared in analogous manner to example 20 using
2-(((Z)-(2-(((2R,3S)-2-(((S)-3-amino-2-oxopyrrolidin-1-yl)methyl)-4-oxo-1-
-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)o-
xy)-2-methylpropanoic acid and 1H-pyrazole-1-carboximidamide HCl.
LCMS: m/z=576.2 (M+1); .sup.1H NMR (400 MHz, D.sub.2O): .delta.
6.95 (s, 1H), 5.31 (d, J=6.0 Hz, 1H), 4.72-4.57 (m, 1H), 4.27 (t,
J=9.6 & 9.2 Hz, 1H), 3.85 (dd, J=9.6 Hz, 1H), 3.59 (t, J=9.2,
8.8 Hz, 1H), 3.49 (q, 1H), 3.34 (dd, 1H), 2.46 (m, 1H), 1.88 (m,
1H), 1.35 (s, 3H), 1.33 (s, 3H).
Example 81:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-(N-((1R,5S,6s)-3-azabicyclo[3.1.0]hexan-6-yl)carbamimidoyl)phenoxy)propa-
noic Acid
##STR00135##
[0757] Prepared in analogous manner to example 31, using
(1R,5S,6s)-tert-butyl
6-(4-((R)-2-(aminooxy)-3-(benzhydryloxy)-3-oxopropoxy)benzimidamido)-3-az-
abicyclo[3.1.0]hexane-3-carboxylate hydrate. LCMS: R.sub.t=0.42
min, m/z=704.2 (M+1) Method 2m_acidic; .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 9.70 (br s, 1H), 9.56-9.45 (m, 2H), 9.14-8.96
(m, 2H), 8.54 (br s, 1H), 8.36 (s, 1H), 7.88 (s, 1H), 7.63 (d,
J=7.9 Hz, 2H), 7.28 (br s, 2H), 6.88 (d, J=9.6 Hz, 2H), 6.78 (s,
1H), 5.10-5.02 (m, 2H), 4.54-4.48 (m, 1H), 4.45-4.35 (m, 3H),
4.23-4.17 (m, 1H), 3.61-3.54 (m, 4H), 2.73-2.68 (m, 1H), 2.25 (br
s, 2H).
Example 82:
2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)isoxazol-3-yl)methyl)-4-oxo-1-sul-
foazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)--
2-methylpropanoic Acid
Step 1: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((E)-2-methoxyvinyl)-4-oxoazetidin-3-y-
l)carbamate
[0758] To a suspension of (methoxymethyl)triphenylphosphonium
chloride (10.34 g, 30.2 mmol) in THF (100 mL) at -78.degree. C. was
added KHMDS (in toluene) (66.3 ml, 33.1 mmol) slowly. After
stirring for 30 min, the above prepared ylide soln was added to a
soln of benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-formyl-4-oxoazetidin-3-yl)carbamate
(3 g, 7.53 mmol) in THF (38 ml) at -78.degree. C. Afer 3 h, the
reaction mixture was quenched with saturated NaHCO.sub.3 (aq, 60
mL), and it was stirred overnight. The mixture was diluted with
EtOAc, and the layers were separated. The aqueous layer was
extracted with EtOAc (2.times.), and the combined organic layers
were washed with brine, dried with Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude residue was purified via silica
gel chromatography (EtOAc-Heptane, 0-60%) to afford the title
compound (1.6 g, 49%) along with the trans-isomer (0.8 g, 25%).
LCMS: R.sub.t=0.91 min, m/z=427.0 (M+1). Method 2m_acidic.
Step 2: Benzyl
((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-(2-oxoethyl)azetidin-3-yl)carbam-
ate
[0759] To a solution of benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((E)-2-methoxyvinyl)-4-oxoazetidin-3-y-
l)carbamate (1.58 g, 3.70 mmol) in dioxane (37 ml) was added HCl
(7.4 ml, 7.4 mmol) and heated to 50.degree. C. for 4 h. After
cooling to rt, the reaction mixture was quenched with saturated
NaHCO.sub.3 (aq) and extracted with EtOAc (3.times.). The combined
organic layers were washed with brine, dried with Na.sub.2SO.sub.4
and concentrated in vacuo. The crude residue was purified by silica
gel chromatography (EtOAc-Heptane, 0-80%) to afford the title
compound (0.89 g, 58%). LCMS: R.sub.t=0.86 min, m/z=413.0 (M+1).
Method 2m_acidic.
Step 3: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((E)-2-(hydroxyimino)ethyl)-4-oxoazeti-
din-3-yl)carbamate
[0760] To a solution of hydroxylamine hydrochloride (160 mg, 2.25
mmol) and sodium bicarbonate (2.4 mL, 2.23 mmol) in water (6 mL)
was added a solution of benzyl
((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-(2-oxoethyl)azetidin-3-yl)carbam-
ate (886 mg, 2.15 mmol) in EtOH (200 .mu.L) followed by an EtOH
(200 .mu.L) wash. After stirring for 20 h, the reaction mixture was
partially concentrated in vacuo and partitioned between DCM and
brine. The aqueous layer was extracted with DCM (2.times.). The
combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The crude
residue was used as such in the following step. LCMS: R.sub.t=0.76
min, m/z=428.1 (M+1). Method 2m_acidic.
Step 4
[0761] To a solution of benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((E)-2-(hydroxyimino)ethyl)-4-oxoazeti-
din-3-yl)carbamate (403 mg, 0.94 mmol) and N-Boc-propargylamine
(156 mg, 0.97 mmol) in DCM (12 mL) at 0.degree. C. was added sodium
hypochlorite (5%, 2.6 mL, 1.89 mmol) dropwise. After stirring for
18 h, the reaction mixture was diluted with DCM and water. The
aqueous layer was extracted with DCM (2.times.). The combined
organic layers were washed with brine, dried over Na.sub.2SO.sub.4
and concentrated in vacuo. The crude residue was purified by silica
gel chromatography (EtOAc-Heptane, 0-80%), affording the title
compound (127 mg, 23%). LCMS: R.sub.t=0.96 min, m/z=581.2 (M+1).
Method 2m_acidic.
Step 5
[0762] To a solution of intermediate from step 4 (279 mg, 0.48
mmol) in acetonitrile (4.6 mL, ratio: 2) and water (2.3 mL, ratio:
1) was added potassium peroxydisulfate (169 mg, 0.62 mmol), and
potassium phosphate, dibasic (192 mg, 1.1 mmol) and heated to
90.degree. C. After 3h, more potassium peroxydisulfate (81 mg, 0.3
mmol) was added and heated to 90.degree. C. After 2 h of additional
heating, the reaction mixture was quenched with NaHCO.sub.3 and
extracted with EtOAc (3.times.). The combined organic layers were
washed with brine, dried over Na.sub.2SO.sub.4 and concentrated in
vacuo. The crude residue was purified by silica gel chromatography
(EtOAc-Heptane, 0-80%), affording the title compound (71 mg, 34%).
LCMS: R.sub.t=0.77 min, m/z=431.0 (M+1). Method 2m_acidic.
Step 6: Tert-butyl
((Z)-4-amino-5-((2R,3S)-3-amino-4-oxoazetidin-2-yl)-2-oxopent-3-en-1-yl)c-
arbamate
[0763] To a solution of intermediate from step 5 (84 mg, 0.20 mmol)
in EtOH (1.9 mL, ratio: 2) and MeOH (0.93 mL, ratio: 1) was added
Pd--C (22 mg, 20 .mu.mol) and purged with N.sub.2. The flask was
fitted with a H.sub.2 balloon, evacuated and backfilled with
H.sub.2 (3.times.). After 1.5 h, the reaction mixture was filtered
through celite with MeOH wash (3.times.). The filtrate was
concentrated in vacuo and azeotropped with toluene. The crude
residue was used as such in the following step. LCMS: R.sub.t=0.39
min, m/z=229.1 (M+1). Method 2m_acidic.
Step 7: Tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((Z)-2-amino-5-((tert-butoxycarbonyl)amino)-4-oxop-
ent-2-en-1-yl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)-
thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0764] Prepared in analogous manner to example 4 step 4, using
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (100 mg, 0.23 mmol),
HATU (89 mg, 0.23 mmol), DIPEA (68 .mu.l, 0.39 mmol), tert-butyl
((Z)-4-amino-5-((2R,3S)-3-amino-4-oxoazetidin-2-yl)-2-oxopent-3-en-1-yl)c-
arbamate (58 mg, 0.19 mmol) and DCM:DMF (3:1, 2 mL). 79 mg. LCMS:
R.sub.t=0.98 min, m/z=710.4 (M+1). Method 2m_acidic.
Step 8: Tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((5-(((tert-butoxycarbonyl)amino)methyl)isoxazol-3-
-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thi-
azol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0765] To a solution of tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((Z)-2-amino-5-((tert-butoxycarbonyl)amino)-4-oxop-
ent-2-en-1-yl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)-
thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (77 mg,
0.108 mmol)) in ethanol (0.4 mL) was added hydroxylamine
hydrochloride (19 mg, 0.27 mmol) and potassium carbonate (18 mg,
0.13 mmol) and heated to 60.degree. C. After 6 h, the reaction
mixture was partially concentrated in vacuo and partitioned between
EtOAc and water. The aqueous layer was extracted with EtOAc
(3.times.). Combined organic layers were washed with brine, dried
over Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The
crude residue was purified by column chromatography (EtOAc-Heptane,
5-90%) to afford the title compound (13 mg, 17%). LCMS:
R.sub.t=1.04 min, m/z=708.3 (M+1). Method 2m_acidic.
Step 9:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(((t-
ert-butoxycarbonyl)amino)methyl)isoxazol-3-yl)methyl)-4-oxoazetidine-1-sul-
fonic Acid
[0766] Prepared in analogous manner to example 4 step 5, using
tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((5-(((tert-butoxycarbonyl)amino)methyl)isoxazol-3-
-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thi-
azol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate (13 mg, 18
.mu.mol), SO.sub.3.DMF (16.8 mg, 0.11 mmol), DMF (200 .mu.l). The
crude residue was used as such in the following step. LCMS:
R.sub.t=0.94 min, m/z=788.4 (M+1). Method 2m_acidic.
Step 10:
2-(((Z)-(2-(((2R,3S)-2-((5-(aminomethyl)isoxazol-3-yl)methyl)-4-o-
xo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoic Acid
##STR00136##
[0768] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(((te-
rt
butoxycarbonyl)amino)methyl)isoxazol-3-yl)methyl)-4-oxoazetidine-1-sulf-
onic acid (10.9 mg, 14 .mu.mol), TFA (70 .mu.l, 0.91 mmol), and DCM
(0.2 mL). The crude residue was purified by reverse phase prep HPLC
(Xselect CSH, 19.times.100 mm, 5 .mu.M, C18 column; ACN-water with
0.1% formic acid modifier, 24 mL/min) to afford the title compound
(1.7 mg, 17%). LCMS: R.sub.t=0.48 min, m/z=532.1 (M+1). Method
2m_acidic_polar. .sup.1H NMR (400 MHz, D.sub.2O) .delta. 6.85 (s,
1H), 6.52 (s, 1H), 5.38 (d, J=5.6 Hz, 1H), 4.26 (s, 2H), 3.22 (dd,
J=16.2, 7.1 Hz, 2H), 3.10 (dd, J=16.2, 6.0 Hz, 1H), 1.33 (s, 3H),
1.29 (s, 3H).
Example 83:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((benzyl(methyl)amino)-
methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2--
oxoethylidene)amino)oxy)-2-methylpropanoic Acid
##STR00137##
[0770] Prepared in analogous manner to example 52, using
N-((2H-1,2,3-triazol-4-yl)methyl)-N-methyl-1-phenylmethanamine.
LCMS: m/z=634.1 (M-1). .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.79
(s, 1H), 7.40-7.31 (m, 5H), 6.89 (s, 1H), 5.43 (d, J=5.2 Hz, 1H),
4.96-4.89 (m, 1H), 4.87-4.83 (m, 2H), 4.70-4.60 (m, 2H, partially
overlapped with D.sub.2O signal), 4.36 (s, 2H), 2.64 (s, 3H), 1.28
(s, 3H), 1.27 (s, 3H).
Example 84:
(S)-2-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl-
)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyliden-
e)amino)oxy)-3-(4-(N-(piperidin-4-yl)carbamimidoyl)phenoxy)propanoic
Acid
##STR00138##
[0772] Prepared in analogous manner to example 31, using tert-butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)me-
thyl)carbamate. LCMS: R.sub.t=0.44 min, m/z=735.3 (M+1). Method
2m_acidic. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.63-9.48
(m, 1H), 9.45-9.33 (m, 2H), 9.02 (s, 1H), 8.56 (br s, 1H), 8.44 (br
s, 1H), 8.22 (s, 3H), 7.74-7.67 (m, 3H), 7.26 (br s, 2H), 7.19 (d,
J=8.6 Hz, 2H), 6.72 (s, 1H), 5.38-5.30 (m, 1H), 5.01-4.96 (m, 1H),
4.93-4.86 (m, 1H), 4.77-4.68 (m, 1H), 4.49-4.35 (m, 3H), 4.08 (br
s, 2H), 3.85 (br s, 2H), 2.96-2.84 (m, 2H), 2.13-2.03 (m, 2H),
1.83-1.70 (m, 2H).
Example 85:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(((azetidin-3-ylmethyl-
)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)am-
ino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 1: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylate
[0773] To a solution of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (218 mg, 0.39 mmol) in DCM
(5 mL) and DMF (1 ml) at 0.degree. C. was added DIPEA (0.11 mL,
0.61 mmol), HATU (170 mg, 0.446 mmol), and
(3S,4R)-3-amino-4-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)azetid-
in-2-one (80 mg, 0.41 mmol). After stirring at 0.degree. C. for 1
h, the reaction mixture was diluted with DCM, washed with water,
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The
crude residue was purified via silica gel chromatography (MeOH-DCM,
0-5%), affording the title compound (250 mg, 86%). LCMS: Rt=0.98
min, m/z=717.3 (M+1). Method 2m_acidic.
Step 2: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate
[0774] To a solution of benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylate (440 mg, 0.614
mmol) in THF (4 mL) was added MnO.sub.2 (1.2 g, 13.51 mmol). After
stirring at rt for 20 h, the reaction mixture was filtered through
a pad of celite with THF wash (20 mL). The filtrate was
concentrated, and the residue was purified via silica gel
chromatography (MeOH-DCM, 0-5%) to afford the title compound (300
mg, 68%). LCMS: R.sub.t=1.04 min, m/z=715.3 (M+H). Method
2m_acidic.
Step 3: Tert-butyl
3-((((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imin-
o)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidin--
2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)amino)methyl)azetidine-1-carboxy-
late
[0775] To a solution of benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate (150 mg, 0.21 mmol) in DCE
(4 ml) at 0.degree. C. was added tert-butyl
3-(aminomethyl)azetidine-1-carboxylate (78 mg, 0.420 mmol), sodium
triacetoxyborohydride (66.7 mg, 0.315 mmol), and DMF (0.4 mL).
After stirring at rt for 3 h, the reaction mixture was quenched
with saturated NaHCO.sub.3 (aq) and diluted with 10% EtOH/DCM (40
mL). The organic layer was separated, dried with Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The crude residue was used as
such in the following step. LCMS: R.sub.t=0.55 min, m/z=885.5
(M+1). Method 2m_acidic.
Step 4: Tert-butyl
3-((((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imin-
o)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidin--
2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)(tert-butoxycarbonyl)amino)methy-
l)azetidine-1-carboxylate
[0776] To a solution of tert-butyl
3-((((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imin-
o)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidin--
2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)amino)methyl)azetidine-1-carboxy-
late (186 mg, 0.21 mmol) and saturated NaHCO.sub.3 (aq, 4 ml, 0.210
mmol) in DCM (4 mL) was added Boc.sub.2O (137 mg, 0.630 mmol).
After stirring at rt for 12 h, the reaction mixture layers were
separated. The aqueous layer was extracted with DCM, and the
combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The crude
residue was purified by silica gel chromatography (EtOAc-Hept,
50-80%) to afford the title compound (120 mg, 58%). LCMS:
R.sub.t=1.24 min, m/z=985.7 (M+1). Method 2m_acidic.
Step 5:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-but-
oxycarbonyl)((1-(tert-butoxycarbonyl)azetidin-3-yl)methyl)amino)methyl)-2H-
-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic Acid
[0777] Prepared in analogous manner to example 19 step 3, using
tert-butyl
3-((((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imin-
o)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidin--
2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)(tert-butoxycarbonyl)amino)methy-
l)azetidine-1-carboxylate (120 mg, 0.122 mmol), SO.sub.3.DMF (192
mg, 1.22 mmol), and DMF (1.2 mL). The crude residue was used as
such in the following step. LCMS: R.sub.t=1.12 min, m/z=1065.7
(M+1). Method 2m_acidic.
Step 6:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(((azetidin-3-y-
lmethyl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin--
3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00139##
[0779] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-buto-
xycarbonyl)((1-(tert-butoxycarbonyl)azetidin-3-yl)methyl)amino)methyl)-2H--
1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic acid (130 mg,
0.122 mmol), TFA (0.56 mL, 7.32 mmol), and DCM (1.5 mL). 6.3 mg.
LCMS: R.sub.t=0.47 min, m/z=599.3 (M+1). Method 2m_acidic_polar.
.sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.82 (s, 1H), 7.10 (s, 1H),
5.61 (d, J=5.9 Hz, 1H), 5.01 (q, J=5.6 Hz, 1H), 4.95-4.85 (m, 2H),
4.36 (s, 2H), 4.26-4.15 (m, 2H) 4.11-3.97 (m, 2H), 3.46-3.30 (m,
3H), 1.26 (s, 2H), 1.20-1.05 (m, 2H).
Example 86:
2-(((Z)-(2-(((2R,3S)-2-(((R)-3-amino-2-oxopyrrolidin-1-yl)methyl)-4-oxo-1-
-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)o-
xy)-2-methylpropanoic Acid
##STR00140##
[0781] Prepared in analogous manner to example 76, using (R)-methyl
4-bromo-2-((tert-butoxycarbonyl)amino)butanoate. LCMS: m/z=532.0
(M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta.6.96 (s, 1H), 5.28
(d, J=6.0 Hz, 1H), 4.53 (m, 1H), 3.96 (t, J=10.0 & 9.2 Hz, 1H),
3.85 (dd, J=10.4 & 10.0 Hz, 1H), 3.58 (m, 1H), 3.44 (m, 1H),
3.31 (dd, 1H), 2.47 (m, 1H), 1.96 (m, 1H), 1.34 (s, 3H), 1.34 (s,
3H).
Example 87:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxo-2,3-di-
hydro-1H-imidazol-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino-
)oxy)-2-methylpropanoic Acid
Step 1: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((2,5-dioxoimidazolidin-1-yl)methyl)-4-
-oxoazetidin-3-yl)carbamate
[0782] The general procedure for the Mitsunobu reaction was
followed using intermediate G (10.0 g, 25 mmol),
imidazolidine-2,4-dione (2.5 g, 25 mmol), triphenylphosphine (7.9
g, 30 mmol), DIAD (6.1 g, 30 mmol) and THF (200 mL). The resulting
precipitate (8.3 g, 69%) which was slightly contaminated with
triphenylphosphine oxide, was collected by filtration. LCMS:
m/z=481.0 (M-1).
Step 2: tert-Butyl
3-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-oxoa-
zetidin-2-yl)methyl)-2,4-dioxoimidazolidine-1-carboxylate
[0783] To a solution of benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((2,5-dioxoimidazolidin-1-yl)methyl)-4-
-oxoazetidin-3-yl)carbamate (4.60 g, 9.54 mmol) and
di-tert-butyldicarbonate (2.30 g, 10.5 mmol) in DCM (55 mL) was
added DMAP (0.150 g, 1.33 mmol). After 3 h at rt, water was added,
whereupon the layers were separated. The organic layer was dried
over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue
was purified via silica gel chromatography, affording the title
compound (4.20 g, 75%).
Step 3: tert-Butyl
3-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-2,4-
-dioxoimidazolidine-1-carboxylate
[0784] Prepared in an analogous manner to example 4, step 2 using
tert-butyl
3-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-oxoa-
zetidin-2-yl)methyl)-2,4-dioxoimidazolidine-1-carboxylate (900 mg,
1.70 mmol) K.sub.2S.sub.2O.sub.8 (280 mg, 2.89 mmol), and
K.sub.2HPO.sub.4 (680 mg, 2.91 mmol) in ACN:water (2:1, 30 mL)
while heating at 90.degree. C. for 4 h. After cooling to rt, the
mixture was filtered and the filtrate was concentrated in vacuo,
removing most of the ACN. The mixture was diluted with water/EtOAc
and the layers were separated. The aqueous layer was extracted with
EtOAc and the combined organic layers were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (MeOH-DCM, 2-6%) to afford
the title compound (170 mg, 23%). LCMS: m/z=431.0 (M-1).
Step 4: tert-Butyl
3-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-4-h-
ydroxy-2-oxoimidazolidine-1-carboxylate
[0785] To a solution of tert-butyl
3-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-2,4-
-dioxoimidazolidine-1-carboxylate (170 mg, 0.390 mmol) in EtOH (10
mL) at 0.degree. C. was added sodium borohydride (30 mg, 0.78
mmol). After 3 h at 0.degree. C., the mixture was quenched with
saturated NH.sub.4Cl (aq) and partially concentrated in vacuo. The
bilayer was extracted with DCM and the organic layer was dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The resulting residue
was used as such in step 5. LCMS: m/z=457.1 (M+Na).
Step 5: tert-Butyl
3-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-2-o-
xo-2,3-dihydro-1H-imidazole-1-carboxylate
[0786] To a solution of tert-butyl
3-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-4-h-
ydroxy-2-oxoimidazolidine-1-carboxylate (160 mg, 0.368 mmol) in DCM
(5 mL) at 0.degree. C. was added methanesulfonyl chloride (31
.mu.L, 0.41 mmol) followed by TEA (0.15 mL, 1.1 mmol). After
stirring for 1 h at 0.degree. C., the solution was concentrated in
vacuo and purified via silica gel chromatography (MeOH-DCM, 2-5%),
affording the title compound (100 mg, 65%). LCMS: m/z=415.1 (M-1);
.sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.02 (s, 1H), 7.41-7.27
(m, 5H), 7.06 (d, J=8.4 Hz, 1H), 6.61 (d, J=3.2 Hz, 1H), 6.15 (d,
J=3.2 Hz, 1H), 5.21-5.09 (m, 3H), 4.30 (dd, J=14.4, 9.6 Hz, 1H),
4.01-3.94 (m, 1H), 3.49 (dd, J=14.8, 3.2 Hz, 1H), 1.46 (s, 9H).
Step 6: tert-Butyl
3-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2-oxo-2,3-dihydro-1H-imida-
zole-1-carboxylate
[0787] A mixture of tert-Butyl
3-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-2-o-
xo-2,3-dihydro-1H-imidazole-1-carboxylate (490 mg, 1.18 mmol) and
Palladium on carbon (10% wt, 140 mg) in MeOH (60 mL) was evacuated
and backfilled with H.sub.2 (3.times.), bringing the final pressue
up to 30 psi. After 2 h of stirring, the mixture was filtered
through celite and concentrated in vauco. The crude residue was
purified via silica gel chromatography (MeOH-DCM, 6%), affording
the title compound (50 mg, 25%).
Step 7: tert-Butyl
3-(((2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imi-
no)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidin-
-2-yl)methyl)-2-oxo-2,3-dihydro-1H-imidazole-1-carboxylate
[0788] Prepared in analogous manner to example 4 step 4, using
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (117 mg, 0.276
mmol), HATU (105 mg, 0.276 mmol), DIPEA (36 mg, 0.28 mmol),
tert-butyl
3-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2-oxo-2,3-dihydro-1H-imida-
zole-1-carboxylate (65 mg, 0.23 mmol) and DMF (5 mL). The crude
residue was purified via silica gel chromatography (MeOH-DCM, 3%),
affording the title compound (140 mg, 88%). LCMS: m/z=694.0
(M+1).
Step 8:
(2R,3S)-3-((Z)-2-(((1-(tert-Butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((3-(ter-
t-butoxycarbonyl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl)methyl)-4-oxoazetidin-
e-1-sulfonic Acid
[0789] To a solution of tert-butyl
3-(((2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imi-
no)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidin-
-2-yl)methyl)-2-oxo-2,3-dihydro-1H-imidazole-1-carboxylate (140 mg,
0.202 mmol) in DMF (1.0 mL) was added SO.sub.3.DMF (185 mg, 1.21
mmol). After 4 h at rt, the solution was concentrated in vacuo and
purified over HP21 resin (ACN-water, 10-50%), affording the title
compound (90 mg, 58%). LCMS: m/z=772.3 (M-1).
##STR00141##
Step 9:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-ox-
o-2,3-dihydro-1H-imidazol-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylide-
ne)amino)oxy)-2-methylpropanoic Acid
[0790] Followed the general procedure for the acid mediated
deprotection using tert-butyl
3-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2-oxo-2,3-dihydro-1H-imida-
zole-1-carboxylate (prepared from tert-butyl
3-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-2,4-
-dioxoimidazolidine-1-carboxylate) (90 mg, 1.16 mmol), TFA (0.5 mL,
6.4 mmol) and DCM (1.5 mL). The crude residue was purified via
reverse phase prep HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18
column; ACN-water with 0.1% formic acid modifier, 60 mL/min) to
afford the title compound (15.6 mg, 60%) as an off-white solid.
LCMS: m/z=516.0 (M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta.
6.98 (s, 1H), 6.41 (d, J=2.8 Hz, 1H), 6.30 (d, J=2.8 Hz, 1H), 5.30
(d, J=6.0 Hz, 1H), 4.54-4.52 (m, 1H), 4.00-3.95 (m, 1H), 3.84-3.79
(m, 1H), 1.35 (s, 3H), 1.34 (s, 3H).
Example 88:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-3-guanidino-2-oxopyr-
rolidin-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)ami-
no)oxy)-2-methylpropanoic Acid
##STR00142##
[0792] Prepared in analogous manner to example 20, using using
2-(((Z)-(2-(((2R,3S)-2-(((R)-3-amino-2-oxopyrrolidin-1-yl)methyl)-4-oxo-1-
-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)o-
xy)-2-methylpropanoic acid and 1H-pyrazole-1-carboximidamide HCl.
LCMS: m/z=574.1 (M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta.
6.93 (s, 1H), 5.28 (d, J=5.6 Hz, 1H), 4.53 (m, 1H), 4.24 (t, J=9.6
& 9.2 Hz, 1H), 3.85 (dd, J=9.2 & 9.2 Hz, 1H), 3.51 (m, 1H),
3.40 (t, J=9.2 & 8.8 Hz, 1H), 3.32 (dd, 1H), 3.34 (dd, 1H),
2.43 (m, 1H), 1.87 (m, 1H), 1.36 (s, 3H), 1.32 (s, 3H).
Example 89:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-(((R)-pyrr-
olidin-3-ylamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazetidin-3-y-
l)amino)ethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00143##
[0794] Prepared in analogous manner to example 85, using
(R)-tert-butyl 3-aminopyrrolidine-1-carboxylate. LCMS: R.sub.t=0.46
min, m/z=599.3 (M+1) Method 2m_acidic_polar; .sup.1H NMR (400 MHz,
D.sub.2O): .delta. 7.86 (s, 1H), 7.16 (s, 1H), 5.60 (d, J=5.5 Hz,
1H), 4.99 (s, 1H), 4.90 (d, J=3.9 Hz, 2H), 4.46 (d, J=5.1 Hz, 2H),
4.20-4.14 (m, 1H), 3.82 (dd, J=13.1, 8.0 Hz, 1H), 3.65-3.38 (m,
2H), 2.67-2.57 (m, 1H), 2.31-2.20 (m, 1H), 1.34 (t, J=4.3 Hz, 3H),
1.25-1.19 (m, 2H).
Example 90:
1-(((Z)-(2-(((2R,3S)-2-((4-(((3-aminopropyl)amino)methyl)-2H-1,2,3-triazo-
l-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 1: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylate
[0795] To a solution of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (2.5 g, 4.43 mmol) in DCM
(78 mL) and DMF (15 ml) at 0.degree. C. was added DIPEA (1.2 ml,
7.00 mmol), HATU (1.9 g, 5.13 mmol), and
(3S,4R)-3-amino-4-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)azetid-
in-2-one (0.92 g, 4.67 mmol). After stirring at 0.degree. C. for 1
h, the reaction mixture was diluted with DCM, washed with water,
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The
crude residue was purified via silica gel chromatography (MeOH-DCM,
0-5%), affording the title compound (2.5 g, 75%). LCMS:
R.sub.t=0.98 min, m/z=717.3 (M+1) Method 2m_acidic.
Step 2: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate
[0796] To a solution of benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylate (1.8 g, 2.57 mmol)
in THF (21 ml) was added MnO.sub.2 (4.9 g, 56.5 mmol). After
stirring at rt for 20 h, the reaction mixture was filtered through
a pad of celite with THF wash (250 mL). The filtrate was
concentrated, and the residue was purified via silica gel
chromatography (MeOH-DCM, 0-5%) to afford the title compound (1.4
g, 76%). LCMS: R.sub.t=1.04 min, m/z=715.3 (M+H). Method
2m_acidic.
Step 3: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(((3-((tert-butoxycarbonyl)amino)propyl)amino)-
methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropan-
ecarboxylate
[0797] To a solution of benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate (370 mg, 0.52 mmol) in DCE
(4 mL) at 0.degree. C. was added tert-butyl
(3-aminopropyl)carbamate (180 mg, 1.04 mmol) and sodium
triacetoxyhydroborate (165 mg, 0.78 mmol) sequentially. After
stirring at rt for 16 h, the reaction mixture was diluted with DCM,
washed with saturated NaHCO.sub.3 (aq), brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo to give the
title compound (assumed quantitative). The crude residue was used
as such in the following step. LCMS: R.sub.t=0.99 min, m/z=873.2
(M+1). Method 2m_acidic.
Step 4: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(((tert-butoxycarbonyl)(3-((tert-butoxycarbony-
l)amino)propyl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-
-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)-
amino)oxy)cyclopropanecarboxylate
[0798] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(((3-((tert-butoxycarbonyl)amino)propyl)amino)-
methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropan-
ecarboxylate (0.45 g, 0.52 mmol) in DMF (6 mL) at 0.degree. C. was
added Boc-anhydride (0.24 mL, 1.04 mmol). After stirring at rt for
18 h, DIPEA (0.18 mL, 1.04 mmol) was added. After stirring for 36
h, the reaction mixture was poured into water and extracted with
DCM. Combined organic layers were washed with 5% LiCl, brine, dried
over Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The
crude residue was purified via silica gel chromatography
(EtOAc-Heptane, 0-60%) to afford the title compound (0.40 g, 80%).
LCMS: R.sub.t=1.26 min, m/z=973.3 (M+H). Method 2m_acidic.
Step 5:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-but-
oxycarbonyl)(3-((tert-butoxycarbonyl)amino)propyl)amino)methyl)-2H-1,2,3-t-
riazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic Acid
[0799] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(((tert-butoxycarbonyl)(3-((tert-butoxycarbony-
l)amino)propyl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-
-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)-
amino)oxy)cyclopropanecarboxylate (0.40 g, 0.41 mmol) in DMF (5 mL)
at 0.degree. C. was added SO.sub.3.DMF (0.63 g, 4.12 mmol). After
stirring at rt for 1 h, the reaction mixture was diluted with
EtOAc, washed with 5% LiC (aq), brine, dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo to give the title compound (0.42
g, 97%). LCMS: R.sub.t=1.10 min, m/z=1053.6 (M+H). Method
2m_acidic.
Step 6:
1-(((Z)-(2-(((2R,3S)-2-((4-(((3-aminopropyl)amino)methyl)-2H-1,2,3-
-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol--
4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00144##
[0801] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-buto-
xycarbonyl)(3-((tert-butoxycarbonyl)amino)propyl)amino)methyl)-2H-1,2,3-tr-
iazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic acid (0.5 g, 0.48
mmol), DCM (2.5 mL), and TFA (1 mL, 13 mmol) for 1.5 h. The crude
residue was purified by reverse phase prep HPLC (XSelect CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min) affording the title compound (123 mg,
42%). LCMS: R.sub.t=0.31 min, m/z=587.2 (M+1) Method 2m_acidic;
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 9.39 (br s, 1H), 7.76
(s, 1H), 7.22 (s, 2H), 6.73 (s, 1H), 5.33 (dd, J=9.0, 5.5 Hz, 1H),
4.84 (dd, J=14.3, 4.5 Hz, 1H), 4.73-4.61 (m, 1H), 4.61-4.48 (m,
1H), 4.27-4.14 (m, 2H), 3.02-2.89 (m, 3H), 2.85 (t, J=7.4 Hz, 3H),
1.85 (p, J=7.5 Hz, 3H) 1.32-1.04 (m, 6H); .sup.1H NMR (400 MHz,
D.sub.2O) .delta. 7.90 (s, 1H), 7.15 (s, 1H), 5.67 (d, J=5.5 Hz,
1H), 5.12-5.04 (m, 1H), 5.04-4.88 (m, 2H), 4.45 (s, 2H), 3.30-3.22
(m, 2H), 3.16 (t, J=7.6 Hz, 2H), 2.24-2.08 (m, 2H), 1.37-1.26 (m,
2H), 1.26-1.08 (m, 2H).
Example 91:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-(((S)-pyrr-
olidin-3-ylamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazetidin-3-y-
l)amino)ethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00145##
[0803] Prepared in analogous manner to example 90, using
(S)-tert-butyl 3-aminopyrrolidine-1-carboxylate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.3 min, m/z=599.0 (M+1) Method 2m_acidic; .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 9.18 (d, J=9.0 Hz, 1H), 9.04-8.59 (m,
2H), 7.79 (s, 1H), 7.24 (br s, 2H), 6.72 (s, 1H), 5.35 (dd, J=9.0,
5.5 Hz, 1H), 4.93-4.81 (m, 1H), 4.68-4.60 (m, 1H), 4.55 (s, 1H),
4.24 (br s, 2H), 3.95-3.79 (m, 1H), 2.27-2.11 (m, 1H), 2.04-1.90
(m, 1H), 1.38-1.06 (m, 4H).
Example 92:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(aminomethyl)azetidin-1-yl)methyl)-2H-1,2,-
3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-
-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00146##
[0805] Prepared in analogous manner to example 90, using tert-butyl
(azetidin-3-ylmethyl)carbamate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.46 min, m/z=599.4 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, D.sub.2O): .delta. 7.84 (s, 1H) 7.11 (s, 1H) 5.56 (d,
J=5.5 Hz, 1H) 5.00 (m, 1H) 4.89 (m, 2H) 4.52 (s, 2H) 4.35 (m, 2H)
4.23-4.03 (m, 2H) 3.38-3.21 (m, 3H) 1.31 (m, 2H) 1.18 (m, 2H).
Example 93: 1-(((Z)-(2-(((2R,3S)-2-((4-((((1
r,3R)-3-aminocyclobutyl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-
-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino-
)oxy)cyclopropanecarboxylic Acid
##STR00147##
[0807] Prepared in analogous manner to example 90, using tert-butyl
((1r,3r)-3-aminocyclobutyl)carbamate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.46 min, m/z=599.3 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, D.sub.2O): .delta. 7.82 (s, 1H), 7.09 (s, 1H), 5.58 (d,
J=5.9 Hz, 1H), 5.04-4.84 (m, 3H), 4.31 (s, 2H), 4.14-4.00 (m, 2H),
2.81-2.60 (m, 4H) 1.26 (s, 2H), 1.19-1.06 (m, 2H).
Example 94:
(((Z)-(1-(5-amino-1,2,4-thiadiazol-3-yl)-2-(((2R,3S)-2-((4-(((3-aminoprop-
yl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)-
amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00148##
[0809] Prepared in analogous manner to example 90, using
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(5-((tert-butoxy-
carbonyl)amino)-1,2,4-thiadiazol-3-yl)acetic acid. LCMS:
R.sub.t=0.29 min, m/z=588.0 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 9.53-9.29 (m, 1H), 8.15 (s, 2H),
7.75 (s, 1H) 5.40-5.28 (m, 1H), 4.82-4.69 (m, 1H), 4.63 (s, 2H),
4.21 (d, J=5.1 Hz, 2H), 3.00-2.91 (m, 2H), 2.85 (s, 2H), 1.91-1.74
(m, 2H), 1.37-1.04 (m, 4H).
Example 95:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((2,4-dioxooxazolidin-3-yl-
)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclo-
propanecarboxylic Acid
##STR00149##
[0811] Prepared in analogous manner to example 54, using benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(hy-
droxymethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cycloprop-
anecarboxylate and oxazolidine-2,4-dione. LCMS: R.sub.t=0.31 min,
m/z=533.0 (M+1) Method 2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O)
.delta. 7.23 (s, 1H), 5.42 (d, J=5.9 Hz, 1H), 4.86-4.83 (m, 3H),
4.07 (dd, J=14.5, 9.8 Hz, 1H), 3.72 (dd, J=14.5, 3.9 Hz, 1H),
1.58-1.52 (m, 2H), 1.51-1.45 (m, 2H).
Example 96:
1-(((Z)-(2-(((2R,3S)-2-((5-(((3-aminopropyl)amino)methyl)-2H-tetrazol-2-y-
l)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoe-
thylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00150##
[0813] Prepared in analogous manner to procedures described in
examples 54 and 90, using benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(hy-
droxymethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cycloprop-
anecarboxylate and
5-(((tert-butyldimethylsilyl)oxy)methyl)-2H-tetrazole. LCMS:
R.sub.t=0.31 min, m/z=588.4 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.41 (br s, 1H), 7.78 (s, 1H), 7.24
(s, 1H), 6.75 (s, 1H), 5.38-5.32 (m, 1H), 4.86 (dd, J=14.3, 4.5 Hz,
1H), 4.72-4.63 (m, 1H), 4.61-4.55 (m, 1H), 4.28-4.16 (m, 1H),
3.01-2.94 (m, 1H), 2.87 (t, J=7.4 Hz, 1H), 1.92-1.82 (m, 1H),
1.33-1.18 (m, 2H), 1.18-1.08 (m, 1H).
Example 97:
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-(((2-aminoethyl)amino)methyl)-2-oxooxazoli-
din-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-
-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00151##
[0815] Prepared in an analogous manner to example 26, using
tert-butyl (2-bromoethyl)carbamate. LCMS: R.sub.t=0.380 min,
m/z=591.1 (M+1) Method 2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O)
.delta. 6.93 (s, 1H), 5.28 (d, J=5.8 Hz, 1H), 3.85 (t, J=9.3 Hz,
1H), 3.68 (dd, J=15.0, 8.1 Hz, 1H), 3.46-3.36 (m, 2H), 3.25-3.01
(m, 5H), 2.60 (s, 1H), 1.30-1.21 (m, 2H), 1.18-1.09 (m, 2H).
Example 98:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-methyl-5-oxo-4,5-dihyd-
ro-1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoet-
hylidene)amino)oxy)-2-methylpropanoic Acid
##STR00152##
[0817] Prepared in analogous manner to example 31, using
1-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-4-methyl-1H-1,2,4-triazol--
5(4H)-one and
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid. LCMS: m/z=531.0
(M-1); .sup.1H NMR (400 MHz, D.sub.2O): .delta. 7.67 (s, 1H), 7.02
(s, 1H), 5.36 (d, J=5.6 Hz, 1H), 4.70-4.60 (m, 1H, partially
obscured by solvent residual peak), 4.14 (dd, J=15.2 and 7.6 Hz,
1H), 3.96 (dd, J=15.2 and 4.8 Hz, 1H), 3.14 (s, 3H), 1.37 (s, 3H),
1.35 (s, 3H).
Example 99:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((dimethylamino)methyl-
)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoeth-
ylidene)amino)oxy)-2-methylpropanoic Acid
##STR00153##
[0819] Prepared in analogous manner to example 54, using
N,N-dimethyl-1-(2H-1,2,3-triazol-4-yl)methanamine. LCMS: m/z=560.2
(M+1); .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.80 (s, 1H), 6.98
(s, 1H), 5.43 (d, J=4.8 Hz, 1H), 4.94-4.88 (m, 1H), 4.85-4.80 (m,
2H), 4.32 (s, 2H), 2.75 (s, 6H), 1.28 (s, 6H).
Example 100:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((methylamino)methyl)--
2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoic Acid
##STR00154##
[0821] Prepared in analogous manner to example 54, using tert-butyl
((2H-1,2,3-triazol-4-yl)methyl)(methyl)carbamate. LCMS: m/z=544.1
[M-H].sup.-; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.73 (s, 1H),
7.02 (s, 1H), 5.42 (d, J=5.6 Hz, 1H), 4.92-4.86 (m, 1H), 4.82-4.78
(m, 2H), 4.22 (s, 2H), 2.60 (s, 3H), 1.30 (s, 6H).
Example 101:
2-(((Z)-(2-(((2R,3S)-2-((1-(2-aminoethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)a-
mino)oxy)-2-methylpropanoic Acid
##STR00155## ##STR00156##
[0822] Step 1: Benzyl
((2R,3S)-2-(3,3-dibromoallyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)-
(4-methoxybenzyl)carbamate
[0823] To a solution of PPh.sub.3 (302.4 mg, 1.15 mmol) in DCM (1
mL) at 0.degree. C. was added CBr.sub.4 (192 mg, 0.58 mmol). After
10 min, a solution of benzyl
((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-(2-oxoethyl)azetidin-3-yl)(4-met-
hoxybenzyl)carbamate (152.7 mg, 0.29 mmol) in DCM (800 .mu.L) was
added dropwise followed by DCM (800 .mu.L) wash. After 20 min, the
reaction mixture was diluted with DCM and water, and the layers
were separated. The aqueous layer was extracted with DCM
(2.times.). Combined organic layers were washed with brine, dried
over Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The
residue was purified via silica gel chromatography (0-40%
EtOAc-Hept) to afford the title compound (162 mg, 82%). LCMS:
R.sub.t=1.2 min, m/z=689.1 (M+1) Method 2m_acidic.
[0824] Preparation of benzyl
((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-(2-oxoethyl)azetidin-3-yl)(4-met-
hoxybenzyl)carbamate: To a solution of benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((E)-2-methoxyvinyl)-4-oxoazetidin-3-y-
l)carbamate (example 82, step 1, 1.44 g, 3.38 mmol) in DMF (33.8
ml) at -10.degree. C. (salt-ice bath) was added sodium hydride
(60%, 162 mg, 4.05 mmol). After stirring for 30 min,
p-methoxybenzylchloride (506, .mu.L, 3.71 mmol) was added. After
warming to 0.degree. C. and stirring for an additional 30 min, it
was quenched with NH.sub.4Cl (aq, satd) then diluted with EtOAc and
LiCl (5% aq). The layers were separated and aqueous layer was
extracted with EtOAc (2.times.). The combined organic layers washed
with LiCl (5% aq), brine, dried over Na.sub.2SO.sub.4 and concd in
vacuo. The crude material was subjected to conditions described in
example 82, step 2 then purified via silica gel chrmomatogrphy
(EtOAc-Hept, 0-70%) to afford the title compound (684 mg, 38%).
LCMS: R.sub.t=0.97 min, m/z=533.2 (M+1) Method 2m_acidic.
Step 2: Benzyl
((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-(prop-2-yn-1-yl)azetidin-3-yl)(4-
-methoxybenzyl)carbamate
[0825] tert-Butyllithium (0.291 mL, 0.494 mmol) was added to the
solution of benzyl
((2R,3S)-2-(3,3-dibromoallyl)-1-(2,4-dimethoxybenzyl)-4-oxoazet-
idin-3-yl)(4-methoxybenzyl)carbamate (162 mg, 0.235 mmol) in THF
(Volume: 3.4 mL) at -78.degree. C. After 15 min, the reaction
mixture was quenched with NH.sub.4Cl, and diluted with water and
EtOAc. The layers were separated, and the organic layer was
extracted with EtOAc (2.times.). Combined organic layers were
washed with brine, dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The residue was purified via silica gel
chromatography (EtOAc-Hept, 0-40%) to afford the title compound (98
mg, 79%). LCMS: R.sub.t=1.08 min, m/z=529.3 (M+1) Method
2m_acidic.
Step 3: Benzyl
((2R,3S)-2-((1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-1,2,3-triazol-4-y-
l)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)(4-methoxybenzyl)carb-
amate
[0826] To a solution of benzyl
((3S,4R)-1-(2,4-dimethoxybenzyl)-2-oxo-4-(prop-2-yn-1-yl)azetidin-3-yl)(4-
-methoxybenzyl)carbamate (95.6 mg, 0.18 mmol) in a mixture of DMSO
(1.2 mL), tert-butanol (1.2 mL) and water (1.2 mL), was added
copper(II) sulfate pentahydrate (4.5 mg, 0.018 mmol), sodium
L-ascorbate (35.8 mg, 0.18 mmol) and N-Boc-2-azidoethylamine (76
mg, 0.39 mmol). After stirring for 12 h, more copper(II) sulfate
pentahydrate (10.6 mg, 0.23 equiv), sodium L-ascorbate (37.4 mg,
1.04 equiv) and N-Boc-2-azidoethylamine (82.1 mg, 2.44 equiv) were
added. After stirring for 4 days total, the reaction mixture was
diluted with EtOAc and water. The layers were separated, and the
aqueous layer was extracted with EtOAc (2.times.). Combined organic
layers were washed with LiCl (5% aq), brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The residue
was purified via silica gel chromatography (EtOAc-Hep, 0-40%) to
afford the title compound (57.2 mg, 44%). LCMS: R.sub.t=1.06 min,
m/z=715.5 (M+1) Method 2m_acidic.
Step 4: Benzyl
((2R,3S)-2-((1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-1,2,3-triazol-4-y-
l)methyl)-4-oxoazetidin-3-yl)(4-methoxybenzyl)carbamate
[0827] Prepared in analogous manner to example 82 step 5, using
benzyl
((2R,3S)-2-((1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-1,2,3-triazol-4-y-
l)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)(4-methoxybenzyl)carb-
amate (57.2 mg, 0.080 mmol), CH.sub.3CN (762 .mu.l), water (381
.mu.l), potassium peroxydisulfate (31 mg, 0.12 mmol), and potassium
phosphate, dibasic (19 mg, 0.109 mmol). 20.2 mg. LCMS: R.sub.t=0.89
min, m/z=565.3 (M+1). Method 2m_acidic.
Step 5: Tert-butyl
(2-(4-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-
ethyl)carbamate
[0828] To a slurry of benzyl
((2R,3S)-2-((1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-1,2,3-triazol-4-y-
l)methyl)-4-oxoazetidin-3-yl)(4-methoxybenzyl)carbamate (20.2 mg,
0.036 mmol) in MeOH (0.68 mL) was added Pd black (19 mg, 0.018
mmol) and formic acid (31 .mu.l, 0.711 mmol). After stirring at rt
for 3 h, more Pd black (9.7 mg) was added. After stirring at rt for
additional 5.5 h, the reaction mixture was filtered through
cellulose with MeOH eluent, and the filtrate was concentrated in
vacuo. It was used in step 6 without further purification. LCMS:
R.sub.t=0.396 min, m/z=311.1 (M+1). Method 2m_acidic.
Step 6: Tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-1,2,3-
-triazol-4-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl-
)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
[0829] Prepared in analogous manner to example 82 step 7, using
(Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)imino)-2-(2-((tert-
-butoxycarbonyl)amino)thiazol-4-yl)acetic acid (18.55 mg, 0.043
mmol), HATU (17.7 mg, 0.047 mmol), DCM:DMF (1:3, 800 .mu.l), DIPEA
(18.86 .mu.l, 0.108 mmol), tert-butyl
(2-(4-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-1H-1,2,3-triazol-1-yl)-
ethyl)carbamate (11.17 mg, 0.036 mmol). 6.5 mg. LCMS: R.sub.t=0.971
min, m/z=722.4 (M+1). Method 2m_acidic. .sup.1H NMR (400 MHz,
Methanol-d.sub.4) .delta. 7.82 (s, 1H), 7.32 (s, 1H), 5.34 (d,
J=4.9 Hz, 1H), 4.43 (t, J=5.9 Hz, 3H), 4.19 (dt, J=9.3, 4.5 Hz,
1H), 4.09 (q, J=7.1 Hz, 1H), 3.54-3.45 (m, 3H), 3.13 (ddd, J=15.0,
11.8, 6.0 Hz, 2H), 2.93 (dd, J=15.2, 9.6 Hz, 1H), 2.01 (s, 2H),
1.53 (d, J=1.4 Hz, 14H), 1.49 (s, 7H), 1.46 (d, J=1.7 Hz, 15H),
1.38 (s, 14H), 1.23 (t, J=7.1 Hz, 3H).
Step 7:
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)-
imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((1-(2-(-
(tert-butoxycarbonyl)amino)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-oxoazeti-
dine-1-sulfonic Acid
[0830] Prepared in analogous manner to example 82 step 9, using
tert-butyl
2-(((Z)-(2-(((2R,3S)-2-((1-(2-((tert-butoxycarbonyl)amino)ethyl)-1H-1,2,3-
-triazol-4-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl-
)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)-2-methylpropanoate
(6.5 mg, 9.00 .mu.mol), DMF (200 .mu.l), SO.sub.3.DMF (5.8 mg,
0.037 mmol). It was used in step 8 without further purification.
LCMS: R.sub.t=0.911 min, m/z=802.1 (M+1). Method 2m_acidic.
Step 8:
2-(((Z)-(2-(((2R,3S)-2-((1-(2-aminoethyl)-1H-1,2,3-triazol-4-yl)me-
thyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyl-
idene)amino)oxy)-2-methylpropanoic Acid
[0831] Followed the general procedure for the acid mediated
deprotection, using
(2R,3S)-3-((Z)-2-(((1-(tert-butoxy)-2-methyl-1-oxopropan-2-yl)oxy)i-
mino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((1-(2-((-
tert-butoxycarbonyl)amino)ethyl)-1H-1,2,3-triazol-4-yl)methyl)-4-oxoazetid-
ine-1-sulfonic acid (7.22 mg, 9.00 .mu.mol), DCM (200 .mu.l) and
TFA (50 .mu.l, 649 .mu.mol). The crude residue was purified by
reverse phase prep HPLC (XSelect CSH, 19.times.100 mm, 5 .mu.m, C18
column; AcN-water with 0.1% formic acid modifier, 24 mL/min)
affording the title compound (1.2 mg, 24%). LCMS: R.sub.t=0.487
min, m/z=546.2 (M+1). Method 2m_acidic.
Example 102:
1-(((Z)-(2-(((2R,3S)-2-((4-(((2-aminoethyl)amino)methyl)-2H-1,2,3-triazol-
-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2--
oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00157##
[0833] Prepared in analogous manner to example 90, using tert-butyl
(2-aminoethyl)carbamate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.31 min, m/z=573.2 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 9.24 (d, J=9.0 Hz, 1.0H), 7.75 (s,
1H), 7.22 (s, 2H), 6.71 (s, 1H), 5.42-5.28 (m, 1H), 4.86 (dd,
J=14.3, 4.1 Hz, 1H), 4.72-4.59 (m, 1H), 4.53 (ddd, J=7.4, 5.5, 4.3
Hz, 1H), 4.24-4.09 (m, 2H), 3.10-2.97 (m, 5H), 1.34-1.19 (m, 3H),
1.19-1.06 (m, 1H).
Example 103:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((azetidin-3-ylamino)m-
ethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-o-
xoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00158##
[0835] Prepared in analogous manner to example 90, using tert-butyl
3-aminoazetidin-1-carboxylate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.31 min, m/z=585.2 (M+1) Method 2m_acidic; .sup.1H NMR
(500 MHz, D.sub.2O) .delta. 7.84 (s, 1H), 7.14 (s, 1H), 5.60 (d,
J=5.6 Hz, 1H), 5.04-4.87 (m, 3H), 4.52-4.36 (m, 5H), 4.35 (s, 1H),
1.35-1.29 (m, 2H), 1.24-1.14 (m, 2H).
Example 104:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-(((R)-5-(formimidamidometh-
yl)-2-oxooxazolidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoet-
hylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00159##
[0837] Prepared in analogous manner to example 26, using ethyl
formimidate-HCl. LCMS: R.sub.t=0.29 min, m/z=575.0 (M+1) Method
2m_acidic.
Example 105:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((3-cyano-1H-1,2,4-triazol-
-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-
-2-methylpropanoic Acid
##STR00160##
[0839] Prepared in analogous manner to example 54, using
1H-1,2,4-triazole-3-carbonitrile. LCMS: m/z=526.0 [M-H]; .sup.1H
NMR (400 MHz, D.sub.2O) .delta. 8.57 (s, 1H), 6.90 (s, 1H), 5.34
(br s, 1H), 5.20-4.77 (m, 3H), 1.31 (s, 6H).
Example 106:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-aminoazetidin-1-yl)methyl)-2H-1,2,3-triazo-
l-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00161##
[0841] Prepared in analogous manner to example 90, using tert-butyl
(2-oxoethyl)carbamate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3, except there was
an additional workup in the sulfonylation step. The crude
sulfonylation product was treated with pyridine in MeOH at
40.degree. C. for 1h to remove over-sulfonylation product on
azetidine. LCMS: R.sub.t=0.30 min, m/z=585.2 (M+1) Method
2m_acidic; .sup.1H NMR (500 MHz, D.sub.2O) .delta. 7.76 (s, 1H),
7.03 (s, 1H), 5.50 (d, J=5.5 Hz, 1H), 4.97-4.89 (m, 1H), 4.89-4.77
(m, 2H), 4.56-4.48 (m, 3H), 4.46-4.35 (m, 3H), 1.29-1.18 (m, 2H),
1.15-1.08 (m, 2H).
Example 107:
(S)-2-(((Z)-(2-(((2R,3S)-2-((1H-1,2,4-triazol-1-yl)methyl)-4-oxo-1-sulfoa-
zetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)-3-(-
4-carbamimidoylphenoxy)propanoic Acid
##STR00162##
[0843] Prepared in analogous manner to example 68, using
(R)-benzhydryl
2-(aminooxy)-3-(4-(N-(tert-butoxycarbonyl)carbamimidoyl)phenoxy)propanoat-
e (prepared according to WO2013110643). LCMS: R.sub.t=0.30 min,
m/z=623.4 (M+1) Method 2m_acidic; .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 9.14 (s, 2H), 8.68 (br s, 2H), 8.37 (s, 1H),
7.90 (s, 1H), 7.77-7.70 (m, 2H), 7.28 (br s, 2H), 6.95 (br s, 1H),
6.79 (s, 1H), 6.55 (br s, 1H), 5.19-5.11 (m, 1H), 5.07-4.98 (m,
1H), 4.54-4.39 (m, 3H), 4.28-4.22 (m, 1H).
Example 108:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxoimidazo-
lidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopr-
opanecarboxylic Acid
Step 1: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(hy-
droxymethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cycloprop-
anecarboxylate
[0844] To a solution of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (6.66 g, 12.38 mmol) at
0.degree. C. in DCM (61.9 ml, ratio: 1) and DMF (61.9 ml, ratio: 1)
were added DIPEA (6.49 ml, 37.2 mmol) and HATU (5.65 g, 14.86
mmol). After 20 min,
(3S,4S)-3-amino-4-(hydroxymethyl)azetidin-2-one (1.44 g, 12.38
mmol) was added. After stirring for 2 h at rt, the reaction mixture
was concentrated in vacuo and diluted with EtOAc. The organic layer
was washed with water, brine, dried over Na.sub.2SO.sub.4, filtered
and concentrated in vacuo. The crude residue was purified via
silica gel chromatography (Acetone-DCM) to afford the title
compound (4.4 g, 56%). LCMS: R.sub.t=0.97 min, m/z=636.1 (M+1),
Method 2m_acidic. .sup.1H NMR (400 MHz, DMSO-d.sub.6): 11.80 (br s,
1H), 9.08 (d, J=9.0 Hz, 1H), 8.41 (s, 1H), 7.48-7.32 (m, 5H),
7.32-7.15 (m, 6H), 6.84 (s, 1H), 5.20 (ddd, J=9.2, 5.1, 0.9 Hz,
1H), 4.77 (t, J=5.3 Hz, 1H), 3.76-3.70 (m, 1H), 3.62-3.48 (m, 1H),
3.47-3.33 (m, 1H), 1.56-1.33 (m, 13H).
Step 2: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(((-
methylsulfonyl)oxy)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino-
)oxy)cyclopropanecarboxylate
[0845] To a solution of benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(hy-
droxymethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cycloprop-
anecarboxylate (1 g, 1.57 mmol) at 0.degree. C. in THF (15.7 ml)
was added TEA (0.66 ml, 4.7 mmol) and MsCl (25 .mu.l, 0.32 mmol).
After 2 h, the reaction mixture was diluted with EtOAc, washed with
brine, dried over Na.sub.2SO.sub.4, filtered and concentrated in
vacuo, affording the title compound (assumed quantitative). LCMS:
R.sub.t=0.99 min, m/z=714.1 (M+1), Method 2m_acidic.
Step 3: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-(azidomethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropan-
ecarboxylate
[0846] To a solution of benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(((-
methylsulfonyl)oxy)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino-
)oxy)cyclopropanecarboxylate (1.3 g, 1.82 mmol) in DMF (20 ml) was
added NaI (0.82 g, 5.5 mmol) and sodium azide (0.83 g, 12.8 mmol).
After stirring at 60.degree. C. for 6 h, the reaction mixture was
quenched with ice cold water and extracted with EtOAc. Combined
organic layers were washed with water, brine, dried over anhydrous
Na.sub.2SO.sub.4, concentrated in vacuo. The crude residue was
purified via silica gel chromatography (EtOAc-heptane) to afford
the title compound (689 mg, 57%). LCMS: R.sub.t=1.02 min, m/z=661.1
(M+1), Method 2m_acidic.
Step 4: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-(aminomethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropan-
ecarboxylate
[0847] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-(azidomethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropan-
ecarboxylate (689 mg, 1.04 mmol) in THF (10 mL) and MeOH (1.3 mL)
was added Ph.sub.3P (301 mg, 1.15 mmol). After 12 h, the reaction
mixture was concentrated in vacuo. The crude residue was purified
via silica gel chromatography (MeOH-DCM, 0-100%) to afford the
title compound (369 mg, 56%). LCMS: R.sub.t=0.88 min, m/z=635.1
(M+1), Method 2m_acidic.
Step 5: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-(((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)et-
hyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
[0848] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-(aminomethyl)-4-oxoazetidin-3-yl)amino)-1-(2-((ter-
t-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropan-
ecarboxylate (199 mg, 0.29 mmol) in DCE (2.9 mL) was added
(9H-fluoren-9-yl)methyl (2-oxoethyl)carbamate (84 mg, 0.30 mmol)
and sodium triacetoxyborohydride (181 mg, 0.86 mmol). After 12 h,
the reaction mixture was quenched with saturated NaHCO.sub.3 (aq),
diluted with EtOAc, and the layers were separated. The aqueous
layer was extracted with EtOAc, and the combined organic layers
were washed with brine, dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The crude residue was purified via silica
gel chromatography (MeOH-DCM, 0-100%) to afford the title compound
(150 mg, 58%). LCMS: R.sub.t=1.10 min, m/z=900.0 (M+1), Method
2m_acidic. .sup.1H NMR (400 MHz, DMSO-d.sub.6): 9.16 (d, J=9.0 Hz,
1H), 8.35 (s, 1H), 7.87 (d, J=7.4 Hz, 2H), 7.66 (d, J=7.4 Hz, 2H),
7.45-7.18 (m, 16H), 6.83 (s, 1H), 5.24-5.17 (m, 1H), 4.28 (d, J=6.7
Hz, 2H), 4.19 (d, J=6.3 Hz, 1H), 3.79-3.67 (m, 1H), 3.03-2.95 (m,
2H), 2.73-2.63 (m, 1H), 1.54-1.37 (m, 13H).
Step 6: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-(((2-aminoethyl)amino)methyl)-4-oxoazetidin-3-yl)a-
mino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino-
)oxy)cyclopropanecarboxylate
[0849] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-(((2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)et-
hyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
(150 mg, 0.167 mmol) in DCM (1.7 mL) was added piperidine (16.50
.mu.l, 0.167 mmol). After 2 h, the reaction mixture was
concentrated in vacuo and lyophilized in CH.sub.3CN/water mixture
to afford the title compound (assumed quantitative). LCMS:
R.sub.t=0.93 min, m/z=678.5 (M+1), Method 2m_acidic.
Step 7: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxoimidazolidin-1-yl)methyl)azetidin-3-yl)amino)ethylidene)am-
ino)oxy)cyclopropanecarboxylate
[0850] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-(((2-aminoethyl)amino)methyl)-4-oxoazetidin-3-yl)a-
mino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino-
)oxy)cyclopropanecarboxylate (90 mg, 0.133 mmol) in chloroform (2.7
mL) was added CDI (43.1 mg, 0.266 mmol) and TEA (111 .mu.l, 0.797
mmol). After 12 h, the reaction mixture was concentrated in vacuo.
The crude residue was purified via silica gel chromatography
(MeOH-DCM, 0-100%) to afford the title compound (46 mg, 49%). LCMS:
R.sub.t=0.95 min, m/z=704.0 (M+1), Method 2m_acidic.
Step 8:
(3S,4R)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxoim-
idazolidin-1-yl)methyl)azetidine-1-sulfonic acid,
(3S,4R)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((-
tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((3-oxo-1,2,4-tr-
iazinan-1-yl)methyl)azetidine-1-sulfonic Acid
[0851] To a solution of benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((2-oxoimidazolidin-1-yl)methyl)azetidin-3-yl)amino)ethylidene)am-
ino)oxy)cyclopropanecarboxylate (46 mg, 65 .mu.mol) in DMF (654
.mu.l) was added SO.sub.3.DMF (100 mg, 0.654 mmol). After stirring
at rt for 2 h, the reaction mixture was diluted with EtOAc, washed
with brine, dried over Na.sub.2SO.sub.4, filtered and concentrated
in vacuo to afford the title compound (50 mg, 98%). LCMS:
R.sub.t=0.84 min, m/z=784.0 (M+1), Method 2m_acidic. The crude
residue was used as such in the following step.
Step 9:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxo-
imidazolidin-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-
cyclopropanecarboxylic Acid
##STR00163##
[0853] Followed the general procedure for the acid mediated
deprotection using
(3S,4R)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((2-oxoimi-
dazolidin-1-yl)methyl)azetidine-1-sulfonic acid,
(3S,4R)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((-
tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((3-oxo-1,2,4-tr-
iazinan-1-yl)methyl)azetidine-1-sulfonic acid (48 mg, 61 .mu.mol),
DCM (0.61 mL), and TFA (0.28 mL, 3.7 mmol) for 4 h. The crude
residue was purified by reverse phase prep HPLC (XSelect CSH,
30.times.100 mm, 5 .mu.m, C18 column; AcN-water with 0.1% formic
acid modifier, 60 mL/min) affording the title compound (3.6 mg,
10%). LCMS: R.sub.t=0.45 min, m/z=518.1 (M+1), Method 2m_acidic;
.sup.1H NMR (500 MHz, D.sub.2O): .delta.7.01 (s, 1H), 5.32 (d,
J=5.5 Hz, 1H), 4.53-4.39 (m, 1H), 3.61 (dd, J=14.8, 6.9 Hz, 1H),
3.56-3.41 (m, 2H), 3.35-3.21 (m, 3H), 1.46-1.19 (m, 4H).
Example 109:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4,5-bis(aminomethyl)-2H--
1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylide-
ne)amino)oxy)cyclopropanecarboxylic Acid
Step 1
[0854] To a solution of di-tert-butyliminodicarbonate (1.02 g, 4.60
mmol) in DMF (14 mL) at 0.degree. C. was added sodium hydride (0.19
g, 4.83 mmol). The cold bath was removed, and more DMF (20 mL) was
added. After stirring for 15 min, 1,4-dichlorobut-2-yne (0.91 ml,
9.20 mmol) was quickly added. After stirring at rt for 12 h, the
reaction mixture was poured into a cold solution of LiCl (5% aq.).
The aqueous layer was extracted with EtOAc (3.times.), and the
combined organic layers were washed with LiCl (5% aq.), brine,
dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo.
The crude residue was purified via silica gel chromatography
(EtOAc-Heptane, 0-10%) to afford the title compound (467 mg, 33%).
LCMS: R.sub.t=1.07 min, m/z=326.0 (M+Na), Method 2m_acidic; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 4.13 (t, J=1.9 Hz, 2H) 4.40 (t,
J=1.9 Hz, 2H), 1.57-1.51 (m, 18H).
Step 2
[0855] Prepared according to the procedure described in Sharpless,
K. B. Synthesis. 2005, 9, 1514. To a solution of intermediate from
step 1 (466 mg, 1.53 mmol) in 1,4-dioxane (5.8 mL) and water (1.9
mL) was added sodium azide (401 mg, 6.17 mmol) followed by ammonium
chloride (167.8 mg, 3.14 mmol). After heating to 75.degree. C. for
11 h, the reaction mixture was poured into separatory funnel, and
the layers were separated. The aqueous was extracted with EtOAc
(3.times.). The combined organic layers were washed with brine,
dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo.
The crude residue was purified via silica gel chromatography
(EtOAc-Hep, 0-40%) to afford the title compound (224 mg, 41%).
LCMS: R.sub.t=0.90 min, m/z=354.1 (M+1), Method 2m_acidic; .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 4.87 (s, 2H), 4.56 (s, 2H), 1.50
(s, 18H).
Step 3: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(azidomethyl)-5-((bis(tert-butoxycarbonyl)amin-
o)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((t-
ert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cycloprop-
anecarboxylate
[0856] To a slurry of benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2S,3S)-2-(hy-
droxymethyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cycloprop-
anecarboxylate (202 mg, 0.32 mmol), intermediate from step 2 (136
mg, 0.38 mmol) and triphenylphosphine (100 mg, 0.38 mmol) in THF (4
mL) at 0.degree. C. was added DIAD (0.079 mL, 0.38 mmol) dropwise.
After stirring at rt for 12 h, the reaction mixture was diluted
with DCM and concentrated in vacuo. The crude residue was purified
via silica gel chromatography (EtOAc-Hep, 0-70%) to afford the
title compound. LCMS: R.sub.t=1.27 min, m/z=971.5 (M+1), Method
2m_acidic; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.38 (d,
J=9.1 Hz, 1H), 8.56 (d, J=1.7 Hz, 1H), 7.45-7.38 (m, 5H), 7.32-7.20
(m, 7H), 6.84 (s, 1H), 5.41 (dd, J=9.0, 5.2 Hz, 1H), 4.78 (d, J=1.5
Hz, 2H), 4.51 (d, J=1.2 Hz, 2H), 4.48-4.42 (m, 2H), 4.37-4.30 (m,
1H), 1.42 (d, J=39.1 Hz, 31H).
Step 4:
(2R,3S)-2-((4-(azidomethyl)-5-((bis(tert-butoxycarbonyl)amino)meth-
yl)-2H-1,2,3-triazol-2-yl)methyl)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cy-
clopropoxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-
-4-oxoazetidine-1-sulfonic Acid
[0857] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(azidomethyl)-5-((bis(tert-butoxycarbonyl)amin-
o)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((t-
ert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cycloprop-
anecarboxylate (103 mg, 0.11 mol) in DMF (530 .mu.l) at 0.degree.
C. was added SO.sub.3.DMF (33.5 mg, 0.21 mmol). After stirring at
rt for 3 h, the reaction mixture was diluted with EtOAc, washed
with LiCl (5% aq.), brine, dried over Na.sub.2SO.sub.4, filtered
and concentrated in vacuo to afford the title compound (assumed
quantitative). LCMS: R.sub.t=1.16 min, m/z=1051.6 (M+1), Method
2m_acidic. The crude residue was used as such in the following
step.
Step 5:
(2R,3S)-2-((4-(aminomethyl)-5-((bis(tert-butoxycarbonyl)amino)meth-
yl)-2H-1,2,3-triazol-2-yl)methyl)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cy-
clopropoxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-
-4-oxoazetidine-1-sulfonic Acid
[0858] To a solution of
(2R,3S)-2-((4-(azidomethyl)-5-((bis(tert-butoxycarbonyl)amino)methyl)-2H--
1,2,3-triazol-2-yl)methyl)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cycloprop-
oxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoa-
zetidine-1-sulfonic acid (111 mg, 0.11 mmol) in EtOAc (1.1 mL) and
EtOH (0.22 mL) under N.sub.2 was added Pd--C (22 mg, 0.021 mmol).
The system was evacuated and backfilled with H.sub.2 (3.times.).
After stirring at rt for 4 h, the reaction mixture was filtered
through celite with EtOAc and EtOH wash. The filtrate was
concentrated in vacuo to afford the title compound (assumed
quantitative). The crude residue was used as such in the following
step. LCMS: R.sub.t=1.06 min, m/z=1025.7 (M+1), Method
2m_acidic.
Step 6:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4,5-bis(aminometh-
yl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoe-
thylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00164##
[0860] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-2-((4-(aminomethyl)-5-((bis(tert-butoxycarbonyl)amino)methy-
l)-2H-1,2,3-triazol-2-yl)methyl)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyc-
lopropoxy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)--
4-oxoazetidine-1-sulfonic acid (109 mg, 0.11 .mu.mol), DCM (1.1
mL), and TFA (0.49 mL, 6.36 mmol) for 2 h. The crude residue was
purified by reverse phase prep HPLC (XSelect CSH, 30.times.100 mm,
5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier, 60
mL/min) affording the title compound (12 mg, 19%). LCMS:
R.sub.t=0.46 min, m/z=559.2 (M+1), Method 2m_acidic; .sup.1H NMR
(400 MHz, D.sub.2O): .delta. 7.16 (s, 1H), 5.61 (d, J=5.6 Hz, 1H),
5.07-4.88 (m, 3H), 4.34 (s, 4H), 1.39-1.13 (m, 4H).
Example 110:
2-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)am-
ino)oxy)-3-(4-carbamimidoylphenoxy)propanoic Acid
##STR00165##
[0862] Prepared in analogous manner to example 107, using
tert-butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)me-
thyl)carbamate. LCMS: R.sub.t=0.29 min, m/z=652.1 (M+1), Method
2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O): .delta. 7.53 (d, J=8.9
Hz, 2H), 7.43 (s, 1H), 7.03 (s, 1H), 6.82 (d, J=8.9 Hz, 2H),
5.35-5.28 (m, 1H), 4.97-4.91 (m, 1H), 4.77-4.70 (m, 1H), 4.61-4.55
(m, 2H), 4.38-4.29 (m, 1H), 4.27-4.19 (m, 1H), 4.00 (s, 2H).
Example 111:
1-(((Z)-(2-(((2R,3S)-2-(((R)-5-((3-(2-aminoethyl)ureido)methyl)-2-oxooxaz-
olidin-3-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4--
yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00166##
[0864] Prepared in analogous manner to example 26, using tert-butyl
(2-(1H-imidazole-1-carboxamido)ethyl)carbamate. LCMS: R.sub.t=0.31
min, m/z=634.3 (M+1), Method 2m_acidic; .sup.1H NMR (500 MHz,
DMSO-d.sub.6): .delta. 9.18 (d, J=8.8 Hz, 1H), 7.68 (br s, 2H),
7.28 (br s, 2H), 6.82 (s, 1H), 6.41 (t, J=5.9 Hz, 1H), 6.31-6.20
(m, 1H), 5.23 (dd, J=8.9, 5.83 Hz, 1H), 4.52-4.44 (m, 1H),
4.24-4.12 (m, 1H), 3.69-3.58 (m, 1H), 2.90-2.75 (m, 2H), 1.38-1.27
(m, 4H).
Example 112:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-((piperidi-
n-4-ylamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazetidin-3-yl)ami-
no)ethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00167##
[0866] Prepared in analogous manner to 90, using tert-butyl
4-aminopiperidine-1-carboxylate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.31 min, m/z=613.5 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, D.sub.2O): .delta. 7.73 (s, 1H), 7.00 (s, 1H), 5.49 (d,
J=5.6 Hz, 1H), 4.90 (q, J=5.5 Hz, 1H), 4.85-4.74 (m, 2H), 4.33 (s,
2H), 3.53-3.37 (m, 2H), 3.09-2.88 (m, 2H), 2.29 (t, J=12.5 Hz, 2H),
1.87-1.66 (m, 2H), 1.25-1.12 (m, 2H), 1.11-0.95 (m, 2H).
Example 113:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxoazetidi-
n-1-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)-2-methylpr-
opanoic Acid
##STR00168##
[0868] Prepared in analogous manner to example 1, using
3-bromopropanoic acid. LCMS: m/z=503.0 [M-H]; .sup.1H NMR (400 MHz,
D.sub.2O) 6.95 (s, 1H), 5.27 (d, J=5.2 Hz, 1H), 4.52-4.43 (m, 1H),
3.66-3.60 (m, 1H), 3.36-3.31 (m, 2H), 3.28 (m, 1H), 2.76 (t, J=3.6
Hz, 2H), 1.36 (s, 3H), 1.35 (s, 3H).
Example 114:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(((3-guanidinopropyl)a-
mino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amin-
o)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00169##
[0870] Prepared in analogous manner to example 90, using
N-(3-aminopropyl)-N'-tert-butoxycarbonyl guanidine and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.55 min, m/z=629.4 (M+1) Method 2m_acidic_polar; .sup.1H
NMR (400 MHz, D.sub.2O): .delta. 7.80 (s, 1H), 7.05 (s, 1H),
5.68-5.57 (m, 1H), 5.05-4.90 (m, 2H), 4.84-4.79 (m, 1H), 4.34 (s,
2H), 3.29-3.21 (m, 2H), 3.19-3.08 (m, 2H), 2.02-1.91 (m, 2H),
1.29-0.94 (m, 4H).
Example 115:
1-(((Z)-(2-(((2R,3S)-2-((4-(((3-aminopropyl)(methyl)amino)methyl)-2H-1,2,-
3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-
-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00170##
[0872] Prepared in analogous manner to example 90, using tert-butyl
(3-(methylamino)propyl)carbamate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.53 min, m/z=601.4 (M+1) Method 2m_acidic_polar; .sup.1H
NMR (400 MHz, D.sub.2O): .delta. 7.91 (s, 1H), 7.06 (s, 1H), 5.55
(d, 1H, J=6.1 Hz), 5.06-4.88 (m, 3H), 4.49 (s, 2H), 3.26-3.15 (m,
2H), 3.06 (t, 2H, J=7.5 Hz), 2.89 (s, 3H), 2.20-2.07 (m, 2H),
1.30-1.07 (m, 4H).
Example 116:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(((3-(methylamino)prop-
yl)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)-
amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00171##
[0874] Prepared in analogous manner to example 90, using tert-butyl
(3-aminopropyl)(methyl)carbamate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.48 min, m/z=601.4 (M+1) Method 2m_acidic_polar; .sup.1H
NMR (400 MHz, D.sub.2O): .delta. 7.82 (s, 1H), 7.09 (s, 1H),
5.66-5.53 (m, 1H), 5.03-4.87 (m, 3H), 4.37 (s, 2H), 3.21-3.05 (m,
4H), 2.68 (s, 3H), 2.17-2.02 (m, 2H), 1.30-1.04 (m, 4H).
Example 117:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(((2-(methylamino)ethy-
l)amino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)a-
mino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00172##
[0876] Prepared in analogous manner to example 90, using tert-butyl
(2-aminoethyl)(methyl)carbamate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.44 min, m/z=587.2 (M+1) Method 2m_acidic_polar; .sup.1H
NMR (400 MHz, D.sub.2O): .delta. 7.82 (s, 1H), 7.09 (s, 1H), 5.58
(d, J=5.5 Hz, 1H), 5.02-4.82 (m, 3H), 4.42 (s, 2H), 3.55-3.40 (m,
4H), 2.75 (s, 3H), 1.30-1.04 (m, 4H).
Example
118:1-(((Z)-(2-(((2R,3S)-2-((4-(((4-aminobutyl)amino)methyl)-2H-1,-
2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiaz-
ol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00173##
[0878] Prepared in analogous manner to example 90, using tert-butyl
(4-aminobutyl)carbamate and benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethyl-
idene)amino)oxy)cyclopropanecarboxylate in step 3. LCMS:
R.sub.t=0.32 min, m/z=601.3 (M+1) Method 2m_acidic_polar; .sup.1H
NMR (400 MHz, D.sub.2O): .delta. 7.71 (s, 1H), 6.99 (s, 1H), 5.48
(d, J=5.6 Hz, 1H), 4.95-4.69 (m, 3H), 4.24 (s, 2H), 3.00 (t, J=7.3
Hz, 2H), 2.87 (t, J=7.1 Hz, 2H), 1.77-1.51 (m, 4H), 1.23-1.12 (m,
2H), 1.12-0.90 (m, 2H).
Example 119:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(3-aminopropyl)guanidino)methyl)-2H-1,2,3--
triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-
-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 1: tert-Butyl (3-(3-benzoylthioureido)propyl)carbamate
[0879] Prepared according to the procedure described by Jubian at
al. Angew. Chem, 1995, 107, 1343 and Rasmussen et al. Synthesis,
1988, 456. To a solution of benzoyl isothiocyanate (0.93 g, 5.70
mmol) in acetone (10 mL) was added tert-butyl
(3-aminopropyl)carbamate (0.95 g, 5.45 mmol). After heating at
60.degree. C. for 2.5 h, the reaction mixture was concentrated in
vacuo. The crude residue was purified via silica gel chromatography
(EtOAc-heptane, 0-40%), affording the title compound (0.83 g, 43%).
LCMS: R.sub.t=0.93 min, m/z=338.0 (M+1) Method 2m_acidic.
Step 2: Tert-butyl (3-thioureidopropyl)carbamate
[0880] To a solution of tert-butyl
(3-(3-benzoylthioureido)propyl)carbamate (0.83 g, 2.45 mmol) in
MeOH (15 mL) was added sodium hydroxide aqueous solution (1.96 mL,
2.45 mmol). After stirring at rt for 2 h, the reaction mixture was
concentrated in vacuo and azeotropped with toluene. The crude
residue was purified via silica gel chromatography (MeOH-DCM, 9%
with 1% NH.sub.4OH), affording the title compound (0.83 g, 43%).
LCMS: R.sub.t=0.47 min, m/z=234.2 (M+1) Method 2m_acidic.
Step 3: Tert-butyl
(3-((imino(methylthio)methyl)amino)propyl)carbamate
[0881] To a solution of tert-butyl (3-thioureidopropyl)carbamate
(0.29 g, 1.28 mmol) in MeOH (8 mL) was added iodomethane (80 .mu.L,
1.29 mmol). After stirring at rt for 18 h, bicarbonate on polymer
support (0.5 g, 3.5 mmol NaCO.sub.3/g resin) was added to the
reaction mixture. After 30 min, the reaction mixture was filtered,
and the filtrate was concentrated in vacuo to give the desired
product along with the N-methylated product, tert-butyl
(3-(3-methylthioureido)propyl)carbamate (0.28 g, 87%, 2:1 ratio).
The crude residue was used as such in the following step. LCMS:
R.sub.t=0.44 min and 0.49 min, m/z=248.1 (M+1) Method
2m_acidic.
Step 4:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(3-imino-11,11--
dimethyl-9-oxo-10-oxa-2,4,8-triazadodecyl)-2H-1,2,3-triazol-2-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecar-
boxylic Acid
[0882] To a solution of tert-butyl
(3-((imino(methylthio)methyl)amino)propyl)carbamate (32.1 mg, 87
.mu.mol) in dioxane (1 mL, ratio: 2) at rt was added triethylamine
(30 .mu.L, 0.22 mmol),
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)met-
hyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethyli-
dene)amino)oxy)cyclopropanecarboxylic acid (example 19, 23 mg, 43
.mu.mol), and DMF (0.5 mL, ratio: 1). After heated to 60.degree. C.
for 17 h, the reaction mixture was diluted with EtOAc and water.
The aqueous layer was separated, concentrated in vacuo, azeotroped
with toluene, and dried on high vac to give the title compound
(assumed quantitative). LCMS: R.sub.t=0.51 min, m/z=729.6 (M+1),
Method 2m_acidic.
Step 5:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(3-aminopropyl)guanidino)methyl)-2H-
-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminoth-
iazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00174##
[0884] Followed the general procedure for the acid mediated
deprotection using
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-(3-imino-11,11-d-
imethyl-9-oxo-10-oxa-2,4,8-triazadodecyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecarb-
oxylic acid (37 mg, 15 .mu.mol), DCM (0.8 mL), and TFA (0.2 mL,
2.60 mmol) for 1.5 h. The crude residue was purified by reverse
phase prep HPLC (XSelect CSH, 19.times.100 mm, 5 .mu.m, C18 column;
ACN-water with 0.1% formic acid modifier, 24 mL/min) affording the
title compound (5.2 mg, 20%). LCMS: R.sub.t=0.39 min, m/z=629.2
(M+1), Method 2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O) .delta.
7.77 (s, 1H), 7.15 (s, 1H), 5.63 (d, J=5.7 Hz, 1H), 5.06-4.99 (m,
1H), 4.98-4.89 (m, 2H), 4.57 (s, 2H), 3.39-3.34 (m, 2H), 3.14-3.06
(m, 2H), 2.01 (p, J=7.2 Hz, 2H), 1.39-1.29 (m, 2H), 1.26-1.15 (m,
2H).
Example 120:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(3-aminopropyl)guanidino)methyl)-1H-1,2,3--
triazol-1-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-
-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00175##
[0886] Prepared in analogous manner to example 119, using
tert-butyl (3-((imino(methylthio)methyl)amino)propyl)carbamate.
LCMS: R.sub.t=0.30 min, m/z=629.1 (M+1) Method 2m_acidic_polar;
.sup.1H NMR (500 MHz, D.sub.2O) .delta. 7.97 (s, 1H), 7.05 (s, 1H),
5.42 (d, J=5.4 Hz, 1H), 4.87-4.78 (m, 1H), 4.45 (s, 1H), 3.24 (t,
J=6.9 Hz, 1H), 2.98-2.93 (m, 1H), 2.64 (s, 1H), 1.87 (dt, J=14.9,
7.18 Hz, 3H), 1.33-1.25 (m, 3H), 1.21-1.10 (m, 4H).
Example 121:
2-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((2,5-dioxopyrrolidin-1-yl-
)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)-2-me-
thylpropanoic Acid
##STR00176##
[0888] Prepared in analogous manner to example 54, using
pyrrolidine-2,5-dione. LCMS: R.sub.t=0.55 min, m/z=533.3 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (400 MHz, DMSO-d.sub.6:D.sub.2O
(1:1)): .delta. 6.94 (s, 1H), 5.18 (d, J=5.9 Hz, 1H), 4.53-4.43 (m,
1H), 3.96-3.86 (m, 1H), 3.36-3.25 (m, 1H) 2.53 (s, 4H), 1.40 (s,
3H) 1.37 (s, 3H).
Example
122:1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2-oxoimidazolidin-1-y-
l)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoe-
thylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00177##
[0890] Prepared in analogous manner to example 108, using
benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amin-
o)-3-((tert
butoxycarbonyl)amino)propyl)amino)methyl)-4-oxoazetidin-3-yl)amino)-1-(2--
((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclop-
ropanecarboxylate.
[0891] Diastereomer A: 3.1 mg. LCMS: R.sub.t=0.65 min, m/z=547.1
(M+1) Method 2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O): .delta.
7.12 (s, 1H), 5.39 (d, J=6.8 Hz, 1H), 4.60-4.56 (m, 1H), 3.84 (t,
J=9.9 Hz, 1H), 3.59-3.53 (m, 1H), 3.48-3.41 (m, 2H), 3.21-3.09 (m,
3H), 1.46 (br s, 3H), 1.36 (br s, 3H).
[0892] Diastereomer B: 2.9 mg, LCMS: R.sub.t=0.65 min, m/z=547.1
(M+1) Method 2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O): .delta.
7.12 (s, 1H), 5.42 (d, J=5.6 Hz, 1H), 4.61-4.54 (m, 1H), 4.16-4.08
(m, 1H), 3.82-3.72 (m, 2H), 3.55-3.49 (m, 1H), 3.27-3.15 (m, 3H),
1.47 (br s, 3H), 1.37 (br s, 3H).
Example 123:
3-(((2-(((2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-((1-carboxycyclopropoxy-
)imino)acetamido)-4-oxo-1-sulfoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl-
)methyl)amino)-N,N,N-trimethylpropan-1-aminium
##STR00178##
[0894] Prepared in analogous manner to example 90, using
N.sup.1,N.sup.1,N.sup.1-trimethylpropane-1,3-diaminium
2,2,2-trifluoroacetate. LCMS: R.sub.t=0.51 min, m/z=629.5 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O): .delta.
7.81 (s, 1H), 7.09 (s, 1H), 5.70-5.63 (m, 1H), 5.03-4.93 (m, 3H),
4.83-4.82 (m, 1H), 4.37 (s, 2H), 3.44-3.37 (m, 2H), 3.22-3.16 (m,
2H), 3.07 (s, 9H), 2.26-2.17 (m, 2H), 1.29-1.10 (m, 4H).
Example 124:
1-(((Z)-(2-(((2R,3S)-2-((4-((4-aminobutanamido)methyl)-2H-1,2,3-triazol-2-
-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-ox-
oethylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 1: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(((methylsulfonyl)oxy)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-
-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
[0895] To a solution of benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-2-
-oxoethylidene)amino)oxy)cyclopropanecarboxylate (178 mg, 0.25
mmol) and DIPEA (65 .mu.L, 0.37 mmol) in DCM (2.5 mL) at 0.degree.
C. was added MsCl (25 .mu.L, 0.32 mmol). After 1 h at 0.degree. C.,
the reaction mixture was diluted with DCM (10 mL), washed with 0.2
N HCl and saturated NaHCO.sub.3 (aq). The organic layer was dried
over Na.sub.2SO.sub.4, concentrated in vacuo to afford the title
compound (190 mg, 96%). The crude residue was used as such in the
following step. LCMS: R.sub.t=1.05 min, m/z=795.4 (M+1) Method
2m_acidic.
Step 2: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-o-
xoethylidene)amino)oxy)cyclopropanecarboxylate
[0896] To a solution of aq. NH.sub.4OH (2 mL, 28-30% wt) in EtOH (2
mL, ratio: 1) and THF (2 mL, ratio: 1) was added a solution of
benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(((methylsulfonyl)oxy)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-
-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate (190
mg, 0.24 mmol) in THF (1 mL) at -5.degree. C. dropwise. After
stirring at -5.degree. C. for 1 h and rt for 12 h, the reaction
mixture was diluted with 40 mL of DCM and washed with 10 mL of aq.
saturated NaHCO.sub.3 (aq), dried over Na.sub.2SO.sub.4, filtered
and concentrated in vacuo. The residue was purified via silica gel
chromatography (MeOH-DCM, 5-10%) to afford the title compound (120
mg, 49%). LCMS: R.sub.t=0.87 min, m/z=716.4 (M+1) Method
2m_acidic.
Step 3: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((4-((tert-butoxycarbonyl)amino)butanamido)met-
hyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-b-
utoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropaneca-
rboxylate
[0897] To a solution of 4-((tert-butoxycarbonyl)amino)butanoic acid
(30.7 mg, 0.15 mmol) in DCM (2 mL) at 0.degree. C. was added DIPEA
(35 .mu.L, 0.20 mmol) and HATU (65 mg, 0.17 mmol). After 10 min,
benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-o-
xoethylidene)amino)oxy)cyclopropanecarboxylate (90 mg, 0.10 mmol)
was added. After stirring at 0.degree. C. for 1 h, the reaction
mixture was diluted with DCM (40 mL), washed with 2M aq.
Na.sub.2CO.sub.3 (20 mL), brine, dried over Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. The residue was purified via
silica gel chromatography (MeOH-DCM, 5-10%) to afford the title
compound (42 mg, 46%). LCMS: R.sub.t=1.07 min, m/z=901.5 (M+1)
Method 2m_acidic.
Step 4:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((4-((tert--
butoxycarbonyl)amino)butanamido)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-ox-
oazetidine-1-sulfonic Acid
[0898] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((4-((tert-butoxycarbonyl)amino)butanamido)met-
hyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-b-
utoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropaneca-
rboxylate (42 mg, 47 .mu.mol) in DMF (0.47 mL) was added
SO.sub.3.DMF (74 mg, 0.47 mmol). After stirring at rt for 5 h,
another 10 eq of SO.sub.3.DMF was added and stirred at rt for 2 h.
The reaction mixture was diluted with EtOAc (60 mL) and brine (40
mL), and the layers were separated. Aqueous layer was extracted
with EtOAc (40 mL). Combined organic layers were dried with
Na.sub.2SO.sub.4, filtered and concentrated in vacuo to afford the
title compound (45.3 mg, 99%). The crude residue was used as such
in the following step. LCMS: R.sub.t=0.96 min, m/z=981.6 (M+1)
Method 2m_acidic.
Step 5:
1-(((Z)-(2-(((2R,3S)-2-((4-((4-aminobutanamido)methyl)-2H-1,2,3-tr-
iazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-y-
l)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00179##
[0900] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((4-((tert-b-
utoxycarbonyl)amino)butanamido)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-
azetidine-1-sulfonic acid (47 mg, 48 .mu.mol), DCM (0.5 mL), and
TFA (0.2 mL, 2.87 mmol) for 2 h. The reaction mixture was
concentrated in vacuo, and the residue was partitioned between DCM
and ice water. The water layer was purified by reverse phase prep
HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18 column; AcN-water
with 0.1% formic acid modifier, 60 mL/min) affording the title
compound LCMS: R.sub.t=0.53 min, m/z=615.3 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O): .delta. 7.63 (s,
1H), 7.05 (s, 1H), 5.58-5.49 (m, 1H), 4.96-4.83 (m, 3H), 4.41 (br
s, 2H), 3.06-2.90 (m, 2H), 2.44-2.28 (m, 2H), 1.98-1.83 (m, 2H),
1.38-1.04 (m, 4H).
Example 125:1-(((Z)-(2-(((2R,3S)-2-((4-((3-((1
r,3R)-3-aminocyclobutyl)guanidino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)a-
mino)oxy)cyclopropanecarboxylic Acid
##STR00180##
[0902] Prepared in analogous manner to example 119, using
tert-butyl
((1r,3r)-3-((imino(methylthio)methyl)amino)cyclobutyl)carbamate.
LCMS: R.sub.t=0.33 min, m/z=641.0 (M+1) Method 2m_acidic; .sup.1H
NMR (400 MHz, D.sub.2O) .delta. 7.72 (s, 1H), 7.10 (s, 1H), 5.58
(d, J=5.5 Hz, 1H), 5.01-4.95 (m, 1H), 4.89-4.85 (m, 2H), 4.53 (s,
2H), 4.25-4.17 (m, 1H), 4.05-3.95 (m, 1H), 2.69-2.59 (m, 2H),
2.58-2.48 (m, 2H), 1.34-1.27 (m, 2H), 1.19-1.12 (m, 2H).
Example 126:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((3-(azetidin-3-ylmeth-
yl)guanidino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-
-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
Step 1: Tert-butyl
3-((3-((2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)met-
hyl)-2H-1,2,3-triazol-4-yl)methyl)-1,2-bis(tert-butoxycarbonyl)guanidino)m-
ethyl)azetidine-1-carboxylate
[0903] Preparation of benzyl
((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin--
3-yl)carbamate 2,2,2-trifluoroacetate. To a solution of NH-Boc
[benzyl
((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin--
3-yl)carbamate] (368 mg, 0.86 mmol) in DCM (4 mL) was added TFA
(1.05 mL, 13.68 mmol). After stirring at rt for 1 h, the reaction
mixture was concentrated in vacuo to give the title compound as TFA
salt (assume quantitative). The crude residue was used as such in
the following step. LCMS: R.sub.t=0.43 min, m/z=331.0 (M+1) Method
2m_acidic.
[0904] Preparation of tert-butyl
3-((N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboximidamido)methyl)az-
etidine-1-carboxylate. To a solution of
Bis-Boc-pyrazolecarboxamidine (2.49 g, 8.01 mmol),
N-Boc-3-hydroxymethylazetidine (1.50 g, 8.01 mmol) and
triphenylphosphine (2.10 g, 8.01 mmol) in THF (80 mL) at 0.degree.
C. was added DIAD (1.62 g, 8.01 mmol) dropwise. After stirring at
rt for 12 h, the reaction mixture was concentrated in vacuo, and
the residue was dissolved in 10% EtOAc/heptane to triturate
triphenylphosphine oxide. The filtrate was concentrated in vacuo
and chromatographed via silica gel column chromatography
(EtOAc-heptane, 0-35%) to afford the title compound (1.6 g, 41%).
LCMS: R.sub.t=1.12 min, m/z=480.0 (M+1) Method 2m_acidic.
[0905] Preparation of tert-butyl
3-((3-((2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)met-
hyl)-2H-1,2,3-triazol-4-yl)methyl)-1,2-bis(tert-butoxycarbonyl)guanidino)m-
ethyl)azetidine-1-carboxylate. To a solution of benzyl
((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin--
3-yl)carbamate 2,2,2-trifluoroacetate (340 mg, 0.77 mmol) in
dioxane (6 mL) was added DIPEA (0.147 mL, 0.842 mmol) and a
solution of tert-butyl
3-((N,N'-bis(tert-butoxycarbonyl)-1H-pyrazole-1-carboximidamido)methyl)az-
etidine-1-carboxylate (367 mg, 0.765 mmol) in dioxane (1 mL). After
heating to 60.degree. C. for 12 h, the reaction mixture was
concentrated in vacuo and purified via silica gel chromatography
(EtOAc-heptane, 0-95%) to afford the title compound (390 mg, 69%).
LCMS: R.sub.t=0.94 min, m/z=742.5 (M+1) Method 2m_acidic.
Step 2: Tert-butyl
3-((3-((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-
-yl)methyl)-1,2-bis(tert-butoxycarbonyl)guanidino)methyl)azetidine-1-carbo-
xylate
[0906] To a solution of tert-butyl
3-((3-((2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)met-
hyl)-2H-1,2,3-triazol-4-yl)methyl)-1,2-bis(tert-butoxycarbonyl)guanidino)m-
ethyl)azetidine-1-carboxylate (390 mg, 0.526 mmol) in EtOH (10 mL)
and MeOH (10.00 mL) was added Pd/C (5%, 112 mg, 53 .mu.mol) and
hydrogen baloon after evacuation and backfilled with H.sub.2. After
1 h, the reaction mixture was filtered over celite pad, and the
filtrate was concentrated in vacuo to afford title compound (302
mg, 95%). The crude residue was used as such in the following step.
LCMS: R.sub.t=0.74 min, m/z=608.4 (M+1) Method 2m_acidic.
Step 3: Tert-butyl
3-((3-((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)im-
ino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidi-
n-2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)-1,2-bis(tert-butoxycarbonyl)g-
uanidino)methyl)azetidine-1-carboxylate
[0907] To a solution of tert-butyl
3-((3-((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-
-yl)methyl)-1,2-bis(tert-butoxycarbonyl)guanidino)methyl)azetidine-1-carbo-
xylate (309 mg, 0.51 mmol) and
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (273 mg, 0.51 mmol) in DMF
(6 mL, ratio: 1) and DCM (6 mL, ratio: 1) was added HATU (232 mg,
0.61 mmol) followed by DIPEA (0.22 mL, 1.27 mmol). After stirring
at rt for 12 h, EtOAc was added to the reaction mixture and washed
with water, brine, dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The crude residue was purified via silica
gel chromatography (EtOAc-heptane, 0-95%) to afford the title
compound (330 mg, 58%). LCMS: R.sub.t=1.15 min, m/z=1127.8 (M+1)
Method 2m_acidic.
Step 4:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((2,3-bis(t-
ert-butoxycarbonyl)-3-((1-(tert-butoxycarbonyl)azetidin-3-yl)methyl)guanid-
ino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic
Acid
[0908] To a solution of tert-butyl
3-((3-((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)im-
ino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidi-
n-2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)-1,2-bis(tert-butoxycarbonyl)g-
uanidino)methyl)azetidine-1-carboxylate (330 mg, 0.29 mmol) in DMF
(2 mL) at 0.degree. C. was added a solution of SO.sub.3.DMF (359
mg, 2.34 mmol) in DMF (1 mL). After stirring at rt for 5 h, the
reaction mixture was diluted with EtOAc and washed with brine,
dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo to
afford the title compound (300 mg, 85%). The crude residue was used
as such in the following step. LCMS: R.sub.t=1.25 min, m/z=1208.7
(M+1) Method 2m_acidic.
Step 5:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((3-(azetidin-3-
-ylmethyl)guanidino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoaze-
tidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00181##
[0910] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((2,3-bis(te-
rt-butoxycarbonyl)-3-((1-(tert-butoxycarbonyl)azetidin-3-yl)methyl)guanidi-
no)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic
acid (300 mg, 0.248 mmol), DCM (3 mL) and TFA (1.90 mL, 24.85
mmol). The crude residue was purified by reverse phase prep HPLC
(XSelect CSH, 19.times.100 mm, 5 .mu.m, C18 column; AcN-water with
0.1% formic acid modifier, 24 mL/min) affording the title compound
(19 mg, 12%). LCMS: R.sub.t=0.32 min, m/z=641.3 (M+1), Method
2m_acidic; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.10.26 (br s,
1H), 8.79 (br s, 3H), 7.78-7.54 (m, 3H), 7.14 (s, 2H), 6.84 (s,
1H), 5.06 (br s, 1H), 4.88 (dd, J=14.1, 3.94 Hz, 1H), 4.70-4.59 (m,
1H), 4.54-4.46 (m, 1H), 4.35 (d, J=3.8 Hz, 2H), 4.00-3.89 (m, 2H),
3.76-3.65 (m, 2H), 3.08-2.94 (m, 1H), 1.30-1.09 (m, 4H).
Example 127:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(aminomethyl)azetidine-1-carboximidamido)m-
ethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(-
2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
Step 1: Benzyl
((2R,3S)-2-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidi-
n-3-yl)carbamate
[0911] To a solution of benzyl
((2R,3S)-2-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2H-1,2,3-triazol-2--
yl)methyl)-4-oxoazetidin-3-yl)carbamate (1.8 g, 4.04 mmol) in MeOH
(60 mL) was added MeOH pre-washed DOWEX-50W-X4 100-200 (3.60 g,
4.04 mmol) resin. After stirring at rt for 2 h, the reaction
mixture was filtered, and the filtrate was concentrated in vacuo to
give the title compound (assume quantitative). LCMS: R.sub.t=0.52
min, m/z=332.1 (M+1) Method 2m_acidic.
Step 2: Tert-butyl
((2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-2-
H-1,2,3-triazol-4-yl)methyl)(((tert-butoxycarbonyl)imino)(1H-pyrazol-1-yl)-
methyl)carbamate
[0912] To a solution of benzyl
((2R,3S)-2-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidi-
n-3-yl)carbamate (1.33 g, 4.01 mmol) and
bis-Boc-pyrazolecarboxamidine (1.37 g, 4.42 mmol) in THF (50 mL)
was added triphenylphosphine (1.16 g, 4.42 mmol) followed by DIAD
(0.89 g, 4.42 mmol). After stirring at rt for 12 h, the reaction
mixture was concentrated in vacuo. The crude residue was purified
via silica gel chromatography (EtOAc-heptane, 0-90%) to afford the
title compound (1.73 g, 69%). LCMS: R.sub.t=0.99 min, m/z=624.4
(M+1) Method 2m_acidic.
Step 3
[0913] To a solution of tert-butyl
((2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-2-
H-1,2,3-triazol-4-yl)methyl)(((tert-butoxycarbonyl)imino)(1H-pyrazol-1-yl)-
methyl)carbamate (320 mg, 0.51 mmol) in CH.sub.3CN (2 mL) was added
Boc-aminomethylazetidine (105 mg, 0.56 mmol). After heating to
70.degree. C. for 1 h, the reaction mixture was concentrated in
vacuo to afford the title compound. The crude residue was used as
such in the following step. LCMS: R.sub.t=0.91 min, m/z=742.5 (M+1)
Method 2m_acidic.
Step 4: Tert-butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)me-
thyl)((3-(((tert-butoxycarbonyl)amino)methyl)azetidin-1-yl)((tert-butoxyca-
rbonyl)imino)methyl)carbamate
[0914] To a solution of compound from step 3 (570 mg, 0.77 mmol) in
EtOH (10 mL) and MeOH (10 mL) was added Pd/C (5%, 16.35 mg, 77
.mu.mol) and hydrogen balloon after evacuation and backfilled with
H.sub.2. After 4 h, the reaction mixture was filtered over celite
pad, and the filtrate was concentrated in vacuo to afford title
compound (302 mg, 95%). The crude residue was used as such in the
following step. LCMS: R.sub.t=0.68 min, m/z=608.4 (M+1) Method
2m_acidic.
Step 5: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((N,N'-bis(tert-butoxycarbonyl)-3-(((tert-buto-
xycarbonyl)amino)methyl)azetidine-1-carboximidamido)methyl)-2H-1,2,3-triaz-
ol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino-
)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
[0915] Prepared in analogous manner to example 126 step 3, using
tert-butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)me-
thyl)((3-(((tert-butoxycarbonyl)amino)methyl)azetidin-1-yl)((tert-butoxyca-
rbonyl)imino)methyl)carbamate (460 mg, 0.76 mmol),
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid acid (407 mg, 0.76 mmol),
DMF (8 mL), DCM (8 mL), HATU (345 mg, 0.91 mmol) and DIPEA (0.33
.mu.L, 1.89 mmol). The crude residue was purified via silica gel
chromatography (EtOAc-heptane, 0-100%) to afford the title compound
(0.65 g, 76%). LCMS: R.sub.t=1.15 min, m/z=1127.9 (M+1) Method
2m_acidic.
Step 6:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((N,N-bis(t-
ert-butoxycarbonyl)-3-(((tert-butoxycarbonyl)amino)methyl)azetidine-1-carb-
oximidamido)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfoni-
c Acid
[0916] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((N,N'-bis(tert-butoxycarbonyl)-3-(((tert-buto-
xycarbonyl)amino)methyl)azetidine-1-carboximidamido)methyl)-2H-1,2,3-triaz-
ol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino-
)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
(650 mg, 0.58 mmol) in DMF (3 mL) at 0.degree. C. was added a
solution of SO.sub.3.DMF (883 mg, 5.77 mmol) in DMF (1 mL) at
0.degree. C. After stirring at rt for 12 h, the reaction mixture
was diluted with EtOAc and washed with brine, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo to afford the
title compound (assumed quantitative). The crude residue was used
as such in the following step. LCMS: R.sub.t=1.18 min, m/z=1208.5
(M+1) Method 2m_acidic.
Step 7:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(Aminomethyl)azetidine-1-carboximid-
amido)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)ami-
no)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxyl-
ic Acid
##STR00182##
[0918] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((N,N'-bis(t-
ert-butoxycarbonyl)-3-(((tert-butoxycarbonyl)amino)methyl)azetidine-1-carb-
oximidamido)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfoni-
c acid (690 mg, 0.57 mmol), DCM (3 mL) and TFA (2.1 mL, 27.4 mmol).
The crude residue was purified via reverse phase prep HPLC (XSelect
CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1%
formic acid modifier, 60 mL/min) affording the title compound (98
mg, 27%). LCMS: R.sub.t=0.32 min, m/z=641.3 (M+1), Method
2m_acidic; .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.73 (s,
1H), 8.06 (s, 1H), 7.72-7.54 (m, 3H), 7.18 (s, 2H), 6.74 (s, 1H),
5.25 (dd, J=8.9, 5.5 Hz, 1H), 4.88 (dd, J=14.2, 4.3 Hz, 1H), 4.65
(dd, J=14.2, 7.7 Hz, 1H), 4.53 (ddd, J=7.6, 5.6, 4.4 Hz, 1H),
4.46-4.31 (m, 2H), 4.15 (td, J=8.7, 5.0 Hz, 2H), 3.96-3.81 (m, 2H),
3.11 (d, J=7.3 Hz, 2H assumed; partially obscured by water), 2.91
(p, J=6.8 Hz, 1H), 1.26-1.11 (m, 2H), 1.08-0.95 (m, 2H).
Example 128:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-((3-(piper-
idin-4-yl)guanidino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazetidin--
3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00183##
[0920] Prepared in analogous manner to example 119, using
tert-butyl
4-((imino(methylthio)methyl)amino)piperidine-1-carboxylate. LCMS:
R.sub.t=0.32 min, m/z=655.1 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, D.sub.2O) .delta. 7.73 (s, 1H), 7.14 (s, 1H), 5.59 (d,
J=5.6 Hz, 1H), 5.01-4.94 (m, 1H), 4.90-4.84 (m, 1H), 4.80 (s, 1H),
4.54 (s, 2H), 3.80-3.71 (m, 1H), 3.48 (d, J=13.4 Hz, 2H), 3.10 (t,
J=12.5 Hz, 2H), 2.21 (d, J=12.9 Hz, 2H), 1.85-1.71 (m, 2H),
1.38-1.31 (m, 2H), 1.24-1.16 (m, 2H).
Example 129:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(2-aminoethyl)guanidino)methyl)-2H-1,2,3-t-
riazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4--
yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00184##
[0922] Prepared in analogous manner to example 119, using
tert-butyl (2-((imino(methylthio)methyl)amino)ethyl)carbamate.
LCMS: R.sub.t=0.31 min, m/z=615.4 (M+1) Method 2m_acidic; .sup.1H
NMR (400 MHz, D.sub.2O) .delta. 7.63 (s, 1H), 7.02 (s, 1H), 5.49
(d, J=5.6 Hz, 1H), 4.88 (q, J=5.6 Hz, 1H), 4.77 (d, J=5.6 Hz, 2H),
4.44 (s, 2H), 3.48 (t, J=5.9 Hz, 2H), 3.14 (t, J=5.9 Hz, 2H),
1.28-1.15 (m, 2H), 1.12-1.00 (m, 2H).
Example 130:
1-(((Z)-(2-(((2R,3S)-2-((4-((1-(3-aminopropyl)guanidino)methyl)-2H-1,2,3--
triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-
-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 1: Benzyl
((2R,3S)-2-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidi-
n-3-yl)carbamate
[0923] To a solution of benzyl
((2R,3S)-2-((4-(((tert-butyldimethylsilyl)oxy)methyl)-2H-1,2,3-triazol-2--
yl)methyl)-4-oxoazetidin-3-yl)carbamate (500 mg, 1.12 mmol) in MeOH
(15 mL) was added DOWEX-50W-X4 100-200 (1 g, 1.12 mmol) resin.
After stirring at rt for 3 h, the reaction mixture was filtered,
and the filtrate was concentrated in vacuo to give the title
compound (assume quantitative). LCMS: R.sub.t=0.51 min, m/z=332.1
(M+1) Method 2m_acidic.
Step 2: Benzyl
((2R,3S)-2-((4-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)ca-
rbamate
[0924] To a solution of benzyl
((2R,3S)-2-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidi-
n-3-yl)carbamate (385 mg, 1.16 mmol) in THF (10 mL) was added
manganese dioxide (2.0 g, 23 mmol). After stirring at rt for 12 h,
another 1 g of MnO.sub.2 was added and stirred for another 1 h. The
reaction mixture was filtered over celite with MeOH wash. The
filtrate was concentrated in vacuo to give the title compound (340
mg, 89%). The crude residue was used as such in the following step.
LCMS: R.sub.t=0.61 min, m/z=330.0 (M+1) Method 2m_acidic.
Step 3
[0925] To a solution of benzyl
((2R,3S)-2-((4-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)ca-
rbamate (340 mg, 1.03 mmol) and Boc-1,3-diaminopropane (360 mg,
2.07 mmol) in DCE (16 mL) and THF (6 mL) at 0.degree. C. was added
sodium triacetoxyborohydride (328 mg, 1.55 mmol). After stirring at
rt for 18 h, the reaction mixture was concentrated in vacuo,
re-dissolved in DCM, washed with 5% sodium bicarbonate, brine,
dried over MgSO4, filtered and concentrated in vacuo to give the
title compound (470 mg, 93%). The crude residue was used as such in
the following step. LCMS: R.sub.t=0.64 min, m/z=488.2 (M+1) Method
2m_acidic.
Step 4
[0926] To a solution of DIPEA (0.17 mL, 0.96 mmol) and product from
step 3 (470 mg, 0.96 mmol) in dioxane (15 mL) was added
bis-Boc-pyrazolecarboxamidine (359 mg, 1.16 mmol). After heated to
60.degree. C. for 3 h, the reaction mixture was concentrated in
vacuo and purified via silica gel chromatography (EtOAc-Heptane,
20-100%) to afford the title compound (130 mg, 18%). LCMS:
R.sub.t=0.93 min, m/z=730.5 (M+1) Method 2m_acidic.
Step 5
[0927] Prepared in analogous manner to example 126 step 2, using
product from step 4 (130 mg, 0.178 mmol), EtOH (5 mL) and methanol
(3 mL), Pd/C (5%, 37.9 mg, 18 .mu.mol). The crude residue was used
as such in the following step (100 mg, 94%). LCMS: R.sub.t=0.70
min, m/z=596.0 (M+1) Method 2m_acidic.
Step 6: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((2,3-bis(tert-butoxycarbonyl)-1-(3-((tert-but-
oxycarbonyl)amino)propyl)guanidino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-
-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2--
oxoethylidene)amino)oxy)cyclopropanecarboxylate
[0928] Prepared in analogous manner to example 126 step 3, using
product from step 5 (100 mg, 0.168 mmol), tert-butyl
3-((3-((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-
-yl)methyl)-1,2-bis(tert-butoxycarbonyl)guanidino)methyl)azetidine-1-carbo-
xylate (309 mg, 0.51 mmol) and
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid acid (90 mg, 0.17 mmol),
DMF (3 mL), DCM (2 mL), HATU (83 mg, 0.22 mmol) and DIPEA (73
.mu.L, 0.42 mmol). The crude residue was purified via silica gel
chromatography (EtOAc-heptane, 15-90%) to afford the title compound
(110 mg, 59%) along with the bis-Boc product. LCMS: R.sub.t=1.13
min, m/z=1115.7 (M+1) Method 2m_acidic.
Step 7:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((2,3-bis(t-
ert-butoxycarbonyl)-1-(3-((tert-butoxycarbonyl)amino)propyl)guanidino)meth-
yl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic
Acid
[0929] Prepared in analogous manner to example 126 step 4, using
benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((2,3-bis(tert-butoxycarbonyl)-1-(3-((tert-but-
oxycarbonyl)amino)propyl)guanidino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-
-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2--
oxoethylidene)amino)oxy)cyclopropanecarboxylate (110 mg, 99
.mu.mol), DMF (2 mL), a solution of SO.sub.3.DMF (121 mg, 0.79
mmol) in DMF (1 mL) followed by another 140 mg of SO.sub.3.DMF. The
crude residue was used as such in the following step (assumed
quantitative). LCMS: R.sub.t=1.15 min, m/z=1195.9 (M+1) Method
2m_acidic.
Step 8:
1-(((Z)-(2-(((2R,3S)-2-((4-((1-(3-aminopropyl)guanidino)methyl)-2H-
-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminoth-
iazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00185##
[0931] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((2,3-bis(te-
rt-butoxycarbonyl)-1-(3-((tert-butoxycarbonyl)amino)propyl)guanidino)methy-
l)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic acid
(118 mg, 99 .mu.mol), DCM (2 mL) and TFA (2.0 mL, 26 mmol). The
crude residue was purified via reverse phase prep HPLC (XSelect
CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1%
formic acid modifier, 60 mL/min) affording the title compound (5.1
mg, 8%). LCMS: R.sub.t=0.28 min, m/z=629.4 (M+1). Method
2m_acidic.
Example 131:
1-(((Z)-(2-(((2R,3S)-2-((4-(((3-amino-3-methylbutyl)amino)methyl)-2H-1,2,-
3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-
-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00186##
[0933] Prepared in analogous manner to example 90, using tert-butyl
(4-amino-2-methylbutan-2-yl)carbamate. The crude residue was
purified by reverse phase prep HPLC (XSelect CSH, 30.times.100 mm,
5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier, 60
mL/min). LCMS: R.sub.t=0.33 min, m/z=615.3 (M+1) Method 2m_acidic;
.sup.1H NMR (400 MHz, D.sub.2O): .delta. 7.76 (s, 1H), 7.03 (s,
1H), 5.52 (d, J=5.6 Hz, 1H), 4.97-4.90 (m, 1H), 4.88-4.74 (m, 2H),
4.31 (s, 2H), 3.18-3.08 (m, 2H), 2.04-1.94 (m, 2H), 1.29 (s, 6H),
1.23-1.18 (m, 2H), 1.14-0.99 (m, 2H).
Example 132:
1-(((Z)-(2-(((2R,3S)-2-((4-(((4-amino-2-methylbutan-2-yl)amino)methyl)-2H-
-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminoth-
iazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00187##
[0935] Prepared in analogous manner to example 90, using tert-butyl
(3-amino-3-methylbutyl)carbamate (Boc protection was not necessary
due to hindered amine). The crude residue was purified by reverse
phase prep HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18 column;
ACN-water with 0.1% formic acid modifier, 60 mL/min). LCMS:
R.sub.t=0.49 min, m/z=615.3 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, D.sub.2O): .delta. 7.86 (s, 1H), 7.16 (s, 1H), 5.62 (d,
J=5.4 Hz, 1H), 5.07-4.91 (m, 2H), 4.88-4.79 (m, 3H), 4.40 (s, 2H),
3.23-3.13 (m, 2H), 2.22-2.12 (m, 2H), 1.49 (s, 6H), 1.39-1.11 (m,
4H).
Example 133:
1-(((Z)-(2-(((2R,3S)-2-((4-((((2-aminoethoxy)carbonyl)amino)methyl)-2H-1,-
2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiaz-
ol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 2-((tert-butoxycarbonyl)amino)ethyl
1H-imidazole-1-carboxylate
[0936] To a solution of CDI (218 mg, 1.30 mmol) in DCM (4 mL) was
added a solution of tert-butyl (2-hydroxyethyl)carbamate (0.22 mL,
1.37 mmol) in DCM (1 mL). After stirring at rt for 1 h, the
reaction mixture was used directly in DCM for the next step.
Step 2: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(10,10-dimethyl-3,8-dioxo-4,9-dioxa-2,7-diazaundecyl)-2H-1,2,3-triazol-2--
yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropan-
ecarboxylate
[0937] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-o-
xoethylidene)amino)oxy)cyclopropanecarboxylate (90 mg, 0.13 mmol)
in DCM (2 mL) at 0.degree. C. was added a solution of
2-((tert-butoxycarbonyl)amino)ethyl 1H-imidazole-1-carboxylate
(0.59 ml, 0.19 mmol) in DCM (0.6 mL). After stirring at rt for 12
h, another 3 equiv 2-((tert-butoxycarbonyl)amino)ethyl
1H-imidazole-1-carboxylate (1.18 ml, 0.38 mmol) was added. After
stirring at rt for additional 60 h, the reaction mixture was
partitioned between DCM (40 mL) and water (20 mL). The organic
layer was dried with Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The crude residue was purified via silica gel chromatography
(MeOH-DCM, 0-5%) to afford the title compound (64 mg, 56%). LCMS:
R.sub.t=1.09 min, m/z=903.5 (M+1) Method 2m_acidic.
Step 3:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(10,10-dime-
thyl-3,8-dioxo-4,9-dioxa-2,7-diazaundecyl)-2H-1,2,3-triazol-2-yl)methyl)-4-
-oxoazetidine-1-sulfonic Acid
[0938] To a solution of benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(10,10-dimethyl-3,8-dioxo-4,9-dioxa-2,7-diazaundecyl)-2H-1,2,3-triazol-2--
yl)methyl)-4-oxoazetidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropan-
ecarboxylate (108 mg, 0.120 mmol) in DMF (1.2 mL) was added
SO.sub.3.DMF (189 mg, 1.20 mmol). After stirring at rt for 5 h, the
reaction mixture was diluted with EtOAc (60 mL) and brine (20 mL).
Aqueous layer was extracted with EtOAc (20 mL). Combined organic
layers were dried with Na.sub.2SO.sub.4, filtered and concentrated
in vacuo to give the title compound (68 mg, 58%). The crude residue
was used as such in the following step. LCMS: R.sub.t=0.96 min,
m/z=983.6 (M+1) Method 2m_acidic.
Step 4:
1-(((Z)-(2-(((2R,3S)-2-((4-((((2-aminoethoxy)carbonyl)amino)methyl-
)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-ami-
nothiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00188##
[0940] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(10,10-dimet-
hyl-3,8-dioxo-4,9-dioxa-2,7-diazaundecyl)-2H-1,2,3-triazol-2-yl)methyl)-4--
oxoazetidine-1-sulfonic acid (68 mg, 69 .mu.mol), DCM (0.7 mL) and
TFA (0.32 mL, 4.15 mmol). The crude residue was purified by reverse
phase prep HPLC (XSelect CSH, 30.times.100 mm, 5 .mu.m, C18 column;
ACN-water with 0.1% formic acid modifier, 60 mL/min), affording the
title compound (19 mg, 44%). LCMS: R.sub.t=0.54 min, m/z=617.3
(M+1) Method 2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O)
.delta. 7.67 (s, 1H), 7.10 (s, 1H), 5.60-5.52 (m, 1H), 5.01-4.84
(m, 3H), 4.43-4.37 (s, 2H), 4.35-4.27 (m, 2H), 3.33-3.25 (m, 2H),
1.36-1.13 (m, 4H).
Example 134:
1-(((Z)-(2-(((2R,3S)-2-((4-((2-aminoacetamido)methyl)-2H-1,2,3-triazol-2--
yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxo-
ethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00189##
[0942] Prepared in analogous manner to example 124, using
2-((tert-butoxycarbonyl)amino)acetic acid. The crude residue was
purified by reverse phase prep HPLC (XSelect CSH, 30.times.100 mm,
5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier, 60
mL/min). LCMS: R.sub.t=0.48 min, m/z=587.2 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.68 (s,
1H), 7.12 (s, 1H), 5.57-5.53 (m, 1H), 4.96 (m, 3H), 4.51 (s, 2H),
3.84 (s, 2H), 1.35 (m, 4H).
Example 135:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(2-aminoethyl)ureido)methyl)-2H-1,2,3-tria-
zol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-
-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00190##
[0944] Prepared in analogous manner to example 133, using
tert-butyl (2-(1H-imidazole-1-carboxamido)ethyl)carbamate (without
additional base) in step 2. The crude residue was purified by
reverse phase prep HPLC (Xselect CSH, 30.times.100 mm, 5 .mu.m, C18
column; ACN-water with 0.1% formic acid modifier, 60 mL/min). LCMS:
R.sub.t=0.51 min, m/z=616.3 (M+1) Method 2m_acidic_polar; .sup.1H
NMR (400 MHz, D.sub.2O) .delta. 7.62 (s, 1H), 7.07 (s, 1H),
5.55-5.49 (m, 1H), 4.97-4.86 (m, 3H), 4.34 (s, 2H), 3.44-3.35 (m,
2H), 3.12-3.03 (m, 2H), 1.36-1.10 (m, 4H).
Example 136:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(3-aminopropyl)ureido)methyl)-2H-1,2,3-tri-
azol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl-
)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00191##
[0946] Prepared in analogous manner to example 133, tert-butyl
(3-(1H-imidazole-1-carboxamido)propyl)carbamate (without additional
base) in step 2. The crude residue was purified by reverse phase
prep HPLC (Xselect CSH, 30.times.100 mm, 5 .mu.m, C18 column;
AcN-water with 0.1% formic acid modifier, 60 mL/min). LCMS:
R.sub.t=0.52 min, m/z=630.4 (M+1) Method 2m_acidic_polar; .sup.1H
NMR (400 MHz, D.sub.2O) .delta. 7.60 (s, 1H), 7.07 (s, 1H),
5.57-5.48 (m, 1H), 4.97-4.86 (m, 3H), 4.32 (s, 2H), 3.18 (m, 2H),
2.97 (m, 2H), 1.79 (m, 2H), 1.33 (m, 4H).
Example 137:
(2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-((1-carboxycyclopropoxy)-imino)a-
cetamido)-2-((4-((((1-methylpyridin-1-ium-3-yl)methyl)amino)methyl)-2H-1,2-
,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonate
Step 1:
3-((((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropo-
xy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoaz-
etidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)amino)methyl)-1-methylpyr-
idin-1-ium Chloride
[0947] To a suspension of 3-(ammoniomethyl)-1-methylpyridin-1-ium
(147 mg, 0.755 mmol) in THF:EtOH (1:1, 1.26 mL) was added
triethylamine (175 .mu.l, 1.26 mmol) followed by a solution of
benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(((methylsulfonyl)oxy)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-
-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropane-carboxylate
(200 mg, 0.252 mmol) in THF (500 uL), dropwise. After stirring at
rt for 20 h, the mixture was concentrated in vacuo then
re-dissolved in DMSO and purified by reverse phase prep HPLC
(Xselect CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water with
0.1% formic acid modifier, 60 mL/min), affording the title compound
(50 mg, 23%) as a white solid. LCMS: R.sub.t=0.85 min, m/z=821.3
(M+) Method 2m_acidic.
Step 2:
3-((((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropo-
xy)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoaz-
etidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)(tert-butoxycarbonyl)amin-
o)methyl)-1-methylpyridin-1-ium Chloride
[0948] Prepared in an anologous manner to example 85, step 4 using
3-((((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imin-
o)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidin--
2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)amino)methyl)-1-methylpyridin-1--
ium chloride (50 mg, 0.058 mmol), Boc-anhydride (0.027 mL, 0.115
mmol), NaHCO.sub.3 (satd aq, 1.22 mL) and DCM (1.15 mL). LCMS:
R.sub.t=0.99 min, m/z=921.3 (M+) Method 2m_acidic.
Step 3:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-but-
oxycarbonyl)((1-methylpyridin-1-ium-3-yl)methyl)amino)methyl)-2H-1,2,3-tri-
azol-2-yl)methyl)-4-oxoazetidine-1-sulfonate
[0949] Prepared in analogous manner to example 19, step 3 using
3-((((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imin-
o)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidin--
2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)(tert-butoxycarbonyl)-amino)meth-
yl)-1-methylpyridin-1-ium chloride (49 mg, 0.051 mmol),
SO.sub.3.DMF (78 mg, 0.51 mmol) and DMF (1 mL). LCMS: R.sub.t=0.99
min, m/z=1002 (M+) Method 2m_acidic.
Step 4:
(2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-((1-carboxycyclopropoxy)--
imino)acetamido)-2-((4-((((1-methylpyridin-1-ium-3-yl)methyl)amino)methyl)-
-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonate
##STR00192##
[0951] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-buto-
xycarbonyl)((1-methylpyridin-1-ium-3-yl)methyl)amino)methyl)-2H-1,2,3-tria-
zol-2-yl)methyl)-4-oxoazetidine-1-sulfonate (53 mg, 0.053 mmol),
TFA (81 .mu.l, 1.1 mmol) and DCM (72 mL). The crude residue
purified by reverse phase prep HPLC (Xselect CSH, 30.times.100 mm,
5 .mu.m, C18 column; ACN-water with 0.1% formic acid modifier, 60
mL/min), affording the title compound (13 mg, 35%) as a white
powder. LCMS: R.sub.t=0.30 min, m/z=635.3 (M+1) Method 2m_acidic;
.sup.1H NMR (400 MHz, D.sub.2O) .delta. 9.00 (s, 1H), 8.78-8.67 (m,
2H), 7.97 (t, J=7.1 Hz, 1H), 7.86 (s, 1H), 6.93 (s, 1H), 5.75 (d,
J=5.3 Hz, 1H), 5.11 (dd, J=14.4, 3.7 Hz, 1H), 5.06-4.99 (m, 1H),
4.70-4.46 (m, 4H), 4.38 (s, 3H), 3.77-3.62 (m, 1H), 1.35-1.26 (m,
1H), 1.20-1.10 (m, 2H), 0.93-0.82 (m, 1H).
Example 138:
1-(((Z)-(2-(((2R,3S)-2-((4-((4-aminopiperidin-1-yl)methyl)-2H-1,2,3-triaz-
ol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)--
2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 1: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((4-((tert-butoxycarbonyl)amino)piperidin-1-yl-
)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((te-
rt-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropa-
necarboxylate
[0952] Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(((methylsulfonyl)oxy)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-
-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate (64
mg, 0.081 mmol) and sodium iodide (18.1 mg, 0.121 mmol) were
stirred in DMF (700 .mu.L) for 14 h, whereupon cesium carbonate
(33.4 mg, 0.103 mmol) and tert-butyl piperidin-4-ylcarbamate (17.7
mg, 0.089 mmol) were added. After 3 h of additional stirring the
mixture was diluted with EtOAc and LiCl (5% aq) solution. The
aqueous layer was extracted with EtOAc (2.times.) and the combined
organic layers were washed with LiCl (5% aq) solution, brine, dried
over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue
was purified via silica gel chromatography (1-8% MeOH-DCM),
affording the title compound (52.6 mg, 73%) as an off-white solid.
LCMS: R.sub.t=0.98 min, m/z=899.7 (M+1) Method 2m_acidic.
Step 2:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((4-((tert--
butoxycarbonyl)amino)piperidin-1-yl)methyl)-2H-1,2,3-triazol-2-yl)methyl)--
4-oxoazetidine-1-sulfonic Acid
[0953] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((4-((tert-butoxycarbonyl)amino)piperidin-1-yl-
)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((te-
rt-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropa-
necarboxylate (53 mg, 59 .mu.mol) in DMF (293 .mu.L) at 0.degree.
C. was added SO.sub.3.DMF (24.3 mg, 0.159 mmol). After stirring for
2 h at rt, more SO.sub.3.DMF (24.3 mg, 81 .mu.mol) was added. After
additional stirring for 16h, the solution was concentrated in
vacuo. The crude material was used directly in step 3. LCMS:
R.sub.t=0.97 min, m/z=979.9 (M+1) Method 2m_acidic.
Step 3:
1-(((Z)-(2-(((2R,3S)-2-((4-((4-aminopiperidin-1-yl)methyl)-2H-1,2,-
3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-
-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00193##
[0955] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((4-((tert-b-
utoxycarbonyl)amino)piperidin-1-yl)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-
-oxoazetidine-1-sulfonic acid (58 mg, 59 .mu.mol), DCM (590 .mu.L),
anisole (13 .mu.L, 0.12 mmol) and TFA (273 .mu.L, 3.54 mmol). The
crude residue was purified by reverse phase prep HPLC (Xselect CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min), affording the title compound (2.7 mg,
7.3%) as an off-white powder. LCMS: R.sub.t=0.50 min, m/z=613.4
(M+1) Method 2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O)
.delta. 7.93 (s, 1H), 7.12 (s, 1H), 5.59 (d, J=5.5 Hz, 1H),
5.07-5.00 (m, 1H), 4.99-4.96 (m, 1H), 4.93-4.90 (m, 1H), 4.39 (s,
2H), 3.75-3.62 (m, 2H), 3.63-3.51 (m, 1H), 3.28-3.08 (m, 2H), 2.33
(d, J=13.7 Hz, 2H), 2.04-1.89 (m, 2H), 1.38-1.11 (m, 4H).
Example 139:
(2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-((1-carboxycyclopropoxy)imino)ac-
etamido)-2-((4-(((6,7-dihyd
ro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)thio)methyl)-2H-1,2,3-tria-
zol-2-yl)methyl)-4-oxoazetidine-1-sulfonate
Step 1:
6-(((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropox-
y)imino)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoaze-
tidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)thio)-6,7-dihydro-5H-pyraz-
olo[1,2-a][1,2,4]triazol-4-ium Chloride
[0956] Prepared in an analogous manner to example 138, step 1 using
benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(((2R,3S)-2-((4-
-(((methylsulfonyl)oxy)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-
-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate (54
mg, 0.068 mmol), sodium iodide (17.2 mg, 0.115 mmol), cesium
carbonate (24.5 mg, 0.075 mmol),
6-mercapto-6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium
chloride (13.4 mg, 0.075 mmol) and DMF (600 .mu.L). The slurry was
concentrated in vacuo, and the crude residue was purified via
reverse phase prep HPLC (Xselect CSH, 30.times.100 mm, 5 .mu.m, C18
column; ACN-water with 0.1% formic acid modifier, 60 mL/min),
affording the title compound (19.7 mg, 34%) as white solid. LCMS:
R.sub.t=0.91 min, m/z=840.4 (M+) Method 2m_acidic.
Step 2:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((6,7-dihy-
d
ro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)thio)methyl)-2H-1,2,3-tri-
azol-2-yl)methyl)-4-oxoazetidine-1-sulfonate
[0957] Prepared in an analogous manner to example 138, step 2 using
6-(((2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino-
)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidin-2-
-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl)thio)-6,7-dihydro-5H-pyrazolo[1,2-
-a][1,2,4]triazol-4-ium chloride (21 mg, 0.025 mmol), DMF (250
.mu.L), SO.sub.3.DMF (18.9 mg, 0.123 mmol) then additional
SO.sub.3.DMF (22.3 mg, 0.146 mmol). The crude material was used
directly in step 3. LCMS: R.sub.t=0.92 min, m/z=921.7 (M+1) Method
2m_acidic.
Step 3:
(2R,3S)-3-((Z)-2-(2-aminothiazol-4-yl)-2-((1-carboxycyclopropoxy)i-
mino)-acetamido)-2-((4-(((6,7-dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-4-i-
um-6-yl)thio)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfon-
ate
##STR00194##
[0959] Prepared in analogous manner to example 138, step 3 using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((-
tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((6,7-dihydro-5H--
pyrazolo[1,2-a][1,2,4]triazol-4-ium-6-yl)thio)methyl)-2H-1,2,3-triazol-2-y-
l)methyl)-4-oxoazetidine-1-sulfonate (23 mg, 0.025 mmol), anisole
(5.5 .mu.L, 0.050 mmol), TFA (116 .mu.L, 1.50 mmol) and DCM (300
.mu.L). The crude residue purified by reverse phase prep HPLC
(Xselect CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water with
0.1% formic acid modifier, 60 mL/min), affording the title compound
(1.5 mg, 8%). LCMS: R.sub.t=0.60 min, m/z=654.4 (M+1) Method
2m_acidic; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 9.02 (d, J=4.8
Hz, 2H), 7.84 (s, 1H), 7.17 (s, 1H), 5.65 (d, J=5.8 Hz, 1H),
5.12-4.97 (m, 3H), 4.94-4.89 (m, 1H), 4.64-4.50 (m, 4H), 4.09 (s,
2H), 1.48-1.36 (m, 2H), 1.32-1.24 (m, 2H).
Example 140: 1-(((Z)-(2-(((2R,3S)-2-((4-((3-((1
s,3S)-3-aminocyclobutyl)guanidino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-
-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethylidene)a-
mino)oxy)cyclopropanecarboxylic Acid
##STR00195##
[0961] Prepared in analogous manner to example 119, using
tert-butyl
((1S,3S)-3-((imino(methylthio)methyl)amino)cyclobutyl)carbamate.
LCMS: R.sub.t=0.49 min, m/z=641.2 (M+1) Method 2m_acidic; .sup.1H
NMR (400 MHz, D.sub.2O) .delta. ppm 7.61 (s, 1H) 7.00 (s, 1H) 5.47
(d, J=5.6 Hz, 1H) 4.91-4.84 (m, 1H) 4.79-4.76 (m, 3H) 4.41 (s, 3H)
3.78 (t, J=7.6 Hz, 1H) 3.51 (t, J=8.0 Hz, 1H) 2.84-2.67 (m, 1H)
2.12 (d, J=9.7 Hz, 1H) 1.23-1.19 (m, 2H) 1.05 (d, J=4.5 Hz,
2H).
Example 141:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-((3-((S)-p-
yrrolidin-3-yl)guanidino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazet-
idin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00196##
[0963] Prepared in analogous manner to example 119, using
(S)-tert-butyl
3-((imino(methylthio)methyl)amino)pyrrolidine-1-carboxylate. LCMS:
R.sub.t=0.49 min, m/z=640.8 (M+1) Method 2m_acidic; .sup.1H NMR
(400 MHz, D.sub.2O) .delta. ppm 7.62 (s, 1H) 7.00 (s, 1H) 5.49 (d,
J=5.6 Hz, 1H) 4.83-4.91 (m, 1H) 4.80-4.75 (m, 2H) 4.44 (s, 2H) 4.30
(t, J=4.0 Hz, 1H) 3.60-3.18 (m, 5H) 2.38-2.24 (m, 1H) 2.04 (dq,
J=12.5, 6.5 Hz, 1H) 1.24-1.12 (m, 2H) 1.04 (br s, 2H).
Example 142:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((4-((3-(200-p-
yrrolidin-3-yl)guanidino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-sulfoazet-
idin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00197##
[0965] Prepared in analogous manner to example 119,
Usi.RTM.(R)-tert-butyl
3-((imino(methylthio)methyl)amino)pyrrolidine-1-carboxylate. LCMS:
R.sub.t=0.29 min, m/z=641.1 (M+1) Method 2m; .sup.1H NMR (400 MHz,
D.sub.2O) .delta. ppm 7.62 (s, 1H) 7.01 (s, 1H) 5.49 (d, J=5.6 Hz,
1H) 4.87 (q, J=5.7 Hz, 1H) 4.80-4.75 (m, 2H) 4.44 (s, 2H) 4.31 (t,
J=4.0 Hz, 1H) 3.61-3.20 (m, 4H) 2.41-2.21 (m, 1H) 2.08-2.00 (m, 1H)
1.18 (m, 2H) 1.14 (m, 2H).
Example 143:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-5-methyl-2H-1,2,3-triazol-2-yl)m-
ethyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethy-
lidene)amino)oxy)cyclopropanecarboxylic Acid
[0966] Step 1: 4-(azidomethyl)-5-methyl-2H-1,2,3-triazole
[0967] To a solution of 1-bromo-2-butyne (640 .mu.L, 7.31 mmol) in
1,4-dioxane/Water (3:1, 36 mL) was added sodium azide (1.901 g,
29.2 mmol) followed by ammonium chloride (782 mg, 14.6 mmol). The
slurry was heated to 75.degree. C. for 8 h. The layers were
separated and the aqueous was extracted with EtOAc (3.times.). The
combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4 and concd in vacuo to yield a crude material (833
mg, 78%) that was used directly in step 2. LCMS: R.sub.t=0.35 min,
m/z=138.9 (M+1) Method 2m_acidic.
Step 2: tert-Butyl
((5-methyl-2H-1,2,3-triazol-4-yl)methyl)carbamate
[0968] A slurry of 4-(azidomethyl)-5-methyl-2H-1,2,3-triazole (803
mg, 5.81 mmol), Boc-anhydride (1.36 mL, 5.88 mmol) and Pd--C (157
mg, 0.148 mmol) in EtOH (39 mL) was evacuated and recharged with
H.sub.2 (3.times.). The reaction mixture was stirred under H.sub.2
for 1h 45 min. The resulting black suspension was filtered through
celite and eluted with EtOAc. The filtrate was concentrated in
vacuo. The crude residue was purified via silica gel chromatography
(EtOAc-Heptane, 0-60%) to afford the title compound (878 mg, 71%).
LCMS: R.sub.t=0.82 min, m/z=213.0 (M+1) Method 2m_acidic.
Step 3
[0969] To a solution of benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)car-
bamate (331 mg, 0.826 mmol), tert-butyl
((5-methyl-2H-1,2,3-triazol-4-yl)methyl)carbamate (235.3 mg, 1.109
mmol) and triphenylphosphine (265.6 mg, 1.013 mmol) in THF (8.3 mL)
at 0.degree. C. was added DIAD (0.210 mL, 1.016 mmol), drop-wise.
After stirring at room temperature for 2 h, the reaction mixture
was concentrated onto silica gel. Purification via silica gel
chromatography (EtOAc-Heptane, 0-60%) afforded the desired compound
(360 mg, 73%). LCMS: R.sub.t=0.99 min, m/z=595.3 (M+1) Method
2m_acidic.
Step 4
[0970] A slurry of the product from the above step (step 4) (396.8
mg, 0.667 mmol), K.sub.2S.sub.2O.sub.8 (243 mg, 0.870 mmol) and
K.sub.2HPO.sub.4 (268.1 mg, 1.539 mmol) in ACN/water (2:1, 9.4 mL)
was heated to 90.degree. C. for 2 h. Additional
K.sub.2S.sub.2O.sub.8 (55.6 mg, 0.200 mmol) was added and continued
heating for an additional 2 h. The reaction mixture was partially
concentrated in vacuo then quenched with NaHCO.sub.3 and extracted
with EtOAc (3.times.). The combined organic layers were washed with
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
Purification via silica gel chromatography (EtOAc-Heptane, 0-90%),
then HPLC (OBD C18, 5.mu., 30.times.100 mm, 30-70% ACN/H.sub.2O
w/0.1% TFA buffer over 18 min, 60 mL/min), afforded the desired
compound (157 mg, 53%) as a white solid. LCMS: R.sub.t=0.80 min,
m/z=445.2 (M+1) Method 2m_acidic.
Step 5: tert-Butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-5-methyl-2H-1,2,3-triazo-
l-4-yl)methyl)carbamate
[0971] To a N.sub.2 flushed flask containing product from the above
step (93.2 mg, 0.210 mmol) and Pd--C (18 mg) was added ethanol (1.6
mL) followed by methanol (0.4 mL). The slurry was evacuated and
backfilled with H.sub.2 (3.times.). The reaction mixture was
stirred under H.sub.2 for 2 h. The resulting black suspension was
filtered through celite, eluting with methanol. The filtrate was
concentrated in vacuo and the crude residue was used as such in
step 6. LCMS: R.sub.t=0.46 min, m/z=311.1 (M+1) Method
2m_acidic.
Step 6: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(((tert-butoxycarbonyl)amino)methyl)-5-methyl--
2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxy-
late
[0972] To a solution of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (120 mg, 0.213 mmol),
tert-butyl
((2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-5-methyl-2H-1,2,3-triazo-
l-4-yl)methyl)carbamate (65.2 mg, 0.210 mmol) and HATU (86 mg, 0.22
mmol) in DMF (2.1 mL) at 0.degree. C., was added DIPEA (0.073 mL,
0.420 mmol). After stirring for 16 h, the reaction mixture was
diluted with EtOAc and washed with LiCl solution (5% aq). The
aqueous layer was extracted with EtOAc (3.times.) and the combined
organic layers were washed with LiCl solution (5% aq), saturated
NaHCO.sub.3 (aq), brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. Purification of the crude residue via silica
gel chromatography (EtOAc-Heptane, 0-90%) afforded the title
compound (144 mg, 82%). LCMS: R.sub.t=1.12 min, m/z=830.5 (M+1)
Method 2m_acidic.
Step 7:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-but-
oxycarbonyl)amino)methyl)-5-methyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazet-
idine-1-sulfonic Acid
[0973] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(((tert-butoxycarbonyl)amino)methyl)-5-methyl--
2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxy-
late (140 mg, 0.170 mmol) in DMF (848 .mu.l) at 0.degree. C. was
added SO.sub.3.DMF (54.4 mg, 0.355 mmol). The reaction mixture was
stirred for 2.5 h, whereupon additional SO.sub.3.DMF (27.4 mg,
0.170 mmol) was added. After an additional 22 h the solution was
diluted with EtOAc and poured into the cold LiCl solution (5%, aq).
The layers were separated and the aqueous layer was extracted with
EtOAc (2.times.). The combined organic layers were washed with LiCl
(5% aq), brine, dried over Na.sub.2SO.sub.4 and concentrated in
vacuo to afford 163.1 mg of the crude material which was used in
step 8 without further purification. LCMS: R.sub.t=1.01 min,
m/z=910.5 (M+1) Method 2m_acidic.
Step 8:
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-5-methyl-2H-1,2,3-triazol-
-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2--
oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00198##
[0975] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(((tert-buto-
xycarbonyl)amino)methyl)-5-methyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazeti-
dine-1-sulfonic acid (155 mg, 0.170 mmol), DCM (1.70 mL), anisole
(37 .mu.L, 0.34 mmol) and TFA (0.787 mL, 10.2 mmol). The crude
material was purified by reverse phase preparative HPLC (XSELECT
C18, 5.mu., 30.times.100 mm, ACN-H.sub.2O w/0.1% formic acid
buffer, 60 mL/min), affording the title compound (55 mg, 57%) as an
off-white solid. LCMS: R.sub.t=0.49 min, m/z=544.1 (M+1) Method
2m_acidic_polar. .sup.1H NMR (400 MHz, D.sub.2O) 87.04 (s, 1H),
5.46 (d, J=5.6 Hz, 1H), 4.91-4.84 (m, 1H), 4.84-4.76 (m, 1H),
4.62-4.56 (m, 1H assumed; obscured by solvent residual peak), 4.13
(s, 2H), 2.16 (s, 3H), 1.32-1.18 (m, 2H), 1.18-1.00 (m, 2H).
Example 144:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(3-aminopropyl)guanidino)methyl)-5-methyl--
2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-amino-
thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
[0976] Step 1: tert-Butyl
(3-((tert-butoxycarbonyl)amino)propyl)(((tert-butoxycarbonyl)imino)(1H-py-
razol-1-yl)methyl)carbamate.
[0977] To an ice cold solution of tert-butyl
(((tert-butoxycarbonyl)amino)(1H-pyrazol-1-yl)methylene)carbamate
(500 mg, 1.611 mmol), tert-butyl (3-hydroxypropyl)carbamate (282
mg, 1.611 mmol) and triphenylphosphine (634 mg, 2.417 mmol)
dissolved in THF (16 mL) was added DIAD (470 .mu.l, 2.417 mmol) and
stirred for 16 h. The reaction mixture was concentrated in vacuo
and the crude residue was purified via silica gel chromatography
(EtOAc-Heptane) to afford the title compound (600 mg, 80%). LCMS:
R.sub.t=1.02 min, m/z=468.4 (M+1) Method 2m_acidic.
Step 2:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((Z)-4-(tert-bu-
toxycarbonyl)-3-((tert-butoxycarbonyl)imino)-11,11-dimethyl-9-oxo-10-oxa-2-
,4,8-triazadodecyl)-5-methyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoaz-
etidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
[0978] To a soln of
1-(((Z)-(2-(((2R,3S)-2-((4-(aminomethyl)-5-methyl-2H-1,2,3-triazol-2-yl)m-
ethyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-2-oxoethy-
lidene)amino)oxy)cyclopropanecarboxylic acid (33.9 mg, 0.062 mmol)
and tert-butyl
(3-((tert-butoxycarbonyl)amino)propyl)((tert-butoxycarbonyl)imino)(1H-pyr-
azol-1-yl)methyl)carbamate (54.2 mg, 0.116 mmol) in DMF (624 .mu.l)
at 0.degree. C. was added DIPEA (32.7 .mu.l, 0.187 mmol). After
stirring at rtfor 16 h, the solution was concentrated in vacuo and
used as such without further purification. LCMS: R.sub.t=0.75 min,
m/z=943.7 (M+1) Method 2m_acidic.
Step 3:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(3-aminopropyl)guanidino)methyl)-5--
methyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(-
2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00199##
[0980] Followed the general procedure for the acid mediated
deprotection using
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((Z)-4-(tert-but-
oxycarbonyl)-3-((tert-butoxycarbonyl)imino)-11,11-dimethyl-9-oxo-10-oxa-2,-
4,8-triazadodecyl)-5-methyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoaze-
tidin-3-yl)amino)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
acid (58.5 mg, 0.062 mmol), DCM (621 .mu.L), anisole (20.4 .mu.L,
0.186 mmol) and TFA (427 .mu.L, 4.55 mmol). The reaction mixture
was diluted with ice-cold water (1 mL) and the layers were
separated. The organic layer was extracted with water (1 mL) and
the combined aqueous layers were washed with DCM (1 mL) and then
purified by reverse phase preparative HPLC (XSELECT C18, 5.mu.,
30.times.100 mm, 1-20% ACN/H.sub.2O w/0.1% formic acid buffer over
18 min, 60 mL/min), affording the title compound (19 mg, 44%) as an
off-white solid. LCMS: R.sub.t=0.54 min, m/z=643.2 (M+1) Method
2m_acidic_polar. .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.11 (s,
1H), 5.62 (d, J=5.6 Hz, 1H), 5.01-4.94 (m, 1H), 4.91-4.74 (m, 2H
assumed; obscured by solvent residual peak), 4.50 (br s, 2H), 3.36
(t, J=6.9 Hz, 2H), 3.11 (t, J=7.8 Hz, 2H), 2.29 (s, 3H), 2.01 (p,
J=7.2 Hz, 2H), 1.35-1.25 (m, 2H), 1.21-1.05 (m, 2H).
Example 145:
1-(((Z)-(2-(((2R,3S)-2-((4-(1-(3-(3-aminopropyl)guanidino)ethyl)-2H-1,2,3-
-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol--
4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 1: 1-(2H-1,2,3-triazol-4-yl)ethanol
[0981] To a solution of but-3-yn-2-ol (3.63 g, 50.2 mmol) in DMF
(40 ml) and MeOH (10 ml) was added azidotrimethylsilane (10.22 ml,
75 mmol). The reaction mixture was heated at 100.degree. C. for 16
h. The reaction was cooled and filtered through a celite pad. The
filtrate was concentrated to .about.25 ml and used directly in next
step. LCMS: R.sub.t=0.16 min, m/z=113.8 (M+1) Method
2m_acidic_polar.
Step 2:
4-(1-((tert-butyldiphenylsilyl)oxy)ethyl)-1H-1,2,3-triazole
[0982] To a solution of 1-(1H-1,2,3-triazol-4-yl)ethanol (50.2
mmol) and imidazole (5.13 mg, 75 mmol) in DCM (50 ml) 0.degree. C.
was added TBDPSCI (14.6 mL, 55.2 mmol). After stirring at room
temperature overnight the mixture was filtered through a celite pad
and then concentrated to dryness. The resulting residue was
dissolved in EtOAc, washed with water, brine, dried with sodium
sulfate and concentrated. Purification of the crude residue via
silica gel chromatography (EtOAc-Heptane, 5-25%) afforded the title
compound (8.16 g, 46%) as a yellow oil. LCMS: R.sub.t=1.09 min,
m/z=352.1 (M+1) Method 2m_acidic. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 7.71 (d, J=6.5 Hz, 2H) 7.64-7.54 (m, 3H) 7.49-7.28 (m,
6H) 5.14 (q, J=6.3 Hz, 1H) 1.46 (dd, J=6.3, 3.0 Hz, 3H) 1.08 (s,
9H).
Step 3: Benzyl
((2R,3S)-2-((4-(1-((tert-butyldiphenylsilyl)oxy)ethyl)-2H-1,2,3-triazol-2-
-yl)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carbamate
[0983] To a solution of
4-(1-((tert-butyldiphenylsilyl)oxy)ethyl)-1H-1,2,3-triazole (2.42
g, 6.88 mmol), benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)car-
bamate (2.76 g, 6.88 mmol), and PPh.sub.3 (2.17 mg, 8.26 mmol) in
THF (35 ml) at 0.degree. C. was added DIAD (1.60 ml, 8.26 mmol)
dropwise. The reaction was stirred at room temperature for 5 h then
concentrated in vacuo. Purification of the crude residue via silica
gel chromatography (EtOAc-Heptane, 30-60%) afforded the title
compound (4.32 g, 85%) as a solid. LCMS: R.sub.t=1.12 min, m/z=734
(M+1) Method 2m_acidic.
Step 4: Benzyl
((2R,3S)-2-((4-(1-((tert-butyldiphenylsilyl)oxy)ethyl)-2H-1,2,3-triazol-2-
-yl)methyl)-4-oxoazetidin-3-yl)carbamate
[0984] To a solution of benzyl
((2R,3S)-2-((4-(1-((tert-butyldiphenylsilyl)oxy)ethyl)-2H-1,2,3-triazol-2-
-yl)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carbamate
(2.50 g, 3.41 mmol) in ACN/water (2:1, 45 mL) at room temperature
was added K.sub.2S.sub.2O.sub.8 (1.57 mg, 5.79 mmol) and
K.sub.2HPO.sub.4 (949 mg, 5.45 mmol). The mixture was heated to
90.degree. C. under nitrogen with stirring for 6 h. The reaction
mixture was concentrated in vacuo to remove ACN. To the resulting
slurry was added EtOAc and water. The organic layer was separated
and the aqueous layer was extracted with EtOAc (2.times.). The
organic portions were combined, dried with Na.sub.2SO.sub.4,
filtered and concentrated in vacuo. Purification of the crude
residue via silica gel chromatography (EtOAc-Heptane, 30-60%)
afforded the title compound (1.35 g, 68%). LCMS: R.sub.t=1.18 min,
m/z=584.3 (M+1) Method 2m_acidic.
Step 5: Benzyl
((2R,3S)-2-((4-(1-hydroxyethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetid-
in-3-yl)carbamate
[0985] A mixture of
((2R,3S)-2-((4-(1-((tert-butyldiphenylsilyl)oxy)ethyl)-2H-1,2,3-triazol-2-
-yl)methyl)-4-oxoazetidin-3-yl)carbamate (1.35 g, 2.31 mmol) and
TBAF (1 M in THF, 4.63 ml, 4.63 mmol) in THF (23 ml) was stirred at
room temperature 3 h. The solvent was removed and the residue was
purified via silica gel chromatography (EtOAc-Heptane) to afford
the title compound (450 mg, 56%) as a light yellow solid. LCMS:
R.sub.t=0.53 min, m/z=346.1 (M+1) Method 2m_acidic.
Step 6: tert-Butyl
(1-(2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-
-2H-1,2,3-triazol-4-yl)ethyl)((Z)-((tert-butoxycarbonyl)imino)(1H-pyrazol--
1-yl)methyl)carbamate
[0986] To a solution of benzyl
((2R,3S)-2-((4-(1-hydroxyethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetid-
in-3-yl)carbamate (460 mg, 1.33 mmol), (E)-tert-butyl
(((tert-butoxycarbonyl)imino)(1H-pyrazol-1-yl)methyl)carbamate (455
mg, 1.465 mmol), and triphenylphosphine (419 mg, 1.60 mmol) in THF
(7 ml) at 0.degree. C. was added DIAD (0.311 ml, 1.598 mmol)
dropwise. The reaction was stirred at room temperature overnight
and concentrated to dryness. Purification of the crude residue via
silica gel chromatography (EtOAc-Heptane, 30-60%) afforded the
title compound (190 mg, 22%) as a light yellow solid. LCMS:
R.sub.t=0.99 min, m/z=638.4 (M+1) Method 2m_acidic.
Step 7
[0987] A mixture of tert-butyl
(1-(2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-
-2H-1,2,3-triazol-4-yl)ethyl)((Z)-((tert-butoxycarbonyl)imino)(1H-pyrazol--
1-yl)methyl)carbamate (190 mg, 0.298 mmol) and tert-butyl
(3-aminopropyl)carbamate (57.1 mg, 0.328 mmol) in ACN (1490 .mu.l)
was stirred at room temperature for 16 h. The solvent was then
removed in vacuo and the crude residue was purified via silica gel
chromatography (EtOAc-Heptane, 50-80%), affording the desired
compound (100 mg, 45%). LCMS: R.sub.t=0.91 min, m/z=744.5 (M+1)
Method 2m_acidic.
Step 8
[0988] A mixture of the product obtained from step 7 (100 mg, 0.134
mmol) and 10% Pd--C (30 mg, 0.134 mmol) in EtOH (2 ml) and MeOH (1
ml) was stirred under hydrogen for 4 h. Palladium was filtered off
through a celite pad and the solvent was removed to give the crude
material which was used in step 9 without further purification.
LCMS: R.sub.t=0.68 min, m/z=610.4 (M+1) Method 2m_acidic.
Step 9: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((E)-3-(tert-butoxycarbonyl)-4-((tert-butoxyca-
rbonyl)imino)-12,12-dimethyl-10-oxo-11-oxa-3,5,9-triazatridecan-2-yl)-2H-1-
,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarb-
onyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
[0989] To a solution of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (76 mg, 0.13 mmol) and
DIPEA (35.1 .mu.l, 0.201 mmol) in DCM/DMF (2:1, 1.34 mL) at
0.degree. C. was added HATU (61.1 mg, 0.161 mmol). This mixture was
stirred at 0.degree. C. for 30 min. To this was added the product
obtained from step 8 (82 mg, 0.13 mmol). The reaction mixture was
stirred at 0.degree. C. for 30 min then diluted with EtOAc (60 ml),
washed with saturated aqueous Na.sub.2CO.sub.3, brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. Purification of the
crude residue via silica gel chromatography (EtOAc-Heptane, 40-60%)
afforded the title compound (150 mg, 99%) as a light yellow solid.
LCMS: R.sub.t=1.12 min, m/z=1129.8 (M+1) Method 2m_acidic.
Step 10:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-
-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((E)-3-(te-
rt-butoxycarbonyl)-4-((tert-butoxycarbonyl)imino)-12,12-dimethyl-10-oxo-11-
-oxa-3,5,9-triazatridecan-2-yl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidi-
ne-1-sulfonic acid
[0990] To a solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((E)-3-(tert-butoxycarbonyl)-4-((tert-butoxyca-
rbonyl)imino)-12,12-dimethyl-10-oxo-11-oxa-3,5,9-triazatridecan-2-yl)-2H-1-
,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarb-
onyl)amino)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
(150 mg, 0.133 mmol) in DMF (1 ml) at 0.degree. C. was added
SO.sub.3.DMF complex (203 mg, 1.33 mmol). After stirring at rt for
2.5 h the solution was diluted with EtOAc, washed cold brine, dried
with Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The
crude residue was used as such in step 11. LCMS: R.sub.t=1.15 min,
m/z=1210.5 (M+1) Method 2m_acidic.
Step 11:
1-(((Z)-(2-(((2R,3S)-2-((4-(1-(3-(3-aminopropyl)guanidino)ethyl)--
2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-amino-
thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00200##
[0992] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((E)-3-(tert-
-butoxycarbonyl)-4-((tert-butoxycarbonyl)imino)-12,12-dimethyl-10-oxo-11-o-
xa-3,5,9-triazatridecan-2-yl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-
-1-sulfonic acid (0.133 mmol), TFA (410 .mu.l, 5.32 mmol) anisole
(29 .mu.L, 0.27 mmol) and DCM (1.33 mL). The reaction mixture was
cooled to 0.degree. C. and diluted with DCM and ice water,
Whereupon the layers were separated. The aqueous layer was purified
by reverse phase preparative HPLC (XSELECT, C18 5 um 30.times.100
mm; ACN-water with 0.1% formic acid), affording the title compound
(34 mg, 39%) as a white powder. LCMS: R.sub.t=0.52 min, m/z=643.2
(M+1) Method 2m_acidic_polar. .sup.1H NMR (400 MHz, D.sub.2O,
reported as a 1:1 mixture of diastereomers) .delta. 7.79 (s, 1H)
7.77 (s, 1H), 7.12 (s, 1H), 7.12 (s, 1H), 5.64 (d, J=5.6 Hz, 1H),
5.61 (d, J=5.6 Hz, 1H), 5.05-4.73 (m, 8H assumed; partially
obscured by solvent residual peak), 3.39-3.32 (m, 4H), 3.13-3.05
(m, 4H), 2.00 (p, J=7.0 Hz, 4H), 1.64 (d, J=3.6 Hz, 3H), 1.63 (d,
J=3.7 Hz, 3H), 1.37-1.28 (m, 4H), 1.21-1.12 (m, 4H).
Example 146:
1-(((Z)-(2-(((2R,3S)-2-((4-((S)-1-((3-aminopropyl)amino)ethyl)-2H-1,2,3-t-
riazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4--
yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
[0993] Step 1: (R)-But-3-yn-2-yl methanesulfonate. To a solution of
R-(+)-3-butyn-2-ol (1000 mg, 14.27 mmol) and DIPEA (3.72 ml, 21.4
mmol) in DCM (50 ml) at 0.degree. C. was added methanesulfonyl
chloride (1.44 mL, 18.6 mmol). The mixture was stirred at 0.degree.
C. for 2 h then diluted with DCM, washed with HCl (0.2 N, aq)
followed by saturated NaHCO.sub.3 (aq). The organic layer was dried
over Na.sub.2SO.sub.4 and concentrated in vacuo, providing the
title compound (2.093 g, 99%) as a light orange oil. .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 5.28 (m, J=6.7, 2.1 Hz, 1H) 3.12
(s, 3H) 2.71 (d, J=2.2 Hz, 1H) 1.66 (d, J=6.7 Hz, 3H).
Step 2: (S)-tert-Butyl (3-(but-3-yn-2-ylamino)propyl)carbamate
[0994] A solution of (R)-but-3-yn-2-yl methanesulfonate (2189 mg,
14.77 mmol) in ACN (10 ml) was added dropwise to a suspension of
tert-butyl (3-aminopropyl)carbamate (2831 mg, 16.25 mmol) and
potassium carbonate (2446 mg, 17.72 mmol) in ACN (50 ml). The
reaction mixture was stirred at room temperature for 24 h,
whereupon the slurry was filtered and the filtrate was concentrated
in vacuo. The crude residue was purified via silica gel
chromatography (MeOH-DCM, 0-8%) to afford the title compound (570
mg, 17%) as a light orange oil. LCMS: R.sub.t=0.43 min, m/z=227.0
(M+1) Method 2m_acidic.
Step 3: (S)-tert-Butyl
but-3-yn-2-yl(3-((tert-butoxycarbonyl)amino)propyl)carbamate
[0995] A mixture of (S)-tert-butyl
(3-(but-3-yn-2-ylamino)propyl)carbamate (570 mg, 2.52 mmol),
di-tert-butyl dicarbonate (1.10 g, 5.04 mmol) and saturated
NaHCO.sub.3 (aq, 17 mL) in DCM (16.8 mL) was stirred at rt for 16
h, whereupon the two layers were separated and the organic layer
was dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
Purification via silica gel chromatography (MeOH-DCM, 0-5%)
afforded the title compound (710 mg, 86%) as a vicsous oil. LCMS:
R.sub.t=0.99 min, m/z=327.1 (M+1) Method 2m_acidic.
Step 4: (S)-tert-butyl
(1-(2H-1,2,3-triazol-4-yl)ethyl)(3-((tert-butoxycarbonyl)amino)propyl)car-
bamate
[0996] A mixture of (S)-tert-butyl
but-3-yn-2-yl(3-((tert-butoxycarbonyl)amino)propyl)carbamate (710
mg, 2.18 mmol), azidotrimethylsilane (452 .mu.l, 3.26 mmol) and
copper (1) iodide (21 mg, 0.11 mmol) in DMF/MeOH (1:1, 3.4 mL) was
heated to 100.degree. C. for 8 h. Upon cooling, the mixture was
filtered through a celite pad, and the filtrate was concentrated in
vacuo and purified via silica gel chromatography (EtOAc-Heptane,
30-80%) to afford the title compound (636 mg, 79%) as an oil. LCMS:
R.sub.t=0.78 min, m/z=370.1 (M+1) Method 2m_acidic.
Step 5
[0997] To a solution of (S)-tert-butyl
(1-(1H-1,2,3-triazol-4-yl)ethyl)(3-((tert-butoxycarbonyl)amino)propyl)car-
bamate (636 mg, 1.72 mmol), benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)car-
bamate (689 mg, 1.72 mmol) and triphenylphosphine (542 mg, 2.07
mmol) in THF (8.6 mL) at 0.degree. C. was added DIAD (402 .mu.l,
2.07 mmol), drop-wise. After stirring at rt for 5h the mixture was
concentrated in vacuo. Purification via silica gel chromatography
(EtOAc-Heptane, 30-60%) afforded the desired compound (970 mg, 75%)
as a white solid. LCMS: R.sub.t=1.08 min, m/z=752.1 (M+1) Method
2m_acidic.
Step 6
[0998] A mixture of the product obtained step 5 (970 mg, 1.29
mmol), K.sub.2S.sub.2O.sub.8 (611 mg, 2.19 mmol) and
K.sub.2HPO.sub.4 (360 mg, 2.06 mmol) in ACN/water (2:1, 15 mL) was
heated to 90.degree. C. under nitrogen with for 4 h. The reaction
mixture was concentrated in vacuo to remove ACN. The mixture was
partitioned between EtOAc/water and the layers were separated. The
aqueous layer was extracted with EtOAc and the combined organic
portions were dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. Purification via silica gel chromatography
(EtOAc-Heptane, 50-100%) afforded the desired compound (443 mg,
57%). LCMS: R.sub.t=0.95 min, m/z=602.4 (M+1) Method 2m_acidic.
Step 7: tert-Butyl
((S)-1-(2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-
-yl)ethyl)(3-((tert-butoxycarbonyl)amino)propyl)carbamate
[0999] A mixture of the product obtained from step 6 (443 mg, 0.736
mmol) and 10% Pd/C (100 mg) in EtOH/MeOH (2:1, 15 mL) was stirred
under hydrogen for 4 h, whereupon the mixture was filtered over
celite and the solvent was removed in vacuo to give the title
compound (assumed quantitative) which was used directly without
further purification. LCMS: R.sub.t=0.68 min, m/z=468.3 (M+1)
Method 2m_acidic.
Step 8: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((S)-1-((tert-butoxycarbonyl)(3-((tert-butoxyc-
arbonyl)amino)propyl)amino)ethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazeti-
din-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethyli-
dene)amino)oxy)cyclopropanecarboxylate
[1000] To a mixture of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (416 mg, 0.736 mmol),
tert-butyl
((S)-1-(2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-
-yl)ethyl)(3-((tert-butoxycarbonyl)amino)propyl)carbamate (0.736
mmol) and DIPEA (193 .mu.l, 1.10 mmol) in DCM/DMF (5:1, 7.3 mL) at
0.degree. C. was added HATU (308 mg, 0.810 mmol). After stirring at
0.degree. C. for 1 h it was diluted with EtOAc, washed with water,
brine, dried over sodium sulfate and concentrated in vacuo.
Purification via silica gel chromatography (EtOAc-Heptane, 50-90%)
afforded the desired compound (700 mg, 96%) as a red solid. LCMS:
R.sub.t=1.17 min, m/z=987.7 (M+1) Method 2m_acidic. Chiral SFC
analysis (SFC-X5, CO.sub.2/EtOH=90/10, SFC=5 ml/min, AD column,
Rt=12.28 min) confirmed it was a single diastereomer.
Step 9:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((S)-1-((te-
rt-butoxycarbonyl)(3-((tert-butoxycarbonyl)amino)propyl)amino)ethyl)-2H-1,-
2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic Acid
[1001] To benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-((S)-1-((tert-butoxycarbonyl)(3-((tert-butoxyc-
arbonyl)amino)propyl)amino)ethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazeti-
din-3-yl)amino)-1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxoethyli-
dene)amino)oxy)cyclopropanecarboxylate (700 mg, 0.709 mmol) in DMF
(3.5 ml) at 0.degree. C. was added SO.sub.3.DMF (760 mg, 4.96
mmol). The reaction mixture was stirred at room temperature for 2
h, whereupon additional 3 equiv of SO.sub.3.DMF was added and
stirred for another 2 h. The reaction mixture was diluted with
EtOAc, washed with LiCl (5%, aq, 2.times.), brine, dried with
Na.sub.2SO.sub.4, filtered and concentrated in vacuo to give the
title compound (assumed quantitative) which was used as such
without further purification. LCMS: R.sub.t=1.07 min, m/z=1067.6
(M+1) Method 2m_acidic.
Step 10:
1-(((Z)-(2-(((2R,3S)-2-((4-((S)-1-((3-aminopropyl)amino)ethyl)-2H-
-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminoth-
iazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00201##
[1003] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-((S)-1-((ter-
t-butoxycarbonyl)(3-((tert-butoxycarbonyl)amino)propyl)amino)ethyl)-2H-1,2-
,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfonic acid (0.709
mmol), anisole (153 mg, 1.42 mmol), TFA (273 .mu.l, 35.5 mmol) and
DCM (7.1 mL). The reaction mixture was cooled to 0.degree. C. and
diluted with DCM and ice water. After vigorous stirring the two
layers were separated and aqueous layer was purified by reverse
phase prepatory HPLC (XSELECT, C18, 5 um 30.times.100 mm ACN-water
with with 0.1 formic acid), affording title compound (110 mg, 25%)
as a white solid. LCMS: R.sub.t=0.50 min, m/z=601.3 (M+1) Method
2m_acidic_polar; .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.87 (s,
1H) 7.04 (s, 1H) 5.61 (d, J=5.6 Hz, 1H) 5.04-4.97 (m, 1H) 4.89 (d,
J=5.4 Hz, 2H) 4.69-4.62 (m, 1H) 3.13-3.00 (m, 4H) 2.04 (t, J=4.0
Hz, 2H) 1.68 (d, J=6.9 Hz, 3H) 1.23 (t, J=3.9 Hz, 2H) 1.11-1.02 (m,
2H).
Example 147:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(2-(2-aminoethoxy)ethyl)guanidino)methyl)--
2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-amino-
thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00202##
[1005] Prepared in analogous manner to example 119, using
tert-butyl
(2-(2-((imino(methylthio)methyl)amino)ethoxy)ethyl)carbamate. LCMS:
R.sub.t=0.31 min, m/z=659.0 (M+1) Method 2m_acidic. .sup.1H NMR
(500 MHz, D.sub.2O) .delta. ppm 7.61 (s, 1H), 6.99 (s, 1H), 5.47
(d, J=5.7 Hz, 1H), 4.87 (q, J=5.6 Hz, 1H), 4.81-4.70 (m, 2H
assumed; partially obscured by solvent residual peak), 4.42 (s,
2H), 3.66-3.54 (m, 4H), 3.32 (t, J=5.0 Hz, 2H), 3.13-3.06 (m, 2H),
1.28-0.93 (m, 4H).
Example 148:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(3-aminopropyl)-1-methylguanidino)methyl)--
2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-amino-
thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
acid
Step 1: tert-Butyl
(3-((tert-butoxycarbonyl)amino)propyl)(((tert-butoxycarbonyl)imino)(1H-py-
razol-1-yl)methyl)carbamate
[1006] To an ice-cold solution of tert-butyl
(((tert-butoxycarbonyl)amino)(1H-pyrazol-1-yl)methylene)carbamate
(500 mg, 1.61 mmol), tert-butyl (3-hydroxypropyl)carbamate (282 mg,
1.611 mmol) and triphenylphosphine (634 mg, 2.42 mmol) in THF (16
mL) was added DIAD (470 .mu.l, 2.42 mmol). The mixture was stirred
at room temperature for 16 h, whereupon the volatiles were removed
in vacuo. Purification via silica gel chromatography
(EtOAc-Heptane, 0-100%) afforded the title compound (600 mg, 80%).
LCMS: R.sub.t=1.02 min, m/z=468.4 (M+1) Method 2m_acidic.
Step 2: Benzyl
((2R,3S)-2-((4-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)ca-
rbamate
[1007] A mixture of benzyl
((2R,3S)-2-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidi-
n-3-yl)carbamate (360 mg, 1.09 mmol) and MnO.sub.2 (2.36 g, 27.2
mmol) in THF (11 mL) was stirred at room temperature for 2 h,
whereupon the mixture was filtered through celite and concentrated.
The resulting material (340 mg, 95%) was used as such in step
3.
Step 3: Benzyl
((2R,3S)-2-((4-((methylamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoa-
zetidin-3-yl)carbamate
[1008] To a solution of benzyl
((2R,3S)-2-((4-formyl-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)ca-
rbamate (340 mg, 1.03 mmol) in DCE (10 mL) was added MeNH.sub.2
(1032 .mu.l, 2.065 mmol). After stirring for 1 h at rt, sodium
triacetoxyborohydride (438 mg, 2.07 mmol) was added and the mixture
was stirred overnight, whereupon it was quenched with saturated
NaHCO.sub.3 (aq) at 0.degree. C. and extracted with EtOAc
(2.times.). The organic extracts were combined, washed with brine,
dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo.
The resulting crude material (assumed quantitative) was used as
such in step 4.
Step 4
[1009] A solution of benzyl
((2R,3S)-2-((4-((methylamino)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoa-
zetidin-3-yl)carbamate (93 mg, 0.27 mmol), tert-butyl
(3-((tert-butoxycarbonyl)amino)propyl)(((tert-butoxycarbonyl)imino)(1H-py-
razol-1-yl)methyl)carbamate (152 mg, 0.324 mmol), DIPEA (94 .mu.l,
0.540 mmol) in ACN (1800 .mu.l) was heated to 90.degree. C.
overnight. All volatiles were removed in vacuo and purification of
the crude residue via silica gel chromatography (EtOAc-Heptane)
afforded the desired product. LCMS: R.sub.t=0.94 min, m/z=744.6
(M+1) Method 2m_acidic.
Step 5
[1010] A mixture of the product from step 4 (46 mg, 0.062 mmol) and
Pd on C (10% wt, 23 mg) in EtOH/MeOH (4:1, 620 .mu.L) was stirred
under hydrogen for 16 h. The reaction mixture was filtered through
a celite pad and concentrated and the resulting material (assumed
quantitative) was used as such without further purification.
Step 6: Benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(4-(tert-butoxycarbonyl)-3-((tert-butoxycarbon-
yl)imino)-2,11,11-trimethyl-9-oxo-10-oxa-2,4,8-triazadodecyl)-2H-1,2,3-tri-
azol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
[1011] A solution of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (30.9 mg, 0.057 mmol),
DIPEA (30.1 .mu.l, 0.172 mmol) and HATU (26.2 mg, 0.069 mmol) in
DCM/DMF (1:1, 574 .mu.l) was stirred for 20 min, whereupon the
product from step 5 (35 mg, 0.057 mmol) was added. The resulting
mixture was stirred for and additional 2 h, at which point the
volatiles were removed in vacuo and the material was diluted with
EtOAc, washed with brine, dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. Purification via silica gel chromatography
(EtOAc-Heptane) afforded the title compound. LCMS: R.sub.t=1.11
min, m/z=1029.9 (M+1) Method 2m_acidic.
Step 7:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(4-(tert-bu-
toxycarbonyl)-3-((tert-butoxycarbonyl)imino)-2,11,11-trimethyl-9-oxo-1-oxa-
-2,4,8-triazadodecyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfo-
nic Acid
[1012] To an ice-cold solution of benzhydryl
1-(((Z)-(2-(((2R,3S)-2-((4-(4-(tert-butoxycarbonyl)-3-((tert-butoxycarbon-
yl)imino)-2,11,11-trimethyl-9-oxo-10-oxa-2,4,8-triazadodecyl)-2H-1,2,3-tri-
azol-2-yl)methyl)-4-oxoazetidin-3-yl)amino)-1-(2-((tert-butoxycarbonyl)ami-
no)thiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylate
(32 mg, 0.028 mmol) in DMF (283 .mu.l) was added SO.sub.3.DMF (43.4
mg, 0.283 mmol). After stirring for 2 h, the reaction mixture was
diluted with EtOAc, washed with brine, dried over Na.sub.2SO.sub.4
and concentrated in vacuo. This crude residue was used in the next
step without further purification.
Step 8:
1-(((Z)-(2-(((2R,3S)-2-((4-((3-(3-aminopropyl)-1-methylguanidino)m-
ethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(-
2-aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00203##
[1014] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-
-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((4-(4-(tert-but-
oxycarbonyl)-3-((tert-butoxycarbonyl)imino)-2,11,11-trimethyl-9-oxo-10-oxa-
-2,4,8-triazadodecyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidine-1-sulfo-
nic acid (27 mg, 0.022 mmol), TFA (103 .mu.l, 1.34 mmol) and DCM
(223 .mu.l). The crude material was purified by reverse phase
preparative HPLC (XSELECT C18, 5.mu., 30.times.100 mm, ACN/H.sub.2O
w/0.1% formic acid buffer), affording the title compound (1.1 mg,
7%) as a white solid. LCMS: R.sub.t=0.32 min, m/z=643.3 (M+1)
Method 2m_acidic. .sup.1H NMR (500 MHz, D.sub.2O) .delta. ppm 7.65
(s, 1H) 7.00 (s, 1H) 5.48 (d, J=5.7 Hz, 1H) 4.89-4.83 (m, 1H)
4.60-4.45 (m, 2H) 3.25 (td, J=6.9, 3.6 Hz, 2H) 2.95 (t, J=7.7 Hz,
2H) 2.91 (s, 3H) 1.98-1.74 (m, 2H) 1.23-1.10 (m, 2H) 1.05-1.00 (m,
2H).
Example 149:
1-(((Z)-(2-(((2R,3S)-2-((4-(((3-(aminomethyl)azetidine-1-carbonyl)oxy)met-
hyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2--
aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00204##
[1016] Prepared in an analogous manner to example 126 using
(2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-2H-
-1,2,3-triazol-4-yl)methyl
3-(((tert-butoxycarbonyl)amino)methyl)azetidine-1-carboxylate in
step 2. LCMS: R.sub.t=0.52 min, m/z=643.2 (M+1) Method
2m_acidic_polar. .sup.1H NMR (400 MHz, D.sub.2O) .delta. 7.83 (s,
1H), 7.11 (s, 1H), 5.61 (d, J=5.3 Hz, 1H), 5.25-5.16 (m, 2H),
5.08-4.97 (m, 2H), 4.93-4.86 (m, 1H assumed; partially obscured by
the solvent residual peak), 4.22 (t, J=8.6 Hz, 2H), 3.89-3.77 (m,
2H), 3.32 (d, J=7.6 Hz, 2H), 3.07-2.95 (m, 1H), 1.49-1.37 (m, 2H),
1.34-1.19 (m, 2H).
[1017] Preparation of
(2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-2H-
-1,2,3-triazol-4-yl)methyl
3-(((tert-butoxycarbonyl)amino)methyl)azetidine-1-carboxylate.
Prepared in an anologous manner as example 4, step 2 using
(2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-oxo-
azetidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl
3-(((tert-butoxycarbonyl)amino)methyl)azetidine-1-carboxylate (410
mg, 0.591 mmol), K.sub.2S.sub.2O.sub.8 (272 mg, 1.01 mmol) and
K.sub.2HPO.sub.4 (165 mg, 0.946 mmol) in ACN:water (2:1, 7.2 mL)
while heating for 5 h at 90.degree. C. The crude residue was
purified via silica gel chromatography (EtOAc-Heptane, 30-90%),
affording the title compound (80 mg, 25%) as a solid. LCMS:
R.sub.t=0.78 min, m/z=544.2 (M+1) Method 2m_acidic.
[1018] Preparation of
(2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-oxo-
azetidin-2-yl)methyl)-2H-1,2,3-triazol-4-yl)methyl
3-(((tert-butoxycarbonyl)amino)methyl)azetidine-1-carboxylate. A 20
mL scintillation vial was charged with benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-
-yl)methyl)-4-oxoazetidin-3-yl)carbamate (660 mg, 1.37 mmol,
obtained as a by-product during the preparation of intermediate V),
CDI (252 mg, 1.51 mmol) and DCM (11.4 mL). After stirring for 2 h,
tert-butyl (azetidin-3-ylmethyl)carbamate (383 mg, 2.06 mmol) was
added and it was stirred for an additional 16 h. The mixture was
concentrated in vacuo and purified via silica gel chromatography
(EtOAc-Heptane, 40-90%), affording the title compound (410 mg, 43%)
as a solid. R.sub.t=0.94 min, m/z=694.3 (M+1) Method 2m_acidic.
Example 150:
1-(((Z)-(2-(((2R,3S)-2-((4-(((S)-3-aminopyrrolidine-1-carboximidamido)met-
hyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2--
aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00205##
[1020] Prepared in an anologous manner to example 127 using
(S)-tert-butyl pyrrolidin-3-ylcarbamate in step 3. R.sub.t=0.25
min, m/z=641.4 (M+1) Method 2m_acidic. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.55-10.15 (m, 1H), 8.06-7.78 (m, 1H), 7.66
(d, J=1.4 Hz, 1H), 7.59 (br s, 2H), 7.20 (s, 2H), 6.74 (d, J=3.9
Hz, 1H), 5.23 (ddd, J=14.6, 8.8, 5.5 Hz, 1H), 4.90 (dt, J=13.8, 3.7
Hz, 1H), 4.71-4.60 (m, 1H), 4.59-4.35 (m, 3H), 3.90 (br s, 1H),
3.70-3.38 (m, 3H assumed; overlaps with water peak), 2.30-2.15 (m,
1H), 2.09-1.98 (m, 1H), 1.30-1.13 (m, 2H), 1.13-0.98 (m, 2H).
Example 151:
1-(((Z)-(2-(((2R,3S)-2-((4-(1-((3-aminopropyl)amino)ethyl)-2H-1,2,3-triaz-
ol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)--
2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00206##
[1022] Prepared in an analogous manner to example 146 using
3-bromobut-1-yne in step 2. LCMS: R.sub.t=0.50 min, m/z=601.2 (M+1)
Method 2m_acidic_polar. .sup.1H NMR (400 MHz, D.sub.2O, reported as
a 1.3:1 mixture of diastereomers) .delta. 7.94 (s, 0.75H), 7.90 (s,
1H), 5.69 (d, J=5.6 Hz, 0.75H), 5.64 (d, J=5.6 Hz, 1H), 5.08 (q,
J=5.5 Hz, 1.8H), 4.97 (q, J=9.3, 7.7 Hz, 3.9H), 4.76-4.68 (m, 1.7H
assumed; partially obscured by solvent residual peak), 3.24-3.02
(m, 7.5H), 2.21-2.02 (m, 3.8H), 1.76 (d, J=7.0 Hz, 2.35H), 1.73 (d,
J=6.9 Hz, 3.1H), 1.41-1.21 (m, 4.9H), 1.20-1.08 (m, 2.5H).
Example 152:
1-(((Z)-(2-(((2R,3S)-2-((4-(((2-aminoethyl)sulfonyl)methyl)-2H-1,2,3-tria-
zol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazol-4-yl)-
-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 1:
(2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)met-
hyl)-2H-1,2,3-triazol-4-yl)methyl methanesulfonate
[1023] To a solution of benzyl
((2R,3S)-2-((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidi-
n-3-yl)carbamate (100 mg, 0.302 mmol, obtained during the
preparation of intermediate V) in DCM (3.0 mL) at 0.degree. C. was
added TEA (84 .mu.L, 0.60 mmol) followed by methanesulfonyl
chloride (28.2 .mu.L, 0.362 mmol). After stirring at rt for 2 h,
the solution was diluted with DCM, washed with saturated
NaHCO.sub.3 (aq), brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude residue was used with no
additional purification. LCMS: R.sub.t=0.66 min, m/z=410.2 (M+1)
Method 2m_acidic.
Step 2
[1024] Prepared in an anologous manner to example 138, step 1 using
the product from step 1 (525 mg, 1.28 mmol), tert-butyl
(2-mercaptoethyl)carbamate (273 mg, 1.53 mmol), sodium iodide (192
mg, 1.28 mmol) and cesium carbonate (836 mg, 2.56 mmol) in DMF
(12.8 mL). The crude residue was purified via silica gel
chromatography (EtOAc-Heptane) to afford the product (190 mg, 30%).
LCMS: R.sub.t=0.80 min, m/z=491.2 (M+1) Method 2m_acidic.
Step 3
[1025] To a solution of the product (190 mg, 0.387 mmol) from step
2 in DCM (3.9 mL) at 0.degree. C. was added m-CPBA (147 mg, 0.852
mmol). After stirring for 1 h, it was partioned between water/DCM.
The aqueous layer was extracted with DCM and the combined organic
layers were dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
The crude residue was purified via silica gel chromatography
(EtOAc-Heptane), affording the product (148 mg, 73%). LCMS:
R.sub.t=0.72 min, m/z=523.2 (M+1) Method 2m_acidic.
Step 4:
1-(((Z)-(2-(((2R,3S)-2-((4-(((2-aminoethyl)sulfonyl)methyl)-2H-1,2-
,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2-aminothiazo-
l-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00207##
[1027] Prepared in an analogous manner to example 4, steps 3-6.
LCMS: R.sub.t=0.31 min, m/z=622.1 (M+1) Method 2m_acidic. .sup.1H
NMR (500 MHz, D.sub.2O) .delta. 7.90 (s, 1H), 7.15 (s, 1H), 5.59
(d, J=5.7 Hz, 1H), 5.03 (q, J=5.6 Hz, 1H), 4.91 (d, J=5.6 Hz, 2H),
4.78 (s, 2H assumed; obscured by solvent residual peak), 3.63-3.58
(m, 2H), 3.54-3.50 (m, 2H), 1.41-1.33 (m, 2H), 1.24 (t, J=3.2 Hz,
2H).
Example 153:
1-(((Z)-(2-(((2R,3S)-2-((4-(((R)-3-aminopyrrolidine-1-carboximidamido)met-
hyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-1-(2--
aminothiazol-4-yl)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic
Acid
##STR00208##
[1029] Prepared in an analogous manner to example 127 using
(R)-tert-butyl pyrrolidin-3-ylcarbamate in step 3. R.sub.t=0.30
min, m/z=641.4 (M+1) Method 2m_acidic. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.51-9.87 (m, 1H), 8.07-7.75 (m, 1H), 7.66
(s, 1H), 7.59 (br s, 2H), 7.20 (s, 2H), 6.73 (d, J=5.6 Hz, 1H),
5.22 (ddd, J=15.1, 8.8, 5.4 Hz, 1H), 4.94-4.85 (m, 1H), 4.70-4.59
(m, 1H), 4.59-4.36 (m, 3H), 3.97-3.83 (m, 1H), 3.70-3.38 (m, 3H
assumed; overlaps with water peak), 2.29-2.17 (m, 1H), 2.08-1.98
(m, 1H), 1.27-1.15 (m, 2H), 1.13-1.01 (m, 2H).
Example 154:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((5,6-dihydropyrrolo[3,4-d-
][1,2,3]triazol-2(4H)-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoet-
hylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 1: tert-Butyl((4-chlorobut-2-yn-1-yl)oxy)diphenylsilane
[1030] To a solution of imidazole (691 mg, 10.2 mmol) and
tert-butylchlorodiphenylsilane (2.65 ml, 10.1 mmol) in DCM (15.3
mL) at 0.degree. C. was added 4-chlorobut-2-yn-1-ol (824 .mu.L,
9.18 mmol). After 2 h of stirring at rt it was diluted with
DCM/water and the layers were separated. The aqueous layer was
extracted with DCM (2.times.) and the combined organic layers were
washed with brine, dried over Na.sub.2SO.sub.4 and concentrated in
vacuo. The crude residue dissolved in dioxane and reconcentrated
(2.times.) then used directly without further purification.
Step 2:
5-(azidomethyl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1H-1,2,3--
triazole
[1031] To a solution of
tert-butyl((4-chlorobut-2-yn-1-yl)oxy)diphenylsilane (3.15 g, 9.18
mmol) in dioxane/water (46 mL, 3:1) was added ammonium chloride
(982 mg, 18.4 mmol) followed by sodium azide (2.39 g, 36.8 mmol).
The biphasic solution was heated to 75.degree. C. for 33 h,
whereupon the layers were separated and the aqueous was extracted
with EtOAc (3.times.20 mL). The combined organic layers were washed
with water, brine, dried over Na.sub.2SO.sub.4 and concentrated in
vacuo. The crude residue was purified via silica gel chromatography
(EtOAc-Heptane, 0-35%) to afford the title compound (1.692 g, 47%)
as a white solid. R.sub.t=1.11 min, m/z=393.2 (M+1) Method
2m_acidic. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 11.54 (s, 1H),
7.71-7.63 (m, 4H), 7.49-7.36 (m, 6H), 4.87 (s, 2H), 4.46 (s, 2H),
1.58 (s, 2H), 1.07 (s, 9H).
Step 3: tert-butyl
((4-(((tert-butyldiphenylsilyl)oxy)methyl)-1H-1,2,3-triazol-5-yl)methyl)c-
arbamate
[1032] A flask was charged with
5-(azidomethyl)-4-(((tert-butyldiphenylsilyl)oxy)methyl)-1H-1,2,3-triazol-
e (1.044 g, 2.420 mmol), Boc-anhydride (581 mg, 2.66 mmol) and
Pd--C (5%, 200 mg). After flushing the system with N.sub.2, EtOH
(24.2 ml) was added. The mixture was then evacuated and recharged
with H.sub.2 (3.times.). After vigorously stirring for 17 h the
system was purged with N.sub.2 and the slurry was filtered over
celite and concentrated in vacuo. The crude residue was purified
via silica gel chromatography (EtOAc-Heptane, 0-50%) to afford the
title compound (777 mg, 69%) as a white solid. R.sub.t=1.12 min,
m/z=467.1 (M+1) Method 2m_acidic. .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta. 7.71-7.64 (m, 4H), 7.49-7.36 (m, 6H), 4.87 (s, 2H), 4.40
(br s, 2H), 1.43 (s, 9H), 1.08 (s, 9H).
Step 4
[1033] To a solution of benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)car-
bamate (674 mg, 1.68 mmol), tert-butyl
((4-(((tert-butyldiphenylsilyl)oxy)methyl)-1H-1,2,3-triazol-5-yl)methyl)c-
arbamate (777 mg, 1.67 mmol) and triphenylphosphine (525 mg, 2.00
mmol) in THF (16.7 mL) at 0.degree. C. was added DIAD (414 .mu.L,
1.10 mmol), drop-wise. After stirring at rt for 11 h, the mixture
was concentrated onto silica gel and purified via silica gel
chromatography (EtOAc-Heptane, 0-50%) to afford the product (1.196
g, 85%) as a white solid. R.sub.t=1.31 min, m/z=849.4 (M+1) Method
2m_acidic.
Step 5: Benzyl
((2R,3S)-2-((4-(aminomethyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2H--
1,2,3-triazol-2-yl)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carb-
amate
[1034] To a solution of the product from step 4 (265 mg, 0.312
mmol) in DCM (3.1 mL) at 0.degree. C. was added TFA (721 .mu.L,
9.36 mmol). After stirring at 0.degree. C. for 3 h it was diluted
with DCE and concentrated in vacuo. The residue was redisolved in
DCM and washed with saturated NaHCO.sub.3 (aq). The aqueous layer
was extracted with DCM (3.times.) and the combined organic layers
were dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The
crude residue was used as such without further purification.
R.sub.t=1.03 min, m/z=749.4 (M+1) Method 2m_acidic.
Step 6: Benzyl
((2R,3S)-2-((4-(((tert-butyldiphenylsilyl)oxy)methyl)-5-((2-nitrophenylsu-
lfonamido)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-(2,4-dimethoxybenzyl)-4--
oxoazetidin-3-yl)carbamate
[1035] To a solution of benzyl
((2R,3S)-2-((4-(aminomethyl)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2H--
1,2,3-triazol-2-yl)methyl)-1-(2,4-dimethoxybenzyl)-4-oxoazetidin-3-yl)carb-
amate (234 mg, 0.312 mmol) in DCM (3.1 mL) at 0.degree. C. was
added 2-nitrobenzene-1-sulfonyl chloride (77.2 mg, 0.338 mmol)
followed by TEA (87 .mu.L, 0.62 mmol). After 2.2 h of stirring at
rt, it was diluted with DCM and washed with KHSO.sub.4 (2%, aq).
The aqueous layer was extracted with DCM (3.times.) and the
combined organic layers were washed with brine, dried over
Na.sub.2SO.sub.4 and concd in vacuo. The crude residue was purified
via silica gel chromatography (EtOAc-Heptane, 0-60%), affording the
title compound (252 mg, 87%) as an off-white solid. R.sub.t=1.24
min, m/z=934.4 (M+1) Method 2m_acidic.
Step 7: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((4-(hydroxymethyl)-5-((2-nitrophenyls-
ulfonamido)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)carbam-
ate
[1036] To a solution of benzyl
((2R,3S)-2-((4-(((tert-butyldiphenylsilyl)oxy)methyl)-5-((2-nitrophenylsu-
lfonamido)methyl)-2H-1,2,3-triazol-2-yl)methyl)-1-(2,4-dimethoxybenzyl)-4--
oxoazetidin-3-yl)carbamate (252 mg, 0.270 mmol) in THF (2.8 mL) at
0.degree. C. was added TBAF (1.0 M in THF, 270 .mu.L, 0.270 mmol).
After stirring for 2.6 h, the solution was diluted with EtOAc and
partially concentrated in vacuo. Additional EtOAc was added along
with KHSO.sub.4 (2%, aq) and water. The layers were separated and
the aqueous layer was extracted with EtOAc (3.times.). The combined
organic layers were washed with brine, dried over Na.sub.2SO.sub.4
and concentrated in vacuo. The crude residue was purified via
silica gel chromatography (EtOAc-Heptane, 0-100%), affording the
title compound (165 mg, 88%) as a white solid. R.sub.t=0.83 min,
m/z=696.3 (M+1) Method 2m_acidic.
Step 8: Benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((5-((2-nitrophenyl)sulfonyl)-5,6-dihy-
dropyrrolo[3,4-d][1,2,3]triazol-2(4H)-yl)methyl)-4-oxoazetidin-3-yl)carbam-
ate
[1037] To a soln of benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((4-(hydroxymethyl)-5-((2-nitrophenyls-
ulfonamido)methyl)-2H-1,2,3-triazol-2-yl)methyl)-4-oxoazetidin-3-yl)carbam-
ate (165 mg, 0.237 mmol), and triphenylphosphine (91.6 mg, 0.349
mmol) in THF (11.9 mL) at 0.degree. C. was added DIAD (72 .mu.L,
0.35 mmol), drop-wise. After 3 h, more triphenylphosphine (46.4 mg,
0.177 mmol) was added, whereupon it was cooled to 0.degree. C.
followed by addition of DIAD (37 .mu.L, 0.18 mmol). After stirring
at rt for 2.5 h it was concentrated in vacuo and purified via
silica gel chromatography (EtOAc-Heptane, 0-100%) to afford the
title compound (318 mg), which was contaminated with
triphenylphosphine oxide. R.sub.t=0.93 min, m/z=678.3 (M+1) Method
2m_acidic.
Step 9: tert-Butyl
2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-oxoa-
zetidin-2-yl)methyl)-4,6-dihydropyrrolo[3,4-d][1,2,3]triazole-5(2H)-carbox-
ylate
[1038] To a slurry of benzyl
((2R,3S)-1-(2,4-dimethoxybenzyl)-2-((5-((2-nitrophenyl)sulfonyl)-5,6-dihy-
dropyrrolo[3,4-d][1,2,3]triazol-2(4H)-yl)methyl)-4-oxoazetidin-3-yl)carbam-
ate (241 mg, .about.50%/wt, .about.0.178 mmol) and potassium
carbonate (77.4 mg, 0.560 mmol) in DMF (3.0 mL) was added
thiophenol (23.8 .mu.l, 0.231 mmol). After stirring at rt for 2 h,
Boc-anhydride (78 mg, 0.36 mmol) was added. After an additional 2
h, the slurry was diluted with EtOAc and washed with saturated
NaHCO.sub.3 (aq). The aqueous layer was extracted with EtOAc
(2.times.) and the combined organic layers were washed with LiCl
(5% aq), brine, dried over Na.sub.2SO.sub.4 and concd in vacuo. The
crude residue was combined with the residues from 2 like
transformations (15 mg and 20 mg scales) and purified via silica
gel chromatography (EtOAc-Heptane, 0-100%) to afford the title
compound (85.5 mg, 81% combined). R.sub.t=0.96 min, m/z=593.2 (M+1)
Method 2m_acidic. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 8.21
(d, J=9.6 Hz, 1H), 7.40-7.27 (m, 5H), 6.92 (d, J=8.3 Hz, 1H), 6.49
(d, J=2.1 Hz, 1H), 6.40 (d, J=8.3 Hz, 1H), 5.04 (s, 2H), 5.00 (dd,
J=9.6, 5.1 Hz, 1H), 4.65 (dd, J=14.0, 7.1 Hz, 1H), 4.56 (dd, J=4.1,
6.2 Hz, 1H), 4.38-4.24 (m, 5H), 4.12 (q, J=6.2 Hz, 1H), 3.86 (d,
J=15.1 Hz, 1H), 3.74 (s, 3H), 3.72 (s, 3H), 1.46 (s, 9H).
Step 10: tert-Butyl
2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-4,6-
-dihydropyrrolo[3,4-d][1,2,3]triazole-5(2H)-carboxylate
[1039] Slurried tert-butyl
2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-1-(2,4-dimethoxybenzyl)-4-oxoa-
zetidin-2-yl)methyl)-4,6-dihydropyrrolo[3,4-d][1,2,3]triazole-5(2H)-carbox-
ylate (85.5 mg, 0.144 mmol), potassium peroxydisulfate (51.8 mg,
0.186 mmol) and potassium phosphate, dibasic (57 mg, 0.33 mmol) in
ACN/water (2 mL, 2:1) for 5 min, then heated to 90.degree. C. for
1.5 h. More potassium peroxydisulfate (13.9 mg, 0.050 mmol) was
added and it was heated for an additional hour. More potassium
peroxydisulfate (12.1 mg, 0.043 mmol) was added and it was heated
an additional hour, whereupon the slurry was partially concentrated
in vacuo then partitioned between saturated NaHCO.sub.3 (aq) and
EtOAc. After separating the layers, the aqueous was extracted with
EtOAc (3.times.). The combined organic layers were washed with
brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo. The
crude residue was purified via silica gel chromatography
(EtOAc-Heptane, 0-100%) to afford contaminated product (33 mg),
which was repurified by reverse phase HPLC (XSELECT CSH, C18,
5.mu., 30.times.100 mm, ACN/H.sub.2O with 0.1% formic acid buffer,
60 mL/min). The title compound (12.1 mg, 19%) was obtained as a
white solid. R.sub.t=0.78 min, m/z=433.2 (M+1) Method 2m_acidic.
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.8.40 (s, 1H), 8.17 (d,
J=9.7 Hz, 1H), 7.42-7.26 (m, 5H), 5.05 (s, 2H), 5.04-4.99 (m, 1H),
4.58 (d, J=6.6 Hz, 2H), 4.40 (d, J=4.7 Hz, 4H), 4.22 (q, J=6.5 Hz,
1H), 1.45 (s, 9H).
Step 11: tert-Butyl
2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-4,6-dihydropyrrolo[3,4-d][-
1,2,3]triazole-5(2H)-carboxylate
[1040] Slurried tert-butyl
2-(((2R,3S)-3-(((benzyloxy)carbonyl)amino)-4-oxoazetidin-2-yl)methyl)-4,6-
-dihydropyrrolo[3,4-d][1,2,3]triazole-5(2H)-carboxylate (11.8 mg,
0.027 mmol) and Pd--C (5%, 2.3 mg) in MeOH/EtOH (740 .mu.l, 1.7:1)
under N.sub.2, whereupon the system was evacuated and backfilled
with H.sub.2 (3.times.). After vigorous stirring for 1.7 h, the
system was purged with N.sub.2 and the solids were filtered through
a 0.45 .mu.syringe filter. The filtrate was concentrated in vacuo
and used as such without further purification.
Step 12: tert-Butyl
2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)-cyclopropoxy)imino)-2--
(2-((tert-butoxycarbonyl)amino)-thiazol-4-yl)acetamido)-4-oxoazetidin-2-yl-
)methyl)-4,6-dihydropyrrolo[3,4-d][1,2,3]triazole-5(2H)-carboxylate
[1041] To a cooled (0.degree. C.) slurry of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)-imino)-2-(2-((tert-butox-
ycarbonyl)amino)thiazol-4-yl)acetic acid (15.3 mg, 0.028 mmol),
tert-butyl
2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-4,6-dihydropyrrolo[3,4-d][-
1,2,3]triazole-5(2H)-carboxylate (8.3 mg, 0.027 mmol) and HATU
(11.4 mg, 0.029 mmol) in DMF (500 .mu.L) was added DIPEA (9.5
.mu.L, 0.054 mmol). After stirring at rt for 16 h, it was diluted
with EtOAc and washed with LiCl (5%, aq). The aqueous layer was
extracted with EtOAc (3.times.) and the combined organic layers
were washed with brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude residue was purified via silica
gel chromatography (EtOAc-Heptane) to afford the title compound
(18.1 mg, 81%) as a white solid. R.sub.t=1.08 min, m/z=828.5 (M+1)
Method 2m_acidic.
Step 13:
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-
-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(tert-buto-
xycarbonyl)-5,6-dihydropyrrolo[3,4-d][1,2,3]triazol-2(4H)-yl)methyl)-4-oxo-
azetidine-1-sulfonic Acid
[1042] To a soln of tert-butyl
2-(((2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(-
2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-4-oxoazetidin-2-yl)m-
ethyl)-4,6-dihydropyrrolo[3,4-d][1,2,3]triazole-5(2H)-carboxylate
(18.1 mg, 0.022 mmol) in DMF (300 .mu.L) at 0.degree. C. was added
SO.sub.3.DMF (12.3 mg, 0.078 mmol). After stirring at rt for 2 h,
the solution was cooled to 0.degree. C. and more SO.sub.3.DMF (22.2
mg, 0.141 mmol) was added. After an additional 4 h at rt it was
diluted with EtOAc and washed with LiCl (5% aq). The aqueous layer
was extracted with EtOAc (2.times.) and the combined organic layers
were washed with brine, dried over Na.sub.2SO.sub.4 and concd in
vacuo. It was used as such (assumed quantitative) without further
purification. R.sub.t=0.96 min, m/z=908.4 (M+1) Method
2m_acidic.
##STR00209##
Step 14:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((5,6-dihydropyrr-
olo[3,4-d][1,2,3]triazol-2(4H)-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino-
)-2-oxoethylidene)amino)oxy)cyclopropanecarboxylic Acid
[1043] Followed the general procedure for the acid mediated
deprotection using
(2R,3S)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)-cyclopropoxy)imino)--
2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-((5-(tert-butox-
ycarbonyl)-5,6-dihydropyrrolo[3,4-d][1,2,3]triazol-2(4H)-yl)methyl)-4-oxoa-
zetidine-1-sulfonic acid (20 mg, 0.022 mmol), anisole (5 .mu.l,
0.046 mmol), DCM (300 .mu.L) and TFA (51 .mu.L, 0.66 mmol). The
crude residue was purified by reverse phase prep HPLC (XSELECT CSH,
30.times.100 mm, 5 .mu.m, C18 column; ACN-water with 0.1% formic
acid modifier, 60 mL/min), affording the title compound (7.3 mg,
60%) as a white powder. LCMS: R.sub.t=0.37 min, m/z=542.1 (M+1)
Method 2m_acidic_polar; .sup.1H NMR (500 MHz, D.sub.2O) .delta.
7.18 (s, 1H), 5.51 (d, J=5.3 Hz, 1H), 5.01-4.92 (m, 2H), 4.87 (d,
J=6.0 Hz, 1H), 4.61-4.35 (m, 4H), 1.42-1.32 (m, 2H), 1.32-1.23 (m,
2H).
Example 155:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((S)-1,3-diaminopropyl-
)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoeth-
ylidene)amino)oxy)cyclopropanecarboxylic Acid
Example 156:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((R)-1,3-diaminopropyl-
)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoeth-
ylidene)amino)oxy)cyclopropanecarboxylic Acid
Step 1: (S)-tert-butyl
(1-((tert-butyldiphenylsilyl)oxy)-4-oxobutan-2-yl)carbamate
[1044] To a solution of (S)-tert-butyl
(1-((tert-butyldiphenylsilyl)oxy)-4-hydroxybutan-2-yl)carbamate
(prepared according to the procedure described in WO2013124826 A1
using L-aspartic acid) (15.0 g, 33.8 mmol) and DIPEA (29.5 mL, 169
mmol) in DCM (50 mL) at 0.degree. C. was added a slurry of DMSO
(7.20 mL, 101 mmol) and sulfur trioxide pyridine complex (16.14 g,
101 mmol) in DCM (50 mL). After stirring at rt for 1.5 h, the
mixture was diluted with saturated NaHCO.sub.3 (aq) and the layers
were separated. The aqueous layer was extracted with DCM and the
combined organic portions were dried over Na.sub.2SO.sub.4 and
concentrated in vacuo to afford the title compound (16.9 g, assumed
quantitative) as a light brown oil. It was used as such without
further purification. LCMS: R.sub.t=1.20 min, m/z=442.2 (M+1)
Method 2m_acidic.
Step 2: (S)-tert-butyl
(4-(benzylamino)-1-((tert-butyldiphenylsilyl)oxy)butan-2-yl)carbamate
[1045] To (S)-tert-butyl
(1-((tert-butyldiphenylsilyl)oxy)-4-oxobutan-2-yl)carbamate (14.93
g, 33.8 mmol) in DCE (100 mL) at 0.degree. C. was added benzylamine
(3.69 mL, 33.8 mmol) and sodium triacetoxyhydroborate (8.60 g, 40.6
mmol) sequentially. After stirring at rt 18 h, it was quenched by
addition of saturated NaHCO.sub.3 (aq, 300 mL) and stirred for an
additional 30 min. The phases were separated and the aqueous phase
was extracted with EtOAc. The combined organic layers were washed
with brine, dried over Na.sub.2SO.sub.4 and concentrated in vacuo.
The crude material was purified via silica gel chromatography
(EtOAc-Heptane) to afford the title compound (8 g, 44%). LCMS:
R.sub.t=1.08 min, m/z=533.2 (M+1) Method 2m_acidic.
Step 3: (S)-tert-butyl
(4-amino-1-((tert-butyldiphenylsilyl)oxy)butan-2-yl)carbamate
[1046] To (S)-tert-butyl
(4-(benzylamino)-1-((tert-butyldiphenylsilyl)oxy)butan-2-yl)carbamate
(8.0 g, 15.0 mmol) in MeOH (100 mL) was added ammonium formate
(9.47 g, 150 mmol) and Pd(OH).sub.2 (1.054 g, 1.502 mmol). The
reaction mixture was stirred at 70.degree. C. for 1.5 h then cooled
to rt and filtered through a celite, eluting with MeOH/EtOAc (1:2,
.about.800 mL). The filtrate was concentrated in vacuo to afford
the title compound (7 g) of a light brown residue which was used as
such without further purification. LCMS: R.sub.t=0.95 min,
m/z=443.2 (M+1) Method 2m_acidic.
Step 4: (S)-di-tert-butyl
(4-((tert-butyldiphenylsilyl)oxy)butane-1,3-diyl)dicarbamate
[1047] To (S)-tert-butyl
(4-amino-1-((tert-butyldiphenylsilyl)oxy)butan-2-yl)carbamate (6.65
g, 15.02 mmol) in DCM (75 mL) was added saturated NaHCO.sub.3 (aq,
50 mL) and di-tert-butyl dicarbonate (5.24 g, 24.03 mmol),
sequentially. After stirring for 16 h, the layers of were separated
and the organic layer was washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (EtOAc-Heptane) to afford
the title compound (6.25 g, 77%). LCMS: R.sub.t=1.31 min, m/z=543.2
(M+1) Method 2m_acidic. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 7.70-7.58 (m, 4H) 7.49-7.34 (m, 6H) 5.29-5.12 (m, 1H) 4.83-4.56
(m, 1H) 3.72 (d, J=8.4 Hz, 2H) 3.63-3.51 (m, 1H) 3.48-3.27 (m, 1H)
3.04-2.73 (m, 1H) 1.58 (d, J=4.9 Hz, 2H) 1.44 (s, 9H) 1.43, (s,
9H), 1.06 (s, 9H).
Step 5: (S)-di-tert-butyl (4-hydroxybutane-1,3-diyl)dicarbamate
[1048] To a solution of (S)-di-tert-butyl
(4-((tert-butyldiphenylsilyl)oxy)butane-1,3-diyl)dicarbamate (6.25
g, 11.51 mmol) in MeOH (100 mL) was added sodium hydroxide (1.38 g,
34.5 mmol) in water (20.0 mL). The mixture was heated to 70.degree.
C. for 18 h then cooled to room temperature and partially
concentrated in vacuo. DCM was then added and the mixture was
cooled to 0.degree. C., whereupon acetic acid (2.31 mL, 40.3 mmol)
was added. The organic layer was then separated, washed with
saturated NaHCO.sub.3 (aq) and brine. The combined aqueous portions
were extracted with DCM and the combined organic layers were dried
over Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue
was purified via silica gel chromatography (EtOAc-Heptane) to
afford the title compound (1.67 g, 48%). LCMS: R.sub.t=0.67 min,
m/z=305.1 (M+1) Method 2m_acidic. .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 5.06 (br s, 1H) 4.83 (br s, 1H) 3.82-3.64 (m, 2H) 3.61
(dd, J=10.3, 4.9 Hz, 1H) 3.43-3.25 (m, 1H) 3.11-2.93 (m, 1H) 2.18
(br s, 1H) 1.79-1.65 (m, 1H) 1.64-1.58 (m, 1H) 1.51-1.36 (m,
18H).
Step 6: (S)-di-tert-butyl (4-oxobutane-1,3-diyl)dicarbamate
[1049] To a solution of (S)-di-tert-butyl
(4-oxobutane-1,3-diyl)dicarbamate (1.67 g, 5.49 mmol) and DIPEA
(3.83 mL, 21.95 mmol) in DCM (20 mL) at 0.degree. C. was added a
slurry of DMSO (1.061 mL, 13.72 mmol) and sulfur trioxide pyridine
complex (2.183 g, 13.72 mmol) in DCM (20 mL). After stirring at rt
for 30 min, the mixture was diluted with saturated NaHCO.sub.3 (aq)
and the layers were separated. The aqueous layer was extracted with
DCM and the combined organic layers were dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude residue was
purified via silica gel chromatography (EtOAc-Heptane) to afford
the title compound (1.47 g, 89%). LCMS: R.sub.t=0.70 min, m/z=325.0
(M+Na) Method 2m_acidic.
Step 7: (S)-di-tert-butyl pent-4-yne-1,3-diyldicarbamate
[1050] To a solution of (S)-di-tert-butyl
(4-oxobutane-1,3-diyl)dicarbamate (1.47 g, 4.86 mmol) in MeOH (30
mL) was added potassium carbonate (1.680 g, 12.15 mmol) and
dimethyl (1-diazo-2-oxopropyl)phosphonate (1.40 mL, 7.29 mmol),
sequentially. After stirring for 15 h, the mixture was diluted with
EtOAc, washed with water, brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude material was purified via silica
gel chromatography (EtOAc-Heptane) to afford the title compound
(0.943 g, 65%). LCMS: R.sub.t=0.81 min, m/z=321.1 (M+Na) Method
2m_acidic.
Step 8: (S)-di-tert-butyl
(1-(2H-1,2,3-triazol-4-yl)propane-1,3-diyl)dicarbamate
[1051] To a solution of (S)-di-tert-butyl
pent-4-yne-1,3-diyldicarbamate in DMF/MeOH (3.7 mL, 1.2:1) was
added azidotrimethylsilane (330 .mu.L, 2.38 mmol) and copper iodide
(15 mg, 0.079 mmol). The mixture was heated at 100.degree. C. for
16 h, cooled to rt then filtered through celite. The filtrate was
concentrated in vacuo and the crude residue was purified via silica
gel chromatography (EtOAc-Heptane) to afford the title compound.
LCMS: R.sub.t=0.68 min, m/z=342.1 (M+1) Method 2m_acidic.
Step 9
[1052] To a solution of (S)-di-tert-butyl
(1-(2H-1,2,3-triazol-4-yl)propane-1,3-diyl)dicarbamate (852 mg,
2.50 mmol), benzyl
((2S,3S)-1-(2,4-dimethoxybenzyl)-2-(hydroxymethyl)-4-oxoazetidin-3-yl)car-
bamate (1.05 g, 2.62 mmol) and PPh.sub.3 (785 mg, 2.99 mmol) in THF
(13 mL) at 0.degree. C. was added DIAD (0.582 ml, 2.99 mmol),
dropwise. After stirring at rt for 7 h, it was concentrated in
vacuo and purified via silica gel chromatography (EtOAc-Heptane) to
afford the product (1.24 g, 68%). LCMS: R.sub.t=1.01 min, m/z=724.5
(M+1) Method 2m_acidic.
Step 10
[1053] To the product of step 9 (1.240 g, 1.713 mmol) in
acetonitrile (20 mL) was added K.sub.2S.sub.2O.sub.8 (621 mg, 2.227
mmol) and a solution of K.sub.2HPO.sub.4 (477 mg, 2.74 mmol) in
water (10 mL), sequentially. After heating at 90.degree. C. with
vigorous stirring for 1 h, additional K.sub.2S.sub.2O.sub.8 (185
mg, 0.685 mmol) was added along with K.sub.3PO.sub.4 (363 mg, 1.71
mmol). The mixture was heated to 90.degree. C. for 5 h then cooled
to rt and diluted with EtOAc (120 mL). The layers were separated
and the organic layer was washed with brine, dried over
Na.sub.2SO.sub.4 and concentrated in vacuo. The crude material was
purified via silica gel chromatography (EtOAc-Heptane) to afford
the product (590 mg, 60%). LCMS: R.sub.t=0.85 min, m/z=574.2 (M+1)
Method 2m_acidic.
Step 11: Di-tert-butyl
((S)-1-(2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-
-yl)propane-1,3-diyl)dicarbamate
[1054] Slurried the product of step 10 (590 mg, 1.03 mmol) and
Pd--C (10% 200 mg) in EtOH/MeOH (21 mL, 2:1), whereupon the system
was evacuated and recharged with H.sub.2 (3.times.). After 4 h of
vigorous stirring, the mixture was filtered through celite, washing
with EtOH/DCM. The filtrate was concentrated in vacuo, affording
the title compound (assumed quantitative) as a light yellow solid
which was used as such without further purification. LCMS:
R.sub.t=0.61 min, m/z=440.2 (M+1) Method 2m_acidic.
Step 12: Benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((4-((S)-2,2,12,12-tetramethyl-4,10-dioxo-3,11-dioxa-5,9-diazatri-
decan-6-yl)-2H-1,2,3-triazol-2-yl)methyl)azetidin-3-yl)amino)ethylidene)am-
ino)oxy)cyclopropanecarboxylate
[1055] A mixture of
(Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-2-(2-((tert-butoxy-
carbonyl)amino)thiazol-4-yl)acetic acid (582 mg, 1.028 mmol), DIPEA
(0.269 mL, 1.543 mmol) and HATU (430 mg, 1.131 mmol) in DCM/DMF (12
mL, 5:1) was stirred at 0.degree. C. for 30 min. To this mixture
was added di-tert-butyl
((S)-1-(2-(((2R,3S)-3-amino-4-oxoazetidin-2-yl)methyl)-2H-1,2,3-triazol-4-
-yl)propane-1,3-diyl)dicarbamate (1.03 mmol). After stirring for an
additional 30 min at 0.degree. C., it was diluted with EtOAc,
washed with water, brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo. The crude material was purified via silica
gel chromatography (EtOAc-Heptane) to afford the title compound
(760 mg, 77%). LCMS: R.sub.t=1.12 min, m/z=959.6 (M+1) Method
2m_acidic.
Step 13:
(3S,4R)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino)-
-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((4-((S)-
-2,2,12,12-tetramethyl-4,10-dioxo-3,11-dioxa-5,9-diazatridecan-6-yl)-2H-1,-
2,3-triazol-2-yl)methyl)azetidine-1-sulfonic acid
[1056] To benzhydryl
1-(((Z)-(1-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-oxo-2-(((3S,4R)-
-2-oxo-4-((4-((S)-2,2,12,12-tetramethyl-4,10-dioxo-3,11-dioxa-5,9-diazatri-
decan-6-yl)-2H-1,2,3-triazol-2-yl)methyl)azetidin-3-yl)amino)ethylidene)am-
ino)oxy)cyclopropanecarboxylate (760 mg, 0.792 mmol) in DMF (4 mL)
at 0.degree. C. was added SO.sub.3.DMF (850 mg, 5.55 mmol). After
stirring for 2 h at rt, the solution was diluted with EtOAc, washed
with LiCl (5% aq), brine, dried over Na.sub.2SO.sub.4 and
concentrated in vacuo to afford the title compound (assumed
quantitative) as an orange oil which was used directly without
further purification. LCMS: R.sub.t=1.01 min, m/z=1039.6 (M+1)
Method 2m_acidic.
Step 14, Compound 1:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((S)-1,3-diaminopropyl-
)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoeth-
ylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00210##
[1057] Step 14, Compound 2:
1-(((Z)-(1-(2-aminothiazol-4-yl)-2-(((2R,3S)-2-((4-((R)-1,3-diaminopropyl-
)-2H-1,2,3-triazol-2-yl)methyl)-4-oxo-1-sulfoazetidin-3-yl)amino)-2-oxoeth-
ylidene)amino)oxy)cyclopropanecarboxylic Acid
##STR00211##
[1059] To
(3S,4R)-3-((Z)-2-((1-((benzhydryloxy)carbonyl)cyclopropoxy)imino-
)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)acetamido)-2-oxo-4-((4-((S-
)-2,2,12,12-tetramethyl-4,10-dioxo-3,11-dioxa-5,9-diazatridecan-6-yl)-2H-1-
,2,3-triazol-2-yl)methyl)azetidine-1-sulfonic acid (5.55 mmol) in
formic acid (4 mL) at 0.degree. C. was added anisole (173 .mu.L,
1.58 mmol). The solution was heated at 40.degree. C. for 2 h,
whereupon it was cooled to rt and concentrated in vacuo. To the
resulting residue was added DCM (15 mL) then ice-water (12 mL) and
this was vigorously stirred for 1 h. The layers were separated and
the aqueous layer was directly purified by reverse phase HPLC
(XSELECT CSH, 30.times.100 mm, 5 .mu.m, C18 column; ACN-water with
0.1% formic acid modifier, 60 mL/min), affording compound 1 (170
mg, 37%) and compound 2 (21 mg, 5%) as white solids. Compound 2 is
thought to arise from slight epimerization of the stereocenter
during step 7. 1-LCMS: R.sub.t=0.31 min, m/z=573.3 (M+1) Method
2m_acidic_polar. .sup.1H NMR (400 MHz, D.sub.2O) .delta. ppm 7.86
(s, 1H) 7.07 (s, 1H) 5.60 (d, J=5.6 Hz, 1H) 5.03-4.82 (m, 4H
assumed; partially obscured by solvent residual peak) 3.12-2.85 (m,
2H) 2.54-2.34 (m, 2H) 1.28-1.08 (m, 4H). 2-LCMS: Rt=0.30 min,
m/z=573.3 (M+1) Method 2m_acidic_polar. .sup.1H NMR (400 MHz,
D.sub.2O) .delta. ppm 7.86 (s, 1H) 7.07 (s, 1H) 5.58 (d, J=5.5 Hz,
1H) 5.07-4.85 (m, 4H assumed; partially obscured by solvent
residual peak) 3.12-2.84 (m, 2H) 2.53-2.34 (m, 2H) 1.30-1.03 (m,
4H).
Bacterial Screens and Cultures
[1060] Bacterial isolates were cultivated from -70.degree. C.
frozen stocks by two consecutive overnight passages at 35.degree.
C. in ambient air on 5% blood agar (Remel, Lenexa, Kans.). Quality
control and P. aeruginosa ATCC 27853) is from the American Type
Culture Collection (ATCC; Rockville, Md.) and PAO1 was received
from Dr. K. Poole.
[1061] Construction of Escherichia coli isogenic strains Strains
NB27273-CDY0026 (parent), NB27273-CDY0033 (KPC2) and
NB27273-CDY0030 (SHV12)
[1062] Strain NB27273 (BW25113 pspB::Km.sup.r) was obtained from
the Keio transposon insertion collection. The strain has the pspB
gene replaced by a kanamycin resistance marker (BW25113
pspB::Km.sup.r). This strain was cured of the transposon in pspB
via FLP recombinase using published methodology. The resulting
strain, BW25113 pspB, was used as a host for multicopy vectors
expressing key .beta.-lactamases. Multicopy plasmids directing
constitutive expression of .beta.-lactamases were established as
follows: Synthetic, codon optimized genes encoding E. coli KPC2 and
SHV12 .beta.-lactamases were made by DNA2.0 (Palo Alto, Calif.).
Each of the synthetic fragments were designed to contain Notl and
Ncol restriction sites at their termini, allowing ligation into a
Notl/Ncol digested pET28a(+) derivative for protein expression. The
inserts in these vectors served as template DNA for PCR
amplification of the gene encoding KPC2 and SHV12, using primer
pairs E225 (tcgcCTCGAGgcgactgcgctgacgaatttgg) (SEQ ID NO:1) and
E202 (aatcGAATTCttactgaccattaacgcccaagc) (SEQ ID NO:2) and E227
(tcgcCTCGAGgcgagcccgcaaccgctgga) (SEQ ID NO:3) and E204
(aatcGAATTCttaacgctgccagtgctcaatc) (SEQ ID NO:4), respectively. The
codon optimized nucleotide sequences and relevant primer
recognition information is shown below:
TABLE-US-00003 SHV12 (SEQ ID NO: 5)
ATGGGCCATCATCATCATCATCACAGCAGCGGCCTGGAAGTTCTGTTCCAG
GGGCCCGCGAGCCCGCAACCGCTGGAGCAGATCAAGCAGTCTGAGAGCCAG
CTGAGCGGCCGTGTGGGTATGATCGAGATGGATCTGGCTTCCGGCCGTACG
CTGACGGCATGGCGTGCCGACGAACGTTTCCCGATGATGTCGACCTTTAAA
GTTGTTCTGTGTGGTGCGGTCTTGGCACGTGTAGACGCGGGTGACGAACAA
CTGGAGCGCAAGATCCATTACCGCCAACAGGACTTGGTCGACTACAGCCCG
GTTAGCGAAAAGCACCTGGCGGATGGCATGACCGTGGGTGAATTGTGCGCC
GCTGCGATTACCATGAGCGACAATAGCGCGGCTAATCTGCTGTTGGCGACC
GTTGGTGGCCCAGCGGGCTTGACCGCATTTCTGCGTCAAATCGGCGATAAT
GTTACGCGTCTGGATCGCTGGGAAACGGAGCTGAACGAGGCACTGCCGGGT
GATGCCCGTGATACCACGACTCCTGCTAGCATGGCAGCGACCCTGCGTAAA
CTGCTGACCAGCCAGCGTCTGAGCGCACGTAGCCAACGCCAGCTGCTGCAA
TGGATGGTGGATGACCGCGTGGCGGGTCCGCTGATCCGCTCCGTCCTGCCA
GCAGGCTGGTTCATTGCGGACAAAACTGGTGCCTCTAAGCGTGGTGCGCGT
GGTATCGTCGCGCTGCTGGGTCCGAACAACAAAGCCGAACGTATTGTGGTT
ATCTATCTGCGCGACACCCCGGCAAGCATGGCCGAGCGCAACCAGCAAATT
GCGGGCATTGGTGCGGCACTGATTGAGCACTGGCAGCGTTAACGCCGGCG E227 (SEQ ID NO:
6) TCGCCTCGAGGCGAGCCCGCAACCGCTGGA E204 (SEQ ID NO: 7)
AATCGAATTCTTAACGCTGCCAGTGCTCAATC REV. COMP. E204 (SEQ ID NO: 8)
GATTGAGCACTGGCAGCGTTAAGAATTCGATT KPC2 (SEQ ID NO: 9)
ATGGGCCATCATCATCATCATCACAGCAGCGGCCTGGAAGTTCTGTTCCAG
GGGCCCGCGACTGCGCTGACGAATTTGGTGGCCGAGCCGTTCGCGAAATTG
GAGCAAGATTTTGGTGGTTCGATCGGTGTCTACGCGATGGACACCGGTAGC
GGTGCCACCGTGAGCTACCGTGCCGAAGAGCGTTTTCCGCTGTGTAGCTCT
TTCAAGGGTTTTCTGGCCGCAGCCGTGCTGGCACGCAGCCAACAGCAAGCG
GGCCTGCTGGACACCCCGATCCGTTACGGCAAAAATGCGCTGGTTCCGTGG
AGCCCGATTAGCGAAAAGTACCTGACCACCGGCATGACGGTGGCGGAGTTG
AGCGCTGCGGCGGTTCAGTATTCCGATAACGCTGCGGCAAATCTGCTGCTG
AAAGAACTGGGCGGTCCAGCGGGTCTGACGGCTTTCATGCGTTCTATTGGC
GACACCACCTTTCGCTTGGACCGCTGGGAGCTGGAGCTGAACAGCGCGATT
CCGGGCGACGCACGTGATACGAGCAGCCCGCGTGCAGTGACCGAGAGCCTG
CAGAAGCTGACCCTGGGCAGCGCACTGGCCGCACCGCAGCGCCAACAGTTC
GTCGATTGGCTGAAGGGTAACACCACCGGTAACCATCGTATTCGCGCAGCG
GTCCCGGCTGATTGGGCAGTTGGTGACAAGACTGGTACGTGCGGCGTTTAT
GGTACGGCGAATGACTACGCGGTTGTTTGGCCTACGGGTCGTGCGCCGATC
GTCCTGGCGGTGTATACCCGTGCTCCGAACAAAGACGATAAACACTCCGAA
GCGGTCATCGCCGCAGCAGCGCGTCTGGCCCTGGAAGGCTTGGGCGTTAAT
GGTCAGTAACGCCGGCG E225 (SEQ ID NO: 10)
TCGCCTCGAGGCGACTGCGCTGACGAATTTGG E202 (SEQ ID NO: 11)
AATCGAATTCTTACTGACCATTAACGCCCAAGC REV. COMP. E202 (SEQ ID NO: 12)
GCTTGGGCGTTAATGGTCAGTAAGAATTCGATT UNDERLINED = DNA ENCODING BL
[1063] The PCR products were then digested with Xhol and EcoRI and
ligated into similarly digested plasmid pAH63-pstS(BlaP). Plasmid
pAH63-pstS(BlaP) is a derivative of plasmid pAH63 (J
Bacteriol:183(21): 6384-6393) made by cloning the TEM-1 (bla)
promoter and signal peptide encoding region from plasmid pBAD (J
Bacteriol. 1995 July 177(14):4121-30) into plasmid pAH63. This
fragment was PCR amplified from pBAD using primer pair E192
(ttcaCTGCAGtgaacgttgcgaagcaacggC) (SEQ ID NO:13) and E194
(TCGAggatcctcgagagcaaaaacaggaaggcaaaatgccg) (SEQ ID NO:14),
digested with Pstl and BamHI and inserted into similarly digested
plasmid pAH63. Therefore, expression of .beta.-lactamases from
pAH63-pstS(BlaP) based constructs is constitutive and the signal
sequence is provided to direct these proteins to the periplasm.
Plasmid pAH63 based vectors are used for insertion into the genome
in single copy, however, to provide higher expression levels to
allow more sensitive detection of the susceptibility of compounds
to the .beta.-lactamases, the expression inserts contained in these
vectors were moved to the replicative multicopy vector pBAD-Kan (J
Bacteriol. 1995 July 177(14):4121-30). To accomplish this, the
inserts encompassing the .beta.-lactamase genes, with the
associated TEM promoter and signal sequences, were PCR amplified
from their corresponding vectors using primer E269
(ccgTCTAGAcggatggcctttttgcgtttc) (SEQ ID NO:15) and E202
(aatcGAATTCttactgaccattaacgcccaagc) (SEQ ID NO:16) for the KPC2
construct and E204 (aatcGAATTCttaacgctgccagtgctcaatc) (SEQ ID
NO:17) for the SHV12 construct. These fragments were then digested
with Xbal and EcoRI, and each was inserted into pBAD18-kan that had
been digested with the same enzymes to generate a pair of multicopy
vectors expressing KPC2 and SHV12 respectively. These vectors were
transformed into BW25113 pspB to generate strains NB27273-CDY0033
(expressing KPC2) and NB27273-CDY0030 (expressing SHV12). The
pBAD18-kan vector also contains the TEM promoter region and signal
sequence, (but lacks any intact .beta.-lactamase genes) and was
transformed into BW25113 pspB using standard protocols to generate
the control strain NB27273-CDY0026. Expression of the
.beta.-lactamases was confirmed by verifying decreased
susceptibility to example test antibiotics that are known
substrates of KPC2 or SHV12.
Susceptibility Testing
[1064] Minimal Inhibitory Concentrations (MICs) were determined by
the broth microdilution method in accordance with Clinical and
Laboratories Institute (CLSI) guidelines. In brief, fresh overnight
bacterial cultures were suspended in sterile saline, and adjusted
to a 0.5 McFarland turbidity standard. Bacterial suspensions were
then diluted in cation adjusted Mueller-Hinton Broth (MHB II; BBL)
to yield a final inoculum of approximately 5.times.10.sup.5
colony-forming units (CFU)/mL. A master plate of antibiotics was
prepared at a concentration equivalent to hundred-fold the highest
desired final concentration in 100% dimethyl sulfoxide (DMSO). The
master antibiotic plate was then diluted by serial twofold dilution
with a multichannel pipette. The resulting dilution series of
compounds were diluted 1:10 with sterile water leading to a 10%
DMSO final concentration. A volume of 10 .mu.L of the drug dilution
series was transferred to 96-well assay plates. Assay plates were
inoculated with 90 .mu.L of bacterial suspensions and incubated at
35-37.degree. C. for 20 hrs. The assay plates were read using a
microtiter plate reader (Molecular Devices) at 600 nm as well as by
visual observation with a reading mirror. The lowest concentration
of the compound that prevented visible growth was recorded as the
MIC. Performance of the assay was monitored by testing aztreonam
against laboratory quality control strains in accordance with
guidelines of the CLSI.
[1065] Reference compounds: for comparison, the following known
monobactam compounds are used herein:
##STR00212##
TABLE-US-00004 TABLE A Minimum Inhibitory Concentrations (MIC)
against isogenic strains of E. coli, carrying various resistance
determinants. Example Strain 1 MIC Strain 2 MIC Strain 3 MIC number
(.mu.g/mL) (.mu.m g/mL) (.mu.g g/mL) Reference 0.125 >32 >32
compound 1 Reference 0.125 1 >32 compound 2 Reference 0.25 0.5
>32 compound 3 Reference .ltoreq.0.06 0.25 32 compound 4 Example
1 1 2 2 Example 31 0.125 0.25 0.5 Example 22 .ltoreq.0.06 0.125 0.5
Example 4 0.5 8 2 Example 28 .ltoreq.0.06 .ltoreq.0.06 0.5 Strain
1: E. coli NB27273-CDY0026(parent) Strain 2: E. coli
NB27273-CDY0033(KPC2) Strain 3: E. coli NB27273-CDY0030(SHV12)
[1066] The data in Table A shows that compounds of the invention
have good antibacterial potency against E. coli, including strains
that show strong resistance to several known monobactam and
sulfactam antibiotics.
[1067] Activity data for selected compounds of the invention is
provided in the following table. Compounds were tested on E. coli
strain 25922 and an E. coli containing KPC-2 (a known carbapenemase
from Klebsiella pneumoniae), to determine Minimum Inhibitory
Concentrations (MIC), in mg/L. Note that compounds identified as
formate salts were subjected to lyophilization during isolation,
which in some cases removed some formic acid, so the formate
content of those salts may be less than stoichiometric.
TABLE-US-00005 TABLE B Activity of Compounds in the Examples.
Example Ec Ec KPC2 No. Salt 25922 Iso 41 ##STR00213## none 1 2 43
##STR00214## none 2 2 42 ##STR00215## none 1.4 2 46 ##STR00216##
none 48 ##STR00217## none 49 ##STR00218## none 2 16 47 ##STR00219##
none 2 5 50 ##STR00220## none 2 2.8 44 ##STR00221## none 0.67 1.5 7
##STR00222## formate 4 8 8 ##STR00223## formate 2 2 51 ##STR00224##
none >64 16 4 ##STR00225## formate 1 8 1 ##STR00226## none 16 2
55 ##STR00227## none 16 4 5 ##STR00228## formate 1 4 52
##STR00229## formate 0.5 1 54 ##STR00230## formate 2 1 2
##STR00231## none 1 0.5 12 ##STR00232## formate 4 4 10 ##STR00233##
formate 4 11 11 ##STR00234## formate 4 4 13 ##STR00235## formate 16
32 14 ##STR00236## formate 16 8 15 ##STR00237## formate 16 8 56
##STR00238## formate 4 16 3 ##STR00239## none 2 1 16 ##STR00240##
formate 4 2 53 ##STR00241## formate 1 1 6 ##STR00242## formate 4 1
23 ##STR00243## formate 2 1 39 ##STR00244## none 64 >64 38
##STR00245## formate 8 4 40 ##STR00246## none 2 2 18 ##STR00247##
formate 0.5 0.25 62 ##STR00248## formate 0.5 2 17 ##STR00249##
formate 0.5 0.25 9 ##STR00250## formate 1 1 57 ##STR00251## formate
0.5 1 21 ##STR00252## none 0.25 0.5 22 ##STR00253## none 0.25 0.125
37 ##STR00254## formate 2 2 36 ##STR00255## formate 2 1 35
##STR00256## formate 2 1 24 ##STR00257## formate 0.25 1 63
##STR00258## none 32 32 61 ##STR00259## none 8 2 34 ##STR00260##
formate >64 >64 33 ##STR00261## formate 2 2 45 ##STR00262##
formate 0.5 0.5 30 ##STR00263## none 1 1 29 ##STR00264## none 0.25
1 31 ##STR00265## formate 0.25 0.25 28 ##STR00266## formate 0.25
0.125 60 ##STR00267## none 8 8 32 ##STR00268## none 2 1 59
##STR00269## none 16 16 58 ##STR00270## none 2 1 27 ##STR00271##
None .ltoreq.0.06 0.125 25 ##STR00272## none 0.125 .ltoreq.0.06 26
##STR00273## None 0.125 .ltoreq.0.06 19 ##STR00274## None 0.25 0.25
20 ##STR00275## None .ltoreq.0.06 0.125 64 ##STR00276## none 0.5
0.25 65 ##STR00277## none 64 64 66 ##STR00278## none 1 2 67
##STR00279## none 0.25 0.125 68 ##STR00280## none 0.25 0.25 69
##STR00281## formate 0.25 0.125 70 ##STR00282## formate 8 8 71
##STR00283## none 0.25 0.25 72 ##STR00284## none 4 4 73
##STR00285## none 0.25 0.25 74 ##STR00286## none 8 32 75
##STR00287## formate 0.5 0.5 76 ##STR00288## none 1 0.5 77
##STR00289## none 0.25 0.125 78 ##STR00290## none 0.06 0.125 79
##STR00291## formate 0.25 0.25 80 ##STR00292## none 4 4 81
##STR00293## none 0.125 0.125 82 ##STR00294## none 0.5 0.5 83
##STR00295## none 32 32 84 ##STR00296## none 0.5 0.5 85
##STR00297## none 0.5 0.5 86 ##STR00298## none 1 1 87 ##STR00299##
none 1 0.5 88 ##STR00300## none 2 4 89 ##STR00301## none 0.5 1 90
##STR00302## none 0.25 0.25 91 ##STR00303## none 0.125 0.25 92
##STR00304## none 0.25 0.5 93 ##STR00305## none 0.25 0.5 94
##STR00306## none 0.5 1 95 ##STR00307## none 0.25 0.125 96
##STR00308## formate 0.25 1 97 ##STR00309## none 0.125 0.125 98
##STR00310## none 2 0.5 99 ##STR00311## none 2 4 100 ##STR00312##
none 1 4 101 ##STR00313## none 1 1 102 ##STR00314## none 0.25 0.25
103 ##STR00315## none 0.25 104 ##STR00316## none >64 >64 105
##STR00317## none 16 32 106 ##STR00318## none .ltoreq.0.06
.ltoreq.0.06 107 ##STR00319## formate 0.25 0.25 108 ##STR00320##
formate 0.125 .ltoreq.0.06 109 ##STR00321## none 0.125 0.25 110
##STR00322## none 8 8 111 ##STR00323## formate .ltoreq.0.06
.ltoreq.0.06 112 ##STR00324## formate 0.5 0.5 20 ##STR00325## none
2 4 28 ##STR00326## none 4 8 113 ##STR00327## none 4 4 114
##STR00328## none 0.25 .ltoreq.0.06 115 ##STR00329## none 0.125
0.25 116 ##STR00330## none 0.25 0.125 117 ##STR00331## none 0.5 1
118 ##STR00332## none 0.5 0.25 119 ##STR00333## none 0.25 0.25 120
##STR00334## none 0.25 0.5
121 ##STR00335## none 0.25 0.25 122 ##STR00336## formate 0.125
0.125 122 ##STR00337## formate 0.06 0.06 123 ##STR00338## none 1
0.5 124 ##STR00339## none 1 1 125 ##STR00340## none 0.25 0.5 126
##STR00341## none 0.5 0.5 127 ##STR00342## none 0.25 0.25 128
##STR00343## None 0.5 1 129 ##STR00344## None 0.5 1 130
##STR00345## none 1 2 131 ##STR00346## none 1 2 132 ##STR00347##
none 1 1 133 ##STR00348## none 1 0.5 134 ##STR00349## none 0.5 0.25
135 ##STR00350## none 0.5 0.5 136 ##STR00351## none 0.5 0.5 137
##STR00352## none 1 0.5 138 ##STR00353## none 0.5 1 139
##STR00354## none 1 4 140 ##STR00355## none 0.25 0.25 141
##STR00356## none 0.5 0.5 142 ##STR00357## none 0.5 0.25 143
##STR00358## none 0.5 0.25 144 ##STR00359## none 1 1 145
##STR00360## none 0.5 0.5 146 ##STR00361## none 0.5 0.5 147
##STR00362## none 0.5 0.5 148 ##STR00363## none 1 1 149
##STR00364## none 0.5 0.5 150 ##STR00365## none 1 0.5 151
##STR00366## none 0.5 0.5 152 ##STR00367## none 0.5 0.5 153
##STR00368## None 154 ##STR00369## None 155 ##STR00370## None 156
##STR00371## none
[1068] By the same methods described herein, additional compounds
can readily be prepared from known starting materials with use of
ordinary skill. Examples of these compounds that are expected to
have similar biological activity include:
##STR00372## ##STR00373##
[1069] Those skilled in the art will recognize, or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments and methods described
herein. Such equivalents are intended to be encompassed by the
scope of the following claims.
Sequence CWU 1
1
17132DNAArtificial SequenceSynthetic Oligonucleotide 1tcgcctcgag
gcgactgcgc tgacgaattt gg 32233DNAArtificial SequenceSynthetic
Oligonucleotide 2aatcgaattc ttactgacca ttaacgccca agc
33330DNAArtificial SequenceSynthetic Oligonucleotide 3tcgcctcgag
gcgagcccgc aaccgctgga 30432DNAArtificial SequenceSynthetic
Oligonucleotide 4aatcgaattc ttaacgctgc cagtgctcaa tc
325866DNAArtificial SequenceSynthetic Polynucleotide 5atgggccatc
atcatcatca tcacagcagc ggcctggaag ttctgttcca ggggcccgcg 60agcccgcaac
cgctggagca gatcaagcag tctgagagcc agctgagcgg ccgtgtgggt
120atgatcgaga tggatctggc ttccggccgt acgctgacgg catggcgtgc
cgacgaacgt 180ttcccgatga tgtcgacctt taaagttgtt ctgtgtggtg
cggtcttggc acgtgtagac 240gcgggtgacg aacaactgga gcgcaagatc
cattaccgcc aacaggactt ggtcgactac 300agcccggtta gcgaaaagca
cctggcggat ggcatgaccg tgggtgaatt gtgcgccgct 360gcgattacca
tgagcgacaa tagcgcggct aatctgctgt tggcgaccgt tggtggccca
420gcgggcttga ccgcatttct gcgtcaaatc ggcgataatg ttacgcgtct
ggatcgctgg 480gaaacggagc tgaacgaggc actgccgggt gatgcccgtg
ataccacgac tcctgctagc 540atggcagcga ccctgcgtaa actgctgacc
agccagcgtc tgagcgcacg tagccaacgc 600cagctgctgc aatggatggt
ggatgaccgc gtggcgggtc cgctgatccg ctccgtcctg 660ccagcaggct
ggttcattgc ggacaaaact ggtgcctcta agcgtggtgc gcgtggtatc
720gtcgcgctgc tgggtccgaa caacaaagcc gaacgtattg tggttatcta
tctgcgcgac 780accccggcaa gcatggccga gcgcaaccag caaattgcgg
gcattggtgc ggcactgatt 840gagcactggc agcgttaacg ccggcg
866630DNAArtificial SequenceSynthetic Oligonucleotide 6tcgcctcgag
gcgagcccgc aaccgctgga 30732DNAArtificial SequenceSynthetic
Oligonucleotide 7aatcgaattc ttaacgctgc cagtgctcaa tc
32832DNAArtificial SequenceSynthetic Oligonucleotide 8gattgagcac
tggcagcgtt aagaattcga tt 329884DNAArtificial SequenceSynthetic
Polynucleotide 9atgggccatc atcatcatca tcacagcagc ggcctggaag
ttctgttcca ggggcccgcg 60actgcgctga cgaatttggt ggccgagccg ttcgcgaaat
tggagcaaga ttttggtggt 120tcgatcggtg tctacgcgat ggacaccggt
agcggtgcca ccgtgagcta ccgtgccgaa 180gagcgttttc cgctgtgtag
ctctttcaag ggttttctgg ccgcagccgt gctggcacgc 240agccaacagc
aagcgggcct gctggacacc ccgatccgtt acggcaaaaa tgcgctggtt
300ccgtggagcc cgattagcga aaagtacctg accaccggca tgacggtggc
ggagttgagc 360gctgcggcgg ttcagtattc cgataacgct gcggcaaatc
tgctgctgaa agaactgggc 420ggtccagcgg gtctgacggc tttcatgcgt
tctattggcg acaccacctt tcgcttggac 480cgctgggagc tggagctgaa
cagcgcgatt ccgggcgacg cacgtgatac gagcagcccg 540cgtgcagtga
ccgagagcct gcagaagctg accctgggca gcgcactggc cgcaccgcag
600cgccaacagt tcgtcgattg gctgaagggt aacaccaccg gtaaccatcg
tattcgcgca 660gcggtcccgg ctgattgggc agttggtgac aagactggta
cgtgcggcgt ttatggtacg 720gcgaatgact acgcggttgt ttggcctacg
ggtcgtgcgc cgatcgtcct ggcggtgtat 780acccgtgctc cgaacaaaga
cgataaacac tccgaagcgg tcatcgccgc agcagcgcgt 840ctggccctgg
aaggcttggg cgttaatggt cagtaacgcc ggcg 8841032DNAArtificial
SequenceSynthetic Oligonucleotide 10tcgcctcgag gcgactgcgc
tgacgaattt gg 321133DNAArtificial SequenceSynthetic Oligonucleotide
11aatcgaattc ttactgacca ttaacgccca agc 331233DNAArtificial
SequenceSynthetic Oligonucleotide 12gcttgggcgt taatggtcag
taagaattcg att 331331DNAArtificial SequenceSynthetic
Oligonucleotide 13ttcactgcag tgaacgttgc gaagcaacgg c
311441DNAArtificial SequenceSynthetic Oligonucleotide 14tcgaggatcc
tcgagagcaa aaacaggaag gcaaaatgcc g 411530DNAArtificial
SequenceSynthetic Oligonucleotide 15ccgtctagac ggatggcctt
tttgcgtttc 301633DNAArtificial SequenceSynthetic Oligonucleotide
16aatcgaattc ttactgacca ttaacgccca agc 331732DNAArtificial
SequenceSynthetic Oligonucleotide 17aatcgaattc ttaacgctgc
cagtgctcaa tc 32
* * * * *